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Ovine pulmonary adenocarcinoma (OPA) is a lung cancer that affects sheep, 
caused by jaagsiekte sheep retrovirus (JSRV). OPA is present in most sheep-
rearing countries of the world, but, at present, there are no reliable early-stage 
tests to diagnose the disease, and OPA continues to pose an animal welfare threat 
and cause substantial economic losses. In addition, OPA is a valuable animal 
model to study early oncogenic events in human lung cancer. Specifically, OPA 
and some types of human lung cancer present similarities in activated signalling 
pathways (Ras-MEK-ERK1/2 and PI3K-AKT-mTOR) and their association with 
type II pneumocytes. Nevertheless, study of the molecular pathogenesis of OPA 
has been hindered due to the lack of a permissive cell line for JSRV replication. 
JSRV encodes an unusual envelope protein (Env) which is actively oncogenic and 
sufficient to drive transformation in vivo and in vitro. Despite the lack of a 
permissive cell line, early oncogenic events induced by JSRV can be studied by 
transfection of cell lines with plasmids encoding JSRV Env.  
MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression 
and essential cell processes such as cell proliferation and apoptosis. miRNAs are 
being extensively studied as biomarkers of several diseases, including cancer. 
The aims of this project were to investigate the role of miRNAs in the early 
oncogenic events induced by JSRV and to investigate their potential as OPA 
biomarkers.  
miRNA expression levels were investigated using small RNA sequencing in lung 
tissue from cases of experimentally induced OPA. No evidence of JSRV-encoded 
miRNAs was found, but levels of 40 miRNAs were found differentially expressed 
between affected and control sheep. Of those, upregulation of nine microRNAs 
(miR-135b, miR-182, miR-183, miR-21, miR-200b, miR-205, miR-31, miR-503 
and miR-96) was confirmed by RT-qPCR in experimental and natural cases of 
OPA, suggesting that increased levels of these miRNAs were characteristic of 
OPA affected lung tissue. To investigate miRNAs as potential biomarkers, miRNA 
expression was measured in serum and bronchoalveolar lavage fluid (BALF) 
macrophages of OPA affected sheep. small RNA sequencing revealed 74 
microRNAs and 85 miRNAs differentially expressed in serum and BALF 
xviii 
macrophages, respectively. Interestingly, BALF macrophage microRNA 
expression was found to resemble more closely that of OPA affected sheep lungs. 
In addition, miRNA expression levels varied at different stages of the disease and 
no miRNAs were found to be consistently dysregulated in serum of OPA affected 
animals. Discordances in miRNA signatures in lung tissue and serum are not 
entirely unexpected. Lung tissue miRNAs might represent the tumour 
microenvironment and localised response to it, whereas miRNAs in serum may 
represent the global state of the animal, and tumour miRNAs might be released 
into circulation at low levels, making them difficult to detect. 
Expression of the nine upregulated miRNAs was then investigated in in vitro 
models to study their involvement in transformation. Lentiviral vectors encoding 
green fluorescent protein (GFP) or a GFP-2A-Env fusion protein were produced 
and used to transduce cell lines. Transformation was verified by 
immunocytochemical detection of the transformation markers P-Akt and P-
ERK1/2. Nevertheless, miRNA expression levels in culture did not resemble those 
observed in lung tissue of OPA-affected sheep. These differences might be due 
to species variation, upregulation of miRNAs late in the transformation process, 
or involvement of other cell types in tissue besides the transformed cells. To study 
these questions further, JSRV and the GFP-2A-Env encoding lentiviral vectors 
were used to infect lung slices in culture. Expression levels of miRNAs did not, in 
any of the cases, resemble lung tissue findings. Fewer than 5% of cells in lung 
slices were found to be infected, suggesting that changes in miRNA expression 
could be masked by the background of normal cells. Nevertheless, increasing 
JSRV21 concentration did not yield higher infection levels, indicating that those 
might be more dependent on the availability of JSRV’s target cells, dividing type 
II pneumocytes, than viral concentration. 
Taken together, this study has revealed new information on miRNA expression in 
OPA-affected sheep, including expression patterns in lung and serum. Future 
work should focus on developing a permissive replication system to allow the 




Ovine pulmonary adenocarcinoma (OPA) is a lung cancer that affects sheep, 
caused by the jaagsiekte sheep retrovirus. OPA is present in most sheep-rearing 
countries of the world, but there are no diagnostic tests available for detection of 
the disease in its early stages. The disease is associated with significant economic 
losses for farmers and is a serious animal welfare issue. In addition, OPA has 
similarities to human lung cancer and can be used to study the human disease. 
However, advances in our understanding of OPA are slow because JSRV cannot 
be grown in laboratory settings. So far, our knowledge on the growth of tumours 
in OPA has derived from using a specific protein of JSRV that triggers the process 
of tumour formation.  
In this thesis, I have investigated the relationship of a class of small molecules, 
called microRNAs (miRNAs), with OPA. miRNAs are present in all animals and 
regulate processes such as cell growth and cell death. In addition, they can be 
detected in tissues and body fluids, and the abundance of some miRNAs can be 
indicative of certain diseases. Improved understanding of how miRNAs change in 
sheep with OPA would provide a better understanding of the disease, and might 
allow us to use this class of molecules to detect the disease at an early stage. 
When the abundance of miRNA was compared in lung tissue of OPA-affected 
sheep and unaffected sheep, the levels of 40 different miRNAs were discovered 
to be different in OPA-affected sheep. A panel of nine of those miRNAs was used 
to confirm in different groups of sheep that levels of those nine miRNAs appeared 
to be related to OPA disease. Also, the changes in the nine miRNAs could be 
observed in early stages and advanced stages of OPA.    
Given that the nine miRNAs studied in lung seemed to distinguish between OPA-
affected and unaffected sheep, their ability to diagnose OPA was assessed. 
Taking into consideration the potential use of a diagnostic test in the field, 
detection of the nine miRNAs was attempted in blood serum because it is more 
accessible than lung tissue. However, levels of the nine miRNAs in serum were 
not different between OPA-affected and unaffected sheep, indicating that they 
could not be used for diagnosis. Other miRNAs were detected in sheep serum, 
xx 
but their levels were not clearly different between OPA-affected and unaffected 
sheep.  
To discover the function of the nine miRNAs associated with OPA lung tissue, I 
performed experiments in cells grown in the laboratory. Cells in culture were 
exposed to the JSRV protein and tumour formation was observed. I then 
investigated if those cells in culture had similar abundance of the nine miRNAs 
compared to OPA lung tissue. However, levels of miRNAs in cultured cells were 
not a reflection of their levels in lung tissue. Because the cells grown and used in 
that experiment are different from the cells in sheep lung, the experiment was 
repeated in lung slices cultured in the laboratory. However, tumour formation was 
observed in a very small part of the lung slices, and quantities of the nine miRNAs 
were not similar to those in OPA lung tissue.  
In summary, this study has provided new information on miRNAs and their relation 
to OPA, including their abundance in lung tissue and blood. Future work should 
focus on developing a system to grow JSRV in laboratory settings and study the 
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Chapter 1 Literature review 
1.1 Ovine Pulmonary Adenocarcinoma  
Ovine pulmonary adenocarcinoma (OPA) is a lung tumour caused by jaagsiekte 
sheep retrovirus (JSRV). The disease affects sheep and occasionally goats and 
mouflon, although they suffer from a less pathogenic form, cattle and other 
animals are not affected by it. OPA is an important issue for animal welfare and 
sheep production, due to the economic losses associated with it. In addition, OPA 
is an important model of human lung adenocarcinoma. Interestingly, JSRV is able 
to drive tumour formation due to an unusual Env protein, which is oncogenic and 
sufficient to drive transformation of cell lines in vitro, and tumour formation in vivo.  
1.1.1 Clinical presentation 
The presence of OPA in a flock is usually signalled by an increased number of 
adult sheep suffering from pneumonia that does not respond to antibiotic 
treatment (Griffiths et al, 2010). In individuals, signs of the illness include loss of 
weight, difficulty to breathe, cough and fluid discharge from the nostrils when the 
animal’s head is lowered (De las Heras et al, 2003). This is known as the 
wheelbarrow test, and the presence of fluid discharge is a pathognomonic sign of 
OPA (Cousens et al, 2009; Sharp et al, 1983). 
1.1.2 History and epidemiology of OPA 
One of the first reports of OPA originated from South Africa in 1825, where it was 
described as “Jaagsiekte”, an Afrikaans word that means chase-sickness, 
referring to the affected animals laboriously breathing, as if they had been chased 
(York & Querat, 2003). Similar descriptions were found a few years later in France 
and England (York & Querat, 2003). In 1888, a report detailed the pathology and 
clinical presentation of a disease outbreak causing extensive deaths in sheep 
flocks (Dykes & M'Fadyean, 1888). The disease description matched Jaagsiekte, 
but observation of parasite eggs led to the belief that Strongylus was the causative 
agent. Nevertheless, this was one of the first reports to suggest the contagious 
nature of Jaagsiekte and remark the unusual nature of the lung lesions observed. 
In 1891, further description of the disease and relation to an infectious agent was 
published (Hutcheon, 1891).  
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The disease continued to be described in several countries, and a number of 
terminologies were used to refer to it: sheep pulmonary adenomatosis, jaagsiekte, 
ovine pulmonary carcinoma (Palmarini & Fan, 2001; York & Querat, 2003). Until 
ovine pulmonary adenocarcinoma (OPA) was accepted as the term to describe 
the disease (Palmarini & Fan, 2001).  
OPA has been reported in most sheep rearing countries of the world except for 
Australia and New Zealand (Fig. 1.1) (York & Querat, 2003). In 1952 it was 
successfully eradicated from Iceland after a strict slaughter policy (Pálsson, 1985). 
The prevalence of OPA varies between countries, and in endemic countries, such 
as South Africa and the UK, it is believed to account for up to 70% of sheep 
tumours, and imposes an animal health and economic burden (De las Heras et al, 
2003; Griffiths et al, 2010). 
 
Figure 1.1. OPA distribution in the world. Countries in which OPA cases have been reported 
are coloured in black. Countries free of OPA are coloured in yellow. Countries in which the 
OPA status is unknown are coloured in grey.  
Nonetheless, the true prevalence of JSRV and OPA is not known as not all JSRV-
infected animals develop the disease, and many affected animals don’t show 
clinical signs during their life span (Caporale et al, 2005; Salvatori et al, 2004). In 
addition, OPA is not a notifiable disease in most countries, with some exceptions: 
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for example, there is a requirement to notify OPA in Northern Ireland (Lee et al, 
2017).  
OPA mortality rates vary depending on how long the infection has been present 
in a flock. The epidemic in Iceland reported mortality between 30-50% in the first 
years after introduction of the disease, but once the disease became endemic 
mortality dropped to 1-5% (Dungal et al, 1938; Shirlaw, 1959; Tustin, 1969). 
Longitudinal studies of flocks where OPA is endemic, confirmed disease losses 
vary between 2-10%, and is estimated that only 30% of sheep in affected flocks 
develop OPA lesions (Sharp & DeMartini, 2003).  
Sheep of all ages are susceptible to OPA, but most clinical OPA cases are seen 
in sheep 1-4 years old. Clinical disease is rarely seen in animals younger than 9 
months (Dungal et al, 1938; González et al, 1993; Hunter & Munro, 1983; Tustin, 
1969). In the majority of sheep, clinical signs of OPA are thought to start after a 
long incubation time, estimated to last between several months to years (Griffiths 
et al, 2010). OPA cases are observed throughout the year, with a peak incidence 
in winter (Hunter & Munro, 1983; Tustin, 1969). Although no breed or gender 
susceptibility to OPA has been demonstrated, it is possible that some breeds 
show greater or reduced susceptibility to developing the disease. Indeed, reports 
of affected flocks in Iceland, showed that up to 90% Gottorp breed sheep died but 
losses in the Aldalbol breed were only 10%, suggesting some inherent resistance 
to OPA (Dungal et al, 1938).  
1.1.3 Pathology of ovine pulmonary adenocarcinoma 
OPA tumours derive from proliferating type II pneumocytes, but, other cell types 
such as club cells, previously known as clara cells, and undifferentiated cells have 
also been detected in tumours (De las Heras et al, 2014; Martineau et al, 2011; 
Murgia et al, 2011). When tumours are small they have no clinical manifestations. 
Clinical signs of OPA start when the tumour is of considerable size and interferes 
with lung function. Sheep initially appear less active, have difficulty breathing and 
lose condition. As disease advances, sheep remain alert but respiration becomes 
deeper and more frequent and is associated with abdominal lift. Excess secretions 
build-up in the lungs, causing coughing and compromising respiration further (De 
las Heras et al, 2003). In some cases, lung fluid discharge from the nostrils can 
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be observed when the animal’s head is lowered, and is a pathognomonic 
symptom of the disease (Cousens et al, 2009; Sharp et al, 1983). Importantly, 
lung fluid contains infectious JSRV particles that can spread the disease (Cousens 
et al, 2009; Martin et al, 1976; Sharp et al, 1983). Bacterial infections and visna-
maedi virus (VMV), in countries where it is present, are often seen associated with 
OPA and exacerbate the pathology of OPA (Dungal et al, 1938; González et al, 
1993; Markson et al, 1983). Death invariably occurs within a few weeks to months 
after the start of the clinical disease (Dungal et al, 1938). 
Goats are believed to be less susceptible to OPA and suffer from a subclinical 
form of the disease. No clinical signs of OPA in goats have been described, natural 
cases of the disease are usually an incidental finding. In experimental infections 
of goats clinical signs were not observed, even though OPA lesions were apparent 
at necropsy (Sharp et al, 1983; Sharp et al, 1986; Tustin et al, 1988). OPA lesions 
in goats have an encapsulated appearance, suggesting cells were infected and 
transformed but that the virus did not spread within the lung. No metastases have 
been recorded in affected goats (Caporale et al, 2013).  
1.1.3.1 Gross pathology 
Pathological changes associated with OPA are usually restricted to the lungs, but 
thoracic lymph nodes are sometimes affected. Lung lesions vary from small 
discrete nodules to extensive tumours and are most frequently found in the 
cranioventral parts of all lung lobes, but any part of the lung can be affected. OPA 
tumours usually involve both lungs but not to the same extent. There are two 
histopathological forms of the disease: classical and atypical (De las Heras et al, 
2003; Griffiths et al, 2010). 
In classical OPA, lungs are enlarged and they do not collapse when the chest is 
opened at post-mortem. Lung weight is usually increased up to three times 
compared to normal lungs. Tumours are diffuse or nodular and light purple or light 
grey in colour, they do not protrude and have increased consistency (Cutlip & 
Young, 1982; Dungal et al, 1938; Tustin, 1969; Wandera, 1971). There is usually 
an emphysematous area surrounding the neoplastic lung, and pleurisy is a 
common finding. When the tumour is dissected, the cut surface exhibits multiple 
small nodules coalescing, and frothy fluid pours from bronchioles and bronchi 
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(Cutlip & Young, 1982; Dungal et al, 1938; Rosadio et al, 1988; Sharp & Angus, 
1990; Wandera, 1971). In early cases, with no clinical presentation, solitary 
tumour nodules might be the only finding (Tustin, 1969). In more advanced cases, 
affected areas are fibrotic and appear white, solid and hard. It is common to find 
lesions of bacterial pneumonia, abscesses and maedi. Occasionally, small 
metastases can be seen in regional lymph nodes. In rare occasions, it has been 
observed in distant organs (Hunter & Munro, 1983; Mackay & Nisbet, 1966; 
Nobel et al, 1969). The existence of metastases in some animals provides 
evidence of the malignant nature of OPA. 
Atypical OPA is a subclinical form of the disease found at necropsy, in which 
tumours appear more nodular in early and advanced cases(De las Heras et al, 
2003; Garcia-Goti et al, 2000). Tumours are usually found in the diaphragmatic 
lobes, and are pearly white nodules of hard consistency. When the lung is 
sectioned, tumours appear very well demarcated and dry. In some cases multiple 
nodules 0.5-1 cm in diameter are found throughout the lung. 
These two forms of OPA can coexist in a flock and in an individual sheep (Garcia-
Goti et al, 2000). When analysed, no molecular differences were found between 
the JSRV associated with classical and atypical OPA. These two disease forms 
have been suggested to be extremes of disease spectrum rather than two 
separate forms (Garcia-Goti et al, 2000).  
1.1.3.2 Histopathology 
Histopathologically, OPA lesions present as epithelial cell neoplastic proliferation 
in alveolar and bronchiolar regions. These proliferations mostly have papillary 
appearance and can compress neighbouring alveoli and coalesce as they 
increase in size (De las Heras et al, 2003). Electron microscopy confirmed the 
majority of transformed cells constituting tumour tissue as type II pneumocytes, 
due to the presence of lamellar structures and microvilli in the apical surface of 
the cells (Cutlip & Young, 1982; Sharp & Angus, 1990). The cytoplasm of these 
transformed cells stains positively for glycogen deposits (Sharp & Angus, 1990; 
Wandera, 1971).  
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Another hystopathological feature are polypoid ingrowths in the terminal 
bronchioles arising from the bronchiolar epithelium (De las Heras et al, 2003). A 
moderate to severe inflammatory response, which includes lymphocytes, plasma 
cells and macrophages, can be seen surrounding affected bronchioles (De las 
Heras et al, 2003). A common finding is the presence of highly abundant 
macrophages surrounding neoplastic alveoli, whereas presence of neutrophils 
might indicate secondary bacterial infections (De las Heras et al, 2003; Sharp & 
Angus, 1990) . The stroma is generally thin except in advanced cases where it 
may be fibrotic (De las Heras et al, 2003; Sharp & Angus, 1990) . 
The histopathological findings of atypical OPA are similar to those observed in the 
classical form of OPA. However, atypical OPA has a pattern more often acinar 
than papillary, and the stroma is more heavily infiltrated by lymphocytes, plasma 
cells and connective fibres (De las Heras et al, 1992; Garcia-Goti et al, 2000). 
Lymphoid proliferations can be observed in the neighbouring bronchioles, and 
fewer cells are positive for JSRV compared to classical OPA (Garcia-Goti et al, 
2000). The histopathology of OPA in affected goats and mouflon closely 
resembles the described findings in sheep (Rajya & Singh, 1964; Sanna et al, 
2001).  
1.1.3.3 Similarities of OPA with human lepidic carcinoma 
Human lepidic carcinoma, previously known as bronchioloalveolar carcinoma, 
shares several features in common with OPA.  
Human lepidic carcinoma is described as an adenocarcinoma with pure 
bronchioloalveolar growth. It appears as multifocal nodules that evolve towards 
pneumonia with pulmonary shunting. Neoplastic cells are seen following alveolar 
septa, described as lepidic spread, and no invasion of stroma, vascular system or 
pleura is observed (Travis et al, 2015). Lepidic carcinoma is a rare form of lung 
cancer, and the survival rates for affected patients are better than in other forms 
of non-small cell lung cancer (NSCLC) (Mornex et al, 2003; Youssef et al, 2015). 
A more common occurrence is the presence of tumours containing areas of lepidic 
carcinoma and either papillary or acinar adenocarcinoma, these are known as 
mixed adenocarcinoma (Travis et al, 2015).  
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Following human lung cancer classification criteria, OPA would be described as a 
mixed adenocarcinoma, with a combination of lepidic carcinoma and papillary or 
acinar growth in advanced stages of the disease (Gray et al, 2019; Youssef et al, 
2015)). In contrast, early cases of OPA would be described as minimally invasive 
carcinomas (Youssef et al, 2015).  
In human and ovine malignancies tumours are generally well-differentiated, 
multifocal and found in the periphery (Palmarini & Fan, 2001; Youssef et al, 2015). 
Cells derived from tumours express markers of type II pneumocytes and club cells 
(Liu & Miller, 2007). Moreover, common signalling pathways can be seen 
activated in NSCLC and OPA: Ras-MEK-ERK1/2 and PI3K-AKT-mTOR (review 
by Youssef et al (2015)). Increased telomerase activity has also been detected in 
tumour cells of NSCLC and OPA (Suau et al, 2006).  
Similarities between NSCLC and OPA raised the controversial question of 
whether JSRV or a related virus could be involved in human lung cancer (Linnerth-
Petrik et al, 2014; Perk & Hod, 1982). The association of JSRV with the human 
disease was tested using antibodies raised against JSRV Gag in different human 
lung cancer types. Some authors reported 30-40% cases cross-reacting with 
antibodies against JSRV Gag, whereas other authors failed to detect JSRV in 
human tissue (De las Heras et al, 2000; De Las Heras et al, 2007; Hopwood et al, 
2010; Linnerth-Petrik et al, 2014; Miller et al, 2017). The association of JSRV or a 
related retrovirus to human lung cancer was also tested using PCR and 
sequencing approaches but no retroviral genome was detected (Berthet et al, 
2015; Yousem et al, 2001).  
Although JSRV might not be associated with human lung cancer, OPA remains a 
good model for epithelial neoplasia in human malignancy (Gray et al, 2019; 
Youssef et al, 2015). In addition, OPA provides the opportunity to study early 
events of lung cancer, as human samples of early stages are rarely available. 
Furthermore, although there are murine models of human lung cancer, the use of 
sheep as model of NSCLC would have several advantages due to closer similarity 
in physiology and anatomy (Gray et al, 2019; Youssef et al, 2015). Sheep lungs 
are similar to human lungs in branching pattern, distribution of differentiated 
epithelial cells and size (Fig. 1.2) (reviewed by Gray et al (2019)). Moreover, 
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sheep are already used as models of human disease in asthma and cystic fibrosis 
(McLachlan et al, 2011).  
 
Figure 1.2. A. Anatomy of the ovine lower respiratory tract. B. Anatomy of the human 
lower respiratory tract. Reproduced from Gray et al (2019). 
1.1.4 Aetiology of ovine pulmonary adenocarcinoma 
The first sign that OPA was caused by a retrovirus was the observation of retroviral 
particles in the lungs of affected sheep using electron microscopy (Perk et al, 
1974). Later on, reverse transcriptase activity and retroviral RNA were detected 
in tumour extracts. In 1976, particles with reverse transcriptase activity were 
successfully used to transmit OPA (Martin et al, 1976). Further investigation 
revealed an inverse relationship between the amount of reverse transcriptase and 
the time for appearance of clinical signs (Verwoerd 1981). Several years later, 
these findings were confirmed by the purification of JSRV from lung fluid of 
affected animals and their use to transmit the disease (DeMartini et al, 1987; 
Sharp et al, 1983).  
JSRV cannot be grown in cell culture and early research focused on methods of 
isolation of the virus from tumour cells and lung fluid (Verwoerd et al, 1983). 
Optimal isolation was achieved from sucrose density gradient ultracentrifugation 
of lung fluid, and extracting the fraction with the peak of reverse transcriptase, 
which had a density of 1.186 g/ml in JSRV (reviewed by York & Querat (2003)). 
The initial description of JSRV as the causative agent of OPA was complicated by 
frequent coinfection with the lentivirus maedi-visna virus (VMV). The finding that 
JSRV crossreacts with serum raised against the betaretroviruses mouse 
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mammary tumour virus (MMTV) and Mason-Pfizer monkey virus (MPMV) allowed 
distinction between the two (Sharp et al, 1983).  
Further research had been hampered by the lack of a culture system for JSRV 
but, in 1992, the complete genome of JSRV was cloned and sequenced (York et 
al, 1992). An infectious molecular clone from an UK isolate (JSRV21) was later 
used to produce virus in vitro and inoculate sheep to prove JSRV’s involvement 
in OPA (Palmarini et al, 1999a). Production of JSRV particles in vitro was achieved 
by swapping the viral 5’ U3 of JSRV21 for the human cytomegalovirus (HCMV) 
immediate early promoter. This allowed for efficient expression of JSRV in 293T 
cells in culture and release of infectious particles, without the HCMV promoter, in 
the culture supernatant.  
JSRV21 particles were used to infect new-born lambs by intratracheal injection, 
and the experimental findings subsequently confirmed JSRV is sufficient and 
necessary to cause OPA (Palmarini et al, 1999b). Nevertheless, other agents 
such as lungworm, ovine herpesvirus and mycoplasma, consistently found 
associated with natural OPA, might enhance disease progression in the field 
(Dungal et al, 1938; Dykes & M'Fadyean, 1888; Krauss & Wandera, 1970; Tustin, 
1969). 
1.1.4.1 Transmission of JSRV 
The natural route of JSRV transmission is mainly through the aerogenous route 
(Tustin, 1969; Wandera, 1971). Aerosols produced by infected animals are 
inhaled by uninfected animals, and it is believed that close quarters in sheep flocks 
facilitate this route of transmission. Lung fluid produced by affected animals 
contains high concentrations of JSRV particles and is considered the most 
efficient way of spreading the disease (Dungal, 1946).  
An increasing number of studies have also reported transmission to newborn 
lambs via colostrum or milk from infected ewes (Borobia et al, 2016; Grego et al, 
2008). Control strategies based on milk and colostrum management have proved 
effective in preventing virus spread from mother to lamb (Voigt et al, 2007b).  
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1.2 Retroviruses  
JSRV, the causative agent of OPA, belongs to the Retroviridae family of viruses. 
Retroviruses are RNA viruses widespread in nature. They have been found to 
infect most vertebrate and many non-vertebrate species and are capable of 
inducing a wide range of diseases (Rosenberg & Jolicoeur, 1997). However, 
retrovirus which have best-adapted to their hosts do not cause clinical symptoms.  
Members of the Retroviridae family present similarities in their virion structure, 
genomic organisation and replication cycle. Retrovirus virions are spherical with 
diameter between 100-150 nm, and are surrounded by an envelope with spikes 
composed of virus encoded glycoproteins (Rosenberg & Jolicoeur, 1997). 
The internal viral core contains the viral genome and can either be spherical or 
rod-shaped, depending on the virus. The retroviral genome is between 7-10 kb in 
length, and composed of two copies of single stranded positive sense RNA 
(Rosenberg & Jolicoeur, 1997). The viral genomic RNA has similar features to 
mRNAs: a 5′ methylated cap and polyA tail at the 3′ end. Each of the genomic 
RNA copies is associated with a specific tRNA molecule at the primer binding site 
near the 5′ end of the RNA. These tRNA molecules are necessary to initiate the 
process of reverse transcription (Goff, 2013).  
1.2.1 Retrovirus phylogeny and evolution 
Retroviruses are classified into seven genera: alpharetroviruses, betaretroviruses, 
gammaretroviruses, deltaretroviruses, epsilonretroviruses, lentiviruses and 
spumaretroviruses (Fig. 1.3). This classification has recently been updated to 
categorise members of the spumaretrovirinae subfamily in five genera (Walker et 
al, 2019). 
JSRV is classified as a betaretrovirus like MMTV and human endogenous 
retrovirus K (HERV-K). Historically, betaretroviruses have been separated into 
type B and type D virus. Differences between the two groups include core 
morphology, mode of RNA nuclear export, length of their long terminal repeats 
(LTRs) and presence of accessory genes. Phylogenetically, type B and type D 
retroviruses have evolved from an ancestor with the particular ability to assemble 
Gag particles in the cytoplasm, generating structures called A-type particles. The 
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ancestor of type D virus is believed to have acquired a new env gene, probably 
from primates. JSRV presents genetic similarity to B-type virus, in env, and D-type 
virus, in gag and pol (York 1992).  
 
Figure 1.3. Phylogenetic tree of the Retroviridae family, representative members of each 
genera are shown. BFV: bovine foamy virus, PFV: prototype foamy virus, SFV-3: simian 
foamy virus type 3, BLV: bovine leukemia virus, HTLV-1: human t-lymphotropic virus type  1, 
HTLV-2: human t-lymphotropic virus type 2, FIV: feline immunodeficiency virus, MVV: maedi-
visna virus, HIV-1: human immunodeficiency virus type 1, SIV: simian immunodeficiency virus, 
EIAV: equine infectious anemia virus, ENTV-2: enzootic nasal tumour virus type 2, ENTV-1: 
enzootic nasal tumour virus type 2, JSRV: jaagsiekte sheep retrovirus, MPMV: Mason-Pfizer 
monkey virus, MMTV: mouse mammary tumour virus, HERV-K: human endogenous retrovirus 
K, RSV: Rous sarcoma virus, MMLV: Moloney murine leukemia virus, FELV: feline leukemia 
virus, GALV: gibbon ape leukemia virus, WDSV: walleye dermal sarcoma virus, WEHV-1: 
walleye epidermal hyperplasia virus type 1, WEHV-2: walleye epidermal hyperplasia virus type 
2. Reproduced from Griffiths et al (2010).  
 
1.2.2 The retroviral genome 
All retroviral genomes contain four main genes encoding proteins in the same 
order: gag-pro-pol-env. The gag gene encodes three proteins: the matrix protein 
(MA), the major capsid protein (CA) and the nucleocapsid protein (NC). The pro 
gene encodes a protease (PR). The pol gene encodes reverse transcriptase (RT) 
and integrase (IN). In some retroviruses there is no separate gene encoding the 
  
Chapter 1: Literature review 12 
protease, in alpharetroviruses PR is encoded by gag, and gammaretroviruses and 
lentiviruses encode PR in the pol gene. The env gene encodes the envelope 
glycoproteins surface (SU), and transmembrane (TM) (Rosenberg & Jolicoeur, 
1997). 
At the ends of the retroviral genome there are non-coding regions which are 
essential for their replication cycle. These regions are R, repeated at both ends, 
U5 present at 5′ and U3 present at 3′ end. The U3 region contains a basal RNA 
pol II promoter and enhancer sequences. The R-U5 region contains the 
polyadenylation and cleavage site (Rosenberg & Jolicoeur, 1997). 
Retroviruses are considered simple if they encode only the genes described 
above. Complex retroviruses encode additional virion and non-virion proteins, 
which they use to regulate viral expression (see below, section 1.2.5). 
1.2.2.1 Genetic structure of JSRV 
Information on the genetic structure of JSRV comes from sequencing three strains 
of JSRV: JSRV21 (Palmarini et al, 1999a), JSRV-SA (York 1991, York 1992), a 
South-African isolate, and JSRV-JS7, isolated from the JS7 cell line derived from 
an OPA tumour from the UK (DeMartini et al, 2001). Sequencing results indicated 
very low diversity between isolates. JSRV21 and JSRV-JS7, strains isolated 10 
years apart from the UK, have a 99.2% sequence similarity (DeMartini et al, 2001). 
Comparison of the UK isolates with JSRV-SA, an isolate from South Africa, 
revealed 93.3% identity to the South African sequence (DeMartini et al, 2001; 
Palmarini et al, 1999a). 
The JSRV genome is approximately 7455 nt in length. It contains the classical 
retroviral gene arrangement (gag-pro-pol-env) with pro encoded in a different ORF 
than pol, and overlapping gag and pol (Fig. 1.4) (York et al, 1992). In addition to 
the protease, pro also encodes a dUTPase, an enzyme that catalyses the 
hydrolysis of deoxyuridine triphosphate into deoxyuridine monophosphate and 
prevents incorporation of uracil into viral DNA. The reverse transcriptase enzyme 
encoded by pol has an RNaseH domain which degrades viral RNA once it has 
been reverse transcribed into DNA (Palmarini & Fan, 2003).  
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Besides the classical retroviral genes, there is an ORF called orf-x, which overlaps 
with gag. Orf-x has a different codon usage than other protein coding regions in 
the JSRV genome and has no homologs in any other betaretrovirus. 
Nevertheless, orf-x is conserved across all JSRV isolates and, in the closely 
related enzootic nasal tumour virus (ENTV-1) orf-x is only interrupted by the 
presence of two stop codons (Cousens et al, 1999; Walsh et al, 2010). There are 
two splice acceptor sites close to orf-x, suggesting that the mRNA is expressed, 
but no protein has been detected. The predicted protein is very hydrophobic and 
contains 4 putative transmembrane domains and, although its function remains 
unknown, it has low sequence similarity to the adenosine 3A receptor 
(Auchampach et al, 1997).  
Compared to other retroviruses, the envelope protein of JSRV is reported to be 
more resistant to degradation. In one study, a retroviral vector displaying the JSRV 
envelope was subjected to six freeze-thaw cycles or 30 minutes at room 
temperature with no reduction in infectious titre. In contrast, these same conditions 
decreased the titre of the retroviral vector displaying the murine leukemia virus 
(MuLV) envelope by 40% and 30% respectively. In addition, JSRV is resistant to 
lung surfactant, which is consistent with its role in lung colonisation (Coil et al, 
2001).  
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Figure 1.4. JSRV virion structure. A. Representation of the JSRV virion structure, the main 
proteins are shown and colour-coded according to the gene they are encoded in. B. Structure 
of the JSRV genome, ORFs and encoded proteins are depicted. Adapted from Griffiths et al 
(2010). Produced with Biorender.  
1.2.3 Retroviral replication 
Infection proceeds with a retrovirus particle binding one or more specific receptors 
on the surface of a cell. After binding, the envelope protein performs a 
conformational change that exposes a fusion domain. Exposure of the fusion 
domain triggers either fusion of the virion with the cell membrane, or internalisation 
of the virion by endocytosis and fusion with the endosomal membrane. In both 
cases, the virus core is released into the cytoplasm where the genome is uncoated 
(Goff, 2013). JSRV is internalised by endocytosis and requires low pH to trigger 
fusion (Cote et al, 2008).  
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After entry into the cell, the viral RNA genome is reverse-transcribed into DNA by 
the viral reverse transcriptase in the cytoplasm of the cell. During reverse 
transcription the viral DNA acquires the LTRs at either end, each LTR contains 
sequences of viral RNA U3-R-U5. LTRs are important for viral replication as they 
have sequences for initiation and termination of viral transcription and for viral 
integration (Rosenberg & Jolicoeur, 1997).  
All retroviruses, except for lentiviruses, can only gain access to the cell nucleus 
efficiently during cellular division, when the nuclear membrane is disrupted. It is 
during division that the viral DNA is transferred to the nucleus and integrated in 
the cell genome by the integrase, forming a provirus. Once integrated, the provirus 
uses the host’s cell machinery for transcription and translation of viral proteins. 
Transcription begins at the U3-R junction in the upstream LTR (Rosenberg & 
Jolicoeur, 1997). The replication cycle of a retroviruses is summarised in Fig. 1.5.  
For most retroviruses, Env proteins are transcribed from a single spliced mRNA, 
while Gag and Pol are translated from unspliced viral RNA. Pol proteins are 
translated from read through of pro or gag genes by ribosomal shifting or amber 
suppression. Retroviral proteins are initially translated as polyproteins and 
cleaved during virion morphogenesis. Cleavage of polyproteins is performed by 
the viral protease in the case of Gag and Pol polyproteins whereas, a cellular 
protease carries out the cleavage of Env into SU and TM (Rosenberg & Jolicoeur, 
1997).  
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Figure 1.5. Retroviral replication cycle. Retroviral particles bind to receptors on the cell 
surface. Binding to receptors triggers fusion of the retrovirus and host cell. In the cytoplasm, 
the viral RNA is reverse transcribed into DNA. DNA enters the cell nucleus and is inserted into 
the host cell genomic DNA by action of the integrase. Once integrated, the provirus uses the 
cell-machinery for transcription and translation of its proteins. After translation, the retroviral 
protease processes polyproteins, and assembly of virions takes place near the cell membrane. 
From the cell membrane retroviral particles bud and are released. Produced with Biorender.  
1.2.4 Retroviral receptors and tropism 
Viral receptors are important determinants of host range and the type of disease 
induced. The cellular receptor for JSRV is hyaluronidase-2 (Hyal2), a 
glycosylphosphatidylinosityl anchored protein ubiquitously expressed on the 
surface of cells. Interaction with Hyal-2 occurs through Env SU. SU is anchored 
to the lipid bilayer of the envelope through the transmembrane domain of TM 
(Miller, 2008; Rai et al, 2001).  
In humans, Hyal2, is encoded in a region of the chromosome 3 that is often 
deleted in cancer, suggesting it might be a tumour suppressor (Rai et al, 2001; 
Wistuba et al, 1997). In the context of OPA, the interaction of JSRV Env with Hyal-
2 has been investigated (Danilkovitch-Miagkova et al, 2003) (section 1.2.6).  
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Despite the ubiquitous expression of Hyal2, JSRV can only efficiently replicate in 
secretory cells of the lungs (Palmarini et al, 2000a). In fact, JSRV RNA and DNA 
has been detected in lymphoid and myeloid cells, but high levels of expression 
occur only in type II pneumocytes and club cells (Holland et al, 1999). This 
specificity is due to the other determinant of cell tropism, the viral LTR. The 
upstream LTR of all retroviruses have a viral promoter and enhancer sequence, 
including a TATA sequence in U3. The LTR is able to bind cellular factors and 
RNA polymerase II to initiate transcription. In JSRV’s case, only type II 
pneumocytes and club cells possess the transcription factors necessary to bind 
the LTR regions and activate them, allowing its efficient expression (McGee-
Estrada & Fan, 2007; McGee-Estrada et al, 2002; Palmarini et al, 2000a). 
1.2.5 Transcription 
Retroviruses that use two mRNAs, full length for translation of gag pro pol, and 
single spliced for translation of env, are referred to as a simple retrovirus. Simple 
retroviruses regulate levels of their mRNAs by cis-acting elements located in the 
RNAs (Rosenberg & Jolicoeur, 1997). MPMV is an example of a simple retrovirus 
that contains a cis-acting element, called constitutive transport element (CTE), at 
the 3′ end. Unspliced RNA is usually not allowed to leave the nucleus. Many 
viruses, including retroviruses, need to export genomic RNA which is unspliced 
so various mechanisms have evolved for this. CTE ensures efficient export of 
unspliced viral transcripts from the nucleus by recruiting cellular factors (Bray et 
al, 1994). Complex retroviruses, on the other hand, encode additional spliced 
mRNAs that generate proteins that regulate transport and splicing of other 
retroviral mRNA species (Rosenberg & Jolicoeur, 1997). Complex retroviruses 
show a two stage expression pattern, in which regulatory proteins are expressed 
early, and the canonical genes gag pol and env are expressed later on 
(Rosenberg & Jolicoeur, 1997). Examples of regulatory proteins from complex 
retroviruses include Tat and Rev in HIV-1, and Rem in MMTV (Cullen, 2003; Indik 
et al, 2005). 
Although JSRV was considered to be a simple retrovirus, a trans-acting factor 
named Rej or SP, encoded in the viral genome, was found to increase viral particle 
production (Caporale et al, 2009; Hofacre et al, 2009). Rej is located in the signal 
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peptide region of Env and its function depends on a responsive element located 
in the 3′ of env the viral genome (Caporale et al, 2009; Hofacre et al, 2009). 
Similarly to the MMTV encoded Rem factor, deletion of rej abolished production 
of Gag polyprotein (Hofacre et al, 2009). Rej was found to be involved in 
translation of unspliced RNA and transport, but these results were dependent on 
the cell line used for the study(Nitta et al, 2009).  
Analysis of JSRV transcripts revealed a double spliced env mRNA from which Rej 
could be expressed (Hofacre et al, 2009). However, it is thought that Rej could 
also originate from cleavage of the Env polyprotein, specifically the signal peptide 
of JSRV Env (Caporale et al, 2009).  
Alternative transcripts, apart from the two predicted mRNAs, have also been 
observed in JSRV infected cells and natural OPA tumours, suggesting their 
biological relevance. All spliced viral mRNAs derive from a 5′ splice donor site, 
and subgenomic mRNAs share 3′ and 5′ ends. These transcripts also revealed an 
alternative splice acceptor upstream of orf-x, and a spliced mRNA from which the 
putative Orf-x protein could potentially be expressed. JSRV transcripts 
experimentally detected are summarised in Fig. 1.6 (Palmarini & Fan, 2003; 
Palmarini et al, 2002).  
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Figure 1.6. Structure of JSRV RNA and mRNA transcripts identified. A. full-length JSRV 
mRNA, splice donor (193) and splice acceptor (5347) are indicated. PBS indicates primer 
binding site. B. Env-spliced transcript. C. full-length transcript prematurely polyadenylated. D. 
Env-spliced prematurely polyadenylated. E. Prematurely polyadenylated gag. F. Prematurely 
polyadenylated gag-spliced transcript. G. orf-x/env transcript, prematurely spliced, might be 
derived from internal promoter. H and I. double spliced mRNA species that might give origin 
to Rej protein from the signal peptide of env. Adapted from Palmarini & Fan (2003) and Hofacre 
et al (2009). Produced with Biorender.  
 
1.2.6 Retroviral transformation and oncogenesis 
Many retroviruses are known for their capacity to induce transformation and 
oncogenic events in their hosts. Oncogenic retroviruses have historically been 
categorised depending on how fast they induce transformation. One group is the 
acute transforming retroviruses, which induce neoplasms rapidly. Usually, these 
viruses can induce tumours within a few weeks of infection and tumours are 
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generally polyclonal. Acute transforming retroviruses can also transform cells in 
culture. These properties are associated with the presence of viral oncogenes. 
Most retroviral oncogenes are derived from cellular genes (proto-oncogenes). 
Viral oncogenes have mutations compared to cellular proto-oncogenes that result 
in uncontrolled stimulation of cell growth (Rosenberg & Jolicoeur, 1997). These 
oncogenes are not required for viral replication, most acute transforming retrovirus 
are replication deficient and require co-infection with a replication competent 
retrovirus (Helper) (Rosenberg & Jolicoeur, 1997). This is the case with Abelson 
murine leukemia virus (A-MuLV), which encodes a modified version of the proto-
oncogene c-abl (Gallo et al, 2012; Poirier et al, 1988). 
Non-acute retroviruses are the second group of oncogenic retroviruses. They are 
replication competent and do not have oncogenes. They induce tumours slowly, 
taking months to years, and are not able to transform cells in vitro. They usually 
cause oncogenesis by insertional activation of proto-oncogenes. Insertion sites 
are usually random but there have been found to be preferred sites (Rosenberg 
& Jolicoeur, 1997). For instance, avian leukosis virus (ALV) causes lymphomas 
by integrating close to c-myc (Hayward et al, 1981). Activation of proto-oncogenes 
can be mediated by insertion close to a cellular proto-oncogene, putting the proto-
oncogene under transcriptional control of the viral LTR (Hayward et al, 1981). 
Another activation mechanism is enhancer activation, in which the viral enhancer 
influences the cellular promoter of the proto-oncogene activating its expression, 
the insertion site can be distant from the gene (Payne et al, 1982). Non-acute 
retroviruses require longer time to cause tumourigenesis, because more rounds 
of infection and insertion are needed to end up activating a proto-oncogene. In 
addition, to successfully initiate tumourigenesis, activation of more than one proto-
oncogene or inactivation of more than one tumour suppressor might be needed 
(Bear et al, 1989). The prototypic betaretrovirus MMTV is a non-acute 
transforming retrovirus (Ross et al, 1997).  
Although JSRV requires a long incubation period to cause tumours in natural 
cases, it also has features that are more in line with those of acute transforming 
retrovirus. In experimental settings, JSRV is able to produce tumours in short 
periods of time, normally around 6 weeks but has been reported to produce 
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tumours in 10 days (Sharp et al, 1983; Verwoerd et al, 1983; Verwoerd et al, 
1980). These differences in incubation period are associated with the sheep’s age 
at infection and can be explained by the higher number of proliferating type II 
pneumocytes in young lambs (Martineau et al, 2011; Murgia et al, 2011; Salvatori 
et al, 2004). Moreover, OPA tumours are generally multifocal, a feature shared 
with acute transforming retroviruses.  
However, at first sight, there were no obvious oncogenes encoded by JSRV’s 
genome. Another important feature of acute transforming virus is their capacity to 
transform cells in vitro. The ability of JSRV to transform cells in culture was 
investigated by transfecting NIH 3T3 cells in culture with pJSRV21, which resulted 
in transformation (Maeda et al, 2001). JSRV DNA could be detected in all 
transformants and similar results were achieved when the 208F cell line was used 
(Rai et al, 2001). 
As orf-x had no known function, it was thought to be a good candidate as JSRV’s 
oncogene. Nevertheless, mutations in orf-x did not affect transforming capacity in 
vitro or, as later shown, in vivo (Caporale et al, 2006; Cousens et al, 2007; Maeda 
et al, 2001; Wootton et al, 2005).  
Identification of JSRV’s oncogene was made by deleting gag and pol and mutating 
orf-x, leaving env intact. Transfection with this mutated clone was still sufficient to 
induce transformation, proving that env was the oncogene. JSRV’s env 
transforming capacities were the first report of a functional retroviral env gene able 
to transform cells (Maeda et al, 2001). In subsequent experiments JSRV env was 
proven to form tumours when delivered by viral vectors into nude mice (Linnerth-
Petrik et al, 2012; Wootton et al, 2005) and into sheep (Caporale et al, 2006; 
Cousens et al, 2007), and Env protein alone was later on found to be sufficient to 
cause tumours in mice (Wootton et al, 2005). 
In summary, JSRV encodes an oncogene able to transform cells in vitro, a feature 
characteristic of acute transforming retrovirus. However, in animal disease, the 
course of the disease can be slow, more characteristic of non-acute transforming 
virus.  
  
Chapter 1: Literature review 22 
Since the demonstration that JSRV Env is oncogenic, several studies have 
investigated the domain involved in transformation, as well as the mechanism of 
transformation that JSRV uses. TM was found to be necessary for transformation, 
in particular the cytoplasmic tail of TM was found to be essential to drive cell 
transformation (Cousens et al, 2007; Liu & Miller, 2005; Palmarini et al, 2001). 
The cytoplasmic tail of TM possesses an YXXM domain, a putative binding site 
for phosphoinositide 3-kinase (PI3K/p85), activation of PI3K could lead to 
activation of transformation pathways in the cell. In this TM domain, mutation of 
Y590 to Y590F abolished transformation, but not infection, of sheep choroid 
plexus cells (Palmarini & Fan, 2003). Mutation of other tyrosine residues in TM did 
not affect transformation (Palmarini et al, 2001). However, in pull-down 
experiments the interaction between PI3K and Env TM has never been detected 
(Hsu et al, 2015; Liu et al, 2003; Liu & Miller, 2007). Y590 might be involved in 
trafficking Env to the cell surface and, thus, have an indirect role in transformation 
by ensuring its localisation at the appropriate site in the cell (Palmarini et al, 2001). 
Despite TM being essential for transformation other domains within the Env 
protein might also participate in transformation. For example, some experiments 
suggest that SU could participate in transformation independently of TM (Hofacre 
& Fan, 2004), and some authors have suggested that SU might interact with toll 
like receptor 4 (TLR4) (cited as unpublished data in Hofacre & Fan (2004)). In 
vivo, both TM and SU have been shown to be necessary to induce oncogenesis 
in sheep. A report also suggested involvement of the Rej protein in transformation, 
after discovering that deletions in the signal peptide, which should not have 
affected the SU sequence, abolished transformation (Hofacre et al, 2009). 
However, co-transfection of N-terminal env mutants with rej did not result in 
transformation (Hofacre et al, 2009). 
Env JSRV was found to be essential for viral replication, something not observed 
for other viral oncogenes. The infectious but transformation deficient Y590F 
mutant was not able to cause tumours in vivo, indicating both functions might be 
encoded by the same protein in JSRV (Cousens et al, 2007). It has been 
hypothesised that JSRV’s oncogenic capacity might have developed as a 
mechanism to replicate efficiently.  
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The mechanisms by which JSRV Env causes cell transformation appears to differ 
depending on cell line and culture conditions used (Hofacre & Fan, 2010; Liu & 
Miller, 2007). For instance, it is believed that the cytoplasmic tail of TM interacts 
with an unidentified molecule and leads to activation of PI3K/Akt and MAPK 
signalling pathways. In a more recent study, it was reported that activation of the 
Akt signalling pathway was a result of binding between Env and RALBP1, an 
interaction found using the yeast two-hybrid system. Nevertheless, several other 
proteins were identified in the same screen but have not been characterised 
further (Monot et al, 2015). Interaction of JSRV Env with a nuclear-localised zinc 
finger protein (zfp111) has also been described, and reported to play a role in 
transformation of rodent fibroblasts (Hsu et al, 2015)  
Activation of Akt and ERK has been shown in JSRV Env transformed cell lines as 
well as tissues obtained from natural cases of OPA and in OPA-derived cell lines 
(Cousens et al, 2015; De Las Heras et al, 2006; Maeda et al, 2005; Palmarini et 
al, 2001). However, relevance of each of these pathways appears to depend on 
the system used for study, reviewed in (Liu & Miller, 2007). Akt activation has been 
shown to be PI3K dependent in some cell lines, but was found to be independent 
of PI3K in NIH 3T3 cells (Maeda et al, 2003), suggesting that in those cells PI3K 
is not essential for transformation, and activation of Akt might be driven by another 
factor. In addition, in chicken fibroblasts (DF-1) mutation of Y590F in TM did not 
abolish transformation, suggesting again that other interactions might be 
responsible for initiation of the transformation process (Allen et al, 2002). 
Phosphorylation of ERK1/2 is detected in MDCK cells transformed by JSRV Env, 
but not when the 208F or NIH 3T3 cell lines are transformed by JSRV Env (Liu et 
al, 2003; Maeda et al, 2005). Nevertheless, in a study, use of inhibitors of the 
pathway abolished transformation of these cells, suggesting that the pathway is 
of importance for JSRV Env driven transformation in NIH 3T3 and 208F cells 
(Maeda et al, 2005) 
In human bronchial epithelium cells (BEAS-2B) another mechanism was found to 
explain JSRV Env induction of oncogenesis. Hyal2 binds RON growth factor 
receptor, but binding of Env to the receptor Hyal2 releases RON, increasing its 
kinase activity and allowing it to activate signalling pathways such as the Akt and 
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MAPK pathways (Danilkovitch-Miagkova et al, 2003). However, RON is not 
expressed in alveolar cells of the lung (Danilkovitch-Miagkova et al, 2003), so the 
relevance of this mechanism in the natural JSRV infection of sheep lung is 
unclear.  
Telomerase activation was reported in lung tissue of OPA affected sheep and 
epithelial cells isolated from OPA tumours (Suau et al, 2006). Telomerase might 
play a role in inhibiting cell senescence in JSRV Env transformed cells and, as 
Akt is an activator of telomerase, the authors suggested that Akt activation might 
drive telomerase activation in OPA tumours (Suau et al, 2006). After initial 
activation of signalling pathways by JSRV Env and induction of proliferation, more 
mutations or lesions might be required for OPA to develop, a scenario consistent 
with the long incubation period of OPA. Pathways such as the Wnt, EGFR and 
hippo pathways were reported to be upregulated in a sequencing study of 
experimental cases of OPA (Karagianni et al, 2019). Insertional mutagenesis 
might also potentiate the oncogenic effect of JSRV Env. 
In summary, the pathways that have been reported to be activated in the cell lines 
transformed in vitro with JSRV Env are PI3K-Akt, Raf-MEK-MAPK and RON-
Hyal2 (Hofacre & Fan, 2010; Liu & Miller, 2007). These pathways are summarised 
in Fig. 1.7. Development of an in vitro model that more closely resembles in vivo 
infection, for example using ovine type II pneumocytes, would provide valuable 
information on which of the signalling pathways and interactions are relevant for 
JSRV sheep infections and OPA.  
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Figure 1.7. Signalling pathways activated by JSRV Env in various cell lines. Reproduced 
from Hofacre & Fan (2010). 
 
1.2.7 Endogenous retrovirus in sheep 
Endogenous retroviruses are a common finding in animal genomes. For example, 
8 to 10 % of the mammalian genome derives from endogenous retroviruses 
(Mager & Stoye, 2015). Several families of endogenous retroviruses have been 
described in the sheep genome, including families related to exogenous 
gammaretroviruses and betaretroviruses. Some of these, are very closely related 
to JSRV, with over 90% nucleotide similarity with JSRV in most of their genome, 
these are called endogenous JSRV (enJSRV) (Palmarini et al, 2004). enJSRVs 
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are found in the genome of the Ovis and Capra genera. The sheep genome was 
initially thought to contain around 27 copies of enJSRV but, in a more recent 
analysis 462 enJSRV insertion sites were found in the genome of members of the 
Ovis genus (Arnaud et al, 2008); (Cumer et al, 2019).  
Of the initial 27 sheep enJSRV, most have at least one of the genes interrupted 
by stop codons, but at least five enJSRV have intact ORFs for all genes, and 
encode viral particles (Black et al, 2010). Although the genome sequences of 
JSRV and enJSRV are highly similar, there are short regions of variability (VR), 
known as VR 1, 2 and 3 within the gag and env genes (Palmarini et al, 2000b). In 
addition, the U3 region of the LTR also differs between all enJSRV and JSRV, 
likely reflecting different cell type transcriptional specificity (Palmarini et al, 2000b).  
enJSRVs are transcriptionally active, and their transcripts have been detected in 
sheep tissues. Expression of enJSRV is most abundantly detected in the female 
reproductive tract and fetal tissue, where the mRNA of env was found to be 
essential for trophectoderm elongation (Dunlap et al, 2006; Varela et al, 2009). 
enJSRV transcripts have also been detected in thymus, lungs, kidney, bone 
marrow, spleen and leukocytes (Palmarini et al, 1996b). Distinction between 
enJSRV and JSRV transcripts can be determined thanks to the presence of the 
SCaI restriction site in CA and the NdeI in SU present in JSRV but not in enJSRV, 
or by PCR of the U3 region (Bai et al, 1996; Palmarini et al, 1996a).  
In general, endogenous retroviruses are thought to have no negative effects for 
the host, but in some cases they may have a role in some pathologies and they 
may reactivate or recombine with exogenous retroviruses. In the case of enJSRV, 
no evidence has been found to suggest a direct contribution to the pathogenesis 
of OPA. Nevertheless, the possibility that there is gene complementation between 
enJSRV and JSRV cannot be excluded (DeMartini et al, 2003).  
In some species, endogenous retroviruses have been reported to have protective 
effects against some infections, for instance an ancient endogenous retrovirus 
found in the mouse genome interferes with MuLV infection (Yap et al, 2014). In 
enJSRV, alleles of enJSRV-20 and enJS56A1 have been found to interfere with 
Gag production and virus assembly (Arnaud et al, 2007; Mura et al, 2004; Murcia 
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et al, 2007). These two loci have alleles with a mutation in gag (arginine to 
tryptophan), which results in a Gag protein that interferes with the exogenous Gag 
protein during replication of JSRV (Arnaud et al, 2007; Murcia et al, 2007). 
Specifically, the enJS56A1 Gag protein is thought to be misfolded and form 
multimers with JSRV Gag (Arnaud et al, 2007). These multimers are 
proteosomally degraded, but their formation also prevented JSRV Gag from 
efficient trafficking to the cell surface and release of JSRV particles (Arnaud et al, 
2007). The protective allele of enJSRV-20, but not enJS56A1, is found in sheep 
populations. In addition, due to the correlation observed between the number of 
enJSRV duplications and number of protective alleles, both alleles are thought to 
have a dose dependent effect (Armezzani et al, 2011; Cumer et al, 2019).  
1.2.8 Immune response to JSRV  
OPA is characterised by the absence of a strong humoral response against JSRV. 
Low titres of neutralising antibodies against JSRV Env have been found in some 
experimentally infected lambs (Caporale et al, 2013; Hudachek et al, 2010), and 
in naturally infected sheep (Griffiths unpublished). In addition, one study 
suggested that neutralising antibodies against JSRV Env could be transferred 
through colostrum (Hudachek et al, 2010).  
Immunisation of sheep with JSRV CA or SU and an adjuvant led to production of 
antibodies, suggesting that sheep can mount an immune response to JSRV 
infection and are not intrinsically unresponsive (Sharp & DeMartini, 2003). The 
explanation for the general lack of antibodies against JSRV in infected sheep is 
suggested to be related to enJSRV encoded in the sheep genome. Expression of 
enJSRV early during development is believed to lead to elimination of JSRV 
specific T-cells during T-cell ontogeny. This hypothesis has not yet been 
experimentally validated, but enJSRV expression was detected in fetal thymus 
(Spencer et al, 2003).  
Moreover, JSRV might interfere with the host immune responses. JSRV infects a 
wide range of myeloid and lymphoid cells, with the greatest proviral burden in 
macrophages, B cells, CD4 T lymphocytes and CD8 T lymphocytes. In natural 
cases of OPA, a marked peripheral neutrophilia and lymphopaenia affecting CD4 
T lymphocytes can be observed, that may be attributed to coexisting bacterial 
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infections (Holland et al, 1999; Rosadio & Sharp, 1992; Summers et al, 2002). 
Alveolar macrophages in OPA affected sheep lungs have been found to produce 
interferon gamma, and tumour cells present downregulation of MHC-I factors. In 
addition, the overproduction of surfactant proteins by tumour cells might have 
immunomodulatory effects and contribute to the inefficient local immune response 
against JSRV (Summers et al, 2005).  
A recent transcriptome analysis of OPA provided evidence of transcriptional 
changes relating to macrophage function, but relatively little evidence for 
lymphocyte related gene expression or for activation of type I interferon response. 
These results suggested that local events in the lung may also play a role 
(Karagianni et al, 2019).  
1.3 Models of OPA 
A number of in vivo and in vitro models of OPA have been developed to facilitate 
the study of OPA and the oncogenic mechanisms used by JSRV. These models 
continue to provide valuable information on OPA and JSRV, and use of these 
models is especially important in the absence of a permissive cell line to grow 
JSRV in vitro. 
1.3.1 Experimental models of OPA 
An optimal procedure to induce OPA in experimental sheep was developed based 
on results of early studies. The procedure involves delivering JSRV particles to 
newborn lambs by intratracheal inoculation. Clinical signs of the disease are 
typically seen within several weeks to months. The incubation time until 
development of clinical signs is linked to both the lamb’s age at inoculation and 
the JSRV dose used at infection (Salvatori et al, 2004). 
The virus source used for infection are tumour extracts, virus isolated from lung 
fluid of OPA affected animals, or JSRV21 produced in vitro by transfection of 293T 
cells with pCMV2JSRV21 (Martin et al, 1976; Palmarini et al, 1999a; Tustin, 1969; 
Wandera, 1971). Pathological findings of experimentally infected animals closely 
resemble early cases of natural OPA cases and invariably have characteristics of 
the classical OPA form. In experimental OPA, multifocal discrete nodules, rather 
than large tumour masses commonly found in natural disease, are usually 
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observed. This is likely due to the fact that experimental cases are culled, for 
welfare reasons, before advanced lesions can develop, so they represent an 
earlier point in pathogenesis (Griffiths 2010). Pulmonary lesions consist of diffuse 
grey nodules with lung fluid being a histopathological finding rather than a clinical 
sign. The major difference between natural cases and experimental cases is the 
shortened incubation time. This is due to the increased number of proliferating 
type II pneumocytes present in newborn lambs compared to adults, meaning 
greater replication efficiency for JSRV (Caporale et al, 2005; Salvatori et al, 2004).  
OPA has also been induced experimentally in goats. However, no clinical signs 
where observed in the case of goats, despite some having pulmonary lesions 
when examined post-mortem. Nevertheless, pulmonary lesions in JSRV-infected 
goats presented a slightly different histological pattern compared to sheep, 
suggestive of restricted viral spread in the goat lung (Caporale et al, 2013). Other 
animal species have been resistant to experimental JSRV infection and OPA 
induction (Sharp & DeMartini, 2003). 
1.3.1.1 Small animal models of OPA 
In mice, production of tumours lined by epithelial cells that resemble OPA 
tumours, was successfully achieved when tumour cells were transplanted in 
athymic nude mice (Verwoerd et al. 1977; Zimber et al. 1984).  
Adeno-associated virus type 6 (AAV6) vectors encoding JSRV env were also used 
to infect immunodeficient mice and were found to drive long-term expression of 
Env, and lung tumour formation in 2-6 months. Lesions observed in mouse lung 
resembled those observed in OPA affected sheep and cells expressed SP-C, but 
the vectors used were also found to drive tumour formation in liver and endothelial 
cells (Wootton et al, 2005; Wootton et al, 2006). In subsequent studies, use of the 
AAV6 vector encoding JSRV env to infect immunocompetent mice also resulted 
in tumour formation (Linnerth-Petrik et al, 2012). The murine Hyal2 is not able to 
act as a receptor of JSRV, but the formation of lung tumours in mice infected with 
the vector encoding JSRV env suggested that interaction between JSRV Env and 
Hyal2 is not necessary to drive transformation, at least in mice (Wootton et al, 
2005).  
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In vivo studies in mice have provided insight into the pathogenesis and molecular 
transformation driven by JSRV. Moreover, the use of small animal models has 
advantages associated with cost and time, added to the greater number of 
molecular biology reagents available to perform assays in mice compared to 
sheep. Nevertheless, biochemical and anatomical differences between the lungs 
of these two organisms, and the fact that JSRV is not able to infect mouse cells, 
could mean that findings in a mouse system might not represent natural cases of 
JSRV Infection (Youssef et al, 2015).  
1.3.2 In vitro models of OPA 
As previously stated, there is currently no permissive cell line that supports JSRV 
replication in vitro. Difficulties in establishing a culture system to grow JSRV are 
due to the nature of its main target cells, type II pneumocytes, which are difficult 
to isolate and readily dedifferentiate in vitro, losing their phenotype and capability 
to allow efficient JSRV replication (Dobbs, 1990; Gruenert et al, 1995; Johnson et 
al, 2011; Mason & Shannon, 1997). Nevertheless, several in vitro systems have 
been used and have provided valuable information on JSRV.  
Initially, the possibility to establish an in vitro model was studied by infecting 
various sheep cell lines with JSRV21. OAT-T3 cells (testes), CP cells (ovine 
choroid plexus), turbinate cells (FLT) and intestinal carcinoma cells (ST6) were 
infected with JSRV21 (Palmarini et al, 1999a). Establishment of infection was 
observed: JSRV DNA was detected by PCR, levels of JSRV DNA increased with 
passages and infected cells released active RT (Palmarini et al, 1999a). 
Moreover, infection could be passed to other cells by co-cultivation. However, the 
amount of virus produced was very low and not a good source for new virus 
(Palmarini et al, 1999a).  
Infection of sheep cell lines with JSRV, evidenced that the receptor was present 
in many cell types, but suggested that other specificity determinants were in place. 
The other determinant of cell specificity was then investigated: JSRV LTR 
activation was compared in several cell types and found to be highest in lung 
epithelial cell lines. In particular high LTR activity was observed in MLE-15 and 
MtCC1-2 (mouse cell lines derived from type II pneumocytes and Club cells) 
(Palmarini et al, 2000a). LTR activation was reduced in H441, H358, A549 (cell 
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lines derived from human lung adenocarcinoma) and JS7 (Palmarini et al, 2000a). 
LTR expression was found to correlate with SP-B expression (Palmarini et al, 
2000a). However, lung epithelial cell lines readily dedifferentiate in vitro, losing 
surfactant production and their ability to trigger efficient LTR activation. On the 
other hand, the use of human lung cancer derived cell lines, might not be 
appropriate because they are already transformed:  their signalling pathways are 
deregulated and might not respond to JSRV infection the way in vivo sheep cells 
would.  
Because no permissive cell line for JSRV replication could be found, experiments 
focused on studying JSRV Env transformation. Various cell lines have been used 
as in vitro models of JSRV Env transformation: NIH 3T3 cells (mouse embryonic 
fibroblasts), 208F cells (rat embryonic fibroblasts), MDCK cells (dog epithelial 
kidney cells), DF-1 cells (chicken embryo fibroblasts) and BEAS-2B cells (human 
bronchial epithelium cells) (Allen et al, 2002; Danilkovitch-Miagkova et al, 2003; 
Liu et al, 2003; Liu & Miller, 2005; Palmarini et al, 2001). Use of these cell lines 
has provided information on activated pathways by JSRV Env transformation, as 
described in 1.2.6. Nevertheless, mechanisms of transformation vary between cell 
lines and might not reflect transformation events in vivo. In addition, use of the 
full-length virus would provide important information on the activation of the first 
signalling molecules after JSRV entry into the cell. For this reason, investigation 
on models that can better resemble JSRV infection and transformation in vivo is 
of serious importance.  
1.3.2.1 OPA-derived cell lines 
Primary cells derived from OPA tumours have been successfully cultured in vitro 
(Archer et al, 2007; DeMartini et al, 2001; Jassim et al, 1987; Suau et al, 2006). 
These cells expressed type II pneumocyte markers such as SP-C and alkaline 
phosphatase activity (Archer et al, 2007) and expressed JSRV. Nevertheless, 
maintenance of these cells in culture resulted in morphological changes, rapid loss 
of type II pneumocyte markers and inability to maintain JSRV expression (Archer 
et al, 2007; Johnson et al, 2011). 
Interestingly, the OPA cell line JS7, which has an integrated copy of JSRV in the 
genome, exhibits different properties when grown in monolayer or 3D culture. 
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When grown in a monolayer, JS7 is not able to support JSRV expression of 
proteins from the LTR, and does not express markers of type II pneumocytes. 
However, growth of JS7 in 3D culture resulted in detection of SP-A and SP-C 
expression as well as JSRV RNA detection (Johnson et al, 2011). In 3D culture, 
JS7 cells were able to form spheres and establish cell to cell interactions (Johnson 
& Fan, 2011). These interactions are particularly important for epithelial cells and 
help maintain polarisation. In contrast, in 2D culture, tight junctions and 
polarisation were lost (Archer et al, 2007; Johnson et al, 2011). These results 
indicated that 3D growth of JS7 cells replicates characteristics of type II 
pneumocytes, and might represent events in sheep lung with more accuracy. 
However, viability of the JS7 cells in 3D culture decreased significantly after 15 
days in culture, and SP-C expression was lower than in primary type II 
pneumocytes (Johnson & Fan, 2011). These findings indicate that optimisation of 
a method to culture lung epithelial cells is still needed.   
1.3.3 Ex vivo models of OPA 
An ex vivo system to model JSRV infection has been developed using precision 
cut lung slices from healthy sheep, which can be maintained in culture for at least 
three weeks (Cousens et al, 2015). JSRV has been shown to infect type II 
pneumocytes within the lung slices, successfully replicating to generate new viral 
particles and stimulate cell proliferation. Infected cells within the lung slices 
express activated ERK1/2 and Akt, similarly to infected cells in vivo (Cousens et 
al, 2015).  
This model allows working with the natural host of JSRV and its main target cells, 
replicating many features observed in vivo and providing results that are more 
likely to reflect events of the in vivo infection. In addition, lung slices maintain 
tissue architecture and the diversity of cells seen in sheep lung, which might also 
play a role in disease development (Cousens et al, 2015). These features, as well 
as being able to study transformation caused by JSRV rather than just JSRV Env, 
might provide valuable information on early events that drive transformation. 
1.4 Disease Control  
To date, there are no treatment or effective methods for controlling the spread of 
OPA (Gray et al, 2019; Griffiths et al, 2010). During the incubation period of the 
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disease, varying from months to years, affected sheep appear normal but can 
transmit the disease.  
Screening and culling strategies have been effective in controlling the spread of 
other diseases, but require a sensitive and specific diagnostic test that allows 
identification of infected animals (Synge & Ritchie, 2010). In OPA, such a test 
remains elusive. Due to lack of JSRV-specific antibodies no serological tests are 
available, and PCR tests are not reliable in early stages of the disease (De Las 
Heras et al, 2005; Ortin et al, 1998). Currently, the best strategy to avoid 
introducing OPA in an OPA-free flock is to quarantine new animals for several 
months (Griffiths et al, 2010). OPA affected animals can also be isolated, and 
contaminated areas disinfected to prevent the spread of OPA (Cousens et al, 
2009). In high-value flocks, embryo transfer can be used to prevent transmission 
from infected ewes to lambs (Parker et al, 1998). However, these strategies are 
expensive and might not be practical for all farms (Griffiths et al, 2010).  
1.4.1 Diagnosis of OPA 
Even though there are no serological tests available to detect OPA, several 
diagnostic tests have been developed to diagnose OPA based on molecular or 
pathology techniques.  
PCR tests to detect JSRV DNA in blood have proved to be highly specific and 
able to distinguish between enJSRV and exJSRV but have shown low sensitivity 
in the field setting, particularly in early stages of the disease when the virus load 
is low (Lewis et al, 2011). This high false-negative rate makes the test unreliable 
for use in individual animals, but it continues to be successfully used to gather 
epidemiological information and to identify infected flocks (Griffiths et al, 2010). 
Use of this PCR test in peripheral blood from sheep of OPA affected flocks 
revealed that 80% of sheep that were not affected by OPA, but in contact with 
affected sheep, were infected by JSRV (Garcia-Goti et al, 2000). 
The PCR test to detect JSRV presence has improved performance when applied 
to bronchoalveolar lavage (BAL) samples instead of blood samples, due to the 
higher viral concentration in this sample type. However, obtaining BAL samples is 
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more laborious, is more invasive, and early cases can still be missed (Voigt et al, 
2007a).  
In the absence of laboratory tests, scanning methods are currently being 
investigated as a potential early screening test for OPA. Transthoracic ultrasound 
is a non-invasive test that allows the visualization of tumours in the lungs of sheep. 
Although it is specific, it has limitations on the tumour size it can accurately detect 
(1-2 cm), so its performance as a tool for early stage diagnosis is under 
investigation (Cousens & Scott, 2015; Scott et al, 2018).  
Despite recent advances in OPA diagnosis, confirmation of the diagnosis still has 
to be done using pathological findings and histopathology post-mortem (Gray et 
al, 2019; Griffiths et al, 2010). 
1.4.2 Vaccine efforts 
An alternative to the screening and culling strategy would be the use of vaccination 
as means of disease control. However, due to the lack of JSRV-specific antibodies 
this is problematic. Although there have been several efforts to develop a vaccine 
for OPA, so far none has been successful. Immunisation with recombinant Gag 
protein and an adjuvant stimulated antibody responses, but challenge studies 
have not been performed (Summers et al, 2006). In addition, two important factors 
need to be considered: high similarity between JSRV and enJSRV could result in 
autoimmunity, and the existence of immune response could select for new strains 
of JSRV evolved by mutation (Overbaugh & Bangham, 2001).  
1.5 microRNAs  
microRNAs (miRNAs) are a class of short regulatory RNAs (~22 nt). In humans, 
they are estimated to represent around 2-3% of the coding genome (Landgraf et 
al, 2007). miRNAs and their associated proteins are one of the most abundant 
ribonucleoprotein complexes in the cell (Bartel, 2004). 
The founding member of the miRNA class, lin-4, was first discovered in 1993 in 
the nematode Caenorhabditis elegans (C. elegans) (Lee et al, 1993). Although 
miRNAs were initially thought to be limited to nematodes, the later discovery of 
let-7 in C. elegans, and its homologues in the genomes of human, mouse and fly, 
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revealed that miRNAs were found in several, and distantly related species 
(Pasquinelli et al, 2000; Reinhart et al, 2000). Since then, miRNAs have been 
identified across the plant and animal kingdoms, and in some virus and protist 
species (Lagos-Quintana et al, 2001; Llave et al, 2002; Molnár et al, 2007; Pfeffer 
et al, 2004). miRNAs are notably well-conserved across species; over one third of 
C.elegans miRNAs have close homologs in humans (Lim et al, 2003). 
Nevertheless, miRNAs differ in their biogenesis, evolution and function depending 
on the kingdom to which the organism belongs (Bartel, 2018). 
1.5.1 Biological relevance of miRNAs  
miRNAs act post-transcriptionally, affecting the expression levels of their target 
mRNAs and their translation into proteins, and represent another layer of gene 
expression regulation (Bartel, 2004; Bushati & Cohen, 2007). miRNAs have a 
regulatory function in several processes such as cell proliferation and death, 
tissue differentiation, developmental timing in worms, haematopoiesis and many 
others (Brennecke et al, 2003; Chen et al, 2004; Kuhn et al, 2011; Xu et al, 2003). 
In an attempt to evaluate the extent of miRNA regulation, studies were performed 
in which independent knock-outs of diverse miRNA families were carried out in 
mouse embryos. These studies revealed that independent knock-out of 52 
mammalian conserved miRNA families resulted in phenotypic alterations in mice. 
Of those, knock-out of 15 families had severe effects such as reduced viability, 
cancer, immune and neurological disorders, and infertility (reviewed in Bartel 
(2018)). These studies highlighted the biological relevance and the diversity of the 
processes regulated by miRNAs. 
1.5.2 Biology and synthesis of metazoan miRNAs 
Although there are other small RNA species involved in RNA silencing, such as 
siRNAs and piwiRNAs, miRNAs differ from other small RNAs in their biogenesis 
and precursor structure (Ambros et al, 2003). 
miRNAs are primarily found in noncoding regions of the genome, processed from 
long-noncoding RNAs. However, some miRNAs have also been found in the 
introns of coding genes. Intron-residing miRNAs constitute up to 25% of miRNAs 
in humans, and are usually found in the same orientation as the pre-mRNA, 
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suggesting they are not transcribed independently from the mRNA (Chiang et al, 
2010; Morlando et al, 2008).  
In animals, biogenesis of a typical miRNA (Fig. 1.8) starts in the cell nucleus, 
where RNA polymerase II transcribes the miRNA gene to form the pri-miRNA 
(Bartel, 2018; Gebert & MacRae, 2019). This pri-miRNA contains a hairpin 
structure and UGU motif which are recognised by the microprocessor complex, 
formed by the RNase III enzyme Drosha and the Digeorge syndrome critical 
region 8 (DGCR8) protein (Bartel, 2018; Treiber et al, 2019). Drosha is 
responsible for pri-miRNA recognition and with DGCR8 cleaves the pri-miRNA 
giving origin to the pre-miRNA. Pre-miRNAs are usually hairpins of around 70 
nucleotides with a 2-nucleotide overhang at the 3′ end, this overhang is 
recognised by Exportin 5 and actively exported to the cell cytoplasm (Gebert 
2019). Once in the cytoplasm, the 5′ phosphate, loop structure and 3′ overhang of 
the pre-miRNA are recognised by another RNAse III enzyme (Dicer) (Gebert & 
MacRae, 2019). Dicer cleaves the pre-miRNA loop structure resulting in a 20 nt 
miRNA duplex with a 5′ phosphate and the 3′ overhang (Bartel, 2018). In 
vertebrates, Dicer action is modulated by an RNA binding protein called TAR 
(TARBP) and protein activator of the interferon- induced protein kinase (PACT) 
(Gebert & MacRae, 2019). One of the strands of the miRNA duplex is then loaded 
into the guide-strand channel of an Argonaute (AGO) protein, forming the 
Silencing complex also known as miRISC, the other strand is cleaved. The 
silencing complex can then target mRNAs for degradation or translational 
repression (Bartel, 2018; Gebert & MacRae, 2019; Treiber et al, 2019). 
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Figure 1.8. Metazoan canonical miRNA biogenesis. miRNA genes are transcribed by pol 
II, generating a pri-miRNA hairpin, the pri-miRNA is then cleaved by the microprocessor 
generating a pre-miRNA. The pre-miRNA is exported to the cytoplasm by the action of 
exportin-5. In the cytoplasm the pre-miRNA is recognised by Dicer that cleaves the loop 
structure, generating a miRNA duplex. One of the duplex strands is then selected and loaded 
into AGO to form the silencing complex. The silencing complex targets mRNAs and depending 
on complementarity causes degradation or translational repression. Reproduced from Bartel 
(2018). 
Binding of the miRISC complex to the 3′UTR of an mRNA leads to silencing via 
translational inhibition or mRNA decay. Translation is inhibited at the initiation 
step: interaction of the miRISC with the eukaryotic initiation factor 4 A- I (eIF4A- I) 
and eIF4A-II promotes dissociation of the factors from mRNAs. Dissociation of 
eIF4A-I and eIF4A-II from mRNAs inhibits assembly of the eIF4 translation 
  
Chapter 1: Literature review 38 
initiation complex, thereby blocking mRNA translation (Fukao et al, 2014; Meijer 
et al, 2013). Nevertheless, the specific mechanism of miRISC translation inhibition 
is still not completely known. The better understood mechanism of mRNA decay 
involves the recruitment of GW182 (TNRC6 in humans) by AGO, which in turn 
interacts with PABPC, recruiting PAN2-PAN3 and CCR4-NOT, and promoting 
mRNA deadenylation. Deadenylation of mRNA triggers mRNA decapping by 
DCP1-DCP2, which renders the mRNA susceptible to degradation by XRN1 
(reviewed in Gebert & MacRae (2019)). These two silencing mechanisms are 
thought to be linked, and mRNA decay has been found responsible for 66-90% of 
miRNA-mediated gene silencing (Eichhorn et al, 2014; Guo et al, 2010). Binding 
of the miRISC complex occasionally leads to mRNA cleavage when base 
complementarity between miRNA and target is extensive (Song et al, 2004; Yekta 
et al, 2004) 
Pri-miRNAs can consist of a single miRNA or a cluster of related miRNAs. miRNAs 
that originate from the same pri-miRNA form a miRNA cluster and are transcribed 
as a multi-cistronic unit (Gebert & MacRae, 2019). In mammals there are four 
different AGO proteins. AGO2 is the one most commonly found forming the 
miRISC complex in humans, and the only one capable of directing mRNA 
cleavage (Diederichs & Haber, 2007; Liu et al, 2004).   
1.5.2.1 Biogenesis of non-canonical miRNAs 
Non-canonical miRNAs might enter the previously described biogenesis pathway 
at several stages. For instance, some intron contained miRNAs, called mirtrons, 
enter the pathway as pre-miRNAs after being processed by the spliceosome 
(Okamura et al, 2007; Ruby et al, 2007). Other mirtrons have a tail of RNA at 3′ 
or 5′ that is cleaved by nucleases before the pre-miRNA enters the miRNA 
biogenesis pathway (Babiarz et al, 2008; Ruby et al, 2007). Non-canonical 
miRNAs can also derive from endogenous short-hairpin RNAs (shRNAs), which 
are Dicer substrates that have a 5′ end determined by transcription and the 3′ end 
cleaved in a drosha-independent manner (Babiarz et al, 2008). Another class of 
non-canonical miRNAs are transcribed in tandem or are part of another small 
RNA, forming a chimeric hairpin that is processed by Dicer (Babiarz et al, 2008; 
Ender et al, 2008).  
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A special case of non-canonical miRNA is miR-451. This miRNA appears to be 
unique in that it requires Drosha but not Dicer during its biogenesis (Cheloufi et 
al, 2010; Yang et al, 2010a). Pre-miR-451 is too short for Dicer and instead is 
directly loaded into AGO2, the exonuclease PARN then performs further 
processing and generates a mature miR-451 (Cifuentes et al, 2010; Yoda et al, 
2013). In general, non-canonical miRNAs of animals are not well conserved and 
are expressed at low levels (Bartel, 2018).  
1.5.3 miRNA targets 
Binding of miRNAs to mRNAs is generally determined by base complementarity 
of nucleotides 2-8 of the miRNA to the 3′UTR of mRNAs. Canonical target sites 
can vary in strength: the strongest ones have absolute complementarity in 
nucleotides 2-8 and also have an A at position 1 of the miRNA. Complementarity 
in positions 2-8 without an A at nucleotide 1 results in weaker targets. Following 
in strength are sites with complementarity in positions 2-7 and an A at nucleotide 
1. The weakest of canonical sites constitute targets with complementarity to 2-7 
or 3-8 and no A at position 1 (Agarwal et al, 2015). The increased affinity for a 
target conferred by the presence of an A at nucleotide 1 of the miRNA, is not 
directly linked to miRNA sequence, instead it is provided by a pocket in AGO that 
recognises and strongly binds A (Schirle et al, 2015; Schirle et al, 2014). 
Non-canonical targets are target sites to which the miRNA seed does not show 
complementarity. These sites have been identified using crosslinking approaches 
and their biological function has been questioned (Agarwal et al, 2015; Helwak et 
al, 2013). A second miRNA region called supplemental (nucleotides 13-16) can 
affect target recognition and might be of particular importance in non-canonical 
sites (Agarwal et al, 2015; Grimson et al, 2007). In addition, the supplemental 
region is thought to enable miRNAs of the same family (with the same seed 
sequence) to target different mRNAs based on this second region of 
complementarity (Broughton et al, 2016). A single mRNA can also be targeted by 
many different miRNAs, and can have several binding sites, whereby occupancy 
of these binding sites by miRNAs can cause cooperative repression (Grimson et 
al, 2007; Saetrom et al, 2007; Selbach et al, 2008). Binding to non-canonical sites 
might be dependent on occupancy of canonical sites (Flamand et al, 2017). 
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Even though one miRNA has the potential to repress numerous target mRNAs, 
the level of repression they exercise in a particular target mRNA is generally 
modest (Selbach et al, 2008). Detectable repression requires high expression 
levels of miRNA. miRNAs enact effective regulation precisely by targeting several 
mRNAs in a network so that the effect of several modest interactions is additive. 
In addition, repression levels can be enhanced if miRNAs bind to several sites in 
a 3′ UTR (Grimson et al, 2007; Saetrom et al, 2007). Indirect effects of miRNA 
expression can also be detected, miRNAs can target transcription factors that will 
affect their downstream genes. The miR-200 family is an example of this in its role 
coordinating epithelial to mesenchymal transition (EMT), this miRNA family has 
multiple bindings sites in the 3′UTR zinc finger E-box binding homeobox 1 (ZEB1) 
exerting a strong repression (Bracken et al, 2016). 
miRNA usually act as negative regulators of their targets, but some have reported 
that miRNAs could increase gene expression by binding complementary promoter 
sequences (Place et al, 2008). miRNA target sites have been reported in 
promoters; for example, miR-373 has a target site in the promoter of E-cadherin 
(Place et al, 2008).  
Although several authors have highlighted the vast number of mRNAs regulated 
by miRNAs, thought to be up to 60% of mRNAs, a report stated that the 
biologically relevant targets of miRNAs have been overestimated (Pinzón et al, 
2016). In this study, the authors analysed the effects of miR-223 in a pool of 
predicted targets and found that, for most targets inter-individual variability was 
higher than the effect of miR-223 repression. In addition, the authors reported that 
miRNA binding site conservation was higher in haplo-insufficient genes, which 
might suggest that the biological relevant targets are dose-dependent, and that 
some targets might not be functionally repressed (Pinzón et al, 2016). It was 
proposed that targets that are evolutionarily conserved but not dose-dependent, 
might act as titrators of miRNAs, and that in many cases phenotype effects might 
be driven by a few responsive targets (Pinzón et al, 2016). Although the study 
presented limitations, it highlighted the effect of inter-individual variation as well 
as the importance of confirming predicted targets and the effect of their repression 
experimentally.  
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1.5.3.1 Competitive endogenous RNA theory 
The competitive endogenous RNA theory (ceRNA theory) proposes that 
repression of a certain target mRNA by a miRNA can be affected by the number 
of different miRNA targets, and the presence of miRNA sponges such as 
pseudogenes and long non coding RNAs, referred to as competitive endogenous 
RNAs (Poliseno et al, 2010; Salmena et al, 2011). According to the ceRNA theory 
the extent to which a miRNA efficiently represses a certain target depends on 
there being enough copies of the miRNA to bind all target mRNA copies (Salmena 
et al, 2011). The influence of ceRNA on miRNA function remains controversial 
and difficult to predict. However, in some cases, this theory might explain changes 
in miRNA function; for example, duplication of the MYCN gene, target of the 
miRNA let-7, results in more copies of MYCN mRNA and hampered let-7 function 
(Powers et al, 2016).  
1.5.3.2 Target prediction 
Several algorithms that aim to identify miRNA targets have been developed. 
These algorithms search for sequences complementary to the miRNA seed in the 
3′UTR of mRNAs (Agarwal et al, 2015; Bartel, 2009). In order to refine the results 
some approaches include assessment of evolutionary conservation, evaluating 
the site position and additional sites within the 3′UTR, the potential for 
supplementary pairing and study of pairing stability (Baek et al, 2008; Bartel, 
2009). Some of the best-performing predictive computer methods include 
TargetScan (Friedman et al, 2009), DIANA-microT (Maragkakis et al, 2009) and 
miRDB (Wong & Wang, 2015). DIANA-TarBase and miRTarBase (Chou et al, 
2018; Karagkouni et al, 2018) are resources which include targets with some level 
of experimental validation. 
In addition to predictive computational methods, experimental methods have also 
been developed to study targets of miRNAs. One of the approaches to investigate 
miRNA targets consists of altering a miRNA and measuring changes in the 
transcriptome using microarrays, miR-sequencing, and ribosome-profiling or 
luciferase assays (Boutz et al, 2011; Leivonen et al, 2009; Lim et al, 2005; 
Uhlmann et al, 2012). These high-throughput methods, with the exception of 
luciferase assays, which detects direct interaction between miRNA and target, 
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identify both direct and indirect targets of the miRNA (bracken 2016). Another 
experimental approach used to discover both canonical and non-canonical targets 
are immunoprecipitation or pull-down methods such as cross-linking, ligation and 
sequencing of hybrids (CLASH) (Helwak et al, 2013; Hendrickson et al, 2009; 
Karginov et al, 2007). During CLASH cross-linking of the miRISC complex is 
performed, followed by ligation of targets interacting with the miRNA of the miRISC 
complex, immunoprecipitation of AGO is then performed and RNA hybrids are 
sequenced (Helwak et al, 2013). Nonetheless, some of the observed interactions 
with these methods are not real and functional significance is not considered, so 
further validation is necessary (Bracken et al, 2016).  
Genetic screening has been used to identify the biological relevance of miRNA-
mRNA interactions (Ding & Grosshans, 2009; Hunter et al, 2013). These methods 
combine some of the previously discussed strategies, such as in mass methods, 
and performing mutations in miRNA genes in vivo. The disadvantages of these 
approaches are its difficulty to be applied in mammals and that it does not consider 
coordinated functions of genes (Bracken et al, 2016).  
Although computer and lab-based methods for target prediction have improved 
their accuracy, false-positive and false-negative results are still observed with both 
approaches. Thus, caution needs to be exercised when interpreting results 
obtained from these methods.  
1.5.4 miRNA nomenclature and classification 
miRBase is the resource responsible for miRNA gene nomenclature. miRBase 
was first established in 2002 as a public repository for miRNA sequences and 
annotation; its current version (22.1) contains miRNA entries from 271 organisms 
and over 48000 mature miRNA sequences (Kozomara et al, 2019).  
miRNA nomenclature was designed to convey information about the particular 
miRNA and in animals obeys the following set of rules: the three first letters of a 
miRNA are an abbreviation of the species name in which that particular miRNA is 
found (Ambros et al, 2003). Hsa- corresponds to Homo sapiens and oar- to Ovis 
aries. The species prefix is followed by either mir- or miR- denoting the pre-miRNA 
or mature miRNA form respectively. Numbers are given to miRNAs in sequential 
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order of discovery and miRNAs conserved through species (orthologues) usually 
have the same number. For example, hsa-miR-10 is a human mature miRNA. 
Paralog miRNAs within a species are denoted by a letter suffix such as hsa-miR-
10a and hsa-miR-10b. Different hairpins which are processed into identical mature 
miRNAs are distinguished by a numerical suffix like the case of: hsa-mir-24-1 and 
hsa-mir-24-2 (Ambros et al, 2003).  
In cases where mature miRNAs have been identified from both arms of the 
precursor hairpin the two sequences are differentiated using the -5p or -3p suffix: 
hsa-miR-10b-5p (Griffiths-Jones et al, 2006; Griffiths-Jones et al, 2008). 
There are some exceptions to this nomenclature including lin-4 and the let-7 family 
of miRNAs, which were given names before the systematic nomenclature rules 
had been established (Griffiths-Jones et al, 2006).  
miRNAs are also found grouped in families based on the similarity of their seed 
sequence (Griffiths-Jones et al, 2008; Kozomara et al, 2019). Members of the 
same seed family are usually, but not in all cases, evolutionary related, and their 
targets overlap (Bartel, 2009; 2018).  
1.5.4.1 miRNA discovery  
An increasing number of miRNAs are being discovered and described with the 
use of deep-sequencing approaches. Although these approaches give the 
opportunity to detect miRNAs expressed at low levels or expressed only in certain 
conditions, they have the potential to misidentify short RNA sequences of other 
origins as miRNAs (Bartel, 2018; Kozomara et al, 2019). Confidence in the 
existence of a new described miRNA is increased if there are reads mapping to 
both the 3′ and 5′ arms of the pre-miRNA, 3′ and 5′ mature miRNAs are expected 
to form a duplex with the characteristic 2 nt 3′ overhangs, and the 5′ terminus of 
the miRNAs is expected to be processed consistently (Kozomara et al, 2019).  
1.5.4.2 miRNA isomers: Isomirs 
Mature miRNAs, processed from the same hairpin, which differ in length or 
sequence are called isomirs (Neilsen et al, 2012). Isomirs can differ in their 
targets, stability and maturation steps. Isomir classification and formation are 
reviewed in Fig.1.9. Some miRNAs have no isomirs, whereas others have many, 
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for instance, miR-21-5p has several isomirs in humans (Telonis et al, 2015). 
Nevertheless, in cases in which a miRNA has several isomirs, it has been shown 
that only a few are expressed at high levels (Guo et al, 2015a). Predominant 
isomirs vary between tissues and are altered in cancer, which has attracted 
interest in their use as biomarkers (Guo et al, 2015a).  
The presence of sequence variants, especially those at the 5′ terminus, may alter 
targets of the miRNAs due to the seed sequence being displaced (Bartel, 2018; 
Bracken et al, 2016). 
 
Figure 1.9. Isomir types and formation mechanisms. Reproduced from Gebert & MacRae 
(2019). 
1.5.5 Regulation of miRNA expression 
Most miRNAs are under RNA polymerase II transcriptional control and can be 
regulated at several steps of their biogenesis. After transcription, other 
mechanisms can regulate miRNA stability and processing, some examples are: 
positive-feedback loops, increase in Dicer or microprocessor availability, to which 
some miRNAs are more sensitive, and A to I editing of pri-miRNAs. RBPs can 
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also impact miRNA expression at all steps of miRNA biogenesis and can have 
positive or negative effects on expression (reviewed in Treiber et al (2019)).  
miRNA turnover is regulated by several factors, and appears to be linked to 
sequence, for example: a 5′ G or C leads to faster turnover rates than a U in this 
position (Guo et al, 2015b). Turnover rates range from minutes to days and differ 
between miRNAs (Gebert & MacRae, 2019).  
1.5.6 miRNA expression in tissue 
miRNA expression has been found to vary depending on tissue type as well as 
developmental stage and disease state of the particular tissue of concern (Lagos-
Quintana et al, 2002; Landgraf et al, 2007). Special interest has been placed in 
identifying miRNAs that are tissue specific due to their potential roles in tissue 
differentiation and disease, along with their appeal as markers. Housekeeping 
miRNAs, those expressed stably in all tissues, have also attracted attention as 
promising controls for miRNA transcriptomics studies and due to their potential 
association with housekeeping processes in cells. Nevertheless, tissue specific 
miRNAs have only been identified in a handful of tissue types: miR-1 and miR-
133 are specifically expressed in heart and muscle (Kloosterman & Plasterk, 
2006; Thum et al, 2008), miR-122 is only expressed at significant levels in liver 
(Chang et al, 2004; Lagos-Quintana et al, 2002), miR-9 and miR-124 are found in 
brain tissue (Landgraf et al, 2007; Ludwig et al, 2016), and miR-142-3p is specific 
of haematopoietic cells (Landgraf et al, 2007; Ludwig et al, 2016). Interestingly, it 
was found that the precursors of those miRNAs could be detected in several tissue 
types whereas the mature forms were only present at very low levels, an 
observation that could suggest that the processing to mature miRNA might be the 
determinant of tissue specificity (Li et al, 2013b; Ludwig et al, 2016).  
Research on miRNA expression across 61 different human tissues found that over 
80% of miRNAs detected did not fall into the definition of tissue-specific or 
housekeeping miRNAs. In addition, 143 miRNAs were found to be expressed in 
all tissue types assessed (Ludwig et al, 2016). Expression abundance of most 
miRNA pair members (-3p/-5p) was positively correlated in each specific tissue, 
as was abundance of cluster members, with the exception of miR-449. The study 
also compared miRNA expression between specific rat and human tissue types, 
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reporting that miRNAs highly abundant in specific human tissue types were 
similarly abundant in the same tissue type for rats (Ludwig et al, 2016). Notably, 
to date, no studies have found lung-specific miRNAs or miRNA families. 
1.5.6.1 miRNA expression in lung tissue 
Several studies have investigated lung miRNA expression in humans and rodents. 
This information can complement the limited information directly obtained from 
research in sheep lung, helping create a picture of miRNA expression in health 
and in association with lung disease.  
In a mouse model of allergic asthma, miR-16, miR-21 and miR-126 were 
significantly upregulated in comparison to controls. Observation of this model 
system helped elucidate the function of miR-126 as a suppressor of the effector 
function of lung Th2 cells and regulator of antibody production- by targeting OBF1 
(Mattes et al, 2009).  
Another study in a murine model of pulmonary fibrosis found a relationship 
between the expression level of miR-155 and the degree of pulmonary fibrosis 
observed. In addition, the authors observed that when bleomycin was delivered to 
induce fibrosis, miR-155 levels increased and subsequently keratinocyte growth 
factor (KGF) decreased, no longer exerting its effect protecting from pulmonary 
fibrosis (Jiang et al, 2010).  
Small RNAs are known to play an essential role in the prenatal development of 
various organs. To study the small RNA effects in lung development, the effects 
of DICER mutations have been researched. Knock out of DICER in the lung 
resulted in  death before gastrulation due to its involvement in cell survival, but 
when DICER was inactivated by conditional mutation in later stages of lung 
formation this resulted in smaller patterns of lung lobation and the formation of 
large epithelial pouches instead of the fine branching observed in normal lung. 
These findings suggest that DICER, and presumably miRNAs, are directly 
involved in lung epithelial morphogenesis (Harris et al, 2006).  
1.5.7 Cell-free miRNAs 
Stable levels of cell-free miRNAs in serum and plasma were first reported in 2008 
(Mitchell et al, 2008). Since then, cell-free miRNAs have been identified in several 
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biological fluids including saliva, urine and milk (Schwarzenbach et al, 2014). 
Initial reports showed that miRNAs could be detected in blood fractions in an 
exceptionally stable form, despite high endogenous RNase concentration in blood 
expected to cause miRNA degradation (Mitchell et al, 2008). Mitchell et al. also 
showed that miRNA levels in plasma remained unaffected after being left at room 
temperature for 24h, and after eight cycles of freeze-thawing. On the other hand, 
addition of synthetic naked miRNAs to plasma resulted in degradation, suggesting 
that resistance to RNases was not an intrinsic property of miRNAs (Mitchell et al, 
2008).  
Subsequent experiments (Arroyo et al, 2011; Wang et al, 2010) identified two 
populations of cell-free miRNAs: vesicle enclosed miRNAs and protein-bound 
miRNAs. Association of miRNA species with either vesicles or proteins was found 
to be protective against RNAse degradation (Arroyo et al, 2011).  
1.5.7.1 Vesicle miRNAs 
Vesicles are cell-derived structures that enclose cargo in lipid bilayers. Vesicles 
are involved in physiological and pathological processes and are an important 
means of cell-to-cell communication. Their cargo includes proteins, lipids and 
nucleic acids (van Niel et al, 2018). Size fractionation of plasma showed that 
miRNAs could be found inside vesicles, specifically in microvesicles and 
exosomes (Arroyo et al, 2011). Microvesicles range from 50-1000 nm in diameter 
and derive from the plasma membrane. Exosomes, on the other hand, are 
generally smaller in size (50-150 nm) and derive from the endosome (van Niel et 
al, 2018) (Fig. 1.10). Although there is some variation in the size range of 
microvesicles and exosomes reported by some authors (van Niel et al, 2018; 
Wang et al, 2010); (Huang-Doran et al, 2017), studies agree that microvesicles 
are generally larger than exosomes.  
Vesicles have attracted great interest in the cancer research field due to their 
involvement in intercellular communication, their role in establishing the tumour 
microenvironment, and their increased abundance in cancer patients (Cortez et 
al, 2011; Schwarzenbach et al, 2014). Thus, several reports have endeavoured to 
study components of cancer cell secreted vesicles. Importantly, the cargo of 
cancer cell derived vesicles was found to be enriched in miRNAs compared to 
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normal exosomes, and miRNAs were more abundant in metastatic cells compared 
to cancer cells (Melo et al, 2014). 
 
Figure 1.10. Formation and release of microvesicles, exosomes and apoptotic bodies. 
EV; extracellular vesicles, MVB: multivesicular bodies. Reproduced from Huang-Doran et al 
(2017). 
Exosomes are secreted by stem cells, immune cells, epithelial cells, neurons and 
cancer cells (Théry, 2011). Cancer cell derived exosomes have also been found 
in the circulation. Exosome levels in serum from breast cancer patients was found 
to be greater than in controls (O'Brien et al, 2013). These exosomes were found 
to be derived from cancer cells and besides containing miRNAs they also contain 
Dicer, TRBP and AGO2, proteins involved in biogenesis of pre-miRNAs to mature 
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miRNAs and miRNA targeting (Melo et al, 2014). Maturation of exosomal miRNAs 
was reported to occur in exosomes. These cancer exosomes were able to alter 
the transcriptome of cancer cells in a Dicer-dependent manner. Impairing Dicer 
function in the exosome hindered tumour growth (Melo et al, 2014). The presence 
of Dicer in exosomes has been suggested as a marker of cancer (Melo et al, 
2014).  
Exosomes were also found to package mature miRNAs without the need for 
processing, for example mir-182-5p. However, for exosomal miRNAs to be able 
to alter the recipient cell’s transcriptome, miRNAs have to be present in the 
exosome at an appropriately high abundance (Melo et al, 2014). Interestingly, 
some studies found that some secreted miRNAs were not represented inside the 
cell of origin, suggesting that they might be specifically expressed and secreted 
for cell-to-cell communication (Valadi et al, 2007). 
Apoptotic bodies were also found to be able to transport miRNAs. Both exosomes 
and apoptotic bodies express phosphatidylserine on their surface which acts as a 
phagocytic signal. Interestingly, the receptor of phosphatidylserine, Tim4 (T-cell 
immunoglobulin- and mucin-domain-containing molecule) was found expressed 
in fibroblasts and was able to promote engulfment of both apoptotic bodies, and 
could also be involved in intercellular signalling mediated by exosomes (Kosaka 
et al, 2010).  
1.5.7.2 Protein-bound miRNAs 
Initially, the resistance of miRNAs to degradation in biological fluids was 
exclusively attributed to their presence inside vesicles. However, fractionation of 
plasma miRNAs identified a second population of miRNAs not associated with 
vesicles, and consistent with a miRNA-protein complex (Arroyo et al, 2011; Wang 
et al, 2010).  
Treatment of those miRNA-protein complexes with protease K rendered miRNAs 
susceptible to the action of RNases, suggesting a protective effect when miRNAs 
are associated with certain proteins. Some of the proteins shown to associate with 
miRNAs in circulation, and protect them from degradation, are AGO2, one of the 
core members of the RISC complex, nucleophosmin 1 (NPM1) (Arroyo et al, 2011; 
  
Chapter 1: Literature review 50 
Wang et al, 2010) and high-density lipoproteins (HDL) (Vickers et al, 2011). 
Association of miRNAs with certain proteins has been suggested to be related to 
sequence preferences, but no mechanisms or evidence has been found yet.  
The mechanism by which cells secrete miRNAs that are protein bound and are 
taken up by recipient cells remains unknown. To date, no evidence of cell surface 
receptors for protein bound miRNAs has been detected (Larrea et al, 2016).  
Evidence that circulating miRNAs constituted two different populations, one 
vesicle enclosed and one protein associated, sparked examination on the 
functional relevance of each of the fractions. These were followed by studies on 
the preferential association of particular miRNAs in each of the populations. In one 
study, the majority of circulating miRNAs were found to cofractionate with proteins 
and not vesicles, specifically 66% of plasma miRNAs and 68% of serum miRNAs 
were not inside vesicles (Arroyo et al, 2011). This finding was confirmed by 
another report (Turchinovich et al, 2011). Particular miRNAs were also found to 
exhibit preference for their association in one of the fractions, such is the case of 
let-7a, preferentially associated with vesicles, and miR-122, preferentially bound 
to AGO2. Other miRNAs were present in both fractions and the authors suggested 
that differences in miRNA secretion and transport could be linked to the cell type 
of origin (Arroyo et al, 2011).  
On the other hand, another study reported that most circulating miRNAs found in 
serum and other biological fluids, such as saliva, are found in vesicles (Gallo et 
al, 2012). In general, the sensitivity of miRNA detection was only marginally 
improved when exosomes were compared to whole serum (Gallo et al, 2012). 
Biomarker sensitivity might be improved by knowing the fraction in which a miRNA 
is present and concentrating miRNAs in that fraction.  
1.5.7.3 Origin and function of circulating miRNAs 
The presence of cell free miRNAs in biological fluids has raised questions on their 
origin, function and biological importance. Circulating miRNAs have 
heterogeneous origins, and the contribution of each of those origins to the cell-
free miRNA population remains unclear. miRNAs are released to the circulation 
as a result of apoptosis and necrotic cell death. Some studies found a high 
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correlation between cell-free miRNAs in blood fractions and miRNAs in blood 
cells, reporting that most miRNAs originated from lysed blood cells (Chen et al, 
2008; Pritchard et al, 2012), whereas another study reported significant 
differences between miRNAs in plasma and blood cells (Turchinovich et al, 2012). 
In general, damaged blood cells are accepted to contribute to the cell-free miRNA 
signature, and the influence of cell counts and haemolysis on the signature has 
been reported (Liang et al, 2014). Cell free miRNAs might also originate from 
endothelial cells or other organs exposed to high blood flow such as the liver, 
kidneys and lung, particularly when tissue damage has occurred (Machado et al, 
2015; Turchinovich et al, 2011). 
However, miRNAs have also been shown to be actively secreted by cells, and 
their function in cell-to-cell communication is being investigated (Larrea et al, 
2016); (Turchinovich et al, 2011). The concept of miRNAs as message 
transmitters in intercellular communication implies that exported miRNAs are 
specifically selected in some way by the cell. Indeed, it has been shown that in 
the contents of vesicles contents are specifically selected and are not just a 
sample of cell contents. In such a mechanism, exporting cells would be able to 
identify and select miRNAs, package them suitably for extracellular transport and 
transport them to the extracellular space. This export is most likely energy 
dependent (Bhome et al, 2018; Guduric-Fuchs et al, 2012; Wang et al, 2011).  
Circulating miRNAs have also been suggested to play a role in immunoregulation. 
Tumour-secreted miRNAs enclosed in exosomes can be transferred from cancer 
cells to surrounding macrophages (Fabbri et al, 2012). Normal cells surrounding 
a tumour might, on the other hand, be secreting tumour suppressor miRNAs 
(Kosaka et al, 2012). 
1.5.8 miRNAs in serum 
miRNA signatures in blood have been studied for a wide range of pathologies. 
miRNA signatures from serum, plasma and whole blood have not been reported 
to be significantly different (Gallo et al, 2012; Moldovan et al, 2014). However, it 
has been shown that the presence of blood cells in the sample has an effect on 
the results. Indeed, it has been reported that the effects of haemolysis in miRNA 
quantification in blood fractions has been underestimated (Moretti et al, 2017).  
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Both serum and plasma are regarded as acceptable sample types to study miRNA 
expression (Moretti et al, 2017). However, serum has less platelet contamination 
than plasma, which could decrease some bias in miRNA quantification (McDonald 
et al, 2011b). Blood cell count has been shown to have an effect on miRNA 
expression levels in plasma (McDonald et al, 2011b; Pritchard et al, 2012). 
Importantly, it is difficult to directly compare studies in plasma and serum samples 
due to differences in sample preparation and measurements (McDonald et al, 
2011b; Moretti et al, 2017). In general, comparisons between studies are also 
problematic due to differences in the normalisers of miRNA expression used. 
Many studies have used endogenous miR-16, but this miRNA has been found to 
be dysregulated in several cancers, including lung cancer (Moretti et al, 2017). 
U6, a small nuclear RNA, was another frequently used normaliser, but is known 
to fluctuate notably across samples, which could contribute to bias in miRNA 
expression levels reported (Xiang et al, 2014).  
Besides blood, other biological fluids can provide information on the state and 
pathologies of organs associated with them (Larrea et al, 2016). For instance, 
miRNA signatures in urine have been investigated as markers of bladder and 
prostate cancer (Zhou et al, 2014). In the lung, miRNA expression in sputum and 
broncholoalveolar lavage fluid (BALF) have been investigated (Kim et al, 2015). 
These specimens have attracted interest due to their potential to reflect the 
pulmonary microenvironment.  
1.5.9 miRNA expression in sheep 
Although being one of the most agricultural important animals, few studies have 
investigated miRNA expression in sheep tissue. For example, miRBase v22.1 
cites only 106 precursors and 153 mature miRNA sequences in domestic sheep 
(O. aries) (Kozomara et al, 2019). In comparison, the miRBase entry for the 
related ruminant species Bos taurus contains 1064 precursors and 1025 mature 
miRNA sequences, and the entry for humans (H. sapiens) boasts 1917 precursors 
and 2654 mature sequences. Given the fact that miRNA sequences are highly 
conserved across species, this suggests that the differences in miRNA numbers 
between these species are likely explained by the number of miRNA studies 
carried out in each of the species. An additional factor that has hindered miRNA 
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research in sheep is the poor annotation of the sheep genome compared to other 
domestic species, which makes target predictions and novel miRNA discovery a 
challenging task.  
Most of the knowledge we presently have on miRNA expression and targets in 
sheep tissue derive from studies that focus on muscle and ovarian tissue 
(Donadeu et al, 2012; Hiard et al, 2010; McBride et al, 2012; Zhou et al, 2017). 
These studies have focused their efforts in investigating miRNA expression linked 
to muscle quantity, fat deposition and fertility, i.e., qualities important for 
production, but little attention has been placed on animal welfare and the study of 
miRNA association with sheep diseases.  
Nevertheless, the published studies have provided a first insight to miRNA 
expression in sheep, and have provided meaningful information on the role of 
some miRNAs and their regulation.  
In the context of sheep miRNAs and retroviral infections Esparza-Baquer et al 
(2015) characterised polymorphisms in the alleles of the restriction factor 
APOBEC3 and found that polymorphisms in the a3z1 gene might influence 
disease pathogenesis; a finding that might be conditioned by the frequency of 
some mutations. Strikingly, a low frequency allele for a3z1 was found to create 
target sites for miR-323 and miR-1287. However, the function of this target site, 
although hypothesised to silence APOBEC3, remains unknown.  
To date, only three recently-published articles have examined miRNA expression 
in the sheep lung. Krauss et al. investigated miRNA expression in the context of 
early cardiopulmonary development in sheep and, despite the small sample size 
of the study, identified differential expression of miR-146a, miR-22, miR-335* and 
miR-210 between late gestation and neonatal lambs (Krauss et al, 2018). These 
findings highlighted the important role miRNAs play in early lung development. 
The observations in sheep were mostly in line with studies in mouse lung that had 
found miR-210 and miR-22 to be differentially expressed in response to oxygen 
levels (Chan et al, 2012); (Caruso et al, 2010). Nevertheless, in contrast to mouse 
studies, the miR-15 family was not found to be differentially expressed in sheep, 
a finding that could be due to sample size, but which also emphasises the possible 
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variations between species, cell type and other characteristics of the system 
studied (Krauss et al, 2018).  
miRNA expression in the sheep lung has been studied in response to two viral 
infections: Visna/Maedi virus (MVV) and Peste-des-petits-ruminants virus 
(PPRV). MVV targets cells of the monocyte/macrophage lineage and the infection 
results in inflammatory lesions in several organs including the lung (Minguijón et 
al, 2015). In a study on lung tissue of MVV-naturally infected sheep (Bilbao-
Arribas et al, 2019), differentially expressed miRNAs were found when 
seropositive animals and uninfected animals were compared, whereas 
comparison between seropositive carrier animals and seropositive animals with 
lesions showed no differential expression of miRNAs. Seropositive and 
seronegative animals showed differential expression of several miRNAs but 
validation of expression levels by RT-qPCR only confirmed the differential 
expression of miR-21 and miR-30c. The miRNA found to be more strongly 
upregulated in seropositive animals was miR-21, with a higher increase in animals 
with lesions (Bilbao-Arribas et al, 2019). Upregulation of miR-21 has been linked 
to viral infection and reported in viral infections caused by hepatitis C, Epstein Barr 
virus and influenza virus (Anastasiadou et al, 2015; Chen et al, 2013; Li et al, 
2010). Some of the roles of miR-21 that might explain its upregulation in viral 
infections are regulation of proliferation and inflammation by targeting components 
of pathways such as PI3k-Akt, MAPK, erbB (Bilbao-Arribas et al, 2019; Chen et 
al, 2013; Pandey et al, 2017; Sheedy, 2015). 
miRNA changes related to PPRV infection were studied in spleen and lung tissue 
of sheep and goats (Pandey et al, 2017). The study reported upregulation of miR-
320a-1, miR-320a-2, miR-1246, miR-363, miR-760-3p and miR-21-3p, and 
downregulation of miR-34b and miR-150 in both infected sheep and goats. 
Nevertheless, these results need to be considered with caution due to the low 
number of specimens included in the study (n=2 each group), which limits the use 
of statistics and is likely to bias the results.  
1.5.9.1 Cell-free miRNAs in sheep 
Few studies have investigated cell-free miRNAs in sheep and, similarly to miRNA 
studies in tissue, most have focused on miRNA signatures in pregnancy. As in 
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humans, circulating miRNAs could be investigated as biomarkers for agricultural 
diseases, as they become easier and more cost-effective diagnostic tests.  
In a study comparing miRNA expression of pregnant ewes at day 30 and day 90 
of pregnancy, and of non-pregnant ewes, authors found that 25 miRNAs were 
differentially expressed. Some of the dysregulated miRNAs found by RT-qPCR 
included miR-183, miR-200b and miR-182. This study was performed in 
exosomes derived from blood and placentomes.  When results were compared, 
only miR-379, out of 94 miRNAs dysregulated in placentomes, was found 
differentially expressed in serum exosomes and placentomes. (Cleys et al, 2014). 
Interesting for the purpose of this thesis a study was carried out examining 
microvesicle formation in sheep uterus and delivery to the conceptus. The study 
found that those microvesicles contained 81 miRNAs as well as the enJSRV 
mRNAs env and gag.  miRNAs contained in the microvesicles included well-
studied miRNAs in reproduction such as the let-7 family, miR-18a, miR-19b, miR-
21, miR-125a, miR-214, miR-223 and miR-423. The authors confirmed that the 
microvesicles could be taken up by cells in culture and that enJSRV RNAs could 
subsequently be detected in those cells (Burns et al, 2014). enJSRV env is 
essential for normal elongation of the conceptus (Dunlap et al, 2006) and the 
findings reported suggest that microvesicles might be the delivery method. 
Moreover, the findings of the study pose further questions on the interplay of the 
miRNAs contained in the microvesicle and the enJSRV genes. Looking at miRNA 
expression in gestation might shed light on possible miRNA interactions with the 
JSRV genome.  
Circulating miRNAs have only been studied in the context of one infection in 
sheep, scrapie (Sanz Rubio et al, 2017). Levels of miRNAs previously shown to 
be overexpressed in brain tissue of scrapie affected sheep and other models of 
prion disease, were measured in the plasma of scrapie affected sheep. Of the 
investigated miRNAs, miR-21-5p and miR-342-5p were found to be 
overexpressed when compared to control unaffected sheep. miRNAs let-7b and 
let-7d also showed higher levels in affected sheep than controls, but quantification 
was not possible as they could not be detected in most control animals. The 
authors noted discrepancies between the results obtained in sheep and in vitro or 
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mice infected models, which they attributed to higher variability in natural disease 
compared to inoculated models. Elevated levels of miR-21-5p were also detected 
in the central nervous system (CNS) of scrapie sheep, and could suggest that the 
elevated levels in plasma have CNS origin. miR-21-5p was shown to mediate an 
anti-inflammatory response in prion-infected neuronal cells in vitro (Sanz Rubio et 
al, 2017). 
1.5.10 miRNAs in cancer 
miRNAs regulate complex networks, made more complex by the fact that some of 
their targets are transcription factors. They regulate cancer pathways at multiple 
levels, allowing them to achieve a stronger degree of regulation and fine-tuning. 
For example, miR-135b regulates EMT by targeting LATS2, NDR2, MOB1 and 
βTCRP, all members of the Hippo pathway (Lin et al, 2013). This pathway is 
involved in the promotion of lung cancer metastasis (Pan, 2010) and is also 
important in type II pneumocyte differentiation (Chung et al, 2013). The role of 
miRNAs as regulators of biological functions such as cell proliferation and death, 
differentiation and metabolism, can affect tumour development (Bracken et al, 
2016). 
While mutations are rarely observed in miRNA genes, dysregulation in their 
expression levels is commonly observed in cancer (reviewed in Bracken et al 
(2016)). Some miRNAs have been classified as tumour suppressors or oncomirs 
due to their ability to suppress or promote tumourigenesis (Esquela-kerscher 
2006). Overexpression of certain oncomirs in mouse models was sufficient to 
drive tumour formation in mouse (Lin Gregory 2015). Nonetheless, the effects of 
miRNAs on tumourigenesis appear to be context dependent: miRNAs can be 
oncomirs or oncosuppressors depending on cancer type. For example: miR-17-
5p acts as an oncomir in hepatocellular carcinoma but is considered an 
oncosuppresor in cervical cancer; similarly, miR-200 can either promote or inhibit 
metastasis and invasion depending on cancer type (Bracken et al, 2016; Esquela-
Kerscher & Slack, 2006).  
The mechanisms of miRNA dysregulation in cancer are varied and can happen at 
various stages of miRNA biogenesis. Starting with transcription of pri-miRNAs 
there are several mechanisms that may alter this process. miRNAs genes are 
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frequently located in genome fragile sites or in sites subject to amplification, 
deletion or translocation (Calin et al, 2004; Esquela-Kerscher & Slack, 2006). 
Such events might affect transcription of the pri-miRNA and subsequently affect 
levels of mature miRNA.  For instance, the loss of the locus which encodes miR-
15a and miR-16-1 has been observed in chronic lymphocytic leukemia (Lerner et 
al, 2009). These two miRNAs usually target BCL2 and control cell apoptosis (Calin 
et al, 2004). Other epigenetic silencing mechanisms directly related to pri-miRNA 
transcription are the hypermethylation of CpG islands found in promoters of 
miRNA genes, resulting in silencing of tumour suppressor miRNAs, or histone 
modifications (Bracken et al, 2016). Increased transcription of pri-miRNAs has 
also been observed related to their transcriptional activators, which in some cases 
are oncogenes or tumour suppressors themselves. The miR-34 family is 
transcriptionally activated by p53 (He et al, 2007). Members of the mir-34 family 
act as tumour suppressors by promoting apoptosis and avoiding uncontrolled cell 
proliferation (He et al, 2007). On the other hand, MYC promotes transcription of 
the oncomirs of the miR-17-92 cluster (Dews et al, 2006).  
Mutations and expression changes in components of the miRNA biogenesis 
pathways are also common and well-reported mechanisms of miRNA 
dysregulation in cancer (reviewed in Lin & Gregory (2015) and Bracken et al 
(2016)). Disruption of components of the pathway accelerated tumour growth in a 
mouse model of lung cancer (Kumar et al, 2009). Levels of key components of the 
canonical miRNA biogenesis pathway like Drosha and Dicer are frequently 
suppressed in cancers such as lung cancer and ovarian cancer (Lin & Gregory, 
2015). Knockdown of Drosha in lung adenocarcinoma was found to result in 
increased tumour proliferation in vivo and in vitro (Kumar et al, 2007). Limited 
expression of these proteins has an effect on all miRNAs that follow the canonical 
pathway, and is thought to be related to the reported global miRNA 
downregulation in cancer (Bushati & Cohen, 2007; Lin & Gregory, 2015). 
However, this global miRNA dysregulation observation remains controversial 
(Volinia et al, 2006). In fact, an upregulation of Drosha levels has been reported 
in multiple cancers and is observed in advanced stages of cervical cancer (Lin & 
Gregory, 2015; Muralidhar et al, 2011). These findings suggest that miRNA 
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dysregulation and the mechanisms by which it occurs are cancer type, and even 
stage, specific.  
Inactivating mutations in exportin 5 (XPO5) are also related to miRNA processing 
defects and increased tumourigenesis in gastric, endometrial cancer and 
increased risk of developing breast cancer (Lin & Gregory, 2015; Melo et al, 2010).  
DICER1 is considered a tumour suppressor, loss of a single copy increased 
tumourigenesis in a mouse model of lung cancer (Kumar et al, 2009). Common 
mutations in DICER1 result in truncated proteins without the C-terminal catalytic 
domains or take place in metal-binding residues of the RNAse IIIb domain. This 
domain cleaves the 3′ end of the 5′ arm of the pre-miRNA, but when it is defective 
due to mutation, it blocks the maturation of 5p miRNAs but not 3p miRNAs 
(Anglesio et al, 2013). A particular example is that of the let-7 family, members of 
which are usually 5p derived (Anglesio et al, 2013). DICER1 mutations are 
observed in hereditary types of cancer like Wilms tumour, cystic nephroma, 
pituitary blastoma and tumour predisposition syndrome (Lin & Gregory, 2015). 
TRBP mutations have also been linked to cancer (Garre et al, 2010). 
In addition, DROSHA, DGCR8, DICER1 and TRBP, components of the 
biogenesis pathway, are all subject to post-translational regulation such as 
phosphorylation or acetylation. Nevertheless, the effects and significance of these 
post-translational modifications in miRNA dysregulation in cancer are unknown 
(reviewed in Ha & Kim (2014)).  
Other factors associated to components of the pathway can cause alterations in 
miRNA processing. For instance, RNA binding proteins associated with 
microprocessor like DDX5 and DDX17 can disrupt its function (van Kouwenhove 
et al, 2011). Other RNA binding proteins like KSRP, SRSF1, FUS bind to regions 
of pri-miRNAs and facilitate drosha recruitment and processing (Lin & Gregory, 
2015). Mediated by DDX5 and DDX17, p53 can also interact with the DROSHA 
complex and promote processing of tumour-suppressive pri-miRNAs (Lin & 
Gregory, 2015).  
In special cases like miR-21, receptor SMADs associate with an element of the 
miR-21 stem loop and increase its processing by Drosha (Bracken et al, 2016). 
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During cancer triggered hypoxia, EGFR is activated, which promotes cell growth 
and oncogenesis. EGFR interacts with AGO2 and promotes its phosphorylation 
inhibiting interaction between DICER1 and AGO and blocking miRNA 
accumulation (Shen et al, 2013). Activation of LIN28A or LIN28B in cancer 
suppresses the tumour suppressor family let-7 and promotes proliferation and 
tumourigenesis. Binding of LIN28 promotes the addition of an oligouridine tail to 
pre-let7, preventing maturation and promoting its degradation. In vitro inactivation 
of these proteins was able to revert tumour growth (Lin & Gregory, 2015).  
Nevertheless, in considering the effects of mutations on expression of Drosha, 
DICER and AGO proteins in cancer, it needs to be acknowledged that these 
proteins also have roles independent of miRNA biogenesis (Bracken et al, 2016).  
miRNA dysregulation has also been observed in cases in which components of 
the biogenesis pathways showed no alteration in function, suggesting that other 
pathways, besides the miRNA biogenesis pathway, play a role in miRNA 
dysregulation (Lin & Gregory, 2015). The Hippo pathway is disrupted in many 
cancers, and YAP1 the downstream effector of hippo pathway is able to regulate 
miRNA biogenesis by targeting DDX17 and inhibiting drosha processing of pri-
miRNAs (Mori et al, 2014).  
Another mechanism to bypass miRNA regulation involves avoiding miRNA 
regulation instead of disrupting miRNA expression. It has been observed that 
some cancer cells produce mRNA isoforms with shorter 3′UTR, as a result of 
alternative cleavage or polyadenylation. As the 3′UTR contains miRNA binding 
sites, shortening of this region could mean lower level of miRNA repression (Mayr 
& Bartel, 2009). An example of this phenomenon is 3′ UTR shortening of PDL1, 
which is related to an increase in cell survival in a variety of cancers (Kataoka et 
al, 2016). This shortened version of PDL1 loses binding sites of miRNAs miR-200 
and miR-34 (Bracken et al, 2016). Although negative selection usually prevents 
the occurrence of SNPs in the 3′UTR of mRNAs, compared to other regions of the 
mRNA, some cases of mutations that result in loss of miRNA-mRNA 
complementarity have been reported. One example is the mutation of the let-7 
binding site in KRAS in non-small cell lung carcinoma (Chin et al, 2008). 
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Despite the insight in biological mechanism and interactions that observing 
several cancer types offers, miRNA dysregulation mechanisms as well as 
expression of particular miRNAs and their function seems to be vastly context 
dependent. It is therefore essential for the purpose of this project to build on these 
general cancer knowledge by specifically looking at lung cancer miRNA 
dysregulation and mechanisms. 
1.5.11 miRNAs as biomarkers 
Research on miRNAs and the discovery that they are deregulated in diseases 
such as cancer, viral infections, nervous system diseases, muscular and 
cardiovascular disorders and diabetes, has attracted great attention to their 
potential as biomarkers of disease (Cortez et al, 2011). In the specific case of 
cancer, research has shown that miRNAs are located in genomic regions often 
amplified or deleted in cancer (Calin et al, 2004). Their function as regulators of 
cellular processes important in cancer initiation, progress and metastasis, has led 
to some miRNAs being considered oncomirs or oncosuppressors: members of the 
let-7 family, for instance, are considered tumour suppressors due to their role 
targeting Ras genes (Esquela-Kerscher & Slack, 2006). In contrast, miR-21 is 
considered an oncomir that targets PTEN and Spry2 and promotes invasion and 
migration (Ma et al, 2011). Some miRNA polymorphisms have also been 
associated with an increased cancer risk, and mutations in components involved 
in miRNA biogenesis, like AGO2, are a common finding in cancer (Lin & Gregory, 
2015).  
Besides their biological role in disease, miRNAs possess other qualities that make 
them good candidates as biomarkers. miRNAs are present in the circulation and 
body fluids such as urine, saliva and cerebrospinal fluid (Larrea et al, 2016). They 
have high stability in formalin-fixed paraffin embedded tissue samples, plasma 
and blood serum (Chen et al, 2008; Xi et al, 2007).  
In cancer diagnosis, a common finding is an inverse relationship between levels 
of miRNAs in tissue and the circulation (Jarry et al, 2014). The mechanism by 
which this occurs is not known, but it might be a sign of dysregulated cancer 
pathways. Nevertheless, this has further complicated the interpretation and 
comparison of findings between studies. 
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In many cases, miRNAs initially identified to have great promise as biomarkers 
have subsequently shown poor specificity and reproducibility. The primary reason 
for this is that most initial studies do not consider other important factors such as 
age, gender and treatment (Armand-Labit & Pradines, 2017; Keller et al, 2017; 
Kosaka et al, 2010). Data reproducibility has also been a problem, standardisation 
of data processing, optimisation and methods is required to minimise variations, 
ensuring reliable results (Armand-Labit & Pradines, 2017; Keller et al, 2017; 
Witwer & Halushka, 2016); (Schwarzenbach et al, 2011). More understanding of 
miRNA biology is still needed for them to be used as specific and reliable markers 
in wide range of patients, and to develop simple detection methods.  
1.5.12  Circulating miRNAs as biomarkers 
Given the increased number of circulating miRNAs in pathologies such as cancer, 
and the increased abundance of specific miRNA species, circulating miRNAs 
have been considered as potential disease biomarkers. In addition, their detection 
in body fluids and use as biomarkers could constitute a minimally invasive test, 
would reduce testing costs, and if methods such as RT-qPCR were used, would 
give quick and easily analysed results (Bernardo et al, 2012; Gilad et al, 2008; 
Schwarzenbach et al, 2014). miRNAs are more stable than mRNAs and therefore 
less susceptible to changes that occur in sample processing (Chen et al, 2008). 
However, certain aspects of miRNA biology remain unknown and that information 
would be valuable in designing the best testing strategy and for interpreting 
results. For instance, the half-life of circulating miRNAs is still unknown and might 
vary between miRNAs (Schwarzenbach et al, 2014).  
In cancer, miRNA signatures appear to be tissue specific, therefore detection of a 
particular miRNA signature in body fluids could potentially allow for distinction of 
cancer origin (Lu et al, 2005; Volinia et al, 2006). These miRNAs would ideally be 
expressed at high levels in affected individuals and low levels in healthy 
individuals, increasing possibilities of sensitive detection. Sensitivity and 
specificity might also be increased by using a panel of miRNAs instead of a single 
miRNA (Hu et al, 2010). The two most frequently investigated circulating miRNAs 
in cancer are miR-10b and miR-21, Fig. 1.11 illustrates some of their roles in 
circulation (Larrea et al, 2016; Schwarzenbach et al, 2014).  
  
Chapter 1: Literature review 62 
One of the first studies to confirm miRNA secretion by tumour cells and their 
potential as biomarkers was by Mitchell et al (2008). In this study, the authors 
xenografted mice with human prostate cancer tumours to determine if cancer 
related miRNAs could be detected in the blood. They found that the presence of 
tumour did not result in a generalised increase of blood miRNAs, but they were 
able to detect the presence of two miRNAs with no murine homologs in the 
circulation. These miRNAs derived from the tumour cells, indicating that these 
cells secrete miRNAs and that they can be detected in body fluids (Mitchell et al, 
2008). Differential expression of certain miRNAs in biological fluids has also been 
found to be indicative of other pathologies.  
Although an increase in the abundance of a certain miRNA in the circulation might 
be indicative of cancer, it was shown that miRNA levels and tumour burden in 
patients only showed moderate correlation (Mitchell et al, 2008). In contrast, in 
pregnancy, correlation between miRNA levels and tissue was found to be high. 
Circulating miRNAs of placental origin were found to increase as pregnancy 
progressed, and declined within a day after delivery, suggesting miRNAs could be 
valuable biomarkers for pregnancy (Chim et al, 2008).  
Due to high sensitivity and specificity, RT-qPCR is the gold-standard method for 
miRNA. miRNA-sequencing has also been used, but has potential limitations such 
as sequence-specific biases due to enzymatic ligation, higher cost and the need 
for trained bioinformaticians to analyse abundant data. Nevertheless, it has the 
advantage of not requiring prior knowledge of miRNAs present, making it a 
powerful exploratory tool (Bernardo et al, 2012; Schwarzenbach et al, 2014).  
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Figure 1.11. Known roles of some circulating miRNAs.  Reproduced from Larrea et al 
(2016). 
1.5.13 miRNA signatures in lung cancer 
Most miRNA studies in lung have focused on discovering differences in miRNA 
expression in lung cancer and normal tissue with the aim of finding new diagnostic, 
prognostic and therapeutic approaches (reviewed in (Inamura, 2017; Yu et al, 
2017)). Indeed, an early study found that miRNAs performed better than mRNAs 
as classifiers of cancer type and distinguished between normal and cancer tissue 
with greater precision (Lu et al, 2005). The findings of the aforementioned studies 
might be of special relevance for the present study due to the discussed 
similarities in histopathology, pathway activation and affected cell type between 
human lung adenocarcinoma and OPA.  
  
Chapter 1: Literature review 64 
Whereas several miRNAs are consistently found in lung adenocarcinoma studies, 
many others have been reported as highly expressed in only a small number 
(Guan et al, 2012). In fact, apart from the differences in detected miRNAs, 
comparison of different studies often shows disagreement in the expression trend, 
with some showing a clear upregulation and others downregulation. Most of these 
disagreements are likely caused by differences in tissue, cell type, disease stage 
or specific lung cancer type. However, sample number, experimental design and 
methods, also need to be considered as potential factors of the observed variance 
between studies. These differences in reported results emphasise the importance 
of consulting multiple sources and highlight the importance of a clear description 
of the sample material and methods followed in a study. 
Some of the miRNAs that have been consistently linked to human lung 
adenocarcinoma are the let-7 family, miR-155, miR-16, the miR-17 cluster, the 
miR-183 family (miR-96, miR-182 and miR-183), miR-21, miR-31, miR-135b, the 
miR-200 family, miR-205, the miR-221 cluster and miR-503 (Table 1.1).  
Nevertheless, due to the nature of miRNAs and similarities in activated pathways 
between cancers, several miRNAs dysregulated in lung cancer have also been 
found dysregulated in other cancer types and diseases (Bracken et al, 2016; Guan 
et al, 2012; Volinia et al, 2006). Hence, a single miRNA is not likely to predict a 
disease accurately. In trials, increased sensitivity and specificity has been 
reported when using not one but a combination of miRNAs as predictors or 
classifiers of disease state (Schwarzenbach et al, 2014). A particularly important 
aim is to find a miRNA signature able to distinguish between cancers or diseases 
of similar clinical or histopathological presentation to support the use of miRNAs 
as disease biomarkers (Shen et al, 2013).   
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Table 1.1.  Summary of miRNAs frequently reported as dysregulated in human lung cancer.  




Downregulated in NSCLC (Takamizawa et 
al, 2004) downregulated in BAC (Inamura 
et al, 2007) Tumour suppressor (Wang et 
al, 2012b) 
RAS, HMGA2, MYC , 
BCL-2, CDC34, 
CYCLIN A2, CDK6 
NSCLC (Esquela-
Kerscher et al, 2008; 
Johnson et al, 2007; 
Takamizawa et al, 
2004) 
Chromosome 3 
Let-7g in 3p21 
implicated in lung 
cancer (Johnson et al, 
2007) 
Transcription 
factors such as N-
MYC, EGR1, also 
let-7 transcripts 
(Gaeta et al, 2017) 
miR-130b NSCLC 
Upregulated, oncogene (Mitra et al, 2014; 
Tian et al, 2016) 
TGFBR2 (Mitra et al, 
2014) PPARγ , ZEB1 
(Tian et al, 2016) 
Chromosome 22 
(Benson et al, 2013) 
Not known in 
NSCLC 
miR-132 NSCLC 
Upregulated in some cancers like lung 
cancer (Yanaihara et al, 2006). 
Downregulated, tumour suppressor (You et 
al, 2014)  
ZEB2 (You et al, 2014) 
ACVR2B, ACVR1, HB-
EGF (Jiang et al, 
2015) 
Chromosome 17, region 
lost in Cancer Cluster 
with miR-212. 
Hypermethylation 
of promoter (You et 
al, 2014)  
miR-135a NSCLC 
Downregulated, tumour suppressor, very 
low levels in lymph node metastasis (Shi et 
al, 2015). Predictor of treatment, related to 
paclitaxel and cisplatin resistance 
(Holleman et al, 2011; Zhou et al, 2013)  
HIF1AN (Holleman et 
al, 2011) KLF8, E-
cadherin and vimentin 
genes (Shi et al, 2015) 
MCL1(Zhou et al, 
2013)  
Encoded by two genes 
at chromosome 3 and 
12 (Zhou et al, 2013)  
DNA methylation of 
CpG islands (Zhou 




Oncogene in most reports. Upregulated (Lin 
et al, 2013). Downregulated in cisplatin 
resistance (Zhou et al, 2013)  
Components of Hippo 
pathway LATS2, ß-
TrCP, NDR2, LZTS1 
(Lin et al, 2013).  
Intronic miRNA(Lin et al, 
2013). Chromosome 
1(Zhou et al, 2013) . 
DNA demethylation 
and NFkb  
signalling (Lin et al, 
2013).  
                                            
1 Type of lung cancer: NSCLC: non-small cell lung cancer, ADC: adenocarcinoma, SCC: squamous cell carcinoma, BAC: bronchioloalveolar carcinoma.  
2 Known targets lists only experimentally validated targets, targets predicted by bioinformatics have not been included.  
3 Genomic information includes clustering and family of miRNAs as well as genomic location in H. sapiens.  
4 Regulation refers to the mechanism by which the miRNA expression is activated or repressed. 
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Table 1.1.  Summary of miRNAs frequently reported as dysregulated in human lung cancer.  
miRNA Cancer type1 Upregulated/downregulated Known targets2 Genomic information3 Regulation4 
miR-146b NSCLC, SCC 
Overexpression related to recurrence after 
surgery, poor prognostic marker  
(Patnaik et al, 2011) Overexpressed in 
serum, higher in stage 2 than others (Rani 
et al, 2013) 
HEF1 (Malleter et al, 
2012) 
Chromosome 10 




(Raponi et al, 
2009) 
miR-153 NSCLC 
Downregulated, tumour suppressor, poor 
prognostic marker (Ren et al, 2019; Shan et 
al, 2015; Xu et al, 2013) 
SNAI1, ZEB2 (Xu et al, 
2013) ADAM19, AKT 
(Shan et al, 
2015)(Yuan et al, 
2015) 
Chromosome 2 
(Benson et al, 2013) 








Overexpressed in lung tumours (Volinia et 
al, 2006) oncogene (Mogilyansky & 
Rigoutsos, 2013). Overexpressed in tumour 
and serum, but low levels detected in blood 
(Osada & Takahashi, 2011) 
Especially overexpressed in small-cell lung 
cancer (Hayashita et al, 2005) 
STAT3, MAPK14 
(Carraro et al, 2009) 
E2F1, HIF-1α, Tsp1, 
PTEN (Osada & 
Takahashi, 
2011),CCND1, CDKN1 
and E2F1 (Shu et al, 
2012)  
Chromosome 13 
(Hayashita et al, 2005) 
Regulated by C-
MYC (Mogilyansky 
& Rigoutsos, 2013; 






Oncogene in most reports. Upregulated in 
primary lung tumours vs metastases (Del 
Vescovo & Denti, 2015; Vosa et al, 2013). 
Upregulation observed in tissue and sera  
(Zhu et al, 2011; Zhu et al, 2016). 
Enhances proliferation in NSCLC cell lines 
(Wang et al, 2018). Favourable prognostic 
marker (Stenvold et al, 2014) and showed 




(Del Vescovo & Denti, 
2015) FOXO3 (W.-B. 
Yang et al. 2014), HIF-
1α (Wang et al, 2018).  
Chromosome 7 (cluster 
with 183, 96) 




et al, 2014) 
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Table 1.1.  Summary of miRNAs frequently reported as dysregulated in human lung cancer.  
miRNA Cancer type1 Upregulated/downregulated Known targets2 Genomic information3 Regulation4 
miR-183 
SCC, ADC. 
Higher in SCC. 
Lymph node 
metastasis 
(Zhu et al., 
2011) 
Oncogene in most reports. Upregulated  
(Dambal et al, 2015; Li et al, 2017a; Zhu et 
al, 2011; Zhu et al, 2016) 
. Upregulation observed in tissue and sera  
(Zhu et al, 2011; Zhu et al, 2016) Different 
results depending on cell line. Yang and 
Wang proved metastasis inhibitor activity 
(Wang et al, 2008; Yang et al, 2014) 
 
FOXO1, EGR1, PTEN 
(Zhu et al, 2011) VIL2 
activity (Wang et al, 
2008; Wang et al, 
2019a) 
Chromosome 7 (cluster 
with 182, 96) (Benson et 
al, 2013) 




Upregulated in tumours and serum (Nadal 
et al, 2015) (Nadal et al. 2015) 
downregulated, tumour suppressor (Hu et 
al, 2012) 
CCND1, uPA (Hu et al, 
2012) 




Downregulated in metastasis compared to 
primary tumours (Baffa et al, 2009; Chen et 
al, 2014a). Low levels part of signature that 
predict recurrence. Overexpressed in 
NSCLC (Pacurari et al, 2013). Promotes 
EMT (Gregory et al, 2008). Enhances 
radiosensitivity (Cortez et al, 2014). Low 
levels associated with poor survival  
(Pecot et al, 2013). 
E2F3, RND3 (Feng et 
al, 2012) DLC1, 
HNRNPA3 and HFE, 
UBA6, UBE2I, ZEB1, 
ZEB2 (Pacurari et al, 
2013) (Chen et al, 
2014a; Gregory et al, 
2008), PRDX2, NRF2 
(Cortez et al, 2014). 
miR-200 family, 
chromosome 1  
(Pacurari et al, 2013) 
Regulated by p53  




(Chen et al, 2014a) 
miR-205 
SCC, ADC, 
higher in SCC 
Upregulated in most reports (Begum et al, 
2015; Li et al, 2017a), higher in SCC 
(Cai et al, 2013; Vosa et al, 2013). Tumour 
suppressor and oncogene (Qin et al, 2013) 
PTEN (Qin et al, 2013)  
PHLPP (Cai et al, 
2013) ZEB1, ZEB2 
(Tellez et al, 2011) 
 
Chromosome 1. Region 
amplified in cancer (Cai 




et al, 2011) 
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Table 1.1.  Summary of miRNAs frequently reported as dysregulated in human lung cancer.  
miRNA Cancer type1 Upregulated/downregulated Known targets2 Genomic information3 Regulation4 
miR-21 NSCLC 
Upregulated early in carcinogenesis (Seike 
et al, 2009) upregulated in lung cancer  
(Markou et al, 2008; Zhang et al, 2010b) 
(An et al, 2018; Bica-Pop et al, 2018) 
PTEN, PDCD4 (Xi et 
al, 2010) SPRY1, 
SPRY2, BTG2, 
APAF1, FASLG, 
RHOB (Hatley et al, 
2010) 
Inside FRAs/ amplified 
in lung cancer 
chromosome 17 
(Yanaihara et al, 2006) 
Activated by EGRF 
(Seike et al, 2009; 
Xi et al, 2010) 
activated by Ras 
(Hatley et al, 2010) 
miR-212 NSCLC 
Downregulated compared with normal lung, 
pro-apoptotic role (Incoronato et al, 2010; 
Incoronato et al, 2011). Tumour promoting, 
upregulated (Li et al, 2012). 
PED (Incoronato et al, 
2011) PTCHI (Li et al, 
2012). 
Chromosome 17, region 




island found in 
promoter of miR-
212 (Incoronato et 
al, 2011) 
miR-31 NSCLC, ADC 
Upregulated, oncogene (Li et al, 2017a; Liu 
et al, 2010; Vosa et al, 2013) Promotes 
metastasis (Chen et al, 2014b; Meng et al, 
2013) 
LATS2, PPP2R2A (Liu 
et al, 2010)  DKK-1, 
DACT3 (Xi et al, 2010) 
Chromosome 9 (Meng 
et al, 2013) 
C/EBP-β activated 
(Xi et al, 
2010)Promoter 
methylation (Meng 
et al, 2013) 
miR-34 NSCLC 
Dowregulated in lung cancer (Okada et al, 
2014) 
Tumour suppressor (Rupaimoole & Slack, 
2017; Zhang et al, 2019)  
CDK4, CDK6, BCL-2, 
MET, MYC, PDL1 
(Feng et al, 2019; 
Hermeking, 2010; 
Okada et al, 2014) 
miR-34 family in 
chromosome 1 
P53 during DNA 
damage response  
(Hermeking, 2007) 
miR-503 NSCLC 
Downregulated, tumor suppressor  
(Li et al., 2014; Yang et al., 2014). 
Regulates cisplatin resistance (Li et al., 
2014) 
PI3K P85,IKK-β ( Yang 
et al., 2014) FANCA, 
BCL-2 (Li et al., 2014) 
Intragenic, chromosome 
X, belongs to miR-16 
family ( Yang et al., 
2014) 
Promoter 
methylation (Li et 
al., 2014) 
miR-592 NSCLC 
Downregulated (Hu et al, 2016). Down in 
primary lung ADC compared to colorectal 
mestastases in lung (Kim et al, 2014) 
CCND3 (Hu et al, 
2016) 
Chromosome 7 (Benson 
et al, 2013) 
No data found 
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Table 1.1.  Summary of miRNAs frequently reported as dysregulated in human lung cancer.  
miRNA Cancer type1 Upregulated/downregulated Known targets2 Genomic information3 Regulation4 
miR-96 
SCC, ADC. 
Higher in SCC 
than ADC. 
Oncogene in most reports (Fei et al, 2018; 
Li et al, 2017a). Upregulated in cancer  vs. 
Normal (Zhu et al, 2011; Zhu et al, 2016). 
Upregulation found in tissue and sera, 
correlation in levels (Cai et al, 2017a; Zhu 
et al, 2011) 
FOXO3 (Zhu et al, 
2011) CHES1 (Zhang 
et al, 2013b) 
 
 
Chromosome 7 (cluster 
with 182, 183) (Benson 
et al, 2013) 
No data found 
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1.5.13.1 Circulating miRNAs as lung cancer biomarkers 
Many studies have investigated circulating miRNAs in connection with lung 
cancer, and have tried to link miRNA signatures to prognosis, diagnosis, 
classification and response to therapy with mixed success. Some of the most 
relevant to the work described in this thesis are summarised in this section.  
A review from 2016 looked at miRNA studies performed in biological fluids to 
diagnose lung cancer (Gyoba et al, 2016). Ten studies performed in serum from 
lung cancer patients reported miRNA signatures as specific and sensitive 
biomarkers, but no common miRNAs were found in these signatures. Similarly, in 
plasma, diagnostic signatures also varied greatly, but miR-21 appeared as part of 
a panel in five studies. miR-155, miR-210 and miR-486-5p were present in three 
studies. The review also included studies performed in sputum, but discussed the 
variability of sputum, including variability in cell numbers and types. Nevertheless, 
studies in sputum showed some consensus including the presence of miR-21, 
miR-31, miR-210 and miR-155 in various studies (Gyoba et al, 2016).  
Another review was published in 2017 looking specifically at circulating miRNAs 
for diagnosis of stage I-II NSCLC (Moretti et al, 2017). Again, great variation was 
found between miRNAs reported to have diagnostic value in different studies. The 
authors of the article suggested screening based on their review findings of 20 
quantitative studies. The suggested screening is a two-step process: first, use of 
four miRNAs reported to offer high sensitivity (miR-223, miR-20a, miR-448 and 
miR-145), followed by use of four miRNAs with high specificity (miR-628-3p, miR-
29c, miR-210 and miR-1224). No reliable signature to distinguish between SCC 
and AC was found (Moretti et al, 2017).  
A common finding reported by authors of both reviews was that the great majority 
of published studies used small sample sizes and did not follow general guidelines 
for biomarker research (Baker et al, 2002). In addition, smoking habits were not 
disclosed by some of the reviewed studies, and some circulating miRNAs have 
been found to be significantly dysregulated by smoking (Moretti et al, 2017).  
Correspondence between miRNA levels in serum and tumours has been reported 
in some studies (Zhu et al, 2011; Zhu et al, 2016), including higher expression of 
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miR-21 and miR-155 in both tumor tissues and serum as predictors of recurrence 
and poor survival in NSCLC (Hou et al, 2016).  However, other authors noted that 
several miRNAs dysregulated in lung tumour tissue compared to healthy 
individuals, including miR-20, miR-106a, miR-17-3p, miR-155, miR-145 miR-93, 
miR-137, miR-372 and miR-182-3p, were not detected in serum from the same 
patients (Hu et al, 2010). It has then been suggested that dysregulation of 
circulating miRNAs might have a predictive role independent of tissue, that could 
be related to other cells and immunity altered in cancer (Hu et al, 2010).  
In lung cancer prognosis, a study found that poor survival of NSCLC patients 
correlated with high serum levels of miR-486, miR-30d and miR-125; and low 
levels of miR-1 and miR-499 (Chen et al, 2008). In an independent study, levels 
of miR-155-5p, miR-223-3p and miR-126-3p in adenocarcinoma patients 
correlated with higher risk of disease progression. This prognostic miRNA 
signature was found to be specific of adenocarcinoma; a different miRNA 
signature was found to be predictive of progression in plasma of SCC patients 
(Sanfiorenzo et al, 2013). Tumour-derived overexpressed miRNAs in plasma were 
significantly downregulated from 10 days to 14 days after surgical resection, giving 
an indication of circulating miRNA turnover, and indicating that at least some of 
the circulating miRNAs are of tumour origin (Le et al, 2012). 
Aside from serum, cell-free miRNAs were studied in pleural effusions of lung 
cancer patients, and high levels of miR-100 and low levels of miR-93, miR-134, 
miR-151 and miR-345, were found to be useful prognostic markers of poor 
survival (Wang et al, 2012a).  
In general, studies on circulating miRNAs as biomarkers of lung cancer present 
high variability on the miRNA signature suggested to have predictive value(Jarry 
et al, 2014). These differences, similarly to tissue, are most likely due to a 
combination of technical and biological variation.  
1.5.14 Viral miRNAs  
Viral infections have also been associated with miRNAs, which may be host-
encoded and virus-encoded. Viruses have been found to use miRNAs in an effort 
to manipulate the host cell machinery for their benefit and have the advantage of 
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being small and non-antigenic (Cullen, 2010; Harwig et al, 2014).  Host miRNAs, 
on the other hand, can target viral transcripts and impair essential functions 
(Bushati & Cohen, 2007).  
The first viral miRNAs were identified in Epstein-Barr virus (EBV), member of the 
herpesvirus family (Pfeffer et al, 2004). Since then, a total of 530 miRNAs from 34 
different viral species have been reported and are now listed in miRBase 
(miRBase v22.1). Most of the viral miRNAs described to date are encoded by 
members of the herpesvirus family, DNA viruses with a large genome. 
Herpesvirus are also more likely to contain a higher number of miRNAs in their 
genome, which might be related to the advantages miRNAs confer in their 
establishment of latent life-long infections in their hosts (Grey, 2015).  
Besides herpesviruses, other nuclear DNA virus, e.g. polyomaviruses and 
papillomaviruses, encode miRNAs (Kincaid & Sullivan, 2012). However, 
cytoplasmic DNA viruses are thought not to encode miRNAs, as it is believed that 
they wouldn’t have access to the cell machinery needed for miRNA biogenesis 
(Cullen, 2010). No viral encoded miRNAs have found in cytoplasmic DNA virus 
families.  
RNA viruses were also initially believed not to encode miRNAs because 
processing of a miRNA from the viral genome by RNA polymerase II would induce 
cleavage and degradation of the genome. However, it has since been discovered 
that miRNAs can also be transcribed by RNApol III, indeed, RNApol III transcribes 
bovine foamy virus miRNAs (Cullen, 2006; Kincaid et al, 2012). 
Viral miRNAs have been found to play a role in several steps of the viral infection. 
For instance, most herpesvirus miRNAs are found expressed in latent cells, and 
bovine herpes virus type 1 (BHV1) miRNAs bhv1-miR-B8 and bhv1-miR-B9, are 
reported to target viral transcripts and potentially limit viral replication (Cullen, 
2006; Kanokudom et al, 2018). BK polyomavirus also encodes a miRNA: bkv-
miR-B1 which auto-regulates early gene expression by cleaving their transcripts 
(Seo et al, 2008). Simian virus 40 (SV40) is reported to encode miRNAs able to 
downregulate expression of the T antigen, regulating the hosts cytokine release 
and, thus, the immune response to infection (Sullivan et al, 2005). Murine 
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gammaherpesvirus 68 (MHV68) encodes miRNAs that have been suggested to 
play important roles in infection and inhibition of the host response (Macrae et al, 
2001). A mutant of MHV68, unable to express miRNAs, was attenuated in vivo: 
infection with the mutant virus resulted in lower levels of viral replication and 
pathogenesis, the inflammatory response to the mutant virus was greater, and the 
host was able to clear the infection faster (Macrae et al, 2001). Other examples of 
viral miRNAs that target host factors include miR-BART6-3p, encoded by EBV. 
miR-BART6-3p was reported to target the retinoic acid-inducible gene 1 (RIG-1), 
inhibiting interferon mediated immune responses (Lu et al, 2017).  
Relevant to the present project, four retroviruses have been found to encode 
miRNAs. Bovine foamy virus (BFV) and simian foamy virus (SFV), members of 
the spumavirus genus, encode 4 and 13 mature miRNAs respectively. Human 
immunodeficiency virus 1 (HIV-1), encodes 4 mature miRNAs, and bovine 
leukemia virus (BLV), encodes 10 mature miRNAs. Retroviral miRNAs and their 
functions are summarised in Table 1.2. 
The presence of HIV-1 encoded miRNAs has been a controversial topic. Some 
authors reported that no miRNAs were encoded by HIV-1 (Lin & Cullen, 2007; 
Pfeffer et al, 2005), whereas others reported that HIV-1 miRNAs could be 
experimentally detected (Bennasser et al, 2005; Omoto & Fujii, 2005; Omoto et 
al, 2004). It has been suggested that differences between these studies could be 
due to very low expression levels of the miRNAs or mutations in the HIV-1 genome 
that could alter miRNA expression (Kaul et al, 2009; Lamers et al, 2010). However, 
the presence of mutations would argue against a meaningful role of the miRNAs 
in HIV1 infection. It has also been suggested that HIV-1 miRNAs could potentially 
be expressed in a limited stage of the infection, or in a specific cell-type (Lamers 
et al, 2010). Of the potential HIV-1 encoded miRNAs, hiv1-miR-TAR appears to 
have good evidence supporting its existence, TAR was shown to be cleaved by 
Dicer and miRNAs processed from both arms of the precursor (Ouellet et al, 
2008). In addition, in a later study hiv1-miR-TAR miRNAs were found to be loaded 
into Argonaute complexes, and reported to target host cell genes that promote 
apoptosis of infected cells (Ouellet et al, 2013). On the other hand, evidence of 
the authenticity of hiv1-miR-HN367 and hiv1-miR-H1 existence is weaker, these 
  
Chapter 1: Literature review 74 
potential miRNAs have been experimentally cloned and hiv1-miR-HN367 has 
been detected in northern blots but further characterisation of their biology or 
processing has not been performed (Balasubramaniam et al, 2018; Omoto & Fujii, 
2005; Omoto et al, 2004). 
The functions of HIV-1 miRNAs have been investigated: hiv1-miR-H1 was 
reported to target apoptosis antagonising transcription factor (AATF) and promote 
apoptosis of monocytes (Kaul et al, 2009). Hiv1-miR-N367 was reported to have 
a similar seed sequence to miR-192, and both were reported to target the poly-A 
binding protein 4 gene (PAPBC4), related to translational repression of infected 
cells (You et al, 2012).  
BLV miRNAs were found in higher abundance than host miRNAs in infected cells, 
suggesting a biological role for them. This was confirmed when the BLV encoded 
blv-miR-B4 was found to have homology with a host miRNA (miR-29) associated 
with B-cell proliferation and oncogenesis (Kincaid et al, 2012). This finding 
indicated that viral miRNAs may play an important part in retroviral-mediated 
transformation (Kincaid et al, 2012). Some of the reported targets of blv-miR-B4-
3p are granzyme A (GZMA), FBJ murine osteosarcoma viral oncogene homolog 
(FOS), and palmitoyl-protein thioesterase 1 (PPT1), which have roles in the 
immune response (Gillet et al, 2016). Interestingly, one study reported the 
presence of polymorphisms in BLV pre-miRNAs (pre-miR-B2, pre-miR-B3, pre-
miR-B4 and pre-miR-B5) and found that some alleles were associated with 
increased white blood cell counts in infected hosts (Zyrianova & Koval'chuk, 
2018). Similarly, Kaposi sarcoma associated herpesvirus (KSHV) and Marek’s 
disease virus (MDV) encode a miRNA ortholog to the host miRNA miR-155, 
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Table 1.2. Summary of retroviral-encoded miRNAs and their functions. 




U3 region of the 
LTR. Transcribed 
by pol III to give a 
long pri-miRNA that 
is cleaved into two 
pre-miRNAs. 
Unknown 













Transcribed by pol 








(Burke et al, 
2014; Kincaid 










 Downstream of the 
NF-κB sites in the 








targeting the LTR 
(Kaul et al, 
2009) 
(Ouellet et al, 
2008) 
(Klase et al, 










U3 region of the 
LTR. Transcribed 
by pol III, drosha 
dependent.  
miR-S4-3p is similar 
to miR-155, which is 
lymphoproliferative 
and induces cell 
survival.  miR-S6-3p 
is similar to miR-
132, an innate 
immune suppressor. 
(Kincaid et al, 
2014) 
1 BFV: bovine foamy virus 
2 BLV: bovine leukemia virus 
3 HIV-1: human immunodeficiency virus 1 
4 SFV: simian foamy virus 
                                            
 
Although there are some examples of virus which share miRNA homology, such 
as EBV and rhesus lymphocryptovirus, most miRNAs are not conserved in viral 
species and don’t have host orthologs (Nair & Zavolan, 2006). Thus, making it 
difficult to predict if a certain virus encodes miRNAs. Many viruses have not been 
found yet to encode miRNAs, but have been reported to alter miRNA expression 
levels in their hosts during infection. These findings indicate that besides from the 
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expression of viral miRNAs, host miRNA expression might be indicative of the 
presence of infection.  
Host miRNAs have been reported to play a role in controlling viral infections by 
inhibiting viral replication, and in some instances, viruses have been reported to 
downregulate these miRNAs to facilitate infection (Cullen, 2013b; Grassmann & 
Jeang, 2008). Nevertheless, it is now thought that most viruses might have 
evolved other mechanisms to avoid being controlled by host miRNAs, such as 
short 3’UTRs (reviewed in Cullen (2013a)). On the other hand, some viruses have 
been found to stimulate the expression of certain host miRNAs that target host 
mRNAs with antiviral potential or other host miRNAs that might benefit them 
(Cullen, 2013b; Grassmann & Jeang, 2008). Some well-known examples of 
dysregulated host miRNAs in viral infection are: EBV induced expression of miR-
155 in infected B cells, miR-155 can promote oncogenic transformation in B cells, 
aiding infection spread (Cameron et al, 2008). A unique mechanism is the one 
used by HCV, miR-122 is known to bind to the 5′-UTR of the viral genome and 
enhance HCV replication (Jopling et al, 2005). In contrast, expression of host 
miRNAs miR-199a and miR-210 reduced replication of HBV by binding to viral 
proteins (Zhang et al, 2010a).  
Some commonly deregulated miRNAs in oncogenic virus infections include miR-
155, miR-21, miR-31, miR-130b, miR-93 (Bolisetty et al, 2009; Vojtechova & 
Tachezy, 2018; Yeung et al, 2008). Roles of these miRNAs include inhibition of 
apoptosis and promoting cell proliferation (Vojtechova & Tachezy, 2018). 
To this date, no betaretroviruses have been reported to encode miRNAs. Analysis 
of MMTV revealed that it does not encode miRNAs, but host miRNA expression 
was found altered during infection. Infection with MMTV increased the expression 
of the oncogenic cluster miR-17-92 and miR-183 (Kincaid et al, 2018). miRNA 
expression has also been examined in ENTV-2 infection, no miRNAs have been 
reported to be encoded by the virus but miRNAs miR-34c, miR-143c, miR-190, 
miR-133a, miR-218, miR-490 and miR-10a were reported to be downregulated in 
nasal tumours of goats (Wang et al, 2016). Serine/threonine-protein kinase B-raf 
(BRAF) was a predicted target of miR-133a and novel identified miRNAs (Wang 
et al, 2016). Downregulation of miR-133a could thus, result in overexpression of 
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BRAF, which is a regulator upstream of the RAS-RAF-MEK-ERK pathway (Wang 
et al, 2016). Upregulation of this signalling pathway could lead to overproliferation. 
Similarities were found between miRNA expression in affected goats and studies 
of human nasopharyngeal carcinoma: miR-200 was found upregulated, and miR-
9, miR-34 and miR-143 dowregulated in both samples from affected goats and 
humans (Wang et al, 2016). In addition, computational predictions have not 
identified miRNA candidates in any other member of the Retroviridae family 
(Burke et al, 2015; Kincaid et al, 2012; Kincaid et al, 2014). However, as previously 
mentioned, computational predictions might not be able to detect miRNAs that do 
not have a predicted morphology or the typical pol III promoter.  
1.6 General aims 
In the present study, it was hypothesised that miRNAs play a role in JSRV-
infection and the oncogenic process. The hypothesis that expression of host 
encoded miRNAs is altered in JSRV-infection and, that JSRV encodes a miRNA 
were explored. In addition, it was hypothesised that differences in miRNA 
expression between JSRV-infected and uninfected animals could be exploited as 
biomarkers of OPA.  
To explore these hypotheses the following aims were established: 
 Detect miRNA expression in lung of JSRV-infected sheep and compare it 
to miRNA expression in uninfected sheep.  
 Detect differences in miRNA expression in JSRV-infected and uninfected 
sheep in biofluids. 
 Develop an in vitro system to study the role of miRNAs in the 
transformation process.  
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Chapter 2 Materials and Methods 
2.1 Preparation of JSRV21 viral particles 
JSRV21 viral particles were produced by in vitro transfection of the 293T cell line 
with the plasmid pCMV2JS21, which encodes an infectious molecular clone 
(Palmarini et al, 1999b). Transfections were performed in T75 flasks with 10 µg 
total DNA per flask using Fugene HD according to the manufacturer’s 
recommendations.  Forty-eight hours post-transfection the supernatant from cell 
culture was collected and concentrated by ultracentrifugation onto a glycerol 
cushion. The concentrated supernatant was subsequently resuspended in PBS 
and by RT-qPCR it was determined to contain 2.5 × 109 RNA copies of JSRV21 
per ml. Mock inoculate was prepared in the same manner using supernatant from 
untransfected cells. Mutant JSRV21 particles were produced in the same way with 
a JSRV-EnvM574A molecular clone, kindly gifted by Professor Hung Fan, 
University of California at Irvine. This molecular clone encodes an infectious but 
transformation deficient JSRV21 mutant with a single amino acid change in the 
cytoplasmic tail region of Env (Hull & Fan, 2006). 
2.2 Experimental infection of SPF lambs 
Samples from two experimental infections that took place in 2007 and 2015 were 
used in this project. Animal experiments were approved by the Moredun Research 
Institute Animal Welfare and Ethical Review Board and performed in conformance 
with the Animal Scientific Procedures Act 1986.  
In experimental infection 07, pregnant ewes were hysterectomised, and full-term 
Scottish blackface lambs still in the uterus were disinfected in tanks. Lambs were 
resuscitated, bottle fed and separated into two groups housed in different rooms 
under specific pathogen free (SPF) conditions. At six days of age lambs were 
inoculated intratracheally using an 18 gauge intravenous cannula to deliver the 
infectious inoculate and the mock inoculate to age-matched control lambs. Lambs 
were euthanised by intravenous injection of barbiturate at the first presentation of 
respiratory distress, and an age-matched control was euthanised at the same 
time.  
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Samples were collected post-mortem following a strict procedure that included 
taking lung tissue samples from 24 fixed sample sites, lymph nodes, kidney, liver 
and spleen to obtain a picture of the disease state of the lamb. Samples were 
preserved in 10% buffered formalin, and liquid nitrogen. Fig. 2.1 shows a 
summary of the experimental design, the complete published study can be found 
at (Martineau et al, 2011).  
 
Figure 2.1. Summary representation of the samples used in this project from the 
experimental infection performed in 2007. Numbers in brackets indicate the number of 
lambs per group. Each square represents an individual lamb with its ID number.  
In experimental infection 15, three groups, each containing 8 lambs, were studied. 
The first group was inoculated with wild-type JSRV, the second group was 
inoculated with the JSRV mutant (JSRVmut) (JSRV-EnvM574A). The third group 
served as control and was mock-inoculated with 293T conditioned medium. The 
experimental infection procedure was carried out as described for infection 07. As 
in the previous experimental infection, animals showing signs of respiratory 
distress were euthanised with age-matched controls from the other two groups. 
Fig. 2.2 shows a summary of the experimental design.  
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Figure 2.2. Summary representation of the experimental infection performed in 2015. 
Numbers in brackets indicate the number of lambs per group. Each square represents an 
individual lamb with the reference SPF number inside. 
 
Table 2.1. Summary of lamb information for the 2007 experimental infection. 







Lung fluid2, OPA 
lesions in both lungs 








Lung fluid, OPA 
lesions in one lung 




Lung fluid, OPA 
lesions and area of 
atelectasis 
Male 85 dpi SPF482 
SPF479 Mock-inoculated None Male 66 dpi - 
SPF481 Mock-inoculated None Male 71 dpi SPF477 
SPF482 Mock-inoculated None Male 85 dpi SPF478 
SPF484 Mock-inoculated None Female 85 dpi SPF476 
1 Only individuals used in RNA-sequencing are shown 
2 In all SPF cases described here, lung fluid was not a clinical finding but a pathological one. It was 
observed when lungs were cut post-mortem.  
3 Dpi: days post-infection.  
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Table 2.2. Summary of lamb information for the 2015 experimental infection. 
ID1 Group Pathology findings Gender Culled Siblings 
SPF4 JSRV21 
Lung lesions typical of OPA. 
Only lamb with lesion within 
bronchus. Allergic response. 
Male 34 dpi2 
SPF5, 
SPF6 
SPF7 JSRV21 Lung lesions typical of OPA Female 39 dpi 
SPF8, 
SPF9 




Lung lesions typical of OPA. 
Allergic reaction.  




Lung lesions typical of OPA.  
Allergic reaction. 
Male 37 dpi SPF21 
SPF23 JSRV21 Lung lesions typical of OPA Male 39 dpi SPF22 
SPF27 JSRV21 Small OPA tumours Female 153 dpi - 




No OPA lesions. Higher number 
of macrophages than control. 
Male 40 dpi SPF3 
SPF5 JSRVmut 
No OPA lesions. Allergic 
reaction. 




No OPA lesions.  Allergic 
reaction. More macrophages 
than control. 




Mild suppurative bronchiolitis. 
Allergic reaction. 




No OPA lesions. Higher number 
of macrophages than control. 
Male 40 dpi 
SPF14, 
SPF15 
SPF3  Mock No OPA lesions Male 40 dpi SPF1 




No OPA lesions. Allergic 
reaction 




No OPA lesions. Allergic 
reaction 
Male 33 dpi 
SPF10, 
SPF11 




Manipulation damage to lungs. 
No OPA lesions. 
Female 61 dpi SPF23 
SPF26 Mock 
No OPA lesions. Allergic 
reaction 
Male 152 dpi - 
SPF29 Mock None.  Female 152 dpi 
SPF30, 
SPF31 
1 Only individuals used in miRNA RT-qPCR or small RNA sequencing are shown 
2 Dpi: days post-infection.  
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2.3 Natural cases of OPA  
Twenty-three adult sheep were received at the post-mortem (PM) rooms of the 
Moredun Research Institute between the 1st of February 2016 and the 11th of 
February 2016 (Table 2.3). All animals were suspected cases of OPA from four 
different farms. Blood samples were extracted prior to euthanasia using 18 gauge 
needles (Greiner Bio-One) and red vacutainers with clot activator (BD 367895) 
(BD). Animals were euthanised by intravenous injection of pentobarbital and post-
mortem, lungs were removed from the carcass. Lungs were visually examined for 
tumour presence and sectioned using a sharp blade; two tissue sections were 
collected in formal saline pots (Cellpath) and two were snap frozen in liquid 
nitrogen and stored at -80ºC for histopathology examination and further analysis.  
In the study of serum, OPA negative sheep received at the post-mortem rooms 
were used as controls, and samples collected in the same manner as samples 
from OPA affected sheep. OPA negative status was confirmed by histological 
examination of several lung sites. As OPA negative animals received at PM rooms 
typically presented with poor condition and body score, four healthy adult sheep 
from the Moredun flock were also used as control blood donors.  
In the study of natural OPA tissue, samples from ten adult sheep, received at the 
Moredun PM rooms, which had tested positive for OPA were used (Table 2.4). 
Six ewes were used as healthy controls, these ewes were the dams of lambs used 
in the experimental infection that took place of 2015 and had tested negative for 
OPA by histological examination of lung sections taken from six sites post-
mortem.  
In the study of miRNA expression from BALF macrophages, 11 adult sheep were 
received at the Moredun PM rooms from Scottish farms. Animals were classified 
in three groups: OPA-affected, Parasite-infected (where only lungworms were 
present) and healthy controls, if the lungs appeared healthy (Table 2.5). 
 
BALF samples were obtained using established methods. Briefly, following 
euthanasia, the trachea was transected and occluded to prevent blood 
contamination of the lungs. The lungs, with trachea attached, were removed and 
transferred to a clean working area. The trachea was again transected at 
  
Chapter 2: Materials and Methods 84 
approximately 14 cm from the carina. Approximately 1 L of sterile PBS (Sigma 
Aldrich) with 5% FBS (Sigma Aldrich) was instilled into the lungs using a cuffed 
endotracheal tube. Following gentle massage of the lungs, the BALF was 
retrieved by gravity. BALF was immediately placed on ice and processed within 
30 minutes of collection. 
Table 2.3. Animal information from healthy controls and natural OPA cases received 
at PM rooms for serum analysis. 
















It had an abscess in the 
lung too, tissue sample 
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Table 2.3. Animal information from healthy controls and natural OPA cases received 
at PM rooms for serum analysis. 





















Little serum recovered, 
instead there was a 
white thick liquid. Could 






































































Female N/A No 
Healthy blood donor 







Female N/A No 
Healthy blood donor 







Female N/A No 
Healthy blood donor 







Female N/A No 
Healthy blood donor 
from Moredun flock. 
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Table 2.4. Animal information from healthy controls and natural OPA cases received at 
PM rooms for lung tissue analysis. 
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Abscess and worm 
lesions in other areas 
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Table 2.5. Animal information from cases received for BALF macrophage isolation. 

































































Female lungworms No  
 
2.3.1 Histopathology examination  
Examination of formalin fixed tissue sections was conducted by the Pathology 
Department at the Moredun Research Institute. Tissue staining with haematoxylin 
and eosin as well as immunohistochemistry for JSRV-Env (section 2.10) were 
performed. Test results were used to determine the presence or absence of OPA 
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2.4 Processing of samples  
2.4.1 Serum extraction from blood samples 
Blood samples collected in vacutainers were left to clot at room temperature. After 
a maximum of 4 hours, blood samples were centrifuged at 1,912 × g for 10 minutes 
at 4ºC. The supernatant, consisting of the serum fraction, was transferred to 
centrifuge tubes and spun at 17,000 × g for 10 minutes at 4ºC to pellet any 
remainders from other blood fractions. Serum was preserved in 1 ml aliquots at -
80ºC for future analysis. 
Several reports have shown that haemolysis affects miRNA detection in serum 
and plasma samples (Kirschner et al, 2011; McDonald et al, 2011a; Pritchard et 
al, 2012). In this study, the extent of haemolysis was controlled by reducing the 
storage time of samples at room temperature to a maximum of 4 hours. Serum 
samples were also visually inspected, and aliquots with a detectable pink colour 
were discarded.  
2.4.2 RNA extraction from serum samples 
RNA extraction from sera was performed using TRIZOL LS (Thermo Fisher 
Scientific) and following the manufacturer’s instructions with some modifications. 
Briefly, samples were first diluted 1:1 with distilled water, three volumes of Trizol 
LS were then added and mixed until homogenised. Chloroform (0.8 volumes) was 
then added and mixed vigorously to facilitate precipitation of DNA and proteins. 
After incubating for 10 minutes at room temperature, samples were spun at 17,000 
× g for 10 minutes at 4ºC in a table-top microcentrifuge. The aqueous phase, 
containing the RNA, was transferred to a new tube and two volumes of 
isopropanol and 1 µl of GlycoBlue (Invitrogen) were added and mixed. GlycoBlue 
consists of a blue dye linked to glycogen, it co-precipitates with nucleic acids and 
aids in pellet visualisation.  After incubating for 10 minutes at room temperature, 
samples were centrifuged 17,000 × g for 30 minutes at 4ºC, and the presence of 
blue pellets containing the precipitated RNA observed in the samples. Two 
washes were performed using two volumes of 70% ethanol. After the second 
wash, pellets were air-dried and resuspended in 15 µl of RNAse-free water. 
Extracted RNA samples were stored at -80ºC.  
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2.4.3 Cryosectioning and homogenisation of lung tissue 
samples 
Sections of lung tissue collected post-mortem were stored at -80ºC until 
cryosections were to be cut. The FSE cryostat (Thermo Fisher Scientific) was set 
at -20ºC chamber temperature, -55ºC cryobar temperature, -20ºC specimen 
temperature and 15 μm cut thickness. Three 15 μm sections from each specimen 
were added to Lysing matrix D 2 ml tubes (MP Biomedical) containing 350 μl of 
RLT plus buffer (Qiagen) with 5% β-mercaptoethanol (BDH). β-mercaptoethanol 
is a reducing agent that when present in the buffer inactivates the RNAses present 
in the sample helping to prevent RNA degradation. 
For experimental cases, eight tissue sections, corresponding to eight distinct lung 
sites, were cryosectioned and extracted per animal. In contrast, for natural cases 
one section was used per animal. These differences in sample processing were 
made based on the nature of the tissue being used. As described in section 1.3.1, 
in early experimental OPA cases tumours tend to be small and diffuse with only a 
small percentage of tumour found per tissue section. Thus, processing eight 
sections from different locations in the lung ensures obtaining a global view of the 
events taking place in the lung. On the other hand, in advanced cases of OPA, 
tumours are larger and take up a higher proportion of the tissue sections obtained 
(in our case around 50%) meaning one section should give us a general 
representation of OPA affected lung. 
Cryosectioned samples were kept on ice and homogenised using the Precellys 
24 (Bertin Technologies).  Two cycles of 30 s at 6,000 rpm, with a 2 minute interval 
on ice, were performed. After homogenisation samples were stored at -80ºC for 
future RNA extraction.  
2.4.4 Processing of BALF samples  
BALF cells (section 2.3) were processed to isolate CD14-positive cells by Anna 
Karagianni, as previously described (Clark et al, 2017; Karagianni et al, 2017). 
Briefly, CD14 positive cells were isolated using human anti-CD14 magnetic 
microbeads (MACS, Miltenyi Biotec), according to the manufacturer’s instructions.  
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Flow cytometry confirmed that over 95% of the purified CD14-positive cells also 
expressed the macrophage marker CD163 (Anna Karagianni, unpublished). 
2.4.5 RNA extraction from lung tissue, BALF and cell culture 
samples 
RNA extraction was performed using the RNeasy Plus micro kit (Qiagen) following 
the manufacturer instructions in Appendix D to obtain total RNA containing the 
small RNA fraction (<200 nt), where miRNAs are expected to be found. This kit 
uses gDNA binding columns to eliminate the small quantities of genomic DNA 
found in the sample, while RNA is eluted due to the high-salt buffer conditions. 
The eluate containing RNA is then mixed with ethanol to enable binding to the 
MinElute columns of the kit. After several washes to remove other contaminants, 
RNA is then eluted in RNAse-free water.  
2.4.6 RNA extraction for high RNA yield 
Some techniques performed in this project required high RNA concentrations and 
thus, higher quantities of starting material, not compatible with the previously 
reported methods for RNA extraction.  
2.4.6.1 From cell culture samples 
RNA extraction from cell culture samples was performed using the RNeasy plus 
mini kit (Qiagen) following the manufacturer’s instructions in appendix D, which 
allow for extraction of total RNA containing small RNAs. Up to 1 × 107 cells were 
stored in 700 µl of RLT+ buffer, and homogenised centrifuging for 2 minutes at 
20,000 × g in Qiashedder columns (Qiagen). Homogenised samples were loaded 
into gDNA eliminator columns and centrifuged at 20,000 × g for 30 s, the flow-
through was saved. The flow-through, containing RNA, was mixed with 1.5 
volumes of 100% ethanol and up to 700 µl loaded into an RNeasy spin column. 
The RNeasy spin columns were centrifuged for 30 s at 20,000 × g and the flow-
through discarded, the process was repeated until all the sample had passed 
through. The column containing the adsorbed RNA was placed in a new collection 
tube and 500 µl RPE buffer added and centrifuged at 20,000 × g for 2 minutes. 
The flow-through was discarded, and the wash process repeated but centrifuging 
for 30 s. Once washed, the column was placed in a new collection tube and 
centrifuged for 1 minute at 20,000 × g to eliminate residual buffer. To elute the 
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RNA, the column was placed in a 1.5 ml tube and 30 µl RNase-free water added 
into the centre of the column. The column was left to stand for 2 minutes and RNA 
eluted by centrifuging 1 minute at 17,000 × g. RNA was kept at -80°C.  
2.4.6.2 From lung tissue 
RNA extraction from lung tissue to obtain high RNA concentrations were 
performed using the Direct-zol RNA miniprep plus procedure (Zymo) and following 
the manufacturer’s directions. All centrifugation steps were performed at 20,000 × 
g.  
Up to 50 mg of lung tissue were placed in Lysing matrix D 2 ml tubes containing 
600 µl of direct-zol reagent. Samples were homogenised in the Precellys 24 (four 
cycles of 30 s at 6000 rpm, with 2-minute intervals on ice). Homogenised samples 
were centrifuged to pellet remaining debris and the supernatant was transferred 
to a new tube, where it was mixed with an equal volume of 100% ethanol. Up to 
700 µl of the sample was then loaded into the column and centrifuged for 30 s, 
the flow-through was discarded and process repeated until all the sample had 
passed through. The column was placed in a new collection tube and 400 µl of 
RNA wash buffer added, the column was centrifuged for 30 s and flow-through 
discarded. 5 µl of DNase were mixed with 75 µl of DNase buffer, loaded into the 
column and incubated for 15 minutes at room temperature to degrade DNA. After 
the incubation, two washes with 400 µl of direct-zol buffer were performed and 
flow-through discarded. 700 µl of RNA wash buffer were then added, centrifuged 
for 2 minutes and flow-through discarded. The column was placed in a 1.5 ml tube 
and 50 µl of RNase-free water added to the centre, left to stand for 1 minute and 
RNA eluted by centrifuging for 1 minute. RNA was stored at -80°C.  
2.4.7 Concentration and purification of RNA samples 
When highly concentrated RNA samples were required, RNA was concentrated 
by ethanol precipitation. 0.1 volumes of 3M sodium acetate (pH 5.0-5.2) (Sigma 
Aldrich) were added to RNA samples, followed by 2 volumes of ice-cold 100% 
ethanol, and 1 µl of 20 mg/ml glycogen (Roche) to aid pellet visualisation. Samples 
were incubated at -80°C for 1 hour. After incubation, samples were centrifuged at 
20,000 × g for 15 minutes. The pellet was then washed with 75 % ethanol twice 
to remove residual phenol, after performing the washes the pellet was left to air-
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dry until fully transparent. RNA was then resuspended in RNase-free water, to 
help RNA dissolve it was heated at 60 ◦C for 10 minutes.  
2.4.8 Assessment of RNA concentration and quality  
Assessing the RNA for integrity and purity is critical to ensure only high quality 
material is used in downstream analysis. It has been reported that low integrity 
and purity of RNA samples affects downstream applications and assays such as 
RT-qPCR, whereas high quality material produces reliable results (Becker 2010).  
2.4.8.1 Spectrophotometric analysis of RNA 
Nanodrop spectrophotometer ND-1000 and Nanodrop ONE (Thermo Scientific) 
were used to analyse the extracted RNA. The RNA measurement option was 
selected and the spectrophotometer blanked with RNase-free water except for 
serum samples, for which the blank contained the equivalent concentration of 
GlycoBlue of the samples to avoid the absorbance of the dye interfering with 
results. 1.1 µl from each sample were assayed. Nucleic acid concentration 
(measured at 260 nm), as well as 230 nm and 280 nm absorbance measures were 
obtained. Absorbance ratios were used to evaluate sample purity. The 260/280 
ratio was used to determine the presence of proteins, which absorb at 280 nm, in 
the sample. For RNA, ratios of 2.0 are considered pure, and ratios above 1.8 are 
considered suitable for expression analysis (Becker et al, 2010). The 230/260 ratio 
indicates presence of contaminants such as phenols or other organic compounds. 
For pure RNA 230/260 ratios are between 2.0-2.2.  
2.4.8.2 Electrophoresis analysis of RNA quality  
Electrophoretic analysis of RNA was performed using the Agilent Bioanalyser 
2100 (Agilent Technologies) and Agilent RNA 6000 Nano assay and RNA Nano 
chip (Agilent Technologies) to obtain concentration, integrity and size 
measurements. RNA samples were thawed on ice and all reagents were 
equilibrated at room temperature 30 minutes before use. The electrophoretic 
analysis was performed as instructed in the manufacturer’s protocol. Electrode 
decontamination was performed using RNasezap (Invitrogen) and RNase-free 
water, before and after running the assay. Prior to the analysis samples were 
denatured at 70°C for 2 minutes. Once set up following manufacturer’s 
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instructions the Nano chip was vortexed at 2400 rpm for 1 minute and processed 
in the Agilent 2100 analyser within 5 minutes of sample addition. 
The Agilent Nanochip system provides measurements of RNA integrity which are 
expressed as RNA integrity numbers (RIN). RIN values are calculated based on 
the ratio of areas under the 18S and 28S peaks of the electropherogram, and can 
range from 1 to 10. A value of 1 indicates fragmentation and a value of 10 indicates 
intact RNA with little degradation. 
Even though this assay was originally designed to measure RNA integrity and the 
RIN values obtained do not assay for small RNA species, such as miRNAs, 
studies have shown that high integrity values for total RNA are positively 
correlated with good integrity of miRNAs. RIN values above 5 have been reported 
to produce reliable results in RT-qPCR (Becker et al, 2010). 
2.5 RNA sequencing  
RNA samples were sent to Edinburgh Genomics to perform small RNA 
sequencing. Library preparation was done using the TruSeq Kit (Illumina) and 
checked by HS Qubit and Bioanalyser. Sequencing was performed using Ilumina 
Hiseq v4 HO 50-base single-end sequencing.  
2.5.1 Bioinformatics analysis of RNA sequencing results  
Bioinformatics analysis of small RNA sequencing data was performed by 
Edinburgh Genomics. In brief, raw data was analysed for quality and low quality 
reads and adapters trimmed using Cutadapt. Reads longer than 28 nt and shorter 
than 17 nt were filtered out. The remaining reads were then mapped to miRBase 
using novoalign (Novocraft Technologies) with parameters: -m, -s 1, -t 30, -h 60. 
Reads were mapped to ovine, bovine, human and caprine entries of mirBase 
v.22.1. Sequence distribution and length distribution plots were created using 
Rstudio.  
Reads that mapped to miRNAs of different species (oar-, bta-, hsa-, chi-) with 
identical sequences were merged with the use of a custom-made R script. Bam 
files were then analysed and raw reads normalised in Matlab based on size 
factors. This normalisation approach consists in considering a size factor for each 
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library to compute the effective library size. The size factors are calculated by 
taking the median of the ratios of observed counts to those of a reference sample, 
whose counts are calculated by calculating the mean of each gene across all 
samples (Anders & Huber, 2010). By dividing the counts of each library by the 
corresponding size factors, all counts are in the same scale, making them 
comparable.  
A threshold was then established to remove reads with low number of normalised 
counts from the differential expression analysis. An average of 50 normalised 
counts across samples was established as a cut-off, based on published literature 
and the present data (Koh et al, 2010; Motameny et al, 2010; Spornraft et al, 2014; 
Taxis et al, 2017).  
Differential expression analysis and statistics were also performed in Matlab using 
the negative binomial model (nbintest) with the 'Constant' option. A threshold of 
FDR < 0.05 was established as statistically significant.  
Data used for PCA plots consisted of normalised counts of all miRNAs above the 
established threshold of an average of 50 normalised counts. PCA plots were 
created using Rstudio, the pam {cluster} function of ggplot2 (ggfortify) was used. 
Default options of the pam function were used except for aesthetics, which were 
based on Group. 
Data used for heatmaps consisted of the DE miRNAs. Heatmaps were created 
using Rstudio, the pheatmap function was used. Default options of the pheatmap 
function were used, with the following exceptions: scale was set to “row”, column 
clustering distance was "correlation", row clustering distance was “euclidean”, 
clustering method was “average” and the annotation_col argument was used to 
show samples assigned to groups in the plot.  
Reads were also mapped to JSRV (AF105220.1) and enJSRV sequences 
(EF680301.1) to look for the presence of viral miRNAs. Reads were counted using 
a custom-made Perl Script that allowed only 1 mismatch. Alignments were 
visualised using IGV.  
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2.6 Reverse transcription quantitative polymerase 
chain reaction (RT-qPCR) for detection of miRNAs 
The expression of miRNAs was assessed using reverse transcription quantitative 
PCR (RT-qPCR). The RT-qPCR approach chosen was the TaqMan™ Advanced 
miRNA cDNA Synthesis Kit (Applied Biosystems) in conjunction with Taqman 
Advanced miRNA assays (Applied Biosystems). The reasons for the selection of 
this approach were the high accuracy and reliability of Taqman probes and the 
ability of the method to detect low miRNA concentrations. All tissue RNA samples 
were diluted to a concentration of 5 ng/µl, and 2 µl used as starting material for 
the protocol, for serum samples 2 µl were used as starting material. All reactions 
were performed according to the manufacturer’s protocol. In brief, the protocol 
included a poly-A tailing reaction and a ligation reaction to be performed before 
the reverse transcription reaction, allowing universal primers to be used in the 
reverse transcription reaction. A universal amplification reaction followed the 
reverse transcription, this reaction increased the starting cDNA input for qPCR. 
All these reactions were performed in the Biometra T-one thermocycler (Analytik 
Jena). Quantitative PCRs (qPCRs) were set up as instructed in the manufacturer’s 
protocol using the Taqman universal PCR mastermix (Applied Biosystems) and 
each of the specific sample-target combinations were assayed in duplicate. qPCR 
reactions were set up in 96-well plates and run in the ABI 7500 Real time PCR 
system (Applied Biosystems) with the following cycling stages: 2 minutes at 50°C,  
10 minutes at 95°C, and 40 cycles of 95°C for 15 seconds followed by 1 minute at 
60 ◦C.  
Levels of nine miRNAs (miR-135b, miR-182, miR-183, miR-200b, miR-205, miR-
21, miR-31, miR-503 and miR-96) and an endogenous control miRNA (miR-191) 
were investigated. miRNA sequences targeted by the assays and the sequences 
found in the small RNA sequencing data can be found in the Appendix. The 
assays selected could detect the miRNA sequences in sheep cells, human cells 
and dog cells. 
2.6.1 Validation of RT-qPCR parameters  
Efficiency was assessed by making six serial dilutions of the template in molecular 
grade water and performing the qPCR reaction in duplicate for each dilution. 
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Master mix preparation and cycling conditions were as stated in section 2.6. qPCR 
efficiency (E) was then calculated by plotting the Ct values of each reaction 
against the logarithm of the template concentration, and fitting a line through the 
points in the plot. The slope of the fitted line was used to calculate the efficiency 
percentage using the following equation: E = (10(-1/slope))-1.  
In ideal conditions the efficiency of the qPCR should be 100%, meaning that in 
each cycle of the logarithmic phase of the reaction the PCR product is doubling. 
Efficiencies that are too low might indicate poor primer or probe design, or need 
for reaction optimisation, whereas higher efficiencies might indicate presence of 
inhibitors in the mix (Bustin, 2004). 
The calculated efficiency for miR-191 was 100.8%, while the efficiencies of miR-
135b, miR-182, miR-183, miR-200b, miR-205, miR-21, miR-31 and miR-503 
ranged from 92.35% to 107.71%. Although the efficiencies deviated from the ideal 
(100%) efficiency, the range of efficiencies achieved fell into what is considered 
acceptable for RT-qPCR studies (90-110%) (Bustin et al, 2009).  
2.6.2 Analysis of RT-qPCR data 
Data obtained from RT-qPCR of miRNAs was analysed following the ddCt method 
(Livak & Schmittgen, 2001). Given that the efficiency of each of the primer assays 
and the control miRNA assay (miR-191) differed by less than 10% (2.6.1), the 
ddCt method was suitable for the analysis of the RT-qPCR results. Because miR-
191 had an efficiency of 100.8%, the base of the equation was not altered, 
reflecting the amplification rate of 2 (Fig. 2.3). 
Briefly, dCts were calculated for each sample individually, averages for each 
group were then calculated and used to calculate ddCt and fold change as shown 
in Fig. 2.3. 
dCt = (Ct target miRNA – Ct reference miRNA) 
ddCt = (dCt treated group – dCt reference group) 
Fold change = (2-ddCt) 
Figure 2.3. Summary of equations used to calculate miRNA expression fold changes, 
based in the ddCt method. 
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Dot plots and bar charts of RT-qPCR data were created using Rstudio. Dot plots 
were used to plot individual dCt values. Dot plots were created using the ggplot 
(geom_point) function and the arguments stat_summary, fun.data, fun.args and 
geom= “crossbar” used to draw the mean ± standard deviation. Bar charts were 
created using ggplot (geom_col) and the argument geom_errorbar to depict 
standard deviations of the log2(fold change).  
Correlation plots were created using Rstudio ggplot. The arguments geom_point, 
geom_smooth and geom_cor were used with default parameters. Confidence 
level was established at 0.95 and chosen method was “pearson”.  
Statistical tests were performed on dCt values using Minitab 17. When pairwise 
comparisons were performed the two-sample t-test was used, when three groups 
were compared the one-way ANOVA test was used. In all cases, the threshold for 
statistical significance was established at p< 0.05.  
2.7 Culture of cell lines  
2.7.1 Heat inactivation of fetal bovine serum  
Fetal bovine serum (FBS) was used in the culture of cell lines to supply growth 
factors needed for optimal in vitro culture. Heat inactivation of FBS was performed 
to inactivate complement factors as well as other factors that could inhibit cell 
growth.  
FBS (Sigma Aldrich) was thawed at 37°C. Once thawed, FBS was heat inactivated 
for 30 minutes at 56°C swirling the FBS bottle every 10 minutes. Heat inactivated 
FBS (HI-FBS) was stored in 25 ml aliquots at -20°C.  
2.7.2 Preparation of growth media  
Preparation of growth media for culture of cell lines was done in class 2 
microbiological safety cabinets (CAS) and maintaining sterility throughout the 
process. Various types of growth media were used and supplemented depending 
on the requirements of the cell lines to be grown. Complete media were kept at 
4°C for up to 1 month. A summary of the growth media and supplements needed 
to culture each cell line can be found in Table 2.6.  
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Table 2.6. Summary of growth media composition for each cell line used. 







Media Eagle (MEME) 
(Sigma Aldrich) 
2 mM glutamine (MRI in-
house), 1% non-essential 
aminoacids (NEAA) (Sigma 
Aldrich), 10% HI-FBS 
MDCK 





Eagle Medium (DMEM) 
(Sigma Aldrich) 
2 mM glutamine, 1% NEAA, 
10% HI-FBS, 20 µg/ml 














(IMDM) (Sigma Aldrich) 
4 mM glutamine, 1% NEAA, 
10% HI-FBS, 20 µg/ml 
















4 mM glutamine, 10% HI-FBS, 
20 µg/ml gentamicin, 1% 
Penicillin/Streptomycin (10,000 
units penicillin/mL, 10,000 μg 
streptomycin/mL) (MRI in-
house), 1.25 µg/ml 








2 mM glutamine, 1% NEAA, 








2 mM glutamine, 1% NEAA, 
10% HI-FBS, 20 µg/ml 
gentamicin 
 
2.7.3 Cell thawing 
Cryovials of cells stored in liquid nitrogen were thawed in a 37°C water bath. 
Thawed cells were then added to a T-75 cell culture flask (Corning) and 20 ml of 
growth medium added dropwise while gently swirling the flask to ensure an even 
mix and to aid the cells in the thawing process, decreasing dimethyl sulfoxide 
(DMSO) (Sigma Aldrich) concentration gradually. 
2.7.4 Passage of cells in culture 
Cell lines were passaged two-three times a week. Briefly, growth medium was 
removed, a phosphate buffered saline (PBS) (MRI in-house) wash was performed 
and a dissociation agent added and incubated at 37°C until cells had detached 
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from the culture vessel. An equal amount of growth medium was added to the 
cells suspended in the dissociation reagent to stop the reaction. The cell 
suspension was then split as required and cultured in new vessels. Table 2.7 lists 
the dissociation reagents used for each cell line.  
Table 2.7. Summary of dissociation reagents used for each cell line. 
Cell line Dissociation reagent Incubation time 
208F, CPT-Tert, JA584, 
JS-7, NIH 3T3 
0.0125% Trypsin and Versene (3.2 
mM EDTA) (MRI in-house) 
5 minutes 
MDCK, CRFK TrypLE express (Gibco) 20 minutes 
293T 
0.00125% Trypsin and Versene (0.32 
mM EDTA) in PBS 
3 minutes 
 
2.7.5 Cryopreservation of cells 
Cells growing in T-75 flasks were harvested as described in section 2.7.4 and after 
the incubation time trypsin or TrypLE express were inactivated with 3 ml HI-FBS. 
The cell suspension was then transferred to a 50 ml Falcon tube and centrifuged 
for 10 minutes at 212 × g at room temperature. For each T-75 flask, three 1 ml 
aliquots were frozen (approximately 1 x 107 cells per vial). After centrifugation, the 
supernatant was discarded and cells resuspended in half the final freezing volume 
of medium containing 20% HI-FBS (e.g. 1.5 ml for each T-75 flask). Next, the 
same volume of medium containing 20% HI-FBS and 20% DMSO was added 
dropwise to facilitate cell adaptation to the DMSO concentration. The final medium 
composition was 20% HI-FBS and 10% DMSO.  Cells were aliquoted in cryovials 
in volumes of 1 ml, placed in a freezing box containing isopropanol and stored at 
-80°C overnight. The use of isopropanol in freezing boxes ensures a controlled 
freezing process, with an approximate temperature decrease of one degree 
Celsius per minute. The following day cells were transferred to liquid nitrogen 
storage. 
2.7.6 Cell counts 
The concentration of cells growing in culture was determined with the use of a 0.1 
mm depth improved Neubauer chamber (Hawksley). Briefly, cells were harvested 
and diluted 1:1 in Trypan blue (Sigma Aldrich) to aid identification of dead cells. 
When using the dye, cells with intact membranes exclude it and appear 
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uncoloured, while dead cells present a dark blue colour when observed under the 
microscope. 100 ul of Trypan blue diluted cells were added to both chambers of 
the haemocytometer and the number of cells in the middle square of each of the 
chambers counted. If the difference in cell number between the two middle 
squares was less than 10% calculations were made from the average cell number. 
Otherwise, all squares were counted and averaged. Cell concentration was 
calculated as below: 
𝑐𝑒𝑙𝑙𝑠/𝑚𝑙 =
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 ∙ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑐ℎ𝑎𝑚𝑏𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (0.0001 𝑚𝑙)
 
 
2.8 Transfection of DNA plasmids  
Introduction of DNA plasmids (Table 2.8) into cells in culture was performed by 
two different means of transfection depending on the ease of introducing DNA 
material in that particular cell line.  
2.8.1 Lipid-based methods of transfection  
Lipid based-transfection methods can be liposomal or non-liposomal. Liposomal 
methods contain lipids which encapsulate the DNA in a phospholipid bilayer, these 
liposomes have affinity for the cell membrane and are incorporated into the cell 
by endocytosis (Felgner et al, 1987; Jacobsen et al, 2004).  
Non-liposomal methods of transfection are formed of a mix of lipids and polymers 
which do not form liposomes, but which also encapsulate the DNA in amphiphilic 
spheroid particles called micelles (Jacobsen et al, 2004).  
Both these lipid-based methods result in transient transfection, meaning that 
unless there is a recombination event and chromosomal integration occurs-and is 
selected for, cells will only express the foreign nucleic acid for a short time period.  
2.8.1.1 Non-liposomal transfection 
The reagent selected to perform non-liposomal transfection was Fugene HD 
(Promega). The optimum ratio of Fugene HD and DNA was trialled by David 
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Griffiths prior to this study and found to be 3:1 (microliters of Fugene per 
micrograms of DNA). 
Transfections were performed in cultures growing at 80% confluency which had 
been passaged two successive days before the transfection procedure was to be 
performed. Transfection complexes were prepared by mixing 150 µl Opti-MEM 
medium (Gibco) (or 1 ml for T-75 flasks) with Fugene HD, and then adding DNA 
at the desired ratio. The reagent mix was incubated at room temperature for 20 
minutes to allow transfection complexes to form. In the meantime, medium from 
cells in culture was replaced with 1 ml of fresh medium per well of 6-well plates or 
7 ml in the case of T-75 flasks.  
Transfection complexes were added dropwise while lightly swirling the plate to 
ensure an even distribution. Transfections were left to proceed overnight at 37°C. 
The following day, cells were observed and media changed.  
To select stably-transfected cells, when appropriate, cells transfected with a 
plasmid containing a neo resistance gene were selected by adding 0.5 mg/ml of 
the antibiotic Geneticin G418 (Sigma Aldrich) to growth media.  
2.8.1.2 Liposomal transfection 
The reagent selected to perform liposomal transfection was Lipofectamine 3000 
(Invitrogen). Lipofectamine 3000 was used to transfect the NIH 3T3 and MDCK 
cell lines, in which the use of Fugene HD had resulted in low transfection 
efficiency. 
P3000 reagent was mixed with DNA at a 2:1 ratio and 50 µl of Opti-MEM. 
Liposomes were prepared mixing Lipofectamine 3000 at 3:1 ratio (3 µl per µg of 
DNA) and 50 µl of Opti-MEM. The DNA mix was then mixed with the liposome mix 
and incubated for 15 minutes at room temperature. In the meantime, medium from 
cells in culture was replaced with 1 ml of fresh medium per well of 6-well plates. 
Transfection complexes were added dropwise while lightly swirling the plate to 
ensure an even distribution. Transfections were incubated overnight at 37 ◦C. The 
following day, cells were observed and medium was changed. 
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2.8.2 Nucleofection  
The nucleofection method is based on the use of electroporation, a technique that 
uses electric pulses to create small pores in the cell membrane and deliver nucleic 
acids into the cell. However, contrary to traditional electroporation, nucleofection 
allows the nucleic acid to be delivered to the nucleus instead of the cell’s 
cytoplasm (Maasho et al, 2004). Like lipid-based methods, nucleofection is a 
transient method of transfection unless stably transfected cells are selected for.  
Nucleofection reagents (Lonza) and protocols are designed for each cell type, and 
compared to other transfection methods result in better transfection efficiencies 
for difficult to transfect cells (Maasho et al, 2004). For this reason, nucleofection 
was used to transfect MDCK and NIH 3T3 cells. 
Briefly, the protocol used for nucleofection involved dissociating the cells from 
plates and using between 5 × 105 and 1 × 106 cells per reaction. Cells were pelleted 
at 212 × g for 10 minutes, supernatant removed and cells resuspended in 100 µl 
of pre-warmed Nucleofector solution, 2 µg of DNA were added and the mix 
transferred into a provided cuvette. The cuvette was inserted in the Nucleofector 
II (Amaxa) and the program used as recommended. Once nucleofection finished, 
0.5 ml of media were added with the provided pipette, gently mixed with cells and 
transferred to a well of a 6-well plate containing 1.5 ml fresh media.  
After several trials, Nucleofection kit L and kit R (Lonza) were used for MDCK and 
NIH 3T3 respectively, due to their higher observed efficiency. Program A-024 was 
used for MDCKs and U-030 for NIH 3T3. 
2.8.3 Transformation assays 
In some instances, cells transfected as described in sections 2.8.1 and 2.8.2 were 
maintained in culture to observe transformation events. In those cases, when cells 
reached confluency, the HI-FBS concentration was reduced to 4 % HI-FBS to slow 
the growth rate of non-transformed cells. Cells continued to be checked and split 
when necessary, and when foci of transformed cells were clearly visible these 
were subcultured into new culture plates. 
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Table 2.8. Summary of plasmids used for transfection of cell lines.  
Plasmid name Description Reference 
pCMV2JS21 
Full-length JSRV21 under the 
control of CMV promoter 
Palmarini et al (1999b) 
pJSRV21 
Full-length molecular clone of 
JSRV21. 
Palmarini et al (1999b) 
pCAG-Jsenv 
JSRV env under the control of 
the CAG promoter 
(Szafran, 2014) 
pCMV3JS-dGPP 
JSRV21 under the control of 
CMV promoter, deletions of 
gag and pol 
Maeda et al (2001) 
pCMV2JSRV-GFP2A-Env 
JSRV21 modified to insert a 
GFP coding region upstream 
and in-frame with env, 
separated by a 2A cleavage 
sequence 
D. Griffiths, unpublished 
pEGFP-flag 
Encodes eGFP and FLAG 
epitope tag 
Created by David Griffiths, 
derived from pEGFP-C1 
(Clontech) 
pmaxGFP 
max GFP under the control of 
the CMV promoter 
Lonza 
 
2.9  Northern blot analysis for detection of miRNAs 
The process of northern blot for detection of miRNAs and miRNA candidates was 
performed over the course of four days.  
2.9.1 Electrophoresis of the denaturing acrylamide gel 
Initially, a 15% acrylamide gel was made by combining 12 g of UREA (Sigma 
Aldrich), 12.5 ml of 30% bisacrylamide (29:1 solution) (Bio-Rad) and 2.5 ml of 5x 
TBE buffer (54 g Tris, 27.5 g boric acid, 2.92 g EDTA and water to 1 L) and 10 ml 
of water. The gel mix was incubated at 55 ◦C until components were dissolved and 
homogenous. 10 µl of TEMED (Sigma Aldrich) and 250 µl of 10% APS (Sigma 
Aldrich) were added to the gel mix, and it was immediately poured into Bio-Rad 
gel casts previously cleaned with RNase-Zap (Invitrogen). Gels were left to set for 
1.5 h and then put in gel tanks with 1 L of 0.5x TBE buffer. Urea was cleaned off 
the gel wells by inserting 0.5x TBE buffer with a syringe and needle until no visible 
residue was left. RNA samples were prepared at a 1:1 ratio with NorthernMax-Gly 
loading dye (Invitrogen) and 26 µl added per well. This dye contains ethidium 
bromide, for nucleic acid visualisation, and bromophenol blue, which travels down 
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the gel and produces a band equivalent to ~10 nt in size that can be later used as 
a size indicator. DNA loading dye 6x (Thermo Scientific) containing xylene cyanol, 
was added to empty wells. This loading dye was included because xylene cyanol 
travels down the gel to produce a band equivalent to ~30 nt in size, which can 
also be used as a size marker. The gel was run at 300 V until the bromophenol 
blue band was ~ 1/3 of the way down. 
2.9.2 Transfer of the acrylamide gel 
Following electrophoresis, gels were removed from the cast and observed in a UV 
box to visualise tRNAs and assess sample degradation. The gels were transferred 
to Amersham hybond-N+ membranes (GE healthcare) by putting the gel in contact 
with the membrane, and sandwiching the gel and membrane with filter paper and 
fibre pads. The sandwich was positioned inside a mini-protean gel cassette (Bio-
rad) with the membrane facing the anode. The transfer was performed inside a 
cuvette filled with 1 L of 0.5x TBE for 45 minutes at 30V, followed by 15 minutes 
at 35 V and 15 minutes at 40 V, a stirrer bar was added to the cuvette to distribute 
the heat produced.  
Once the transfer had been completed, the membranes were taken out of the 
cassettes. The marker bands corresponding to 70 nt (tRNAs observed due to 
ethidium bromide presence), 30 nt (band produced by xylene cyanol) and 10 nt 
(band produced by bromophenol blue) were marked with pencil in the membranes 
as size indicators. 
Crosslinking of the RNA to the membranes was performed in the UV Stratalinker 
1800 (Stratagene) at 1200 μJ/m2. Membranes were left to dry overnight at RT.  
2.9.3 Radioactive labelling of oligo probes 
The procedure described in this section was performed in a designated space for 
the work with radioactive isotopes. Once dried, membranes were put inside 
scintillation vials (Biometra) and 8 ml of pre-warmed ExpressHyb buffer (Clontech) 
added. Membranes were incubated in buffer for 1 h at 55 ◦C.  
Oligo probes were prepared for labelling by mixing 1 µl of 10 pmol oligo (Table 2. 
9), 1 µl 4x T4 polynucleotide kinase (PNK) buffer (NEB), 6 µl of water, 1 µl  T4 
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PNK (NEB), 1 µl ATP [γ-32P] 250 µCi (Perkin Elmer). The mix was incubated at 
37 ◦C for 1h to allow P32 labelling of the probes.  
Table 2.9. Oligonucleotide probes used for northern blot analysis of miRNAs.  
Oligo ID Target sequence Sequence (from 5′ to 3′) Manufacturer 




JS-3p Candidate JSRV miRNA 
(3p)  
AATAATTCTAAAGCAGTTTCA IDT 




After incubation, the labelling mix was diluted in 40 µl of water. In order to separate 
P32-labelled oligonucleotides from free ATP [γ-32P], Illustra Microspin columns 
(GE healthcare) were used following the manufacturer’s instructions.  
2.9.4 Northern blot of miRNAs 
Filtered, P32-labelled oligonucleotide probes were added to the pre-hybridised 
membranes in ExpressHyb buffer and incubated in a rolling incubator biometra 
OV5 (Analytik Jena) at 38.5°C overnight.  
The following day, membranes were washed with 40 ml pre-warmed washing 
buffer (2x SSC (20x SSC stock: 175.3 g of sodium chloride, 88.2 g of Sodium 
Citrate to 1 L with water), 0.1% SDS (Sigma Aldrich) in water). Four washes of 20 
minutes were performed, incubations were performed at 38.5°C in the rolling 
incubator.  
Once membranes had been washed, they were put in contact with filter paper, 
prewetted with 2x SSC, and heat-sealed in seal-o-meal. Sealed membranes were 
positioned in contact with Biomax MR film (Carestream) and inside a Biomax MS 
screen (Carestream) to improve sensitivity. The intensifying screen, containing 
film and membranes, was put inside an exposure cassette and incubated a -80°C 
overnight or for up to four days. The following day the film was developed with a 
SRX-101A film processor (Konica Minolta).  
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2.10 Immunostaining procedures 
2.10.1 Dewaxing and rehydration of paraffin-embedded 
tissue 
The process of dewaxing and rehydration is an essential step performed prior to 
immunostaining, it unmasks epitopes allowing antibodies to access them. 
Dewaxing and rehydration were performed in the Varistain (Thermo Shandon). 
Slides were mounted in station 1 and the preset program 2 was used. Program 2 
takes the slides through decreasing concentrations of xylene through to 100% 
ethanol, ethanol concentration is then gradually decreased while water 
concentration is increased reaching a final solution of 100% water.  
2.10.2 Antigen retrieval 
The fixation steps performed to preserve the tissue result in protein crosslinking 
and the formation of methylene bridges, which conceal antibody binding sites. The 
method of antigen retrieval exposes the antigenic sites for the primary antibody.   
For JSRV-SU, antigen retrieval was performed by autoclaving the slides in citrate 
buffer. Briefly, 1 L of citrate buffer (2.1g of citric acid (Sigma Aldrich) in 1L ddH2O 
at pH6.0 (buffered with 1 M NaOH (Fisher Scientific)) was prepared. Slides were 
placed in a metallic rack and inside a 3 L beaker containing 1 L of the citrate buffer. 
The slides were then autoclaved at 121ºC for 10 minutes. Once the slides had 
cooled down, they were washed twice in Tris buffered saline (TBS) (30 ml 5 M 
NaCl (Fisher Chemical), 10 ml Tris (Promega), 1 L water).  
2.10.3 Blocking of endogenous peroxidase activity 
Endogenous peroxidases found in the tissue sample can react with the substrate 
used to reveal immunostaining, resulting in unspecific background staining. To 
block endogenous peroxidase activity, slides were submerged in 0.03% H2O2 
peroxidase solution (12 ml H2O2 (Sigma Aldrich) in 400 ml of methanol (VWR 
Chemicals) for 30 minutes at room temperature before washing with TBS.   
2.10.4 Cytospin preparation  
Fixation of cells to slides was performed using the cytospin technique. A 
cytofunnel (Thermo Scientific) was mounted to each slide and 200 μl of 5 ×  105 
cells/ml suspension added per slide. The cytospin 2 (Shandon) was used to spin 
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slides at 10000 rpm for 7 minutes. Slides were then fixed by immersion in 
methanol for 10 minutes and air-dried.  
2.10.5  Growth of cells in chamber slides  
An alternative to the cytospin technique is the use of chamber slides to perform 
immunocytochemistry (ICC) of cells in culture. The advantage of using chamber 
slides is that cells grow already attached to the slide that will be then used for ICC, 
meaning that they will retain their adherent morphology instead of presenting the 
rounded morphology of cells in suspension.  
Cells growing in culture were counted, and up to 3 × 104 cells were transferred per 
well of an eight well Nunc lab-Tek II chamber slide (Thermo Scientific). Cells were 
grown overnight in the chambers and the following day the media was carefully 
removed and the chambers detached as per manufacturer’s instructions. Slides 
were then submerged in methanol for 10 minutes in order to fix the cells.   
2.10.6  Immunostaining 
Slides were mounted in immunohistochemistry Sequenza chambers (Thermo 
Shandon), blocked with 100 μl of 25% normal goat serum (NGS) (Vector 
Laboratories) and incubated 30 minutes at room temperature. The primary 
antibody, or a matched isotype control antibody, was then applied and incubated 
at 4ºC overnight. The following day slides were washed three times with either 
PBS/0.1% Tween 20 (PBS-T20), for immunocytochemistry or TBS, for 
immunohistochemistry. 100 μl of a horseradish peroxidase (HRP)-conjugated 
secondary antibody were then added to each of the slides and incubated 30 
minutes at room temperature. Slides were then washed twice with PBST20 or 
TBS, and the substrate 3, 3’-Diaminobenzidine (DAB) (Dako) added and 
incubated for 8 minutes at room temperature. HRP catalyses the oxidation of the 
chromogenic substrate DAB in presence of H2O2, which results in a detectable 
colour change to dark brown. Slides were washed with distilled water and 
unloaded from Sequenza chambers. Counterstaining was performed using the 
Varistain in the preset program 3 that performs staining with haematoxylin-eosin, 
and dehydration with ethanol followed by xylene. Slides were mounted manually 
using Shandon Consul-Mount (Thermo Scientific). A summary of the antibodies 
used can be found in Table 2.10.  
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2.11  Isolation of type II pneumocytes  
Isolation of sheep type II pneumocytes was carried out following a protocol 
established for isolation of human type II pneumocytes (Witherden & Tetley, 
2001).  The following variations were made to the published protocol: DCCM-1 
(Geneflow) was used instead of LPHM and HI-FBS was used instead of newborn 
calf serum (NCS). Penicillin/Streptomycin, Hanks balanced salt solution (HBSS) 
and Glutamine were obtained from MRI in-house facility. Gentamicin and 
Amphotericin B were added to a final concentration of 20 µg/ml and 1.25 μg/ml 
respectively, to inhibit bacterial and fungal growth.  
In preparation for the isolation process, cell culture plates (Corning) were coated 
with 1% dilution of PureCol collagen solution (Purecol). 300 µl and 75 µl of the 1 
% solution were added to each well of 24 and 96-well plates, respectively, and left 
to air-dry overnight in a microbiological safety cabinet.  
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The isolation process took place over two days as suggested in the protocol. On 
the first day, lambs were euthanised by captive bolt at the Moredun PM rooms. 
Lungs were examined for visible signs of bacterial infection and other lesions that 
could compromise the viability of cells in vitro. Three sections of lung tissue were 
obtained from each lamb, and kept submerged in 0.15 M saline (MRI in-house) 
for up to 1 hour. Lung tissue sections were perfused with up to 100 ml of saline to 
wash off erythrocytes. Tissue was then stored overnight in the presence of DCCM-
1 without HI-FBS. The following day, each tissue piece was instilled with 15 ml of 
0.25 % trypsin (Sigma Chemical) until inflated and incubated at 37°C for 15 
minutes, this process was repeated three times to give a total trypsinisation time 
of 45 minutes. After trypsinisation, the tissue was chopped into 1 mm3 with the 
use of scissors. In order to degrade DNA from ruptured cells 250 µg/ml DNaseI 
solution (Sigma Chemical) was added and the suspension shaken vigorously for 
5 minutes. Tissue suspensions were then filtered through a large 300 µm mesh 
filter followed by 40 µm cell strainer (Falcon). The filtrate, containing released 
cells, was centrifuged at 290 × g for 10 minutes at 4°C and the pellet resuspended 
in 30 ml 50% DCCM-1 and 50% HBSS with 100 µg/ml DNaseI. At this stage cell 
number was determined with the use of a haemocytometer. The cell suspension 
was plated in T-75 flasks and incubated at 37°C for 1.5h for macrophages to 
adhere. After the incubation time, the supernatant from the flasks was removed, 
centrifuged again and the pellet was resuspended in 30 ml of complete DCCM-1 
(with antibiotics and 10 % HI-FBS). Resuspended cells were plated in T-75 flasks 
and incubated for 1.5 h at 37°C for fibroblasts to adhere. Finally, the supernatant 
was removed and centrifuged as previously, epithelial cells were counted and 
seeded at 1 × 106 cells/well of coated 24-well plates or 1 × 105 cells/well of coated 
96-well plates. Cells were incubated at 37 ◦C and 5 % CO2 overnight.  
On day 3, the medium was changed in all seeded wells and substituted with fresh 
complete DCCM-1. The following day, a wash with PBS was performed to remove 
any remaining monocytes, and fresh media was added. Cells continued to be 
observed and medium changed every other day.  
On one occasion, selective lysis of erythrocytes was performed by using RBC lysis 
buffer (Life Technologies). Briefly, cell suspensions were pelleted at 290 × g, 
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resuspended in 5 ml of RBC lysis buffer and incubated for 5 minutes at room 
temperature. The lysis reaction was then stopped by adding 20 ml of 1x PBS, cells 
were pelleted and resuspended in DCCM-1 to continue the isolation procedure.  
2.12  Molecular cloning  
2.12.1 Growth of bacterial cultures  
Escherichia coli JM109 competent cells (Promega) were used for molecular 
cloning. Importantly, the strain is endA- and recA-, containing a deletion of 
endonuclease A, which avoids DNA cleavage improving plasmid yield, and 
deletion of recA, which avoids recombination with the bacterial chromosome.  
Cultures were grown on solid media as means to select specific bacterial colonies. 
Liquid media was used when a specific colony or culture was to be propagated. 
Solid cultures were grown at 37°C and liquid cultures were grown at 37°C in a 
shaking incubator at 200 rpm to allow aeration of the culture.  
2.12.1.1 Preparation of growth media  
Preparation of liquid and solid bacterial growth media was done under aseptic 
conditions. A Bunsen burner was used to create a sterility umbrella under which 
reagents were prepared.  
Luria Bertani (LB) liquid medium was used to support the growth in suspension of 
E. coli. LB medium was obtained in-house. LB medium was supplemented with 
ampicillin, when required, at a final concentration of 100 µg/ ml.  
LB agar (MRI in-house) was melted and ampicillin added when required. LB agar 
was poured in sterile petri dishes (Thermo Scientific) and left on the bench until 
solidified. LB agar plates were stored at 4°C up to one month.  
2.12.2  Bacterial transformation  
Competent E. coli JM109 cells (NEB) were transformed with a variety of plasmids 
using the heat-shock procedure. Briefly, JM109 cells were grown overnight at 37 
◦C; the following day 30 µl of the JM109 cells were mixed with 1 µl of the desired 
plasmid and kept in ice for 45 minutes, flicking the tube regularly to mix cells. Cells 
were then incubated at 42 ◦C for 1 minute and put back in ice for 5 minutes. 200 
µl SOC (NEB) medium was then added, and tubes were incubated at 37 ◦C at 200 
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rpm for 30 minutes. Transformed cells were then plated on LB agar plates with 
the appropriate antibiotics and incubated at 37 ◦C overnight. The following day 
colonies were picked and used to inoculate 5 ml flasks.  
2.12.3  Plasmid isolation 
Selected transformed bacterial colonies were grown overnight in either 5 ml liquid 
LB media, for minipreps, or 150 ml for maxipreps.  
2.12.3.1 Small-scale plasmid isolation (miniprep)  
Small-scale plasmid isolation was performed using the QIAprep Spin Miniprep Kit 
(Qiagen) and following the manufacturer instructions. Plasmid isolation is 
achieved through a series of steps: first, bacterial cells are subjected to alkaline 
lysis which disrupts the membrane and releases proteins and DNA. The lysis 
buffer is then neutralised and adjusted to high-salt, which results in genomic DNA 
and protein precipitation, while the smaller plasmid DNA is allowed to renature 
and binds to the silica membrane. The following steps wash remaining 
contaminants, and plasmid DNA is finally eluted in low salt concentration.  
Elution was performed in molecular grade water instead of the provided TE buffer, 
which can interfere with enzymatic reactions such as DNA-sequencing.  
2.12.3.2 Large-scale plasmid isolation (maxiprep) 
Large-scale plasmid isolation was performed using the EndoFree Plasmid Maxi 
Kit (Qiagen), which removes endotoxins from the preparation, following 
manufacturer’s instructions. Plasmid isolation begins with lysis steps similar to 
those used in miniprep isolation. However, the maxi kit uses anion-exchange 
based columns to ensure selective elution of plasmid DNA: plasmid DNA binds to 
the resin in low salt and low pH conditions, a wash in medium-salt conditions 
elutes proteins, RNA and other contaminants. Finally, plasmid DNA is eluted in 
high-salt conditions and salt removed with the use of isopropanol.  
2.12.4  Enzyme restriction  
Restriction reactions were set up depending on enzyme used and using buffers 
supplied by manufacturers as recommended Table 2.11. Reactions were 
incubated between 1-1.5 hours at 37°C.  
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Table 2.11. Summary of restriction enzymes and conditions used for DNA digests. 




3 µg DNA, 1 µl enzyme, 7.5 µl buffer M, 




10 µg DNA, 3 µl enzyme, 5 µl cutsmart 




2 µg DNA, 1 µl enzyme, 5 µl buffer B, 




2 µg DNA, 1 µl enzyme, 4 µl buffer D, 




2 µg DNA, 1 µl enzyme, 4 µl buffer E, 
0.4 µl BSA, water to 20 µl 
 
2.12.5 Agarose gel electrophoresis  
Agarose gels were prepared diluting agarose (Bioline) in Tris-acetate-EDTA (TAE) 
buffer to a 1% concentration with 1:10,000 Gel red (Biotium) nucleic acid dye. 
Electrophoresis was performed at 80 V for 1.5 hours, and bands were visualised 
with Alpha Imager 2200 (Alpha Innotech). Molecular weight markers were 
hyperladder 1Kb (Promega). 
2.12.6 DNA sequencing  
DNA sequencing of plasmids was performed by MWG Eurofins. The primers used 
for sequencing are shown in Table 2.12 and Fig. 2.4. Sequencing analysis was 
perfomed with DNAStar software. 
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Table 2.12. Primer sequences and targets used in DNA-sequencing. 
Primer Sequence (from 5′ to 3′) Target 
5801R GATATGATATGTCAGCTGATACCTG pCSC-JSenv/ pCSC-GFP2AEnv 
5680F CCCGTATATGTTAATGATACGAGC pCSC-JSenv/ pCSC-GFP2AEnv 




6161F TTACAGCCCAATATCAGTGGAAGC pCSC-JSenv/ pCSC-GFP2AEnv 
6569F ATTCAAGCTGCGCACACGGTAGAC pCSC-JSenv/ pCSC-GFP2AEnv 
GFP2A-F CGCATCAAATGCAACGCATGACG pCSC-GFP2AEnv 
pEGFPN1rev GTCCAGCTCGACCAGGAT pCSC-GFP2AEnv 
pEGFPC1for GATCACTCTCGGCATGGAC pCSC-GFP2AEnv 
pCR3.1-
BGHrev 
TAGAAGGCACAGTCGAG pCSC-JSenv/ pCSC-GFP2AEnv 
 
2.12.7  Preparation of glycerol stocks of bacterial cultures  
Glycerol stocks were prepared by mixing an overnight bacterial culture with an 
equal volume of a sterile 40 % solution of glycerol in water. Aliquots were stored 
at -80 ◦C until required. 
2.13  Preparation of lentiviral vectors  
2.13.1 Plasmid design 
For the production of lentiviral vectors a third generation lentiviral vector system 
was used, this system consists of four plasmids that when transfected into 293T 
cells produce a lentiviral vector encoding the gene of interest (Sakuma et al, 2012) 
Table 2.13. 
The transfer vector encoding the gene of interest was created with the use of 
molecular cloning techniques by David Griffiths. Briefly, JSRV env or a construct 
of gfp2Aenv, previously designed and produced also by David Griffiths, were 
amplified by PCR and inserted into the NheI/XhoI sites of the transfer vector (pCS-
CG; Addgene). Plasmids were amplified in JM109 (2.12.2 and 2.12.3), sequences 
were verified by sequencing and plasmids maps created (Fig 2.5 and Fig 2.6). 
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Figure 2.4. Plasmid map of pCSC-GFP2AEnv. Restriction sites of enzyme BglII are shown 
and were used to verify the plasmid map by restriction digest. 
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Figure 2.5. Plasmid map of pCSC-JsEnv. Restriction sites of enzyme BglII are shown and 
were used to verify the plasmid map by restriction digest. 
2.13.2 Production of lentiviral vector particles 
Work with lentiviral vectors was performed in an ACDP containment level 2 
laboratory. Lentiviral vectors were prepared by transfection of 293T cells in T-75 
flasks at 80% confluency using Fugene-HD (section 2.8.1).  Each flask was 
transfected with 5.4 µg of vector plasmid (pCS-CG, pCSC-JSenv or pCSC-
GFP2AEnv), 3.6 µg of gag-pol packaging plasmid (pMDLg/pRRE (Dull et al, 
1998); obtained from Addgene), 1.2 µg of HIV Rev plasmid (pCNC-Rev (Ikeda et 
al, 2003); a kind gift from Dr Yasuhiro Takeuchi, University College London) and 
1.8 µg of a plasmid encoding the vesicular stomatitis virus G protein (pMD2.G, 
Addgene). 
The growth medium was replaced 16-20 hours following transfection and 
supplemented with 5 mM sodium butyrate (Sigma Aldrich). The supernatant 
(containing lentiviral vector particles) was harvested 48 hours post-transfection 
and centrifuged at 850 × g before being filtered through a 0.45 µm cellulose 
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acetate filter (Sartorius Stedim) to remove any cell debris present. Due to the low 
adherence of 293T cells, the supernatant was collected very carefully in order to 
avoid disturbing the cell layer. Fresh growth medium (10 ml, without sodium 
butyrate) was added to the flasks and cells were incubated for a further 24h, at 
which point a second harvest was performed in the same way. The filtered 
supernatants from the two harvests was combined and stored at -80ºC.   
2.14  Concentration of lentiviral vectors 
Lentiviral vectors were concentrated by ultracentrifugation (Optima L-90K, 
SW32Ti rotor; Beckman Coulter. Filtered supernatants were thawed and 
centrifuged for 2 h at 38,080 × g to pellet the lentiviral vector particles. After 
centrifugation, the supernatant was removed and the pellet containing the 
lentiviral vectors was resuspended in appropriate medium (Opti-MEM, DMEM or 
Q286) by gentle pipetting and storage on ice for 30 minutes. The lentiviral vector 
suspension was then stored in cryovials in 250 µl aliquots and stored at -80ºC until 
use.   
2.15  Transduction of cell lines with lentiviral vectors  
Transductions were performed under aseptic conditions. Briefly, cells passaged 
the day before transduction and seeded at 1 x 105 cells/well (of a 24-well plate) 
were used. Growth medium was removed and replaced with medium containing 
the desired lentiviral vector concentration and 8 µg/ml of polybrene (Sigma 
Aldrich). Polybrene has been shown to enhance the lentiviral transduction 
efficiency (Seitz et al, 1998). The final volume per well was 1 ml in 6-well plates, 
500 µl in 12-well plates and 250 µl in 24-well plates. Transductions were incubated 
at 37ºC for 4 hours and then cultures observed for cell death and medium 
replaced. Cultures continued to be checked for cell death and changes, and 
medium changed every other day.  
2.15.1  Transformation assays 
After transduction, when cells had reached confluency, serum concentration was 
reduced to 4% FBS to slow the growth rate of non-transformed cells. Cells 
continued to be checked and split when necessary, when transformed foci were 
clearly visible these were subcultured into new culture plates using pipette tips.  
  
Chapter 2: Materials and Methods 117 
2.16  Flow cytometry 
Flow cytometry was performed to examine transgene expression in transfected or 
transduced cells. Briefly, cell culture supernatant was collected and added to a 
tube containing 5 ml of PBS. Cells were washed with PBS, dissociated, 
resuspended in PBS and centrifuged at 850 × g.  Cells were then resuspended in 
200 µl of PBS containing 1 µl of Vioblue live/dead stain (Miltenyi Biotech) and 
incubated at room temperature for 30 minutes in the dark. 
After incubation a wash with PBS was performed and pelleted cells then 
resuspended in 200 µl 1% paraformaldehyde (PFA) in order to fix the cells. Fixed 
cells were then analysed by flow cytometry measuring GFP+ and Vioblue stain in 
the MACSQuant (Miltenyi Biotech), 50000 events were counted. Analysis was 
performed in the MACSQuant software: GFP expression and Vioblue expression 
were analysed in the blue laser (488 nm) and violet laser (405 nm) respectively. 
Cell size, granularity and doublets were analysed using the forward scatter (FSC) 
and side scatter (SSC). 
2.16.1 Titration of lentiviral vector particles 
Titration of lentiviral vectors that encode GFP was performed by flow cytometry. 
Transductions of cell lines were performed as described in section 2.14, but serial 
dilutions of the lentiviral vectors performed to obtain a more accurate estimate of 
the concentrations.  
Titrations were performed two to three days post-transduction at the peak of 
transgene expression. Preparation of cells and flow cytometry were performed as 
described in 2.16.  
The percentage of live GFP expressing single cells was then used to calculate the 
lentiviral vector concentration using the following formulae: 
𝑇𝑈/𝑚𝑙 =






 TU= Transduction units or lentiviral vector particles able to transduce cells 
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 Target cell number = number of cells in culture when transduction was 
performed 
 % GFP cells= percentage of cells expressing GFP as determined by flow 
cytometry. Wells where 10-20% cells were GFP positive were used to 
calculate titre.  
 Vector volume = volume in ml of vector used in transduction. 
2.17 Cell sorting  
Sample preparation for cell sorting consisted in dissociating the cells and 
resuspending the cell pellet to a concentration of 5 × 106 cells/ml in serum free 
medium. 50 µl of serum free medium were added to each well of 96-well plates in 
preparation for sorting. Cell sorting was performed in the Bioimaging facility of the 
Roslin Institute, University of Edinburgh. The BD FACS Aria IIIu 4-laser was used 
and operated by Bob Fleming and Graeme Robertson. Separation of cells was 
based on the presence of GFP expression with the settings described in Fig. 2.7 
Single cells were sorted into four 96-well plates and a bulk population of GFP-
expressing cells were obtained.  
 
Figure 2.6. Settings used for FACS. 
After cell sorting, 50 µl of conditioned medium, obtained from untransduced MDCK 
cells growing in culture and filtered through a 0.45 µm filter, were added to each 
well. 100 µl of medium containing 50% FBS was also added to each of the wells 
(final concentration 33% FBS). The bulk sorted population was seeded in a T-75 
flask in 10% FBS containing medium. 
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2.18  Amplification of single cells in culture 
Plates containing single sorted cells were examined microscopically daily for 
contamination and growth. After three days in culture, half of the growth medium 
was removed from all wells and replaced with fresh medium. Medium was then 
changed every three days and cells kept growing in the presence of 40% FBS 
concentration in the plates until they reached confluency. Cells were then 
sequentially passaged every time they reached confluency to 12-well plates, 6-
well plates and FBS concentration lowered to 20%, T-25 flasks and finally, T-75 
flasks when the FBS concentration was lowered to 10%. 
2.19  Immunoblotting 
Immunoblotting (western blot) was used to detect the presence of protein in 
samples of interest.  
2.19.1  Preparation of protein extracts 
Protein samples were obtained from cells cultured in 6 well-plates. Cells were 
washed in ice-cold PBS. Cells were scraped off from the culture plate and 
transferred to tubes. Cells were harvested by centrifugation at 2000 g for 2 
minutes. The supernatant was then discarded and the cell pellet resuspended in 
ice cold RIPA buffer (150 mM NaCl, 1% NP40 (Sigma Aldrich), 0.5% sodium 
deoxycholate (Sigma Aldrich), 0.1% SDS, 50 mM Tris pH 8.0, diluted in dH2O) 
containing 0.042 U/µl of  Benzonase (Novagen). The cell suspension was then 
incubated in ice for 30 minutes and then stored at -80 ◦C.  
2.19.2  Quantitation of total protein 
Total protein concentration in extracts was calculated using the Pierce BCA 
protein assay kit (Thermo Scientific) as recommended. The enhanced test was 
used in all samples and both BSA standards and samples were assayed in 
duplicate. Standards and samples were set up in a 96- well plate and incubated 
for 30 minutes at 60 ◦C. The assay was read in a GloMax plate reader (Promega) 
using the BCA settings of the equipment. A standard curve was drawn from the 
results obtained for the standards and was used to determine the concentration 
of the samples 
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2.19.3  Preparation of buffers for immunoblotting 
Buffers for immunoblotting were prepared and stored for up to one year at 
room temperature, except for the blocking solution which was prepared on the 
day of use (Table 2.14).  
Table 2.13. Composition of buffers used for immunobloting. 
Buffer Composition 
Stacking buffer 0.25 M Tris, 0.2% SDS in dH2O (pH 6.8) 
Resolving buffer 1.5 M Tris, 0.4% SDS, in dH2O (pH 8.8) 
Laemmli electrode buffer 
25 mM Tris, 192 mM Glycine (Fisher Chemical), 0.1% SDS, 
in dH2O 
Transfer buffer 20 mM Tris, 0.15 M Glycine, 20% Methanol, in dH2O 
Blocking solution 5% dry milk powder (Marvel) diluted in 0.1% PBS T20 
PBS-T20 0.1% Tween20 in PBS 
4x Loading dye 
120 mM Tris-HCl (pH 6.8), 2% SDS, 20% Sucrose (Thermo 
Fisher Scientific), 100 mM β-mercaptoethanol, bromophenol 
blue crystals, in dH2O 
 
2.19.4  SDS-PAGE electrophoresis 
Gels for SDS-PAGE electrophoresis were prepared in single use Novex 
cassettes (Life Technologies). The stacking gel containing 3% acrylamide was 
made from 1 ml 30% acrylamide (Severn Biotech), 5 ml stacking buffer, 4 ml dH2O, 
10 µl TEMED (Sigma Aldrich) and 50 µl 10% APS (Sigma Aldrich). The resolving 
gel, containing 12% acrylamide, was made up from 5 ml 30% acrylamide, 3 ml 
resolving buffer, 4 ml dH2O, 0.6 g sucrose, 10 µl TEMED and 90 µl 10% APS.  2ml 
of stacking gel were layered onto 6 ml of resolving gel.  
Once the gel had set, it was introduced in Xcell Surelock cuvettes (Life 
Technologies) with Laemmli electrode buffer.  Samples were boiled for 4 minutes 
to denature proteins and then, 5 µl of the Seablue ladder (Invitrogen) and 20 µl of 
the samples (with 1x loading dye) loaded in the wells. The gel was run at 140 V 
for 1.5 hours.  
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2.19.5  Protein transfer 
The proteins contained in the SDS-PAGE gel were transferred to a 0.45 um 
Amersham Protran nitrocellulose membrane (GE Healthcare). Transfer was 
performed in the semidry transfer cell (Biorad) at 15 V for 48 minutes.  
2.19.6  Antibody binding  
Membranes were blocked by soaking in freshly-prepared blocking solution (Table 
2.14) and incubating overnight at 4 ◦C. The following day the primary antibody was 
diluted in 10 ml of blocking solution and membranes soaked in the dilution for 1 
hour at room temperature in a rocking platform. Three fifteen-minute washes were 
then performed with PBS/0.1%T20. The secondary antibody diluted in 10 ml of 
blocking solution was then applied in the same manner as the primary antibody 
and incubated for 1 hour at room temperature. Three fifteen-minute washes were 
performed with 0.1% PBS T20 and a final 3-minute wash performed with PBS. 
Blot was visualised with chemiluminescent substrate (Amersham ECL; GE 
Healthcare and exposed to photographic film (details). Table 2.15 is a summary 
of antibodies and dilutions used in immunoblots. 


















2.20 Culture of lung slices 
2.20.1  Media and reagent preparation 
DMEM was supplemented with 2mM glutamine, 1% penicillin/streptomycin, 1.25 
µg/ml amphotericin B and 20 µg/ml gentamicin. Supplemented DMEM was kept 
at 4 ◦C for up to one month.  
Quantum 286 (Q286) (PAA), designed to support epithelial cell growth, was used 
as growth medium for lung slices, as previously used by Archer et al. for OPA cell 
culture (Archer et al, 2007) Q286 was supplemented with 2mM glutamine, 1% 
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penicillin/streptomycin, 1.25 µg/ml amphotericin B and 20 µg/ml gentamicin. 
Growth factors were also added to support cell survival and maintenance of 
epithelial phenotype. Keratinocyte growth factor (KGF) (Sigma Aldrich) was added 
at a final concentration of 10 ng/ml to promote growth and division of epithelial 
cells  (Rubin et al, 1989). Hepatocyte growth factor (HGF) (Sigma Aldrich) was 
added at a concentration of 5 ng/ml and is a pleiotropic factor with known functions 
as epithelial growth stimulator (Tsubari et al, 1999). Dexamethasone (Sigma 
Aldrich) was added at 100 nM final concentration to inhibit lung cell apoptosis 
(Wen et al, 1997)). 3-Isobutyl-1-methylxanthine (IBMX) (Sigma Aldrich) was 
added at 100 µM final concentration due to its role as phosphodiesterase inhibitor 
and raising cAMP levels (Parsons et al, 1988). 8-Bromoadenosine 3′,5′-cyclic 
monophosphate (8-Br-cAMP) (Sigma Aldrich) was added at 100 µM final 
concentration, 8-Br-cAMP is a cAMP analog that induces surfactant production 
(Ballard, 1989; Wade et al, 2006). Supplemented Q286 was prepared in 50 ml 
aliquots and kept at 4 ◦C for a maximum of one week before use.  
Ultra-low gelling point agarose (LMP) (Sigma) was diluted in HBSS without 
calcium and magnesium (MRI in-house) to a concentration of 2.5%.  
2.20.2 Preparation of lung slices 
Lung slices were obtained from lambs between six and twelve months old 
following an established protocol (Cousens et al, 2015). Briefly, the whole lung 
was removed from the sheep and the right cranial lobe isolated with the use of 
clamps. Using a 50 ml syringe, 2.5% LMP solution at 37 ◦C was introduced into 
the selected lobe until it expanded. The expanded area was dissected from the 
rest of the lung, placed in ice-cold HBSS and stored on ice for 1 hour. The lung 
tissue section was then sliced transversely in approximately 0.75 cm sections, and 
cylindrical cores were prepared using the biopsy cutter (0.8 cm diameter). These 
cores were fed to the lung slicer (Krumdieck) in order to obtain the desired 300 
µm slices. Slices were submerged in universal tubes (Thermo Scientific) 
containing 20 ml of HBSS. Approximately 30 sections were placed in each tube.  
Slices contained in universal tubes were then washed twice with supplemented 
DMEM (Table 2.6) and placed on a rotating platform (1 rpm) at 39°C and 5% CO2. 
Slices were incubated for 30-45 minutes between washes.  
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Supplemented DMEM (500 µl) was then added to wells of 24-well plates and one 
lung slice transferred to each well. After one hour in rotation in the incubator, 
DMEM was removed and 300 µl of supplemented Q286 added per well. Slices 
were incubated overnight with rotation (1 rpm) at 39°C and 5% CO2.  
The following day, lung slices were washed twice with supplemented DMEM to 
remove agarose, red blood cells and factors that could have been released by 
damaged cells. Cells were placed in 300 µl supplemented Q286 and returned to 
culture at 39°C with rotation. Cultures were checked every day for cilia activity and 
contamination and medium was replaced daily.  
2.20.3  Transduction of lung slices with lentiviral vectors 
Transduction of lung slices with lentiviral vectors was performed on the third day 
of culture. Briefly, the desired concentration of lentiviral vector was diluted in 
supplemented Q286 with 8 µg/ ml of polybrene and 150 µl of this transduction mix 
were added per well.  Slices were incubated for 2 h at 39°C, before adding a 
further 150 µl of supplemented Q286 and incubating overnight. The following day, 
lung slices were washed once with supplemented DMEM for 30 minutes to 
remove any remaining vector particles, before adding 300 µl of fresh 
supplemented Q286. Lung slices were kept in culture, and observations and 
medium change performed every day.  
2.20.4  Infection of lung slices with JSRV21 
Infections of lung slices with JSRV21 were performed in the same way as 
transductions of lung slices with lentiviral vectors explained in section 2.20.3. 
The only difference between the protocols was that some infections were left 
to proceed for two days before medium was changed and then, three washes 
with supplemented DMEM were performed to remove remaining viral particles. 
In addition, incubation of lung slices after infection was performed with rotation 
(1 rpm).  
2.20.5  Sample processing  
At the desired time points, samples were collected for miRNA expression analysis, 
immunostaining and immunoblotting. Four lung slices were collected for each 
  
Chapter 2: Materials and Methods 124 
method, time point and treatment. Supernatants were collected at the desired time 
points and stored at -80°C for further analysis. 
For analysis of miRNA expression, lung slices were directly added to lysing matrix 
D tubes containing 800 µl of RLT buffer plus with β-mercaptoethanol and shaken 
thoroughly. Tubes were stored at -80°C until homogenisation and RNA extraction 
were to be performed. RNA extraction and analysis was performed as described 
in section 2.4.5. 
Samples for immunostaining were collected in cellpath biopsy capsule and pad, 
and introduced in cassettes, submerged in formal saline pots and fixed overnight. 
The following day samples were submitted to the Moredun pathology unit for 
processing and serial cutting for slide preparation. Immunostaining was performed 
as described in section 2.10.  
Samples for immunoblotting were collected in lysing matrix D tubes containing 
400 µl of RIPA buffer with Benzonase and shaken thoroughly. Tubes were kept at 
-80 ◦C until homogenisation and immunoblotting were to be performed. 
Immunoblotting was performed as described in section 2.17.  
2.20.5.1 RT-qPCR for the detection of JSRV in lung slices 
Supernatants from lung slices were analysed for the presence of JSRV by RT-
qPCR. RNA was extracted from supernatants following the method described in 
section 2.4.2 but no dilution of the sample was performed in the first step. RNA 
concentration was measured by Nanodrop as described in section 2.4.8. RT-
qPCR was then performed in one step by mixing 20 µl of mastermix with 5 µl of 
RNA sample. The mastermix was prepared by mixing 12.5 µl of reaction mix 
(Thermo Scientific), 0.5 µl 40x RT/Taq (Thermo Scientific), 0.5 µM primers JSRV-
P1 (5′-TGGGAGCTCTTTGGCAAAAGCC-3′) and JSRV-P6 (5′-
TGATATTTCTGTGAAGCAGTGCC-3′) (Palmarini et al, 1996b), and 0.125 µM 
JSRV probe (5′-FAM-AGCAAACATCCGARCCTTAAGAGCTTTCAAAA-BHQ) 
(Cousens et al, 2009) and water to 20 µl.  
RT-qPCR was performed with an ABI 7500 real time machine with cycling 
conditions: 30 minutes at 48 ◦C, 10 minutes at 95 ◦C followed by 40 cycles of 15 
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seconds at 95 ◦C and 1 minute at 60◦C. The results were analysed using ABI 7500 
software. Ct values were compared with the positive controls and Ct values under 
30 considered as positive for JSRV presence.  
2.20.5.2 Reverse Transcriptase-assay for JSRV quantification 
JSRV21 particles were quantified using a colorimetric Reverse Transcriptase (RT) 
assay (Roche) as recommended. The assay uses the ability of RT to synthesise 
DNA, and provides digoxigenin and biotin labelled nucleotides that are 
incorporated into the newly synthesised DNA. The newly synthesised labelled 
DNA is detected and quantified by sandwich ELISA. In the final step, cleavage of 
the substrate results in a coloured product that can be measured at 405 nm. JSRV 
was quantified by reference to the standard curve of known amounts of HIV1 RT 
provided with the kit. 
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Chapter 3  miRNA dysregulation in OPA lung 
tissue 
3.1 Introduction 
To date, no published studies have investigated miRNA expression in OPA. 
Nevertheless, the study of miRNA dysregulation in OPA would further knowledge 
and understanding of the disease in several dimensions. For example, studying 
miRNA expression in the ovine lung could potentially allow the differentiation of 
OPA-affected and unaffected sheep. Differences in miRNA expression could be 
exploited as disease biomarkers and, eventually, help tackle the issue of OPA 
diagnosis and disease control, reviewed in section 1.4.  
Study of miRNA expression in OPA-affected sheep lung might also highlight 
miRNAs related to the transformation process driven by JSRV Env. The targets of 
dysregulated miRNAs could be investigated to understand better how JSRV Env 
activates signalling pathways PI3K-Akt and MAPK (section 1.2.6) in vivo, and to 
find interactions between pathways. Moreover, the study of miRNA expression in 
OPA could also unveil the presence of JSRV-encoded miRNAs. Similarly to other 
retroviral-encoded miRNAs (section 1.5.14), a JSRV-encoded miRNA could have 
significant repercussions on our study of JSRV infection and the Env driven 
transformation process.  
In most infected animals, JSRV infection is known to elicit a poor and ineffective 
immune response (section 1.2.8), and histopathological lesions are normally 
confined to the lung (section 1.1.3). Studies on miRNA expression can be 
performed in other tissues or cell types to investigate molecular changes and 
response to JSRV beyond the infected cells. For instance, JSRV is reportedly 
spread via the aerogenous route to colonise the sheep lung (section 1.1.4). 
Therefore, the study of miRNA dysregulation in OPA in alveolar macrophages, the 
first line of defence in the lung, could reveal transcriptional changes that indicate 
their role in JSRV-infection.  
Comparison of miRNA expression between OPA-affected and unaffected sheep, 
would, in turn, provide valuable information on the miRNA expression pattern of a 
healthy sheep lung. Given the low number of reports on sheep miRNAs, (section 
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1.5.9), such a study could help build a comprehensive database entry that would 
aid future studies on miRNA dysregulation in this important farm animal. In 
addition, further characterisation of OPA and the sheep lung could reveal more 
similarities to human lung cancer, and help to consolidate OPA as a large animal 
model of the human pathology (section 1.1.3).  
In vivo study of miRNA dysregulation in the sheep lung is facilitated by the 
existence of an experimental animal model, reviewed in section 1.3.1. This animal 
model allows the study of early transformation events in neonatal lambs, where a 
small percentage of tissue (~10 %) exhibits a transformed phenotype (Fig. 3.1). 
In addition, use of this model in specified pathogen-free (SPF) animals allows the 
study of OPA alone, without the potentially confounding effects of bacterial 
infections that are commonly found associated with more advanced cases 
(section 1.1.3). Moreover, the availability of tissues from early and advanced 
cases of natural OPA permits a comparison of miRNA dysregulation across 
disease stages.  
 
Figure 3.1. Haematoxylin and eosin staining of a lung section from a JSRV-infected 
lamb, 85 days post-infection. Areas of increased cell density can be observed due to 
increased staining, these areas represent tumour foci. Reproduced from Martineau (2010). 
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3.1.1 Hypothesis and aims 
In this study, it was hypothesised that miRNAs can be detected in lung tissue from 
sheep, and that, when comparing JSRV-infected and uninfected sheep, a number 
of miRNAs would be differentially expressed between the two groups. In addition, 
it was also hypothesised that JSRV-encoded miRNAs could be detected in lung 
tissue of JSRV-infected sheep.  
In order to explore these hypotheses the following aims were established: 
 Detect miRNA expression in lung tissue of sheep 
 Compare miRNA expression of infected and uninfected sheep lung 
 Contrast findings from JSRV experimentally infected sheep and natural 
cases 
 Detect miRNA expression in bronchoalveolar lavage macrophages 
 Identify JSRV-encoded miRNAs or small RNAs in infected lung tissue 
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3.2 Results 
3.2.1 miRNAs in OPA lung tissue identified by sequencing 
In this section, the results for the initial miRNA screen performed in lung tissue 
are presented. The aim of this analysis was to identify viral and host miRNAs in 
lung tissue of JSRV21-infected and mock-infected lambs. Besides the identification 
of miRNAs in the sheep lung we were interested in detecting which specific 
miRNAs, if any, were differentially expressed between the two groups analysed. 
Thus, this first screening would help determine candidates for further study as 
OPA biomarkers. 
The tissues used in this study derived from an experimental infection which took 
place in 2007 (section 2.2). Tissue sections from eight distinct sites in the lung 
were obtained by cryodissection (section 2.4.3), RNA extraction was performed 
and samples from each lamb pooled. The lung tissue of JSRV21-infected animals 
used for RNA extraction was of heterogeneous nature: consisting of mostly 
histologically normal tissue and up to 10% of tumour tissue (Fig. 3.1). 
Cryodissection and RNA extraction was performed by Jeannie Finlayson and 
Anna Karagianni prior to the start of this PhD project. The quality and integrity of 
RNA samples was measured (section 2.4.8) and only samples with RIN > 6, and 
260/280 ratio > 1.9 were submitted for small-RNA sequencing (Table 3.1). 
Table 3.1. RNA concentration of samples submitted for small RNA-sequencing of lung 
tissue.  
Group JSRV-infected 
Sample SPF475 SPF476 SPF477 SPF478 
RNA (ng/µl) 334 387 164 123 
260/280 nm 2.02 1.99 2.05 2.05 
RIN 7.2 7.9 8.4 8.1 
Group Mock-infected 
Sample SPF479 SPF481 SPF482 SPF484 
RNA (ng/µl) 222 220 288 323 
260/280 nm 2.04 2.04 2.02 2.01 
RIN 9 7.8 6.4 6.6 
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RNA samples were sequenced by Edinburgh Genomics (section 2.5). 
Bioinformatics analysis was performed by Siddharth Jayaraman and Deepali 
Vasoya, supervised by myself and with assistance from Mick Watson, David 
Griffiths and Finn Grey (section 2.5.1). Sequencing libraries were successfully 
constructed from all samples and miRNAs were detected in all samples. Total 
reads ranged from 19063580 reads to 29347531 reads, and presented more 
variability within the JSRV21-infected samples (Table 3.2). 
Table 3.2. Summary of reads for each sample of the lung tissue small RNA-sequencing 
study.  
 Group JSRV-infected 
 
Sample SPF475 SPF476 SPF477 SPF478 










 >28 nt 6.51 6.82 8.44 9.93 
miRBase 68.77 72.68 64.66 64.86 
JSRV 0.00216 0.00119 0.00275 0.00156 
 Group Mock-infected 
 
Sample SPF479 SPF481 SPF482 SPF484 










 >28 nt 5.69 9.29 9.60 4.03 
miRBase 69.18 68.43 69.58 79.10 
JSRV 0.00113 0.000765 0.000969 0.000755 
 
The percentage of reads mapping to miRNAs on miRBase and other categories 
was consistent with slight variability between samples (Table 3.2 and Fig. 3.2). 
No statistically significant differences were observed between groups (T-test 
p<0.05) (section 2.6.2). The presence of reads mapping to JSRV genome in 
mock-infected lambs might be due to the sequence similarity in regions of the 
JSRV and enJSRV genomes, some reads might map to both genomes. Sequence 
length distribution (Fig. 3.3) also revealed a similar pattern between JSRV21-
infected and mock-infected samples. These distribution results are comparable to 
previously published small RNA-sequencing studies, see (Chen et al, 2019; Li et 
al, 2013a; Peng et al, 2011).  
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Figure 3.2. Sequence distribution in samples of lung tissue sequencing, presented as 
the percentage of total reads in each sample. Each of the categories is represented by a 
colour shown in the legend. Small nuclear RNA(snRNA), mitochondrial ribosomal RNA 
(Mt_rRNA), small nucleolar RNA (snoRNA), mitochondrial transfer RNA (Mt_tRNA), ribosomal 
RNA (rRNA), miscellaneous RNA (misc_RNA),  long non-coding RNA (lincRNA), JSRV viral 
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Figure 3.3. Length distribution of total sequencing reads after trimming was performed. JSRV21-infected samples (n=4, SPF475, SPF476, SPF477, 
SPF478); Mock-infected samples (n=4, SPF479, SPF481, SPF482, SPF484). The area with high read abundance observed corresponds to miRNA length 
(21-23nt). The length distribution appears similar between JSRV21-infected samples and mock-infected samples. 
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Figure 3.4. PCA plot of miRNA expression levels from lung tissue samples of JSRV21-
infected (n=4) and mock-infected controls (n=4). Greater distance between samples in the 
plot indicates more expression differences between them. Control samples are seen clustering 
towards the left of the plot, whereas JSRV21-infected samples can be seen occupying a larger 
part of the plot towards the right of the plot. Sample SPF476 of the JSRV21-infected group is 
represented closer to the mock-infected group in both PC1 and PC2. The PCA plot indicates 
greater variability between JSRV21-infected samples than among the control group and 
suggests global expression differences between the two groups.  
Comparison of miRNA expression from JSRV21-infected and mock-infected lambs 
revealed 405 miRNAs detected in all analysed samples. Of those, 318 miRNAs 
were not listed in the miRBase entry for O. aries. This section will focus on host 
miRNAs, whereas reads mapping to the JSRV genome are analysed in section 
3.2.6. 
Expression levels of the 405 detected host miRNAs were represented in a 
principal component analysis (PCA) plot (Fig. 3.4). The PCA plot was used as an 
ordination analysis to observe variability among samples and evaluate the 
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clustering relations as a first indication of differences between groups. JSRV21-
infected and mock-infected lambs clustered separately in the PCA plot (Fig. 3.4) 
with higher variability within the JSRV-infected group. Nevertheless, one JSRV-
infected sample, SPF476, was found to cluster closely with the mock-infected 
group, indicating that the global miRNA expression pattern of this sample was 
more similar to mock-infected lambs. This finding is in line with the PCA analysis 
performed in mRNA-sequencing of the same samples (Karagianni et al, 2019). 
The study found that clustering of samples in the PCA plot could largely be 
explained by the number of JSRV transcripts in each sample, samples clustering 
closer to the mock-infected group were found to have a lower viral-burden 
(Karagianni et al, 2019).  
Given that the PCA plot suggested differences between the two groups, statistical 
analysis was performed (section 2.5.1) to identify the miRNAs that were 
differentially expressed between the groups. The fold change threshold was 
established at ≤ 0.75 for downregulated miRNAs and ≥ 1.5 for upregulated 
miRNAs. The decision to establish these fold changes as significant was made 
based on the low percentage of tumour tissue present in the samples to ensure 
potential differences were detected while acknowledging the potential for false 
positives. Of the 405 miRNAs present in all the samples, 32 miRNAs were found 
to be differentially expressed (FDR<0.05) between JSRV-infected and mock-
infected lambs (Fig. 3.5). 26 miRNAs were found upregulated in JSRV-infected 
lambs (Table 3.3), whereas the remaining six miRNAs were downregulated 
(Table 3.4).  
In the clustering analysis performed (Fig. 3.5), the RNA lung tissue sample from 
lamb SPF476 grouped with the mock-infected control group, instead of the JSRV-
infected group, consistent with the PCA and again suggesting that the expression 
of DE miRNAs in this lamb resembled more that of control lambs. 
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Figure 3.5. Heatmap of DE miRNAs (FDR<0.05, log2(fold change) ≥ 0.58 or ≤ -0.42) 
between lung tissue of JSRV-infected and mock-infected lambs. Dendrogram showing 
correlation clustering of individuals in groups. Legend represents values of log2 fold change. 
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Table 3.3. Differentially upregulated miRNAs in lung tissue between JSRV-infected 
and mock-infected lambs.   
miRNA average counts1 log2(fold change)2 FDR3 
miR-182 20880.16 3.20 0 
miR-183 7512.52 3.03 4.28E-84 
miR-96 343.43 3.15 5.94E-69 
miR-135b 70.94 4.82 1.28E-61 
miR-205 4802.59 1.29 1.01E-14 
miR-132 118.12 1.40 2.09E-11 
miR-450b 4841.10 1.04 1.25E-08 
miR-424-3p 188.42 1.07 4.56E-07 
miR-193b 1564.57 0.92 5.68E-07 
miR-130b-5p 130.98 1.13 7.09E-07 
miR-215 105.36 1.08 1.66E-06 
miR-31 252.35 0.91 2.06E-05 
miR-424-5p 1250.31 0.87 2.15E-05 
miR-21-5p 28385.89 0.75 5.08E-05 
miR-1247-5p 161.02 0.75 1.53E-04 
miR-450a 1564.13 0.79 1.66E-04 
miR-203b-5p 146.58 0.86 4.95E-04 
miR-3601 141.28 0.82 6.74E-04 
miR-210 547.69 0.70 8.33E-04 
miR-146b 29159.79 0.61 8.61E-04 
miR-21-3p 1407.30 0.69 1.22E-03 
miR-153 94.21 0.74 2.95E-03 
miR-130b 690.02 0.70 2.98E-03 
miR-203a-3p 963.90 0.61 6.78E-03 
miR-146b-3p 58.90 0.72 1.08E-02 
miR-4286 90.54 0.61 4.02E-02 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ 0.58 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 3.4. Differentially downregulated miRNAs in lung tissue between JSRV-infected 
and mock-infected lambs.   
miRNA average counts1 log2(fold change)2 FDR3 
miR-143 3626500.56 -0.57 0 
miR-592 119.44 -0.95 4.83E-05 
miR-30c-1-3p 275.96 -0.53 3.06E-02 
miR-874-3p 514.64 -0.57 3.13E-02 
let-7i-3p 441.42 -0.51 3.72E-02 
miR-4634 395.30 -0.56 3.80E-02 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≤ -0.42 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
                                            
 
3.2.2 Validation of OPA lung tissue miRNA expression by RT-
qPCR 
In order to investigate if the DE miRNAs observed by small RNA-sequencing could 
also be detected using another technique, RT-qPCR was used to analyse miRNA 
expression of the same RNA samples used in 3.2.1. 
The 40 miRNAs detected as differentially expressed from the results of small 
RNA-sequencing were examined for relative expression levels (normalised 
counts), variance of expression among samples of the same group, fold change 
of expression between groups, and involvement in human forms of lung cancer. 
Seven miRNAs were then selected for further validation using RT-qPCR. The 
criteria for selection was: fold change > 1.5, mean normalised counts >50, 
coefficient of variation within groups <50%, FDR<0.01 and a minimum of five 
independent studies reporting their dysregulation or involvement in human lung 
cancer (see Table 1.1).  
The selected miRNAs were: miR-135b-5p, miR-182-5p, miR-183-5p, miR-miR-
205-5p, miR-21-5p, miR-31-5p, and miR-96-5p.  
In addition, miR-200b-5p and miR-503-5p were also added to the validation panel. 
Although they did not meet the criteria for selection (miR-200b-5p:  fold change= 
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1.46, FDR= 0.016 and average counts= 274.65; miR-503-5p: fold change= 1.56, 
FDR= 0.0008 and average counts= 11.72), they were of interest due to their 
known involvement in lung cancer and validated targets (Table 1.1).  
3.2.2.1 Selection of controls for RT-qPCR 
The miRNAs miR-191 (hsa-miR-191-5p) and miR-103 (hsa-miR-103a-3p) were 
assessed as potential endogenous controls. The selection of those two miRNAs 
was made based on high expression level (mean normalised counts >150), low 
variance among all samples (coefficient of variance < 20%), no known 
involvement in lung cancer or viral infection, and was in line with literature and kit 
manufacturer recommendations.  
A first RT-qPCR study to analyse the stability of miR-191-5p and miR-103a-3p 
was performed (section 2.6) with the results revealing 5.6% variance between 
samples and 11.2% variance between samples for miR-191-5p and miR-103a-3p 
respectively. On the basis of those results, miR-191-5p was chosen as the 
endogenous control for RT-qPCR.  
3.2.2.2 RT-qPCR validation of DE miRNAs 
Validation of the small RNA-sequencing results obtained was performed by RT-
qPCR. Aliquots from the same RNA samples used for sequencing were reverse 
transcribed and assayed by qPCR (section 2.6). 
RT-qPCR results were analysed following the ddCt method (section 2.6.2). The 
results showed higher expression levels of the nine selected miRNAs in the JSRV-
infected group compared to the uninfected control group (Fig. 3.6). miR-183, 
detected in infected but not control samples, presented the greatest expression 
difference between groups.  For representation and analysis purposes those 
miRNAs not detected by RT-qPCR were given a value of 40 Ct, the maximum 
number of cycles performed. The results of miRNA expression by RT-qPCR 
shown for each individual sample highlight the variability within groups, already 
observed in small RNA-sequencing results (Fig. 3.6.A). 
Statistical analysis of the dCt values was performed (section 2.6.2). The nine 
assayed miRNAs presented p-values below the established threshold of 0.05, 
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allowing for rejection of the null hypothesis which considered that the means of 
the two groups were equivalent (Table 3.5). These findings indicated that 
dysregulation of miRNAs in OPA lung tissue could also be detected by RT-qPCR 
and validated the small RNA-sequencing results for the selected miRNAs.  
In summary, the results of RT-qPCR confirmed the increased expression of the 
nine selected miRNAs in OPA-affected lung, when using the same RNA sample 
used for small RNA sequencing.  
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Figure 3.6.  miRNA expression levels as detected by RT-qPCR in lung tissue of JSRV-
infected (n=4) in red, and Mock-infected controls (n=4) in blue.  A. relative miRNA 
expression as -dCt (-Ct miR+Ct miR-191) of each individual sample per each miRNA assayed. 
Boxes show standard deviations of the mean, represented with a horizontal line.  B. log2fold 
change for each assayed miRNA between groups, calculated as (section 2.6.2). Error bars 
indicate standard deviation of miRNA expression within groups. 
 
Chapter 3: miRNA dysregulation in OPA lung tissue 142 
Table 3.5. Statistics results of student’s t-test performed on dCt values obtained by RT-
qPCR.  
miRNA Group Mean1 Stdev2 Estimated difference DF3 p-value 
miR-135b 
JSRV-infected 8.967 0.837 
-5.836 5 0 
Mock-infected 14.8 1.19 
miR-182 
JSRV-infected 5.33 1.13 
-7.72 4 0.02 
Mock-infected 10.187 0.562 
miR-183 
JSRV-infected 8.72 1.52 
-15.213 3 0 
Mock-infected 23.931 0.242 
miR-200b 
JSRV-infected 11.087 0.722 
-1.98 3 0.014 
Mock-infected 13.068 0.242 
miR-205 
JSRV-infected 3.469 0.587 
-1.295 4 0.016 
Mock-infected 4.765 0.282 
miR-21 
JSRV-infected -0.322 0.387 
-1.043 5 0.007 
Mock-infected 0.721 0.278 
miR-31 
JSRV-infected 2.229 0.583 
-1.541 5 0.009 
Mock-infected 3.77 0.463 
miR-503 
JSRV-infected 9.519 0.813 
-2.44 4 0.006 
Mock-infected 11.959 0.427 
miR-96 
JSRV-infected 4.485 0.939 
-3.701 3 0.005 
Mock-infected 8.185 0.295 
1 Null-hypothesis= no differences between the means of the two groups assessed, 
confidence level stablished at 95%. 
2 Stdev= standard deviation of the mean. 
3 DF= degrees of freedom. 
                                            
 
3.2.3 Validation of miRNA expression in an independent 
experimental group by RT-qPCR 
The elevated expression levels of miRNAs miR-135b, miR-182, miR-183, miR-21, 
miR-200b, miR-205, miR-31, miR-503 and miR-96 in JSRV-infected lambs were 
further investigated in an independent sample set. The samples were from 
animals experimentally infected in 2015 (section 2.2). In that experimental 
infection, lambs were infected with JSRV21, mock-infected or infected with a JSRV 
mutant (JSRVmut). The JSRVmut contains a point-mutation in Env: JSRV-Env-
M574A. This JSRVmut originated from a panel created to study the role of JSRV 
 
Chapter 3: miRNA dysregulation in OPA lung tissue 143 
CT in transformation that aimed to create a transformation deficient, replication 
efficient form of JSRV (Hull and fan 2006).  Single point mutants were analysed 
for infection and replication efficiency in ovine lung slices in our lab. Most mutants 
screened in lung slices did not infect lung slices efficiently. The JSRVmut used for 
infection of lambs was able to infect and replicate in ovine lung slices, but not as 
efficiently as JSRV21, and it did not present Akt-P staining by IHC. Post-mortem 
examination of JSRVmut-infected lung tissues did not reveal lesions consistent with 
OPA. In addition, Immunohistochemistry analysis of JSRV Env expression in 24 
sites of each of the lambs revealed no positive staining. Overall, the results 
indicated that the JSRVmut was not able to infect and replicate efficiently in sheep 
lung. Nevertheless, gene expression in lung tissue samples from this experimental 
infection was investigated by mRNA-sequencing and changes in expression of 
some mRNAs noted (Karagianni, Griffiths, in preparation). Samples from JSRVmut-
infected lambs were also included in this study to investigate possible miRNA 
expression differences.  
Lung tissue samples from JSRV21-infected lambs (SPF4, SPF7, SPF11, SPF15, 
SPF20 and SPF23), mock-infected lambs (SPF6, SPF8, SPF12, SPF14) and 
JSRVmut infected lambs (SPF1, SPF9, SPF10, SPF13) were used in this study. 
Samples were cryosectioned (section 2.4.3) and RNA extraction performed 
(section 2.4.5). As in the 2007 experimental infection, eight tissue samples from 
each lamb were pooled.  
miRNA expression levels of the selected miRNAs presented high levels of 
variability within groups and smaller fold changes between groups than in the 
original data set (Fig. 3.7). In addition, the expression of miR-183 could not be 
detected in any of the samples assayed, suggesting low copy numbers. 
Statistical analysis on the dCt values obtained by RT-qPCR was performed 
(section 2.6.2). Three out of the eight assayed miRNAs presented p-values below 
the established threshold of 0.05 (Table 3.6). Interestingly, these miRNAs were 
the ones that presented higher fold-changes in the previous study (3.2.1 and 
3.2.2). Based on the means and the distribution of the values in Fig. 3.7 it can be 
predicted that the JSRV-infected group is statistically different to the other two 
groups. The results for the remaining five miRNAs did not allow for rejection of the 
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null hypothesis. This finding might be due to the high variability observed within 
groups, which might be due to age differences between lambs at PM and is further 
discussed in 3.3. 
The variability within groups observed contrasts with the observations of the first 
experimental infection and can be related to some variables: several animals 
(Table 2.2) in all groups suffered from what was diagnosed as an allergic 
response, this has the potential to disrupt the miRNA expression and could explain 
the similarities between groups. Another variable is the length of infection, 
comparing the culling times between the experimental infections we could see 
notable differences: lambs of the 2007 experimental infection were culled between 
72 and 91 days post-infection, whereas lambs of this infection were culled 
between 41 and 68 days post-infection. These differences could indicate different 
susceptibility of the lambs to the JSRV dose administered, or even an interaction 
with the allergy.  
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Figure 3.7. miRNA expression detected by RT-qPCR in lung tissue of JSRV21-infected 
(n=6), mock-infected (n=4), and JSRVmut-infected (n=4) lambs. A. relative miRNA 
expression as -dCt (-Ct miR+Ct miR-191) of each sample per each miRNA assayed. Boxes 
show standard deviations of the mean, represented with a horizontal line.  B. log2fold change 
for each assayed miRNA between groups, calculated as pairwise comparisons JSRV21-
infected or JSRVmut-infected vs. mock infected (section 2.6.2). Error bars indicate standard 
deviation of miRNA expression within groups. 
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Table 3.6. Statistics results of the ANOVA test performed on dCt values obtained by RT-
qPCR.  
miRNA Group Mean1 Stdev2 DF3 p-value 
miR-135b 
JSRV-infected 5.065 1.696 
6.25 0.011 Mock-infected 7.955 0.517 
mutant-infected 8.491 0.523 
miR-182 
JSRV-infected 2.377 1.294 
8.59 0.002 Mock-infected 5.259 1.185 
mutant-infected 6.091 1.084 
miR-200b 
JSRV-infected 10.72 3.69 
7.95 0.898 Mock-infected 9.56 5.7 
mutant-infected 11.08 4.3 
miR-205 
JSRV-infected -0.048 0.557 
6.94 0.212 Mock-infected 0.987 1.605 
mutant-infected 0.424 0.245 
miR-21 
JSRV-infected 7.06 0.808 
6.7 0.336 Mock-infected 7.594 1.517 
mutant-infected 6.672 0.217 
miR-31 
JSRV-infected 5.508 0.595 
8.52 0.462 Mock-infected 5.947 0.566 
mutant-infected 5.584 0.435 
miR-503 
JSRV-infected 6.338 1.768 
7.866 0.165 Mock-infected 8.29 2.3 
mutant-infected 8.175 1.026 
miR-96 
JSRV-infected 6.395 1.773 
6.98 0.039 Mock-infected 8.607 0.632 
mutant-infected 9.343 0.936 
1 Null-hypothesis= no differences between the means of the three groups assessed, 
alternative hypothesis= at least one of the group’s means is different, confidence level 
stablished at 95%. 
2 Stdev= standard deviation of the mean.  
3 DF=degrees of freedom. 
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3.2.4 miRNA expression in lung tissue of natural cases of 
OPA by RT-qPCR 
Given the nature of the experimental infection model, the samples assayed 
represented an early stage of OPA and all corresponded to lungs from young 
lambs (one to 3 months old). As mentioned in section 1.5.11, the miRNA signature 
has been shown to differ depending on disease stage and developmental stage, 
suggesting that the miRNA dysregulation signature observed in experimental 
samples might not equate to that of natural, more advanced, cases of the disease. 
In order to test this, the expression of the nine selected miRNAs (miR-135b, miR-
182, miR-183, miR-21, miR-200b, miR-205, miR-31, miR-503 and miR-96) was 
analysed in samples from adult sheep affected by OPA. Ten lung tissue samples 
from OPA affected sheep (JA874, JA875, JA876, JA894, JA895, JA896, JA898, 
JA899, JA901 and JA902) and six healthy adult sheep (MP15/170, 171, 172, 173, 
174 and 175) were collected and cryosectioned, RNA was extracted. RNA quality 
and integrity assessment was performed and all samples had a RIN >6 and 
260/280 ratio >1.8. RT-qPCR was performed to compare miRNA expression 
levels of the selected miRNAs.  
With the exception of miR-183, not detected in samples from the healthy control 
group, all tested miRNAs were detected in both groups. The same upregulation 
trend observed in samples from lambs’ lung tissue was observed in samples from 
adult sheep (Fig. 3.8).  
Statistical analysis on the dCt values obtained by RT-qPCR revealed that eight 
out of the nine assayed miRNAs presented p-values below the established 
threshold of 0.05. The exception was miR-31, which produced a p-value greater 
than the established threshold, indicating no difference between the groups 
(Table. 3.7). These findings indicate that most of the miRNAs significantly 
upregulated in experimental cases of OPA are also upregulated in natural cases 
of OPA, increasing confidence that they are involved in the pathogenesis of OPA, 
discussed in 3.3. 
The variability observed within groups can be expected of natural cases of the 
disease, the sheep studied came from different farms, were different ages and 
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had suffered the disease for various lengths of time. Nevertheless, a cofounding 
factor should be considered when analysing the results of this particular study: all 
control animals were herd at the Moredun Group farms, whereas the OPA affected 
group were a more heterogeneous group coming from different farms. This could 
potentially bias the results observed and the differences between groups and 
similarities within groups, could in part be explained by the origin of the animals 
(Table 2.4). 
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Figure 3.8. miRNA expression levels as detected by RT-qPCR in lung tissue of OPA-
affected (n=10) and controls (n=6).  A. relative miRNA expression as -dCt (-Ct miR+Ct miR-
191) of each individual sample per each miRNA assayed. Boxes show standard deviations of 
the mean, represented with a horizontal line.  B. log2fold change for each assayed miRNA 
between groups, calculated as (section 2.6.2). Error bars indicate standard deviation of miRNA 
expression within groups. 
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Table 3.7. Statistics results of student’s t-test on dCt values obtained by RT-qPCR.  







OPA-affected 6.51 2.1 




OPA-affected -0.93 1.2 




OPA-affected 4.39 2.43 




OPA-affected 3.24 0.44 




OPA-affected 2.417 0.627 




OPA-affected -5.337 0.641 




OPA-affected 2.827 0.698 




OPA-affected 4.89 2.25 
-3.969 12 0 Unaffected 
control 
8.854 0.816 
1 Null-hypothesis= no differences between the means of the two groups assessed, 
confidence level stablished at 95%. 
2 Stdev= standard deviation of the mean. 
3 DF=degrees of freedom. 
                                            
 
3.2.5 miRNA expression in OPA laser capture microdissected 
lung tissue 
The previous analysis was done using samples from affected lung tissue that was 
not enriched for tumour. Therefore, presence of excess histologically normal 
tissue may reduce sensitivity to detect DE miRNAs in OPA. To address this, Laser 
capture microdissection (LCM) was used with the aim to enrich the samples for 
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tumour-affected tissue. The technique allows for microdissection of selected 
tumour tissue, and avoids the artefacts that a high percentage of normal tissue 
could pose on the analysis.  
The LCM technique was performed in JSRV21-infected (n=3), mock-infected 
control samples (n=3), JSRVmut-infected samples (n=3), from the experimental 
infection that took place in 2015, also used in 3.2.3. Anna Karagianni performed 
laser capture microdissection and RNA extraction from the LCM tissue. RNA 
samples were submitted to Liverpool genomics for sequencing (Table 3.8).  
Table 3.8. RNA concentration of LCM lung tissue samples submitted for small RNA-
sequencing. 
 
Bioinformatics analysis was performed by Siddharth Jayaraman and Deepali 
Vasoya supervised by myself and with guidance from Mick Watson, Finn Grey 
and David Griffiths. Sequencing libraries were successfully constructed from all 
samples. Total reads ranged from 12270528 reads to 33069302 reads, and 
presented more variability within the JSRV21-infected samples (Table 3.9). 
Statistically significant differences were found in the percentage of reads > 28 nt, 
as well as reads mapping to miRBase, between the JSRVmut-infected samples 
and JSRV21-infected or mock-infected samples (p<0.05). Furthermore, the 
Group JSRV-infected 
Sample SPF4 SPF7 SPF20 
RNA (ng/µl) 60.77 68.98 80.64 
260/280 nm 1.81 2.00 1.83 
RIN 8.9 9.4 8.8 
Group Mock-infected 
Sample SPF8 SPF12 SPF14 
RNA (ng/µl) 83.63 62.05 65.42 
260/280 nm 1.90 1.89 1.99 
RIN 8.4 7.3 8.8 
Group Mutant-infected 
Sample SPF1 SPF5 SPF9 
RNA (ng/µl) 87.30 66.69 60.05 
260/280 nm 2.03 1.86 1.8 
RIN 8.8 7.8 7.5 
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proportion of reads mapping to miRBase was lower than in the previously 
performed small RNA sequencing of lung tissue.  
Table 3.9. Summary of reads for each sample of the LCM lung tissue small RNA-
sequencing study. 
 Group JSRV-infected 
Sample SPF4 SPF7 SPF20 










 >28 nt 25.55 20.44 24.87 
miRBase 14.08 37.61 41.47 
JSRV 0.00737 0.0194 0.000514 
 Group Mock-infected 
Sample SPF8 SPF12 SPF14 










 >28 nt 20.90 20.87 21.80 
miRBase 41.23 46.06 42.90 
JSRV 0.00000562 0.0000898 0.0000425 
 Group Mutant-infected 
Sample SPF1 SPF5 SPF9 










 >28 nt 18.42 14.76 13.01 
miRBase 49.14 54.84 61.59 
JSRV 0.0000520 0.0000694 0.0000706 
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Figure 3.9. Sequence distribution in samples of LCM lung tissue sequencing, presented 
as percentage of total reads in each sample. Each of the categories is represented by a 
colour shown in the legend. Small nuclear RNA(snRNA),  mitochondrial ribosomal RNA 
(Mt_rRNA), small nucleolar RNA (snoRNA), mitochondrial transfer RNA (Mt_tRNA), ribosomal 
RNA (rRNA), miscellaneous RNA (misc_RNA),  long non-coding RNA (lincRNA), JSRV viral 
genome (Virus), sheep genome (DNA), reads not  mapping to any of the previous categories 
(Unmapped). 
The variability in reads mapping to different categories of RNA can also be 
appreciated in Fig. 3.9, but it does not appear to be related to total read number, 
RNA concentration or sample quality. Given the low number of samples in each 
group, the differences between groups might be an artifact and not representative. 
Nevertheless, the distinctive distribution pattern presented by SPF4 might be 
related to the lower number of total reads in the sample. Length distribution (Fig. 
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3.10) was found to be similar between groups, with the exception of SPF9, that 
presented a higher number of reads in the miRNA region. 
Sequencing and analysis of the LCM samples detected 374 host miRNAs, a 
similar number to the 405 miRNAs detected in lung tissue in 3.2.1. This section 
will focus on host miRNAs, reads mapping to the JSRV genome are discussed in 
3.2.8. Global miRNA expression between mock-infected controls and JSRVmut-
infected samples showed close clustering between the two groups. JSRV21-
infected samples presented higher within group variability of miRNA expression 
as well as levels of specific miRNAs compared to the other two groups (Fig. 3.11). 
Interestingly, SPF4, the sample that presents greater distance by PC1 to all other 
samples, had the lowest percentage of reads mapping to miRBase (Table 3.9). In 
addition, one of the JSRV21-infected samples, SPF20, clustered closely with the 
mock-infected group. 
Pairwise comparisons were then performed between groups to identify miRNAs 
differentially expressed between groups and to compare the findings with those of 
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Figure 3.10. Length distribution of total sequencing reads after trimming was performed. JSRV21-infected samples (n=3, SPF4 SPF7, SPF20); 
Mock-infected control samples (n=3, SPF8, SPF12, SPF14); JSRVmut-infected samples (n=3, SPF1, SPF5, SPF9). The area with high read abundance 
observed corresponds to miRNA length (21-23nt). Length distribution appears similar between groups, with SPF9 presenting a higher number of reads in 
the miRNA region.  
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Figure 3.11. PCA plot of miRNA expression from LCM lung tissue samples of JSRV21-
infected (n=3), JSRVmut-infected (n=3), and mock-infected lambs (n=3). Control and 
JSRVmut-infected samples cluster together towards the right of the plot, whereas JSRV21-
infected samples occupy a larger part of the plot. The PCA plot indicates greater variability 
between JSRV21-infected samples in PC1 and PC2 than among the other groups. By PC1, 
SPF7 and SPF20 cluster closer to the control group than the JSRV21-infected group. SPF20 
also clusters closely to the control group by PC2. This plot suggests differences between 
JSRV21-infected and the other groups as well as within the group.  
3.2.5.1 DE miRNAs between JSRV21-infected and mock-infected LCM 
lung tissue 
The DE threshold for the study of miRNA expression in LCM samples was 
established at fold change >2 or fold change < 0.5, and FDR <0.05. This threshold 
is more stringent than the one applied in lung tissue because LCM samples are 
enriched for tumour tissue. Therefore, levels of upregulation and downregulation 
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of miRNAs related to OPA were expected to be greater compared to lung tissue 
samples.  
Comparison of DE miRNAs between the JSRV21-infected and the mock-infected 
group revealed 67 miRNAs differentially expressed between the two groups. 60 
miRNAs were upregulated and the remaining 7 were downregulated in the 
JSRV21-infected group (Table 3.10 and Table 3.11). Nevertheless, observing the 
heatmap of DE miRNAs (Fig. 3.12) DE of most miRNAs seems to be driven by 
the expression levels of one sample, either SPF4 or SPF7. In addition, clustering 
showed that SPF8, of the mock-infected group, clustered with JSRV21-infected 
samples, while SPF7, of the JSRV21-infected group clustered with mock-infected 
samples. 
Potential reasons for the observed within group variability are discussed in 3.3. 
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Figure 3.12. Heatmap of differentially expressed (FDR<0.05) miRNAs between JSRV21-
infected (n=3) and Mock-infected groups (n=3). Dendrogram showing correlation clustering 
of individuals in groups. Legend represents values of log2 fold change.Table 3.10. 
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Differentially upregulated miRNAs between LCM tissue of JSRV21-infected lambs and 
mock-infected lambs. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-151-3p 144063.32 1.03 0 
miR-21 236018.57 1.23 0 
miR-423-5p 91283.28 1.62 0 
miR-183 6386.05 5.40 4.12E-34 
miR-182 7534.92 5.00 1.02E-30 
miR-96 660.15 4.64 2.84E-26 
miR-135b 276.31 4.76 4.96E-24 
miR-122 139.89 3.88 4.05E-17 
miR-365-5p 371.17 4.40 8.03E-13 
miR-31 187.68 3.09 1.81E-11 
miR-130b-5p 1329.29 2.83 5.35E-10 
miR-92b-5p 556.75 3.68 5.42E-10 
miR-1246 160.95 2.46 6.72E-09 
miR-205 854.16 2.52 6.04E-08 
miR-206 732.12 3.00 7.39E-08 
miR-1290 99.74 2.43 1.6E-07 
miR-200a-5p 4599.03 2.53 3.3E-07 
miR-424-3p 3104.25 2.33 3.97E-07 
miR-375 16309.86 2.38 5.7E-07 
miR-2478 87.23 3.37 1.29E-06 
miR-450b 2563.28 2.20 2.34E-06 
miR-146a-5p 64.55 2.56 1.29E-05 
miR-200b-5p 1956.40 1.91 1.46E-05 
miR-2411-3p 802.53 1.80 1.57E-05 
miR-370-3p 3685.74 1.98 5.15E-05 
miR-184 307.68 2.54 6.96E-05 
miR-193b-5p 143.39 2.72 7.77E-05 
miR-1343-5p 146.03 3.01 1.05E-04 
miR-146a 19478.62 1.84 1.49E-04 
miR-708-3p 424.97 1.63 2.23E-04 
miR-146b 8434.73 1.78 2.29E-04 
miR-3958-5p 83.03 2.50 2.39E-04 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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miRNA average counts1 log2(fold change)2 FDR3 
miR-429 729.73 1.68 2.58E-04 
miR-342-5p 2019.36 2.45 4.44E-04 
miR-34c 5205.73 1.45 4.97E-04 
miR-200b-3p 16237.08 1.63 5.63E-04 
miR-146b-3p 134.48 1.92 7.14E-04 
miR-92b 29506.68 2.01 7.88E-04 
miR-219 72.79 2.21 1.24E-03 
miR-3956-5p 300.72 2.17 1.46E-03 
miR-34b-5p 169.87 1.57 1.83E-03 
miR-409-3p 14252.99 1.69 1.94E-03 
miR-200a 33209.16 1.48 2.33E-03 
miR-2387 205.81 1.57 4.15E-03 
miR-877-5p 100.91 2.09 4.45E-03 
miR-450a 3249.99 1.48 4.84E-03 
miR-708 242.75 1.66 6.08E-03 
miR-451 13596.90 1.40 9.75E-03 
miR-485-5p 3339.41 1.88 9.81E-03 
miR-34c-5p 14451.31 1.22 9.82E-03 
miR-2332 388.67 1.32 9.86E-03 
miR-760-3p 102.32 1.39 1.15E-02 
miR-222-3p 5379.06 1.22 2.11E-02 
 
Table 3.11. Differentially downregulated miRNAs between LCM tissue of JSRV21-
infected lambs and mock-infected lambs. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-2284u 59.51 -1.86 4.71E-03 
miR-195-5p 60.52 -1.92 8.65E-03 
miR-29d-5p 88.33 -1.27 2.75E-02 
miR-335 585.20 -1.56 2.85E-02 
miR-455-5p 1467.10 -1.26 4.04E-02 
miR-767 223.37 -1.22 4.93E-02 
miR-338 108.57 -1.69 4.96E-02 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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3.2.5.2 DE miRNAs between JSRV21-infected and JSRVmut-infected LCM 
lung tissue 
The aim of this comparison was to observe which miRNAs were DE in the JSRV-
driven transformation process, but not in JSRV viral infection. For this reason, 
miRNA expression in JSRV21-infected samples was compared to that of a JSRVmut 
that was transformation deficient. Comparison of the DE miRNAs between the 
JSRV21-infected and JSRVmut-infected group also revealed differences. 121 
miRNAs were found to be DE between the groups, 87 downregulated and 34 
downregulated in the JSRV21-infected group (Table 3.12 and Table 3.13). 
Nevertheless, although miRNA dysregulation seemed consistent within groups for 
miRNAs represented in the top part of the heatmap, most miRNA DE appeared 
driven by expression in one sample of the JSRV21-infected group (Fig. 3.13). 
Heatmap clustering classified members of each group separately, with JSRV21-
infected samples showing greater variability than JSRVmut-infected ones.   
Interestingly, comparison of JSRV21-infected samples to JSRVmut-infected 
samples resulted in a greater number of DE miRNAs than comparison to mock-
infected samples. This result is likely due to the variability within groups, as the 
mock-infected group presented greater within group variability than the JSRVmut-
infected group, as observed in the PCA plot (Fig. 3.11).  
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Figure 3.13. Heatmap of differentially expressed (FDR<0.05) miRNAs between JSRV21-
infected (n=3) and JSRVmut-infected groups (n=3). Dendrogram showing correlation 
clustering of individuals in groups. Legend represents values of log2 fold change. 
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Table 3.12. Differentially upregulated miRNAs in LCM tissue between JSRV21-
infected lambs and JSRVmut infected lambs. 
miRNA Average counts1 log2(fold change)2  FDR3 
miR-143 823954.95 1.05 0 
miR-21 244120.67 1.07 0 
miR-151-3p 123116.63 1.88 0 
miR-92b 28535.09 2.28 0 
miR-423-5p 80762.92 2.53 0 
miR-375 14990.81 3.38 0 
miR-182 7424.19 5.95 0 
miR-183 6331.96 6.06 0 
miR-135b 269.80 6.34 4.3E-148 
miR-96 660.53 4.62 1.4E-137 
miR-92b-5p 528.86 5.37 4.27E-93 
miR-1246 142.86 4.37 1.59E-80 
miR-3956-5p 257.80 4.39 1.09E-69 
miR-200a-5p 4350.91 3.19 1.64E-68 
miR-206 699.08 3.76 1.06E-67 
miR-365-5p 372.92 4.26 2.17E-61 
miR-31 188.61 3.03 1.24E-52 
miR-2411-3p 723.87 2.64 1.99E-52 
miR-200b-5p 1799.39 2.61 1.23E-50 
miR-370-3p 3466.73 2.49 5.41E-45 
miR-205 867.32 2.38 2.92E-44 
miR-424-3p 3079.77 2.40 3.45E-44 
miR-1290 92.60 3.31 4.29E-44 
miR-122 148.38 2.92 1.25E-42 
miR-130b-5p 1374.82 2.48 3.42E-42 
miR-450b 2587.61 2.12 1.13E-36 
miR-708-3p 387.94 2.27 1.45E-35 
miR-2332 335.82 2.25 2.02E-35 
miR-409-3p 12811.53 2.50 2.47E-35 
miR-485-5p 3042.05 2.66 6.06E-33 
miR-146a 19050.81 1.99 2.21E-31 
miR-1343-5p 138.62 3.91 2.23E-31 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
 
Chapter 3: miRNA dysregulation in OPA lung tissue 164 
Table 3.12. Differentially upregulated miRNAs in LCM tissue between JSRV21-
infected lambs and JSRVmut infected lambs. 
miRNA Average counts1 log2(fold change)2  FDR3 
miR-139-3p 120.27 3.17 2.4E-29 
miR-146b 8270.79 1.91 2.64E-29 
miR-193b-5p 138.48 3.16 2.29E-28 
miR-671-3p 566.09 2.43 2.4E-28 
miR-326 240.28 2.04 1.88E-26 
miR-342-5p 2011.62 2.49 3.24E-26 
miR-1248 345.06 1.90 6.19E-25 
miR-2387 193.28 1.97 8.11E-24 
miR-200b-3p 16129.90 1.67 1.08E-23 
miR-184 310.46 2.46 1.16E-23 
miR-877-5p 92.91 2.86 3.66E-23 
miR-146a-5p 64.63 2.55 5.96E-22 
miR-146b-3p 132.38 2.04 6.85E-22 
miR-3958-5p 79.00 3.06 9.26E-21 
miR-2411-5p 82.48 2.42 4.11E-20 
miR-708 240.96 1.70 1.71E-19 
miR-1307 1080.54 1.59 3.65E-19 
miR-744 2614.55 1.67 3.65E-19 
miR-429 742.05 1.58 7.63E-19 
miR-34c 5135.03 1.53 7.78E-19 
miR-877 101.55 2.09 1.99E-18 
miR-2478 91.10 2.78 2.43E-18 
miR-219 68.37 2.81 3.01E-17 
miR-6529a 4649.69 1.76 3.09E-17 
miR-1307-3p 4355.63 1.50 6.59E-17 
miR-2404 98.10 2.08 2.29E-16 
miR-760-3p 92.48 2.01 3.21E-16 
miR-34c-5p 14055.20 1.36 2.9E-15 
miR-27b-5p 273.17 1.68 8.8E-15 
miR-1468 19901.16 1.86 1.33E-14 
miR-493-3p 6475.72 1.36 1.66E-14 
miR-222-3p 5260.41 1.33 4.23E-14 
miR-210 591.62 1.36 1.34E-13 
miR-200a 34460.91 1.29 1.53E-13 
miR-296-3p 708.17 1.28 1.86E-12 
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Table 3.12. Differentially upregulated miRNAs in LCM tissue between JSRV21-
infected lambs and JSRVmut infected lambs. 
miRNA Average counts1 log2(fold change)2  FDR3 
miR-432 2107.14 1.41 1.9E-12 
miR-34b-3p 5212.67 1.21 2.43E-12 
miR-203a-3p 1692.35 1.22 7.66E-12 
miR-1434-3p 184.09 1.45 7.66E-12 
miR-193b 189.53 1.41 1E-11 
let-7d-3p 10109.76 1.30 8.33E-11 
miR-877-3p 97.85 1.67 1.9E-10 
miR-200c 49514.06 1.08 2.87E-10 
miR-141-5p 67.94 1.52 1.08E-09 
miR-200b 16256.50 1.04 2.13E-09 
miR-2474 56.44 1.95 3.72E-09 
miR-10b 11689.82 1.08 9E-09 
miR-4448 140.48 1.85 1.09E-08 
miR-191-3p 359.99 1.16 1.17E-08 
miR-9-5p 145.45 1.28 1.51E-08 
miR-2366 51.64 1.78 4.78E-08 
miR-23b-5p 290.37 1.26 8.37E-08 
miR-149-5p 187.75 1.07 1.91E-07 
miR-500a-3p 163.87 1.12 8.64E-07 
miR-18a-3p 91.04 1.21 8.88E-07 
 
Table 3.13. Differentially downregulated miRNAs in LCM tissue between JSRV21-
infected lambs and JSRVmut-infected lambs. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-126-3p 985020.21 -1.15 0 
miR-26a 1178136.69 -1.11 0 
miR-455-5p 1850.26 -1.72 1.66E-11 
miR-126-5p 8934.89 -1.63 4.6E-11 
miR-335 651.69 -1.77 1.52E-10 
miR-142-5p 648.82 -1.50 2.99E-10 
miR-2284u 73.11 -2.23 4.09E-10 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
 
Chapter 3: miRNA dysregulation in OPA lung tissue 166 
Table 3.13. Differentially downregulated miRNAs in LCM tissue between JSRV21-
infected lambs and JSRVmut-infected lambs. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-10a-3p 472.05 -1.58 1.57E-09 
miR-374a 3734.71 -1.45 3.52E-09 
miR-30b 93.62 -1.90 1.37E-08 
miR-30f 13493.42 -1.42 1.84E-08 
miR-338 107.48 -1.67 2.06E-08 
miR-140-5p 200.23 -1.40 1.74E-07 
miR-383 192.94 -1.47 3.58E-07 
miR-142-3p 1303.57 -1.12 3.81E-07 
miR-144 148.13 -1.28 3.92E-07 
miR-218a 11111.66 -1.24 4.83E-07 
miR-191 76079.84 -1.18 5.4E-07 
miR-3600 1010.05 -1.03 1.18E-06 
miR-181a 70623.76 -1.11 1.73E-06 
miR-26b 74352.92 -1.15 2.1E-06 
miR-767 227.73 -1.26 2.37E-06 
miR-374b 4622.67 -1.05 3.14E-06 
miR-16b 42191.56 -1.16 5.18E-06 
miR-195-5p 51.24 -1.61 6.29E-06 
miR-874-3p 73.33 -1.36 1.61E-05 
miR-29d-5p 89.68 -1.30 2.25E-05 
miR-199c 382.29 -1.10 2.32E-05 
miR-16a 198.14 -1.09 5.15E-05 
miR-381 89.34 -1.11 9.24E-05 
miR-3432-3p 50.55 -1.47 1.21E-04 
miR-136-3p 232.33 -1.02 1.41E-04 
miR-320b 538.30 -1.02 2.55E-04 
miR-3604 59.99 -1.06 2.75E-03 
 
3.2.5.3 DE miRNAs between JSRVmut-infected and mock-infected LCM 
lung tissue 
The main aim of this comparison was to investigate the effects of solely the JSRV 
infection in lung tissue, without considering the transformation that occurs with the 
wild-type version of JSRV21. In order to investigate miRNA expression differences 
between JSRVmut-infected lambs and mock-infected lambs a DE analysis was 
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performed. 14 miRNAs were found DE between groups, 5 were found to be 
upregulated and 9 downregulated (Table 3.14 and Table 3.15). Heatmap 
clustering revealed the two groups clustering separately and SPF8 presenting the 
most distinct expression pattern (Fig. 3.14).  
These results correlate with the group PCA plot in which the JSRVmut-infected and 
the mock-infected group clustered together, so a low number of DE miRNAs was 
expected. These findings might indicate that JSRVmut infection modifies 
expression of a low set of miRNAs, suggesting that transformation is responsible 
for most miRNA changes observed. However, it should be noted that 
immunostaining analysis of the tissue samples of JSRVmut-infected samples 
revealed no JSRV Env expression, which suggests that the low number of DE 
miRNAs between groups are due to low infection level. In addition, the lack of 
JSRV Env expression in JSRVmut-infected samples raises the question of whether 
DE miRNAs between the analysed groups are genuine, or due to statistical noise. 
This is further discussed in 3.3.  
 
Figure 3.14. Heatmap of differentially expressed (FDR<0.05) miRNAs between JSRVmut-
infected (n=3) and mock-infected groups (n=3). Dendrogram showing correlation clustering 
of individuals in groups. Legend represents values of log2 fold change. 
 
Chapter 3: miRNA dysregulation in OPA lung tissue 168 
Table 3.14. Differentially upregulated miRNAs in LCM tissue between JSRVmut- infected 
lambs and mock-infected lambs.  
miRNA average counts1 log2(fold change)2 FDR3 
miR-142-5p 636.93 1.61 3.17E-11 
miR-144 135.71 1.77 8.55E-11 
miR-144-5p 85.98 1.13 9.37E-05 
miR-34b-5p 128.83 1.01 5.22E-04 
miR-135a 62.90 1.12 1.78E-03 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
                                            
 
Table 3.15. Differentially downregulated miRNAs in LCM tissue between JSRVmut- 
infected lambs and mock-infected lambs. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-3955-5p 195.69 -2.24 1.57E-28 
miR-3956-5p 66.45 -2.22 5.24E-20 
miR-1248 288.63 -1.56 3.38E-16 
miR-92b-5p 52.80 -1.70 1.6E-10 
miR-10b 11987.95 -1.13 1.42E-09 
miR-324 125.01 -1.24 1.89E-08 
miR-375 3941.90 -1.00 6.93E-08 
miR-4448 101.38 -1.22 8.37E-07 
miR-2404 58.91 -1.09 3.84E-05 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
                                            
 
3.2.5.4 Comparison of DE miRNAs between all LCM samples 
To investigate miRNAs DE expressed in samples with either wild-type JSRV21 or 
JSRVmut compared to mock-infected samples, the pairwise comparisons were 
examined. Four miRNAs: miR-3956-5p, miR-92b-5p, miR-375 and miR-34b-5p 
were found DE in infected samples. Nevertheless, all but miR-34b-5p were 
upregulated in wild-type JSRV21-infected samples and downregulated in JSRVmut-
infected samples. Although it could be speculated that miR-34b-5p upregulation 
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might be related to JSRV21-infection, low levels of infection with the JSRVmut form, 
discussed in 3.2.4.3, indicate further evidence is needed. Involvement of these 
miRNAs in JSRV-infection is further investigated in 3.2.7.  
3.2.6 DE miRNAs in bronchoalveolar lavage fluid (BALF) 
macrophages 
Since lung tissue is composed of many cell types, we sought to focus on the 
miRNA expression of enriched cell types in the OPA lung. The use of the LCM 
technique allowed the study of samples enriched in tumour tissue. Nevertheless, 
it was not suitable for the enrichment of a known important cell type in cancer: 
macrophages. Alveolar macrophages are the first line of defence in the lung 
alveoli, and have been shown to increase in abundance in OPA. In addition, they 
may display phenotype variation in OPA (Karagianni et al, 2019). 
In order to investigate if some of the miRNAs DE in lung tissue of OPA-affected 
animals were a result of a potential local immune response to JSRV presence, the 
miRNA expression of BALF macrophages was studied. If alveolar macrophages 
presented significant changes in miRNA expression between OPA-affected 
animals and controls, these could be further investigated as biomarkers of OPA. 
BALF samples were collected from adult sheep received at the Moredun PM 
rooms by Chris Cousens and Anna Karagianni. The intention was to compare 
OPA and healthy animals, but during initial assessment it became clear that three 
of the healthy samples had actually had low levels of parasite infection in the lung. 
Therefore, the samples were divided into three groups: OPA-affected sheep, 
healthy control sheep and parasite-infected sheep. The cases selected had no 
obvious bacterial infection present. The parasite-infected group presented 
lungworms in the lung, and these samples were used to compare the CD14+ 
macrophage response in lungworm infection and JSRV-infection. CD14+ 
macrophages were isolated as described in (section 2.4.4) and RNA extracted (by 
Anna Karagianni). The concentration and quality of RNA samples was measured, 
and samples with 260/280 ratio > 1.8 and RIN number > 6 submitted for small 
RNA-sequencing (Table 3.16).  
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Table 3.16. RNA concentration of BALF CD14+ macrophage samples submitted for small 
RNA-sequencing. 
Group OPA-affected 
Sample OPA1 OPA2 OPA3 OPA4 OPA5 
RNA (ng/µl) 421.20 241.83 547.04 376.24 573.02 
260/280 nm 2.04 1.92 1.95 2.06 2.05 
RIN 9.3 9.4 9.8 9.9 10 
Group Healthy controls 
Sample CON1 CON2 CON3 
RNA (ng/µl) 215.40 320.11 478.80 
260/280 nm 2.02 2.06 2.06 
RIN 9.6 9.9 9.7 
Group Parasite-infected 
Sample PARA1 PARA2 PARA3 
RNA (ng/µl) 550.17 293.2 375.21 
260/280 nm 2 2.05 2 
RIN 9.6 9.8 9.8 
 
Small RNA-sequencing was performed by Edinburgh Genomics and 
bioinformatics analysis by Siddharth Jayaraman and Deepali Vasoya supervised 
by myself and with assistance from Mick Watson, David Griffiths and Finn Grey. 
Sequencing libraries were successfully constructed from all samples, and total 
reads ranged from 40079257 to 24631916 (Table 3.17). No statistically significant 
differences were found between groups in total reads or percentage of reads 
mapping to different categories (t-test p<0.05) (Fig. 3.15). In addition, the 
sequence length distribution (Fig. 3.16) also appeared similar between groups.  
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Table 3.17. Total reads of sequenced BALF CD14+ macrophage samples.  
 
Group OPA-affected 
Sample OPA1 OPA2 OPA3 OPA4 OPA5 










 >28 nt 10.30 2.57 6.19 4.88 9.68 
miRBase 55.17 81.19 73.55 77.58 67.56 
JSRV 0.00334 0.00289 0.00519 0.00387 0.00434 
 
Group Healthy controls 
Sample CON1 CON2 CON3 










 >28 nt 4.71 3.83 7.87 
miRBase 72.36 76.85 73.39 
JSRV 0.00591 0.00429 0.00412 
 
Group Parasite-infected 
Sample PARA1 PARA2 PARA3 










 >28 nt 9.64 6.23 5.97 
miRBase 72.50 73.42 76.64 
JSRV 0.00397 0.00472 0.00417 
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Figure 3.15. Sequence distribution in samples of BALF CD14+macrophages 
sequencing, presented as percentage of total reads in each sample. Each of the 
categories is represented by a colour shown in the legend. Small nuclear RNA(snRNA),  
mitochondrial ribosomal RNA (Mt_rRNA), small nucleolar RNA (snoRNA), mitochondrial 
transfer RNA (Mt_tRNA), ribosomal RNA (rRNA), miscellaneous RNA (misc_RNA),  long non-
coding RNA (lincRNA), JSRV viral genome (Virus), sheep genome (DNA), reads not  mapping 
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Figure 3.16. Length distribution of total sequencing reads after trimming was performed. OPA-affected samples (n=5, OPA1, OPA2, OPA3, OPA4, 
OPA5); control samples (n=3, CON1, CON2, CON3); parasite-infected samples (n=3, PARA1, PARA2, PARA3). The area with high read abundance 
observed corresponds to miRNA length (21-23nt). Length distribution appears similar between groups.  
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Bioinformatics analysis identified 356 miRNAs in all samples. Expression of these 
356 miRNAs was represented in a PCA plot (Fig. 3.17). In the PCA plot, the three 
studied groups clustered separately, and the highest variability was observed 
within the OPA-affected group. This is likely due to individual-specific responses 
to JSRV, which might also be related to different viral-load between animals. 
Notably, OPA5 clustered closely with the parasite-infected group suggesting a 
pattern of miRNA expression more similar to them.  
 
Figure 3.17. PCA plot of miRNA expression from BALF CD14+macrophage samples of 
OPA-affected (n=5), control (n=3), and parasite-infected samples (n=3). The three groups 
can be seen clustering separately and, by PC1, a gradient can be observed with control 
samples towards the left of the plot, OPA-affected samples towards the right and parasite-
infected samples between them. This gradient is not observed by PC2, as groups present 
more variability in this axis. Variability within the OPA-affected group is the greatest, and OPA5 
clusters closely with the parasite-infected group. This plot suggests global miRNA expression 
differences between the three groups.   
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3.2.6.1 DE miRNAs in BALF macrophages of OPA-affected and control 
samples 
In order to investigate DE miRNAs between the groups pairwise comparisons 
were performed.  
Comparison between BALF CD14+ macrophages of OPA-affected sheep and 
healthy controls found 85 miRNAs DE between the two groups, 63 were 
upregulated and 22 were downregulated in OPA-affected sheep (Table 3.18 and 
Table 3.19).  
A heatmap representation of the DE miRNAs (Fig. 3.18) revealed that most DE 
miRNAs showed consistent expression within groups, suggesting that their 
expression might help to distinguish members of each group. Nevertheless, OPA5 
was found to cluster with the control group instead of the OPA-affected group. 
Consistent with the PCA plot representation (Fig. 3.17). Nevertheless, no evident 
reason for the miRNA expression pattern observed was found.  
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Figure 3.18. Heatmap of differentially expressed (FDR<0.05) miRNAs between OPA-
affected (n=5) and control BALF CD14+macrophage samples (n=3). Dendrogram showing 
correlation clustering of individuals in groups. Legend represents values of log2 fold change. 
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Table 3.18. Differentially upregulated miRNAs between BALF CD14+ macrophages 
of OPA affected sheep and healthy controls. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-143 203307.79 1.09 0 
miR-100 91.77 4.17 6.45E-49 
miR-199a-3p 1550.03 2.58 7.88E-47 
miR-182 781.83 2.48 5.44E-42 
miR-223 14922.90 2.23 9.86E-41 
miR-146a 10025.11 2.13 1.19E-39 
miR-338 61.73 3.80 1.26E-38 
miR-127 13132.57 2.18 2.17E-36 
miR-151-3p 5988.08 2.10 3.07E-35 
miR-369-3p 229.45 2.51 1.87E-34 
miR-222 438.58 2.20 2.21E-33 
let-7e 390.07 2.17 5.24E-32 
miR-210 1444.93 1.95 6.83E-32 
miR-543-3p 53.11 2.96 2.3E-28 
miR-151-5p 5795.73 1.82 8.51E-28 
miR-493-3p 322.59 2.06 1.03E-27 
miR-136 97.44 2.52 1.85E-26 
miR-99b 827.70 1.89 2.51E-26 
miR-199a-5p 303.12 2.10 2.89E-26 
miR-487b-3p 195.38 2.12 2.97E-26 
miR-125a-5p 1345.88 1.89 4.45E-26 
miR-196b 271.26 1.84 6.48E-26 
let-7e-5p 631.75 1.73 1.63E-23 
miR-223-5p 856.30 1.55 3.58E-23 
miR-155 2370.15 1.54 8.9E-23 
miR-410-3p 403.24 1.83 1.58E-22 
miR-493-5p 182.55 1.95 2.64E-22 
miR-125a 1036.60 1.65 8.45E-21 
miR-2284f 62.35 2.39 1.11E-20 
miR-3959-5p 186.85 1.86 2.53E-20 
miR-32-5p 2004.30 1.67 8.03E-20 
miR-136-3p 424.13 1.74 1.08E-19 
                                            
1  Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 3.18. Differentially upregulated miRNAs between BALF CD14+ macrophages 
of OPA affected sheep and healthy controls. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-380-3p 455.51 1.68 1.16E-19 
miR-361-3p 6593.80 1.41 6.03E-19 
miR-432 69.03 2.04 2.55E-18 
miR-33b 349.78 1.67 4.59E-18 
miR-323c 77.54 2.00 8.03E-18 
miR-3604 268.92 1.62 9.42E-18 
miR-411a-5p 6756.54 1.53 2.07E-17 
miR-221 10302.37 1.38 3.13E-17 
miR-381 68.50 2.09 6.41E-17 
let-7i-3p 185.79 1.61 2.97E-16 
miR-371 195.38 1.32 1.93E-15 
miR-409-3p 843.37 1.38 2.61E-15 
miR-2285n 51.61 1.87 4.1E-14 
miR-665-3p 115.39 1.52 3.7E-13 
miR-451 484.16 1.35 7.02E-13 
miR-301b 296.61 1.28 1.56E-12 
miR-147 9087.84 1.00 1.2E-11 
miR-429 111.00 1.32 2.36E-10 
miR-2284aa 58.97 1.45 2.58E-10 
miR-582 69.83 1.48 3.24E-10 
miR-369-5p 51.84 1.55 1.64E-09 
miR-126-5p 367.33 1.06 5.86E-09 
miR-362-3p 132.98 1.21 5.37E-08 
miR-335 67.79 1.11 6E-08 
miR-203a-3p 95.32 1.04 6.36E-08 
miR-2284u 117.30 1.10 9.63E-08 
miR-145-3p 190.88 1.03 4.19E-07 
miR-494-3p 92.89 1.13 4.24E-07 
miR-4792 59.16 1.35 6.13E-07 
miR-126-3p 53.22 1.09 2.73E-06 
miR-363-3p 62.29 1.24 2.77E-05 
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Table 3.19. Differentially downregulated miRNAs between BALF CD14+ macrophages 
of OPA affected sheep and healthy controls. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-30a-5p 100812.18 -1.23 0 
miR-30e-5p 314695.85 -1.04 0 
miR-874 170.71 -2.45 6.25E-45 
miR-874-3p 185.01 -2.42 3.11E-44 
miR-215 239.30 -1.65 2.85E-32 
miR-874-5p 111.61 -2.16 3.27E-32 
miR-150 32868.50 -1.53 3.58E-23 
miR-1468 4215.35 -1.66 3.56E-21 
miR-27a-5p 5254.89 -1.31 1.12E-20 
miR-708-3p 31640.20 -1.24 9.1E-20 
miR-30a-3p 695.41 -1.32 3.12E-19 
miR-708 5738.72 -1.24 6.38E-18 
miR-191-3p 2174.74 -1.23 9.37E-17 
miR-30f 276.38 -1.33 3.3E-16 
miR-30c-1-3p 342.99 -1.27 7.5E-16 
miR-30c 7123.43 -1.02 1.84E-13 
miR-365-3p 1651.36 -1.15 4.16E-13 
miR-30e-3p 9456.56 -1.02 1.56E-12 
miR-296-3p 877.33 -1.02 5.59E-12 
miR-340 691.97 -1.00 2.72E-11 
miR-744-3p 77.46 -1.07 1.42E-09 
miR-222-5p 73.49 -1.08 6.57E-08 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
                                            
 
3.2.6.2 DE miRNAs between OPA-affected and parasite-infected BALF 
macrophages 
In order to investigate if miRNA expression in BALF CD14+macrophages was 
different depending on the pathogen (JSRV or lungworm) a DE analysis was 
performed. 59 miRNAs were found DE between OPA-affected and parasite-
infected samples, 45 upregulated and 14 downregulated (Table 3.20 and Table 
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3.21). The number of DE miRNAs was lower in this comparison than between 
OPA and healthy controls, which might suggest that there are common 
dysregulated miRNAs in JSRV infection and parasite infection. Expression levels 
of DE miRNAs also appeared more variable within groups (Fig. 3.19) with OPA2 
presenting the most distinctive pattern. In addition, OPA5 clustered with the 
parasite infected group as in prior comparisons (Fig. 3.17). These findings might 
indicate that the ability to distinguish between OPA-affected sheep and parasite-
infected sheep, based on miRNA expression in BALF CD14+ macrophages, might 
be more difficult than distinction of OPA-affected samples and control samples. 
Although this result is to be expected, it has implications for the potential 
application of this methodology as source of biomarkers because lungworm 
infections are a common finding in farmed sheep (Panuska, 2006). This 
hypothesis is further investigated in 3.2.6.4. 
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Figure 3.19. Heatmap of differentially expressed (FDR<0.05) miRNAs between OPA-
affected (n=5) and parasite-infected BALF CD14+ macrophage samples (n=3). 
Dendrogram showing correlation clustering of individuals in groups. Legend represents values 
of log2 fold change. 
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Table 3.20. Differentially upregulated miRNAs between BALF CD14+ macrophages 
of OPA affected sheep and parasite infected sheep. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-127 11882.88 3.25 2.67E-82 
miR-493-3p 281.01 3.64 1.97E-74 
miR-409-3p 692.56 2.88 1.28E-59 
miR-410-3p 358.05 2.87 3.36E-55 
miR-493-5p 160.71 3.22 2.84E-54 
miR-487b-3p 177.00 3.13 1.12E-53 
miR-411a-5p 5913.34 2.49 2.44E-52 
miR-380-3p 399.36 2.74 4.31E-52 
miR-3959-5p 163.88 3.07 3.04E-51 
miR-199a-3p 1575.11 2.43 2.79E-48 
miR-369-3p 224.08 2.76 2.79E-48 
miR-210 1388.00 2.26 7.97E-44 
miR-136-3p 390.09 2.36 2.64E-41 
let-7e 378.87 2.42 3.9E-41 
miR-99b 781.12 2.33 7.16E-41 
miR-665-3p 96.31 3.00 1.15E-40 
miR-125a-5p 1276.08 2.29 2.74E-40 
miR-182 803.62 2.24 9.48E-39 
let-7e-5p 584.78 2.29 1.06E-38 
miR-381 60.97 3.33 1.48E-38 
miR-323c 68.76 3.20 2.59E-38 
miR-543-3p 51.21 3.50 6.43E-38 
miR-136 95.43 2.74 3.21E-36 
miR-3958-3p 261.68 2.32 3.96E-36 
miR-432 65.13 2.53 7.59E-28 
miR-494-3p 75.85 2.40 1.41E-26 
miR-3604 266.38 1.68 2.49E-22 
miR-125a 1042.52 1.61 1.24E-21 
miR-151-3p 6574.61 1.50 4.96E-21 
miR-199a-5p 327.59 1.59 1.38E-19 
miR-222 496.06 1.41 3.52E-18 
miR-151-5p 6379.96 1.28 1.32E-15 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 3.20. Differentially upregulated miRNAs between BALF CD14+ macrophages 
of OPA affected sheep and parasite infected sheep. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-301b 290.33 1.39 2.66E-14 
miR-130a 190.30 1.34 8.26E-14 
miR-204 460.86 1.09 8.29E-12 
miR-221 11131.96 1.02 1.11E-11 
miR-371 200.07 1.20 1.49E-11 
miR-429 110.69 1.33 2.04E-11 
miR-100 123.23 1.26 3.46E-11 
miR-130b 2204.95 1.02 3.8E-10 
miR-338 81.91 1.24 5.58E-10 
miR-203a-3p 92.45 1.17 2.1E-09 
miR-582 73.59 1.21 1.1E-08 
miR-126-3p 51.78 1.22 1.97E-07 
miR-363-3p 62.77 1.20 2.25E-06 
 
Table 3.21. Differentially downregulated miRNAS between BALF CD14+ 
macrophages of OPA affected sheep and parasite infected sheep. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-874 181.70 -2.56 2.5E-52 
miR-874-3p 177.41 -2.34 8.41E-46 
miR-874-5p 109.31 -2.13 2.91E-34 
miR-34c-5p 3376.07 -1.67 1.88E-32 
miR-10b 565.37 -1.89 5.34E-32 
miR-1468 4095.24 -1.61 3.28E-25 
miR-34b-3p 205.45 -1.56 1.36E-23 
miR-708-3p 34004.57 -1.38 5.34E-19 
miR-27a-5p 4942.85 -1.18 2.64E-16 
miR-708 5703.37 -1.23 8.53E-15 
miR-9-5p 3752.51 -1.16 1.53E-14 
miR-34b-5p 212.61 -1.12 1.84E-13 
miR-139 80.80 -1.35 4.8E-12 
miR-2411-5p 112.62 -1.05 5.21E-08 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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3.2.6.3 DE miRNAs between parasite-infected and control BALF CD14+ 
macrophages 
Lastly, a comparison of miRNA expression between parasite-infected and control 
samples was performed in order to investigate which miRNAs were related to 
infection. 34 miRNAs were found DE between parasite-infected and control 
samples, 19 upregulated and 15 downregulated (Table 3.22 and Table 3.23). 
Heatmap representation (Fig. 3.20) revealed that the two groups clustered 
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Figure 3.20. Heatmap of differentially expressed (FDR<0.05) miRNAs between parasite-
infected (n=3) and control BALF CD14+ macrophage samples (n=3). Dendrogram showing 
correlation clustering of individuals in groups. Legend represents values of log2 fold change. 
 
Table 3.22. Differentially upregulated miRNAs between BALF CD14+ macrophages 
of parasite infected sheep and healthy controls. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-10b 566.82 1.88 2.83E-25 
miR-451 565.08 1.65 1.21E-22 
miR-2284f 69.50 2.57 6.06E-21 
                                            
1  Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 3.22. Differentially upregulated miRNAs between BALF CD14+ macrophages 
of parasite infected sheep and healthy controls. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-32-5p 2070.15 1.73 1.14E-19 
miR-486 2820.43 1.36 5.19E-19 
miR-4634 671.76 1.60 2.54E-18 
miR-223 9778.13 1.45 1.73E-17 
miR-147 10669.36 1.34 2.97E-16 
miR-146a 6276.37 1.25 2.12E-13 
miR-186-3p 222.79 1.44 6.05E-13 
miR-33b 310.65 1.44 9.83E-13 
miR-361-3p 5798.31 1.15 2.67E-11 
let-7i-3p 170.11 1.43 2.85E-11 
miR-2411-5p 102.91 1.50 7.14E-11 
miR-34c 222.25 1.30 1.99E-10 
miR-34b-5p 210.87 1.16 2.68E-09 
miR-2284u 124.66 1.23 5.87E-08 
miR-4792 59.88 1.38 1.16E-07 
miR-362-3p 132.93 1.20 2.5E-07 
 
Table 3.23. Differentially downregulated miRNAs between BALF CD14+ 
macrophages of parasite infected sheep and healthy controls. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-215 235.37 -1.75 2.83E-25 
miR-409-3p 316.70 -1.49 4.57E-16 
miR-493-3p 83.33 -1.58 9.64E-13 
miR-3958-3p 158.48 -1.40 1.49E-12 
miR-127 3503.64 -1.08 3.92E-11 
miR-224 2149.42 -1.17 1.9E-10 
miR-380-3p 160.05 -1.06 5.29E-08 
miR-410-3p 131.41 -1.03 1.57E-07 
miR-193b 69.25 -1.32 1.94E-07 
miR-493-5p 53.02 -1.26 3.06E-07 
miR-3959-5p 57.79 -1.21 3.91E-07 
miR-1260b 205.96 -1.06 4.59E-07 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 3.23. Differentially downregulated miRNAs between BALF CD14+ 
macrophages of parasite infected sheep and healthy controls. 
miRNA Average counts1 log2(fold change)2 FDR3 
miR-2483-3p 87.27 -1.11 1.97E-06 
miR-222-5p 74.31 -1.03 2.23E-05 
miR-487b-3p 54.67 -1.01 6.53E-05 
 
3.2.6.4 Comparison of DE miRNAs between BALF samples 
With the aim to identify specific miRNAs DE in infection and those DE only in 
JSRV-infection the results obtained from the pairwise analysis were compared. 
22 miRNAs were found DE in OPA-affected or parasite-infected samples 
compared to controls, suggesting these miRNAs might be involved in 
transcriptional changes that occur in macrophages during response to infection. 
However, 8 of the 22 DE miRNAs in both infections presented dysregulation in 
different directions, which might indicate different responses depending on the 
pathogen. Interestingly, of the DE miRNAs, miR-215 and miR-33b, have 
consistently been reported as dysregulated in infections and both target XIAP, a 
major regulator of apopotosis (Nielsen et al, 2018). The remaining DE miRNAs in 
OPA-affected samples were not found to be DE in parasite-infected samples, 
suggesting this might be more specific of JSRV infection. To investigate if these 
miRNAs would be able to distinguish between OPA-affected and parasite-infected 
samples, expression of those miRNAs was studied in the pairwise comparison: 
40 miRNAs were found DE in OPA-affected samples compared to either parasite-
infected or control samples. All of these miRNAs presented similar dysregulation 
levels in OPA-affected samples compared to parasite-infected samples or control 
samples. These findings suggest that miRNAs specifically dysregulated in OPA-
affected samples can be detected in BALF macrophages. These miRNAs could 
be further investigated and potentially exploited as biomarkers, this is further 
discussed in 3.3. In addition, the biological relevance of some of those miRNAs is 
further explored by comparing these findings to other datasets in 3.2.7. 
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3.2.7 Comparison of DE miRNAs between datasets 
In order to gain a better understanding of the significance and origin of miRNA 
dysregulation in OPA, the results of DE miRNAs in JSRV-infected animals in the 
datasets presented in this chapter were compared.  
Comparing lung tissue samples, LCM lung tissue samples and BALF CD14+ 
macrophage samples, miR-182 was the only miRNA found to be consistently 
upregulated in JSRV-infected animals of all datasets. Suggesting the involvement 
of this miRNA in OPA. Confidence in the biological significance of miR-182 is 
increased due to results of RT-qPCR, which also found miR-182 significantly 
upregulated in lung tissue samples from independent experimental infections and 
natural OPA cases. In addition, upregulation of this miRNA might be able to 
distinguish JSRV-infected samples from lungworm-infected samples and 
JSRVmut-infected samples. Potential roles of miR-182 in JSRV-infection and OPA 
are further discussed in 3.3.  
Comparison of DE miRNAs in whole lung tissue and LCM lung tissue revealed 12 
miRNAs DE in both datasets: miR-130b-5p, miR-135b, miR-146b, miR-146b-3p, 
miR-182, miR-183, miR-205, miR-31, miR-424-3p, miR-450a, miR-450b and miR-
96. Interestingly, all these miRNAs were upregulated in both datasets. In addition, 
expression of 6 of those miRNAs was validated by RT-qPCR in lung tissue 
samples of experimentally infected and natural cases of OPA. It could thus, be 
hypothesised that these miRNAs are likely to be related to OPA tumour cells and 
transformation, this is further reviewed in 3.3. Differences in DE miRNAs between 
these datasets might be due to biological variation between samples that belong 
to each of the experimental infections but also to the nature of the sample: LCM 
samples are tumour-enriched. LCM lung tissue samples could reveal DE of 
miRNAs masked by the amount of normal tissue in the lung tissue samples of the 
first small RNA-sequencing study, this hypothesis is in line with the finding that all 
miRNAs DE in both datasets are upregulated. Also, the presence of lots of normal 
tissue is likely to mask downregulated miRNAs to a greater degree than 
upregulated miRNAs thus, it was expected that more DE downregulated miRNAs 
would be identified in LCM samples.  
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Five miRNAs were found DE in both JSRV-infected lung tissue and BALF CD14+ 
macrophage datasets in the same direction: miR-182, miR-203a-3p, miR-210, 
miR-30c-1-3p and miR-874-3p. These findings could also indicate that miRNA 
expression detected in lung tissue also includes expression of immune cells 
infiltrating the tumour, discussed in 3.3. 
3.2.8 JSRV genomic reads in lung tissue and BALF CD14+ 
macrophages 
Small RNA-sequencing reads from all datasets were mapped to the JSRV 
genome (AF105220.1) (section 2.5.1) in order to investigate the expression of 
potential miRNAs encoded by JSRV. 
IGV was used to visualise the alignments of sequencing reads to the JSRV 
genome and to identify areas of the genome to which a dis-proportionately high 
number of reads aligned. Where these were consistent between samples, this 
would potentially indicate the presence of a miRNA. One such area was found 
around the nt 6400 of the JSRV genome (Fig. 3.21), this area contrasted with the 
rest of the genome for accumulating a considerably larger number of reads. 
Presence of reads in the same area was confirmed in LCM lung tissue samples 
and BALF macrophage samples (Fig. 3.21 and Fig. 3.22). The accumulation of 
reads mapping to the 6400 nt of the JSRV genome was not detected in mock-
infected lambs, JSRVmut-infected lambs, adult controls or parasite-infected lambs, 
confirming that these reads were specific for JSRV-infected animals.  
Given that the 6400 nt region of the JSRV genome is part of the env gene, which 
is known to structure some splice variants (Nitta et al, 2009), potential structural 
and sequence features that could explain the higher number of reads in this area 
were investigated (Fig. 3.23). However, no splice acceptors or other motifs were 
identified that could explain the results. 
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Figure 3.21. small RNA-sequencing reads of JSRV21-infected lung tissue aligning to 
JSRV’s genomic sequence, presented in the top panel. A. Samples from whole lung tissue. 
B. Samples from LCM lung tissue. The genomic region highlighted in orange is where the 
highest number of reads where detected, only present in JSRV21-infected lambs but not in 
mock-infected controls. Sequencing alignment was observed in IGV.  
 
Figure 3.22. small RNA-sequencing reads of OPA-affected BALF CD14+ macrophage 
samples aligning to JSRV’s genomic sequence, presented in the top panel. The genomic 
region highlighted in orange is where the highest number of reads where detected, only 
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Figure 3.23. Diagram of the JSRV env gene. Proteins encoded and polyA sites are 
represented. All positions are shown in relation to the JSRV sequence AF105220.1. (Hofacre 
et al, 2009; Palmarini & Fan, 2003; Palmarini et al, 1999b) 
Given that no explanation for the accumulation of reads had been found by 
examining the JSRV env gene, the JSRV genomic sequence surrounding 6400 
bp was evaluated to find indications of a potential miRNA being encoded. RNA 
folding prediction programs were used to investigate the presence of a stem-loop 
that might encode a miRNA at 6400 bp. A stem-loop structure of 54 nt was found 
(Fig. 3.24). Although pre-miRNA stem-loops are usually longer (~ 70 nt), some 
retroviral miRNAs, such as the SFV miRNAs have stem-loops of a similar size to 
the one found in JSRV (Kincaid et al, 2014). Nevertheless, by examining the stem-
loop it can be observed that the potential miRNA sequence 
(AATAGCTGAAGCCTGGTATGA) is not entirely encoded in the stem of the stem-
loop structure, a requisite for DICER processing of miRNAs. This might be an 
indication that the reads found do not represent a JSRV miRNA. However, 
biogenesis of viral miRNAs is not entirely understood and biogenesis of some viral 
miRNAs, and some host miRNAs like miR-451, has been found to be DICER 
independent (section 1.5.2) (Cheloufi et al, 2010). In light of these findings, 
expression of this potential miRNA was experimentally evaluated using northern 
blotting.   
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Figure 3.24. Secondary structure prediction of the JSRV nucleotide sequence (6396 – 
6450 bp) surrounding the small RNA detected in small RNA sequencing. Colour legend 
shows the base-pair probabilities. Created with RNAfold: (Langdon et al, 2018) 
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3.2.8.1 Northern-blot for detection of putative JSRV small RNAs 
In order to experimentally validate expression of the potential JSRV miRNA a 
northern blot was performed.  
RNA was purified from lung tissue samples from OPA-affected sheep and healthy 
controls (section 2.4.6). In addition, 293T cells transfected with pEGFP-Flag and 
JSRV encoding plasmids (pCMV2JS21 and pJSRV21), were also harvested and 
RNA extracted (section 2.4.6). Cell culture samples were added to the study with 
two aims: investigate if the potential miRNA was also expressed in vitro and to 
differentiate enJSRV produced reads from JSRV produced reads. 
RNA samples for northern blotting were concentrated to achieve concentrations 
greater than 800 ng/µl (section 2.4.7) (Table 3.24).  
Table 3.24. RNA concentration of samples analysed by northern blot. 
Group Healthy Control 
Sample 172 173 
RNA (ng/µl) 838 785 
260/280 nm 1.89 1.91 
Group OPA-affected 
Sample JA875 JA876 JA898 
RNA (ng/µl) 970 1588 1700 
260/280 nm 1.95 2.00 2.01 
Group Transfected 293T samples 
Sample pCMV2JS21 pJSRV21 pEGFP-Flag 
RNA (ng/µl) 943 1115 1065 
260/280 nm 2.04 2.03 2.05 
 
The northern blot was performed as described in (section 2.9) loading 10 µg of 
each of the samples. Equivalent RNA loading of all samples was confirmed by 
staining the gel with ethidium bromide and observing the presence of tRNAs at 
the top of the gel. Hybridisation was performed with three labelled primers: two to 
detect the 5p and 3p versions of the potential miRNA, and one to detect miR-191, 
which was used as a positive control.  
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Analysis of the northern blot result (Fig. 3.25) revealed a band of ~ 20 nt in size, 
when RNA was hybridised with the labelled miR-191 primer. This result indicated 
that miR-191 could be detected in OPA-affected, control samples and 293T 
samples and that the northern blot technique had been successfully performed. In 
addition to the ~ 20 nt band, samples also presented a band of ~ 70 nt in size. 
This band was most clearly observed after the 4-day incubation and could 
represent the pre-miRNA mir-191. Size of the hybridisation products was 
determined by comparison to size markers, produced with loading dyes as 
described in sections 2.9.1 and 2.9.2.  
 
Figure 3.25. Northern blot analysis to identify the candidate JSRV miRNA. Samples from 
lung tissue and in vitro culture were analysed and are indicated in each lane. Incubation was 
performed for 24 hours or 4 days. miR-191 was used as endogenous positive control. 
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When RNA samples were hybridised with primers to detect -5p or -3p versions of 
the potential miRNA, no bands of the expected miRNA size (~ 21 nt) were 
observed (Fig. 3.25). Hybridisation was performed with both -5p and -3p primers 
because detection of both forms of a miRNA increases the confidence in presence 
of a miRNA (section 1.5.4). A band was detected at the top of some wells of both 
-5p and -3p primer hybridised gels. This band was detected in OPA-affected and 
control sheep samples, and in the 293T sample transfected with pCMV2JS21, 
indicating that the primer was able to hybridise to a sequence present in the 
samples. However, the presence of this sequence in control sheep samples 
indicated that this sequence was not JSRV specific. Given that the band was not 
present in control 293T samples, it is possible that the primer could also be binding 
enJSRV sequences. Indeed, a BLAST search found 18/21 nt identity between the 
primer and some enJSRV forms encoded in the sheep genome, which would 
explain the presence of the band. The primer could, thus, anneal to JSRV 
sequences and enJSRV sequences and would have potentially been able to 
identify mature miRNA sequences produced by both enJSRV and JSRV.  
Overall, the findings of the northern blot did not evidence that the reads found to 
align to the JSRV genome at 6400 nt were miRNAs. The potential origin of the 
sequencing reads detected is not known but may represent unknown genomic 
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3.3 Discussion 
The aim of this chapter was to investigate miRNA expression in the sheep lung, 
and detect expression changes that could be associated with OPA. miRNAs were 
successfully detected in lung tissue of both JSRV21-infected and mock-infected 
sheep. In addition, differences in miRNA expression were detected between the 
two groups. An upregulation trend of nine miRNAs: miR-135b, miR-182, miR-183, 
miR-21, miR-200b, miR-205, miR-31, miR-503 and miR-96 was confirmed by RT-
qPCR in samples from experimental and natural cases of OPA. These miRNAs 
were also found to be upregulated when enriched tumour samples were used, 
suggesting their upregulation originated from OPA lesions. Study of alveolar 
macrophages, highly abundant in OPA, revealed miRNA expression differences 
in OPA-affected sheep, suggesting phenotype alteration of immune cells in 
response to OPA. JSRV was not found to encode viral miRNAs.  
The results presented in this chapter are the first description of miRNA expression 
in OPA cases and, suggest that upregulation of miR-135b, miR-182, miR-183, 
miR-21, miR-200b, miR-205, miR-31, miR-503 and miR-96 is associated with 
OPA. These findings are a first step towards understanding the role of miRNAs in 
OPA and could be potentially exploited as biomarkers of the disease or, as a tool 
to investigate the transformation process. In addition, they are a contribution 
towards further characterisation of OPA gene expression, which could aid the 
exploration of OPA as a human lung cancer model. 
3.3.1 miRNA expression in whole lung tissue 
The results obtained from small RNA-sequencing in lung tissue of experimentally 
infected lambs and controls revealed that miRNAs could be detected in lung tissue 
from sheep. 405 miRNAs were found to map to miRNAs in miRBase: most hits 
belonged to miRNAs of other species (cow, human and goat) and few to sheep. 
The reason for this mapping is likely to be that few miRNA studies have been 
performed in sheep, and there is a lack of annotated miRNAs in this species. Other 
studies (Bilbao-Arribas et al, 2019) have also used the approach of mapping 
sequencing reads to miRBase, and also found most miRNAs mapping to miRNAs 
of related species- emphasising the sequence conservation known of miRNAs. 
Apart from the reads that mapped to annotated miRNAs of the miRBase a 
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percentage of reads were unmapped. Some studies have taken the approach of 
mapping those novel miRNAs to the sheep genome, looking for predictors of 
miRNA stem-loops and other indicators that might suggest the sequence of 
interest is in fact a novel miRNA (Farrell et al, 2015). However, those studies also 
reported that the abundance of those novel miRNAs was very low (Farrell et al, 
2015) and, in a study like the present the relevance of those novel miRNAs in the 
differential analysis is likely to be low and their detection in all samples difficult. 
Differential analysis of lung tissue samples successfully detected 40 DE miRNAs 
in JSRV-infected lambs compared to mock-infected controls. Of those miRNAs 
only six were found downregulated with the vast majority presenting an 
upregulation in infected animals. These findings are in contrast with some reviews 
on miRNA dysregulation in cancer (section 1.5.10) which document that most 
miRNAs in cancer are downregulated. Nevertheless, the findings presented here 
might be explained by the nature of the sample used for the study: in lung tissue 
samples from JSRV21-infected lambs small foci of tumoural cells can be observed, 
but the majority of the sample tissue, as much as 90%, is histologically normal. 
The high proportion of histologically normal tissue might therefore, be masking the 
downregulation of miRNAs and making it undetectable in our system. Such 
samples have greater sensitivity to detect upregulated miRNAs. The nature of the 
tissue used might also lead to the variability of JSRV21-infected samples, as not 
all tissue will have the same proportion of tumour tissue. In addition to tumour 
cells, lung tissue has many cell types, each of which might change in relative 
abundance within the affected tissue, and each of which might change their 
expression phenotype in presence of JSRV-infected cells. The whole tissue 
approach provides a snapshot of global changes in the lung, but cell type specific 
changes require use of enriched or purified cell populations.  
Clustering of samples based on miRNA expression showed that one of the 
JSRV21-infected animals (SPF476) had an expression trend more similar to those 
of mock-infected controls. This unexpected grouping is likely to be related to the 
lower number of JSRV transcripts found in this lamb, as previously mentioned. 
Given that all lambs were administered equal amounts of the JSRV21 preparation, 
this finding highlights that viral uptake by susceptible cells or clearance of the virus 
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is not equal in all lambs. Different levels of infection or tumour burden is a likely 
scenario in in vivo studies, and is likely to be a major factor in the biological 
variability observed.  
Validation of the small RNA-sequencing results by RT-qPCR showed the same 
upregulation trend of the miRNAs of interest. Statistical analysis showed 
significant differences in the expression of all nine miRNAs between groups. 
Nevertheless, the magnitude of the upregulation (i.e. fold change) observed was 
not the same as that of small RNA-sequencing. Differences in miRNA detection 
sensitivity and specificity have previously been reported, and are linked to the way 
platforms identify miRNA isoforms or families, which have a very high sequence 
similarity (Mestdagh et al, 2014). In RT-qPCR, primers are designed to detect the 
canonical sequence of the miRNA but they are unlikely to detect all the isoform 
variants present in the sample. In the case of small RNA-sequencing, library 
construction and bioinformatics analysis performed can too affect the results 
(Giraldez et al, 2018). In addition, there are differences in how expression is 
calculated across platforms: in small RNA-sequencing the counts for a miRNA are 
expressed as relative to the total number detected, whereas in RT-qPCR they are 
calculated in relation to reference miRNAs. 
The validation of miRNA expression in an independent experimental infection, 
discussed in section 3.2.3, showed the same miRNA upregulation trend observed 
in the previous study. However, differences between the JSRV21-infected and 
control groups were not statistically significant for miRNAs miR-21, miR-31, miR-
200b, miR-205 and miR-503. It can be observed how there is more variability 
within groups that may account for this lack of statistical significance. The 
JSRVmut-infected group showed no significant differences in miRNA expression 
when compared to the mock-infected group. The explanation for this result could 
be due to low level of replication of JSRVmut in those animals, as also 
demonstrated by absence of positive IHC staining. If samples from the mock-
infected group and JSRVmut infected group are grouped together, sensitivity to 
detect DE miRNAs in the JSRV21-infected group might increase. 
As several studies have commented on the disease stage dependent miRNA 
dysregulation (section 1.5.10) the expression of the selected miRNAs was also 
 
Chapter 3: miRNA dysregulation in OPA lung tissue 199 
studied in more advanced cases of OPA (natural cases). The same upregulation 
trend was observed for all miRNAs with the exception of miR-31. Differences in 
miR-31 expression could be related to the specific function and interactions with 
pathways that might be activated at this disease stage. Indeed, some of the 
validated targets of miR-31 in Homo sapiens include RHOA, LATS2, PPP2R2A 
and FOXP3, involved in transformation pathways, suggesting a shift in the 
expression of the miRNA could be related to a change in the activation in one of 
the transformation pathways (Begum et al, 2015; Liu et al, 2010; Vosa et al, 2013; 
Xi et al, 2010). Still, predictions on the reason for the observed shift are complex 
due to the multiple targets a miRNA has and the interactions of members of the 
affected pathway with other miRNAs which create an intricate regulatory network. 
Besides from a molecular reason for the change in miR-31 expression, reasons 
such as the age, breed and other health conditions the sheep might be suffering 
from, should be considered. Considering the differences in disease stage, breed 
and animals’ age, the upregulation trend observed largely correlates with the 
results of experimental infections, and suggests an association of the selected 
miRNAs with OPA tumours.  
Nevertheless, the complexity of the tumour and tumour microenvironment needs 
to be taken into account when interpreting the present results. Besides the 
transformed lung cells, other cell populations can be found infiltrating the tumour. 
These other cell populations could contribute to the miRNA signature detected in 
OPA affected lung tissue and the differences observed between JSRV-infected 
and uninfected tissue. In addition, miRNAs with altered expression in the tumour 
microenvironment could have targets and biological relevance not only in 
transformed lung cells but also in other infiltrating cells (Challagundla et al, 2014). 
OPA tumours have been previously shown to recruit immune cells, such as large 
numbers of macrophages, and recent studies have shown expression of T helper 
1 (Th1) and T helper 2 (Th2) markers, indicating lymphocyte recruitment 
(Karagianni et al, 2019; Sharp & Angus, 1990). Although the presence of these 
cells does not affect the finding that the discussed miRNAs are associated with 
the presence of OPA tumours, it makes pinpointing the origin of the miRNA 
signature an intricate task. Whereas some of the dysregulated miRNAs might 
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originate from transformed lung cells, others might stem from other tumour 
infiltrating cells.  
3.3.2 miRNA expression in enriched lung tumour samples 
To study miRNA dysregulation in tumour tissue without normal surrounding tissue 
influencing the results the LCM technique was used in samples from the 
experimental infection of 2015. The PCA plot indicated a similar global miRNA 
expression pattern between mock-infected and JSRVmut-infected lambs, 
potentially due to the JSRVmut not being able to replicate efficiently, and suggests 
that the global pattern of expression of JSRV21-infected lambs, although highly 
variable, is different from the other groups. In fact, total reads varied between 
around twelve million and thirty-three million, with these two extremes belonging 
to samples of the JSRV21-infected group, which might account for the high 
variability observed.  
As expected, the number of DE miRNAs increased in LCM samples, but an 
increase in downregulated miRNAs was not observed. Once again, several 
factors need to be considered as plausible explanations for this observation. First, 
difficulties were encountered in obtaining high quality RNA. This is a recognised 
issue when performing LCM on lung tissue. Therefore, while RINs of samples 
used for library preparation were >7, the quality and amount of RNA may still have 
been an issue. Furthermore, as discussed before, the lambs suffered from allergic 
reactions that could also be contributing to the miRNA patterns observed. In 
addition, this comparison was performed with only three animals per group, which 
might make the data not representative.  
Giraldez et al (2018) showed that results of sequencing can be affected by 
sequencing facility and sample type. This does not appear to have greatly affected 
data in this study, as all but one of the selected miRNAs (miR-503), were also 
found to be upregulated in these samples. Increasing confidence in the 
involvement of these miRNAs in OPA tumours. miR-503 might not appear as DE 
due to low number of counts, below the average of 50 normalised counts threshold 
established for DE analysis.   
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3.3.3 Targets of miRNAs upregulated in OPA lung tissue 
Overall, there seems to be a trend observed across the analysed samples 
suggesting a consistent upregulation of miRNAs: miR-135b, miR-182, miR-183, 
miR-21, miR-200b, miR-205, miR-31, miR-503 and miR-96 in lung tissue samples 
of JSRV21-infected sheep. The timing of the observed upregulation in JSRV 
infection is unknown, miRNAs appear upregulated in OPA tumours but with the 
present knowledge it can’t be discerned if they are upregulated as a result of the 
viral infection per se or as a result of the cell transformation, or what their role in 
transformation is.  
Targets of the nine selected miRNAs have not been investigated in sheep, but 
some potential targets have been identified in humans. Extrapolation between 
human and sheep studies is difficult due to differences in the genes present, 
differences in gene sequences and in regulatory networks. In addition, the poor 
annotation of the sheep genome makes target prediction of sheep miRNA targets 
with computer-based analysis challenging. Nevertheless, given the transcriptional 
similarities between OPA and human lung cancer (Karagianni et al, 2019), 
comparison to human cancer studies can give a first indication of the roles a 
miRNA might be involved in. Interestingly, the miRNAs consistently upregulated 
in these datasets have targets in pathways known to be activated in OPA: MAPK 
and pI3k-Akt (section 1.2.6). For instance, miR-96 targets KRAS in the MAPK 
pathway, and miR-21 targets PTEN in the PI3K-Akt pathway (Yu et al, 2010b; 
Zhang et al, 2010b). miR-183 targets PPP2CB in the PI3K-Akt pathway, PPP2CB 
decreases Akt activation (Ma et al, 2016). miR-205 targets VEGFA, PTEN in the 
Akt pathway (Cai et al, 2013; Li et al, 2017a; Wu & Mo, 2009). miR-31 targets 
RASA1 and SPRED1 in the MAPK pathway (Edmonds et al, 2016). None of the 
nine miRNAs were found to target components of the RON-HYAL2 pathway.  
3.3.4 miRNA expression in alveolar macrophages 
To further investigate the different cell types that could be involved in miRNA 
dysregulation in OPA, alveolar macrophages, were investigated. miRNA 
expression was detected in BALF macrophages and DE miRNAs identified 
between OPA-affected samples and control samples. DE miRNAs were also 
identified between OPA-affected samples and parasite-infected samples, 
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indicating differences in the immune response between the two organisms. The 
DE miRNA miR-33b has been reported dysregulated in macrophages and some 
of its targets are BCL2, involved in cell-death and apoptosis, and PIM1 and 
HMGA2 involved in inflammation (Jiménez-García et al, 2017). Some of the 
miRNAs DE in OPA-affected samples, might be related not only to JSRV-infection 
but also to tumour presence: during the bronchoalveolar lavage and isolation 
process tumour-associated macrophages might have also been isolated.  
These differences in DE miRNAs are an encouraging step to better understand 
the role of alveolar macrophages in JSRV-infection. Moreover, these DE miRNAs 
could be further investigated as diagnostic biomarkers, discussed in 3.3.1. Indeed, 
cell-free miRNAs have been successfully detected in BALF and are being 
investigated as biomarkers (Lee et al, 2016; Li et al, 2017b).  
miR-182, was the only miRNA found consistently and significantly upregulated in 
all datasets. This finding suggests biological relevance of miR-182 upregulation in 
OPA. Reviewing some of the targets of miR-182, it could be speculated that 
upregulation of miR-182 could result in downregulation of FOXO1 and FOXO3, 
which are transcription factors that regulate proliferation, apoptosis and 
inflammation. Decreased levels of FOXO inhibit apoptosis and, interestingly P-Akt 
and P-ERK1/2 have also been found to inactivate FOXO transcription factors 
(Krishnan et al, 2013; Yang et al, 2010b). In addition, miR-182 targets PTEN, 
which decreases PiP3 that promotes Akt activation. Upregulation of miR-182, 
thus, could be expected to decrease levels of PiP3 and disrupt regulation of the 
Akt pathway, resulting in constitutive activation of Akt (Manning & Toker, 2017; 
Wang et al, 2019a; Yao et al, 2017). miR-182 also targets the tumour suppressor 
PDCD4 (Chang et al, 2018).  
3.3.5 Candidate JSRV miRNAs 
A potential JSRV-encoded miRNA was detected in sequencing data alignments 
to the JSRV genome. However, the potential miRNA was not found in northern 
blot analysis of sheep tissue or cell culture samples, arguing against the 
sequencing reads representing a JSRV-encoded miRNA. This finding could be 
further confirmed by RT-qPCR analysis with a primer-probe designed to detect 
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the potential miRNA, a more sensitive method of detection. Nevertheless, lack of 
JSRV-encoded miRNAs is not a striking result as few RNA viruses have so far 
been discovered to encode viral miRNAs, reviewed in section 1.5.14. Only four 
retroviruses have so far been identified to encode miRNAs: BLV, HIV1, SFV and 
BFV (section 1.5.14). In addition, a closely related virus: ENTV, also member of 
the betaretrovirus, was recently found not to encode viral miRNAs but alter hosts 
miRNA expression levels (Wang et al, 2016). A finding similar to the one 
presented in this chapter.  
3.3.6 Limitations of the study 
The studies in this chapter are primarily built on findings from small RNA-
sequencing of whole lung tissue. This sample type is likely to have reduced the 
sensitivity to detect DE miRNAs. To address this, the significance threshold was 
established at fold change ≥ 1.5 or ≤ 0.75, and FDR ≤ 0.05. These cut-offs are 
arbitrary and established to reduce false positives while maximising chances of 
discovering true changes in miRNA expression. In the sequencing studies of 
enriched cell types (tumour and macrophages), the cut-offs established were 
more stringent due to the sample offering more sensitivity to detect DE miRNAs. 
The results obtained would have changed if different cut-offs had been 
established, indicating that caution should be exercised when interpreting the 
results. miRNAs presenting higher fold-changes and smaller FDR values in the 
comparison between groups are more likely to be validated, as confirmed in the 
results obtained by RT-qPCR in this chapter.  
Overall, this chapter has revealed upregulation of miR-135b, miR-182, miR-183, 
miR-21, miR-200b, miR-205, miR-31, miR-503 and miR-96, associated with OPA. 
Nevertheless, the limited animal number used in these studies may have biased 
the results obtained. Further confirmation of the significance of these miRNAs in 
OPA could be confirmed by increasing the number of samples analysed, which 
would increase biological variability. In addition, mechanistic data on the role of 
this miRNAs would also increase confidence in their association with OPA.  
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3.3.7 Conclusions and future work 
Dysregulated host miRNAs were detected in lung tissue of OPA affected animals. 
Nine of those miRNAs were found consistently upregulated in lung tissue of 
experimentally infected lambs and natural cases of OPA. Further studies should 
investigate the targets of these miRNAs in JSRV transformed cells and the 
mechanisms by which expression of those miRNAs is activated. This information 
would help understanding the role of miRNAs in JSRV Env transformation.  
These results suggest that miRNA expression can be used to differentiate 
between OPA-affected animals and controls. Differences in miRNA expression 
could also be exploited as potential biomarkers of OPA. However, for miRNAs to 
be used as biomarkers it would be desirable that they could be detected in 
biological fluids for ease of sampling. OPA miRNA dysregulation was also 
detected in BALF macrophages, suggesting that miRNA expression changes due 
to OPA are not limited to lung tissue. In addition, DE miRNAs could distinguish 
between OPA-affected and lungworm infected samples. However, BALF 
macrophages might not be an appropriate sample for biomarker detection due to 
the long and complex isolation process. BALF or other biological fluids could be 
explored to investigate the potential of these miRNAs as biomarkers of OPA. In 
addition to miRNAs being able to differentiate between lungworm infected sheep 
and JSRV-infected sheep, it would be desirable to find miRNAs able to 
differentiate between bacterial pneumonias and OPA.  
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Chapter 4 Cell-free miRNAs in OPA 
4.1 Introduction 
In Chapter 3, some miRNAs were found to be consistently upregulated in OPA-
affected lung tissue, suggesting that expression levels of these miRNAs could 
differentiate between OPA-affected and unaffected sheep. Those findings 
prompted the idea that the miRNAs upregulated in OPA tissue could be 
investigated as potential biomarkers of OPA. Specifically, they could be examined 
as diagnostic markers of OPA to aid early diagnosis and disease control.  
Nevertheless, for those miRNAs to be used as diagnostic markers, it would be 
desirable to detect their expression levels in biological fluids, which are easier to 
sample than lung tissue. For instance, the expression of those miRNAs could be 
investigated in blood serum and detected by RT-qPCR. Obtaining serum samples 
is a relatively easy and minimally-invasive procedure for sheep. While RT-qPCR 
is a sensitive and specific detection technique and is being successfully optimised 
and applied in the field setting (Biava et al, 2018). Indeed, some studies have 
reported that miRNAs derived from tumour tissue could be detected in the 
circulation either inside exosomes or bound to proteins (section 1.5.7).  
Another approach would be to investigate expression levels of the upregulated 
miRNAs in lung fluid or nasal secretions. Similarly to serum, nasal secretions 
could be easily sampled, and sampling would not be an invasive procedure for 
sheep. In addition, high concentrations of JSRV can be detected in lung fluid 
(section 1.1.3), reflecting infection in the lung, so lung fluid could potentially signal 
miRNA expression levels in the lung too.  
If tumour miRNAs were not found to be dysregulated in biological fluids, as some 
have reported (section 1.5.12), miRNA expression in OPA could be investigated 
in biological fluids using sequencing approaches to identify new biomarker 
candidates. Studies have reported miRNA dysregulation in biological fluids 
originating from cells other than tumour cells and could reflect the host response 
to disease (sections 1.5.13 and 1.5.14).  
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Either way, the dysregulation of miRNAs in biological fluids of OPA-affected sheep 
would be an essential first step towards establishing them as diagnostic markers 
of OPA. Further studies would be necessary to determine if the same miRNAs 
could be used as diagnostic markers for different disease stages or if they would 
be limited to some stages. In addition, for miRNAs to be developed as diagnostic 
markers of OPA, it would be required to test large numbers of sheep and 
determine the sensitivity and specificity of the test. In this regard, it would be 
desirable for miRNAs used as diagnostic markers to be able to differentiate 
between OPA and other pathologies, particularly diseases of similar presentation, 
such as bacterial pneumonia (sections 1.1.1 and 1.1.3).  
Besides the potential of miRNAs as diagnostic markers of OPA in biological fluids, 
studying miRNA dysregulation in biological fluids could unveil considerably more 
about OPA. For instance, it could be indicative of the host response to infection, 
or it could reveal signalling mechanisms used by tumour cells, such as exosomes. 
Furthermore, it could highlight the importance of certain miRNAs in OPA. 
4.1.1 Hypothesis and aims 
In this study, it was hypothesised that miRNAs can be detected in biological fluids 
of sheep, and that a number of miRNAs would be differentially expressed in OPA 
affected sheep when compared to controls. It was also hypothesised that miRNAs 
differentially expressed in lung tissue would also be differentially expressed in 
biological fluids.  
In order to test the hypothesis the following aims were established for the present 
chapter: 
 Detect miRNA expression in serum of sheep 
 Detect miRNA expression in lung fluid  
 Compare miRNA expression of infected and uninfected sheep 
 Contrast findings from sheep experimentally infected with JSRV and 
natural cases 
 Compare findings with data from JSRV-infected lung tissue. 
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4.2 Results 
4.2.1 RT-qPCR of OPA tumour associated miRNAs in serum 
Initially, a pilot analysis was performed to test if some of the miRNAs dysregulated 
in lung tissue could also be detected in serum samples, and to determine if those 
miRNAs were also differentially expressed between serum of OPA affected sheep 
and control animals, which could indicate their potential as biomarkers for the 
presence of OPA tumours.  
In the first experiment, the expression of four miRNAs was measured in serum 
samples from natural cases of OPA and from sheep donated to Moredun, without 
OPA but with other pathologies (Table 2.3). Serum samples were prepared, RNA 
was extracted (sections 2.4.1 and 2.4.2) and RT-qPCR performed for miR-135b, 
miR-182, miR-183 and miR-96, as those had the highest fold-change in OPA 
affected lung tissue samples, and therefore might be predicted to show differential 
expression in the circulation. miR-191 was used as the endogenous control (Fig. 
4.1). Because no previous data on sheep serum miRNAs was available, the 
choice of miR-191 as endogenous control was made based on previous data 
obtained in lung tissue (3.2.2.1). miR-191 expression levels obtained by RT-qPCR 
were compared across OPA-affected and control samples, to evaluate if miR-191 
was an appropriate endogenous control in serum. The calculated coefficient of 
variance across the 8 samples was 2.88%, suggesting low variability in miR-191 
expression and that miR-191 was an appropriate control. 
Although all miRNAs tested by RT-qPCR were detected in sera from all 8 sheep, 
no statistically significant differences in expression (Table 4.1) were observed 
between the OPA-affected and control animals. The four miRNAs tested 
presented p-values above the established threshold of 0.05 thus, the null 
hypothesis, which considered that the means of the two groups were equivalent, 
could not be rejected. Taking into consideration the health status of the control 
animals used and the involvement of miRNAs in several diseases, the study of 
miRNA dysregulation in serum from OPA sheep would benefit from using healthy 
animals as controls to avoid miRNA dysregulation being masked in the initial 
stages of the study.  
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Figure 4.1. miRNA expression in serum samples of OPA-affected animals (n=4) 
compared to controls (n=4).  A. Relative miRNA expression (-dCt= -Ct miR+Ct miR-191) of 
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each individual sample. Boxes show standard deviations of the mean, represented with a 
horizontal line. B. log2(fold change) expression between OPA-affected and control group 
(section 2.6.2). Error bars indicate standard deviation within groups. 
Table 4.1. Statistical analysis (student’s t-test) of dCt values obtained by RT-qPCR. 
miRNA Group Mean1 Stdev2 Estimated difference DF3 p-value 
miR-135b 
OPA-affected 21.81 2.76 
1.32 5 0.512 
Control 20.49 2.54 
miR-182 
OPA-affected 15.08 3.63 
0.46 5 0.844 
Control 14.61 2.64 
miR-183 
OPA-affected 9.54 2.1 
-0.63 5 0.695 
Control 10.16 2.18 
miR-96 
OPA-affected 12.96 1.28 
2.36 5 0.105 
Control 10.59 2.02 
1 Null-hypothesis= no differences between the means of the two groups assessed, confidence level 
stablished at 95%. 
2 Stdev= standard deviation of the mean. 
3 DF= degrees of freedom. 
                                            
 
4.2.2 Serum miRNAs in OPA identified by miRNA sequencing 
(study 1) 
Due to the limited number of miRNAs tested by RT-qPCR and the fact that miRNA 
dysregulation in serum might have an origin other than from the tumour (section 
1.5.13), miRNA expression was subsequently studied using a sequencing 
approach to aid discovery of miRNA expression patterns related to OPA. Initially, 
three OPA-affected samples and three control samples were analysed as a proof 
of concept to evaluate if differences in miRNA expression in serum could be 
detected by sequencing. The decision to test a limited number of samples was 
made due to sequencing costs, and six samples were deemed sufficient to 
evaluate if sequencing was a viable option to detect miRNA patterns in serum 
related to JSRV-infection.  
Samples for sequencing were prepared (section 2.5), the concentration of RNA 
extracted from serum samples was measured by Nanodrop (section 2.4.8) and 
was low due to the nature of the sample, which contains a high concentration of 
RNAses and lower concentration of RNAs compared to tissue samples. Low 
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260/280 nm were anticipated due to low RNA concentration, making 260/280 
measurements unreliable (Table 4.2).  
Table 4.2. RNA concentration of samples submitted for miRNA sequencing study 1.  
 Control OPA affected 
Sample S6230 S6318 S6354 B14 B16 G32 
RNA (ng/µl) 6.36 5.61 26.2 24.11 19.07 34.53 
260/280 nm 1.44 1.31 1.63 1.45 1.4 1.51 
 
Samples were submitted for sequencing and bioinformatics analysis to Edinburgh 
Genomics. Three OPA affected serum samples and three control serum samples 
were sequenced (Table 2.3). Bioinformatics analysis was performed to determine 
the abundance of each miRNA in each sample and to test for statistically 
significant differences between disease groups (section 2.5.1). Despite the low 
amount of RNA, sequencing libraries were successfully constructed from all 
samples. Total reads ranged from 37632783 reads to 50327639 reads, with 
greater variability within the OPA affected samples (Table 4.3). The percentage 
of reads mapping to miRNAs on miRBase and other categories also varied 
between samples, and the percentage of reads mapping to miRBase was notably 
higher in OPA affected samples (Fig. 4.2 and Fig. 4.3).  
Analysis of sequence length distribution (Fig. 4.3) also revealed that control 
samples contained more reads of length between 30-32 nt. Reads of this length 
do not fall into the miRNA category but could correspond to reads of another small 
RNA category called piwi-interacting RNAs (piRNA) (Cheng et al, 2011; Martinez 
et al, 2015; Umu et al, 2018), this possibility will be further reviewed in the 
discussion section 4.3.  
Table 4.3. Summary of reads for each sample of the serum miRNA sequencing study 1. 
 Control OPA-affected 
 
Sample S6230 S6318 S6354 B14 B16 G32 










 >28 nt 55.42 39.43 49.32 22.89 17.04 29.44 
miRBase 11.33 15.53 9.40 38.82 39.81 38.46 
JSRV 7.28E-04 1.62E-03 1.51E-03 6.39E-04 2.50E-04 3.11E-04 
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Figure 4.2. Sequence distribution in samples of sequencing study 1 presented as a 
percentage of total reads in each sample. Each of the categories is represented by a colour 
shown in the legend. Small nuclear RNA(snRNA),  mitochondrial ribosomal RNA (Mt_rRNA), 
small nucleolar RNA (snoRNA), mitochondrial transfer RNA (Mt_tRNA), ribosomal RNA 
(rRNA), miscellaneous RNA (misc_RNA), long non-coding RNA (lincRNA), JSRV viral genome 
(Virus), sheep genome (DNA), reads not  mapping to any of the previous categories 
(Unmapped). 
In order to begin comparing miRNA expression between samples, a threshold of 
≥ 50 average read counts was established as further explained in (section 2.5.1). 
Once miRNAs with read count below the threshold were removed, a total of 275 
miRNAs were identified in serum of sheep. Expression levels of these 275 
miRNAs were plotted with a principal component analysis to analyse global 
patterns of expression, and to investigate clustering of samples that might indicate 
expression differences between groups (Fig. 4.4). PC1 separates OPA and 
control samples in two distinct groups with no overlapping. Control samples, 
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compared to OPA samples, are plotted closer together implying lower within-
group variability. OPA samples show greater divergence by PC2. Sample B14 
appears distanced from all other samples, indicating a distinctive expression 
pattern. Higher variability within OPA samples than controls is not unexpected and 
could be due to different disease presentations or disease stage in individual 
cases. 
Differential expression analysis was then performed to assess statistically 
significant differences in miRNA expression between OPA and control sheep. 74 
miRNAs were found to be DE between groups (log2(fold change) ≥ |1| and false 
discovery rate (FDR) ≤ 0.05) Of those, 43 miRNAs were upregulated and the 
remaining 31 downregulated in OPA affected sheep (Fig. 4.5, Table 4.4 and 
Table 4.5). The heatmap was generated using R studio pheatmap, and clustering 
performed using correlation (section 2.5.1) (Fig. 4.5). Of interest, miR-191, used 
as an endogenous control in the previous RT-qPCR analysis of serum (4.2.1), 
presented low variance among all samples (coefficient of variance 14.45%) 
confirming its suitability as an endogenous control for this study. 
Observing the heatmap (Fig. 4.5), distinct expression patterns between groups 
can be seen, and clustering analysis of samples based on expression of DE 
miRNAs indicates two clusters corresponding to control samples and OPA 
samples. These results suggest that changes in miRNA expression can be 
detected in serum of OPA affected sheep. Nevertheless, due to the small sample 
size of this study and the variation in percentage of reads mapping to miRBase 
(Fig. 4.2), further characterisation of larger sample size groups was performed to 
confirm these results (4.2.3). In addition, it could have had an effect in the analysis 
of DE miRNAs, emphasising the need for further investigation.  
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Figure 4.3. Length distribution of total sequencing reads from sheep sera (Study 1).  The figure shows the length distribution of reads in each serum 
after adapter trimming was performed. Control samples (n=3, S6230, S6318, S6354); OPA samples (n=3, B14, B16, G32). Two areas with high read 
abundance can be observed: corresponding to miRNA length (21-23nt) and longer length (30-32nt), which could correspond to piwi-RNAs. The presence 
reads with a length typical of miRNAs is higher in OPA affected samples, whereas control samples show a higher abundance of longer reads.  
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Figure 4.4. PCA plot of serum miRNA expression from sequencing study 1. OPA affected 
sheep (n=3) and healthy controls (n=3). OPA-affected samples are represented as red circles 
and uninfected controls as turquoise triangles. Greater distance between samples in the plot 
indicates greater expression difference between samples. Control samples are seen clustering 
towards the right of the plot, whereas samples from OPA affected animals can be seen towards 
the left of the plot, occupying much of the vertical axis. The PCA plot suggests global 
expression differences between the two groups and more variability within the OPA affected 
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Figure 4.5. Heatmap of DE miRNAs (FDR ≤ 0.05, log2(fold change) ≥ |1|) between OPA 
samples and controls of sequencing study 1. Dendrogram showing correlation clustering 
of individuals in groups. Legend represents values of log2 fold change. 
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Table 4.4. Differentially upregulated miRNAs between OPA-affected sheep and 
controls. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-25 197889.4 1.22 0 
miR-451 172388.6 1.29 0 
miR-486 4722656 1.46 0 
miR-133a-3p 1871.92 4.76 1.46E-25 
miR-133 1133.45 3.16 1.30E-12 
miR-451-3p 274.67 3.1 2.02E-11 
miR-133a 186.23 2.63 1.22E-08 
miR-144-5p 864.63 2.14 3.77E-06 
miR-16b-3p 299.26 2.11 7.10E-06 
miR-199b 293.63 2.04 1.13E-05 
miR-185 122.64 1.9 4.15E-05 
miR-425-3p 50.92 2.16 5.36E-05 
miR-103 33037.25 1.69 1.74E-04 
miR-2284d 155.02 1.8 1.74E-04 
miR-107 34393.82 1.65 2.39E-04 
miR-2319a 83.91 1.77 2.65E-04 
miR-93 18017.59 1.63 3.25E-04 
miR-33b 326.42 1.71 3.49E-04 
miR-486-3p 642.7 1.56 5.13E-04 
miR-15a 12124.09 1.62 5.80E-04 
miR-2284z 165.49 1.61 9.22E-04 
miR-484 6487.74 1.49 1.03E-03 
miR-296-3p 10239.01 1.38 2.04E-03 
miR-2284aa 80.35 1.44 2.41E-03 
miR-144 1609.13 1.4 3.77E-03 
miR-219 50.95 1.6 4.64E-03 
miR-128 14498.17 1.3 4.93E-03 
miR-2285f 318.81 1.35 5.06E-03 
miR-101 2917.92 1.28 6.07E-03 
miR-18a-3p 879.88 1.25 6.74E-03 
miR-18a 147.58 1.35 6.98E-03 
miR-185-3p 75.26 1.38 7.03E-03 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 4.4. Differentially upregulated miRNAs between OPA-affected sheep and 
controls. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-532-3p 137.15 1.34 7.35E-03 
miR-425-5p 11523.1 1.22 8.18E-03 
miR-324-3p 56.47 1.28 8.61E-03 
miR-17-3p 308.95 1.23 1.09E-02 
miR-339b 4904.6 1.14 1.35E-02 
miR-3184-5p 68.94 1.28 1.38E-02 
miR-505 171.91 1.05 2.29E-02 
miR-1307 1419.68 1.03 2.73E-02 
miR-361-3p 554.58 1.05 2.73E-02 
miR-93-5p 5620.71 1.02 2.90E-02 
miR-324 69.22 1.07 4.92E-02 
Table 4.5. Differentially downregulated miRNAs between OPA-affected sheep and 
controls. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-150 28029.58 -2.58 0 
miR-215 117063.1 -1.33 0 
let-7e 198.07 -2.3 1.89E-06 
miR-146a 125.02 -2.38 4.53E-06 
miR-4532 55.25 -2.45 1.91E-05 
miR-455-5p 50.77 -1.95 2.02E-04 
miR-30e-3p 214.87 -1.84 2.42E-04 
miR-155 246.08 -1.75 3.49E-04 
miR-4448 373.79 -1.54 9.13E-04 
miR-21-5p 858.87 -1.68 9.35E-04 
miR-28 187.92 -1.63 1.03E-03 
miR-140-5p 82.7 -1.49 1.15E-03 
miR-215-3p 345.12 -1.58 2.21E-03 
miR-2478 178.89 -1.5 2.40E-03 
miR-1246 64.04 -1.48 3.03E-03 
miR-26b 2696.43 -1.41 4.10E-03 
                                            
1Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
  
Chapter 4: Cell-free miRNAs in OPA 218 
Table 4.5. Differentially downregulated miRNAs between OPA-affected sheep and 
controls. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-126-3p 917.57 -1.27 4.69E-03 
let-7e-5p 136.2 -1.34 5.98E-03 
miR-181b 1090.97 -1.33 7.82E-03 
let-7f 10253.2 -1.2 8.01E-03 
miR-126-5p 12937.58 -1.17 8.01E-03 
miR-26a 9949.14 -1.27 8.31E-03 
miR-369-3p 89.47 -1.15 8.75E-03 
miR-140-3p 14010.66 -1.17 9.71E-03 
miR-342 3691.33 -1.21 1.23E-02 
miR-497 139.83 -1.08 1.90E-02 
miR-100 511.67 -1 2.66E-02 
miR-214 58.93 -1.09 3.23E-02 
miR-1249 97.49 -1.1 3.98E-02 
miR-194 188.41 -1.04 4.40E-02 
miR-345-3p 445.26 -1.04 4.90E-02 
 
 
4.2.2.1 Comparison of differentially expressed miRNAs between tissue 
and serum 
The results obtained of serum sequencing were compared to previous findings of 
miRNA dysregulation in lung tissue to find commonalities that could be, in the 
future, exploited as biomarkers of OPA. miR-215 and miR-21-5p were both found 
to be significantly upregulated in lung tissue of OPA affected sheep and 
significantly upregulated in this serum sequencing study 1. 
Differences in DE miRNAs between lung tissue and serum could be due to low 
expression levels of certain miRNA in serum, or lung tissue miRNAs not released 
into circulation. To investigate this, expression levels of the nine miRNAs DE in 
lung tissue and validated (miR-135b, miR-18, miR-183, miR-200b, miR-205, miR-
21, miR-31, miR-503 and miR-96) were inspected in serum. miR-182, miR-200b, 
miR-205 and miR-21 were identified in serum sequencing but not found DE 
between groups. miR-183, miR-31, miR-503 and miR-96 were detected below the 
count threshold established for DE analysis. miR-135b was not identified. Out of 
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the nine validated miRNAs, the ones not detected in serum had lower expression 
levels in lung tissue than the ones found in both datasets.  
4.2.3 Serum miRNAs in OPA identified by miRNA sequencing 
(study 2) 
To further study miRNA dysregulation in serum of OPA-affected sheep, a second 
miRNA-sequencing study was performed. In this study, the number of animals per 
group was increased and they were classified into groups depending on the 
disease stage. This classification was devised to allow examination of inter-
individual variation in OPA-affected animals, while allowing comparison of the 
miRNA expression profile at different OPA disease stages.  
Serum RNA samples were prepared for sequencing (section 2.4.1 and 2.4.2) and 
samples (Table 2.2 and Table 2.3) were separated into disease-stage groups for 
comparison (Table 4.6). In cases in which sheep had presentations corresponding 
to both mid-stage OPA and advanced OPA, classification in a group was made 
based on presence or absence of lung fluid.  
Two sets of controls were used to ensure that they were age-matched to OPA-
affected samples. Age-matching controls and samples is crucial in miRNA 
expression experiments, as expression is widely recognised to vary in stages of 
development (Ameling et al, 2015). Thus, early stages of OPA, represented here 
by experimentally-infected lambs, and advanced cases of OPA, represented by 
natural cases of OPA in adult sheep, will present miRNA expression differences 
related to age, in addition to any changes due to disease.  
In addition, samples from the previous sequencing run (study 1) were included in 
this miRNA-sequencing run to assess the repeatability of the method. Similarly to 
study 1, samples had low RNA concentration (Table 4.7), but sequencing libraries 
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Table 4.6.  Criteria for classification of OPA affected sheep in disease-stage groups.  
Group Samples Criteria for inclusion 
Advanced 
OPA 
A50, B14, G22, JA811, 
JA874, JA875 
Presence of lung fluid. Body score condition 
lower than 2, both lungs affected and 40% or 
more of lung affected. 
Mid-stage 
OPA 
A20, A28, A29, B16, 
G32, JA794 
No lung fluid, body condition score 2 or above. 
Less than 40% of lung tissue affected. 
Adult 
control 
S3882, S6230, S6318, 
S6353, S6354, JA856 
Healthy adult sheep with no known pathologies 
and free of OPA. 
Early stage 
OPA 
SPF4, SPF7, SPF15, 
SPF23, SPF27, SPF31 
Experimentally infected SPF lambs that were 




SPF3, SPF8, SPF14, 
SPF22, SPF26, SPF29 
Mock-infected lambs, negative for OPA. 
 
Table 4.7. RNA concentration of samples submitted for serum sequencing study 2. 
Group Advanced_OPA 
Sample A50 B14* G22 JA811 JA874 JA875 
RNA (ng/µl) 10.167 14.324 12.323 17.979 10.547 11.607 
260/280 nm 1.35 1.31 1.32 1.33 1.15 1.30 
Group Mid-stage OPA 
Sample A20 A28 A29 B16* G32* JA794 
RNA (ng/µl) 10.529 6.352 6.779 5.459 10.527 6.318 
260/280 nm 1.33 1.49 1.35 1.47 1.51 1.39 
Group Adult_Control 
Sample S3882 S6230* S6318* S6353 S6354* JA856 
RNA (ng/µl) 8.025 8.753 5.223 8.568 5.223 11.636 
260/280 nm 1.34 1.37 1.42 1.24 1.42 1.33 
Group Early_OPA 
Sample SPF4 SPF7 SPF15 SPF23 SPF27 SPF31 
RNA (ng/µl) 5.809 6.075 15.455 12.001 6.403 9.967 
260/280 nm 1.28 1.58 1.28 1.37 1.14 1.58 
Group Lamb_Control 
Sample SPF3 SPF8 SPF14 SPF22 SPF26 SPF29 
RNA (ng/µl) 40.612 3.744 9.527 8.934 10.959 9.081 
260/280 nm 1.355 1.099 1.315 1.406 1.289 1.305 
                                            
* Indicates samples also sequenced in study 1 
  
Chapter 4: Cell-free miRNAs in OPA 221 
Library sizes ranged from 25433227 reads to 73183413 reads (Table 4.8). In 
general, there was a trend that advanced OPA samples had the highest numbers 
of total reads and early OPA samples had the lowest, greater variation in number 
of reads was also observed within these groups. The percentage of reads 
mapping to miRNAs on miRBase and other categories also varied between 
samples, and percentage of reads mapping to miRBase ranged from 1.8% (SPF4) 
to 44.6% (JA811) (Fig. 4.6 and Fig. 4.7). The differences in the percentage of 
reads mapping to miRBase were significant between adult and lamb groups (t-
test p<0.05) but not within age groups. As with study 1, analysis of sequence 
length distribution in serum small RNAs (Fig. 4.8) also revealed two distinct read 
populations, but no differences in read distribution were observed between the 
animal groups.  
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Table 4.8. Summary of reads for each sample of the serum sequencing study 2. 
 
Group Advanced_OPA 
Sample A50 B14 G22 JA811 JA874 JA875 










 >28 nt 47.24 42.37 30.17 36.34 51.08 42.45 
miRBase 31.13 33.29 22.58 44.59 7.69 27.22 
JSRV 2.61E-04 2.03E-04 4.08E-04 3.47E-04 3.14E-04 7.12E-04 
 
Group Mid-stage OPA 
Sample A20 A28 A29 B16 G32 JA794 










 >28 nt 10.31 29.33 10.67 20.22 23.43 8.22 
miRBase 8.54 14.96 27.75 42.72 34.77 11.15 
JSRV 2.91E-04 3.03E-04 3.32E-04 4.97E-04 1.07E-03 1.02E-03 
 
Group Adult_Control 
Sample S3882 S6230 S6318 S6353 S6354 JA856 










 >28 nt 27.73 34.86 36.12 33.71 51.42 18.51 
miRBase 6.20 22.99 35.79 37.38 6.03 20.49 
JSRV 7.30E-04 7.36E-05 3.92E-04 3.63E-04 1.22E-04 1.68E-03 
 
Group Early_OPA 
Sample SPF4 SPF7 SPF15 SPF23 SPF27 SPF31 










 >28 nt 60.35 41.77 32.96 33.84 6.09 8.47 
miRBase 1.78 2.62 4.98 5.95 8.72 9.62 
JSRV 4.88E-04 3.87E-04 1.17E-03 5.76E-04 3.66E-04 5.48E-04 
 
Group Lamb_Control 
Sample SPF3 SPF8 SPF14 SPF22 SPF26 SPF29 










 >28 nt 52.47 36.22 30.53 34.57 38.00 30.68 
miRBase 8.55 4.98 13.09 2.54 7.79 10.79 
JSRV 1.35E-03 1.35E-03 6.81E-04 1.67E-03 1.60E-03 1.27E-03 
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Figure 4.6 Sequence distribution in samples of sequencing study 2 presented as a percentage of total reads in each sample. Each of the 
categories is represented by a colour shown in the legend. Small nuclear RNA(snRNA),  mitochondrial ribosomal RNA (Mt_rRNA), small nucleolar RNA 
(snoRNA), mitochondrial transfer RNA (Mt_tRNA), ribosomal RNA (rRNA), miscellaneous RNA (misc_RNA), long non-coding RNA (lincRNA), JSRV viral 
genome (Virus), sheep genome (DNA), reads not mapping to any of the previous categories (Unmapped). 
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Figure 4.7.  Length distribution of total sequencing reads after trimming was performed. Two areas with high read abundance can be observed: 
corresponding to miRNA length (21-23nt) and longer length (30-32nt) which could correspond to piwi-RNAs. The abundance of reads in those two areas 
appears similar in all sample groups.  
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4.2.3.1 Age effects on miRNA expression 
Previous studies have reported age-dependent differences in miRNA expression 
in humans (Ameling et al, 2015) and mice (Victoria et al, 2015). To examine 
whether similar changes were evident in the samples of the present study, a 
comparison between control adult samples and control lamb samples was 
performed. Following removal of miRNAs of low abundance, 202 miRNAs were 
detected in the serum of healthy sheep. Expression changes were examined by 
PCA (Fig. 4.8). 
 
Figure 4.8.  PCA plot of miRNA expression levels of adult sheep and lambs in study 2. 
Adult control (n=6) and lamb control (n=6). Adult samples are represented as red circles and 
lambs as turquoise triangles. Greater distance between samples in the plot indicates more 
expression differences between samples. Lamb samples are seen clustering towards the right 
of the plot, whereas adult sheep can be seen towards the left of the plot. The PCA plot 
suggests global expression differences between the two groups. 
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The PCA plot (Fig. 4.8) suggested that adult and lamb samples cluster into two 
separate groups based on miRNA expression levels detected in serum. 
Differential expression analysis between adults and lambs revealed 78 miRNAs 
DE between the two tested age groups (log2(fold change) ≥ |1| and FDR ≤ 0.05). 
Of those, 35 were upregulated and 43 downregulated in adults compared to lambs 
(Fig. 4.9, Table 4.9 and Table 4.10). Interestingly, miR-191 appeared DE 
between adult sheep and lambs, suggesting that expression of this miRNA is 
linked to age. Consequently, miR-191 would not be an adequate endogenous 
control in serum studies with samples from mixed age groups. 
Distinct miRNA expression patterns can be seen between adults and lambs. 
Correlation clustering analysis of samples revealed two clusters corresponding to 
adult sheep samples and lamb samples (Fig. 4.9). However, sample S3882 
clustered with the lamb samples instead of adult sheep samples. Consistent with 
this, sample S3882 also clustered closer to the lamb group in PC1 of the PCA plot 
(Fig. 4.8). These results suggest that changes in miRNA expression linked to age 
can be detected in serum of sheep, as previously shown in humans and mice. 
While the observations presented here are in line with previous published studies, 
it is possible that differences in library size and miRBase mapping could also have 
influenced the observed results. In addition, all lambs and adult sheep in this study 
(study 2) differed in the environment they had been subjected to: lambs were 
raised as SPF, whereas adult sheep lived on farm, therefore the two groups may 
have differed in a number of other ways, such as diet, infection exposure and 
environmental stressors. Consideration of these results indicated that it would be 
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Figure 4.9.  Heatmap of DE miRNAs (FDR ≤ 0.05, log2(fold change) ≥ |1|) between control 
adults and control lambs of sequencing study 2. Dendrogram showing correlation 
clustering of individuals in groups. Legend represents values of log2 fold change. Note that 
the animals cluster by age except for S3883, an adult sheep which clusters with the lambs. 
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Table 4.9. Differentially upregulated miRNAs between adult sheep and lambs. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-451 29989.46 1.01 0 
miR-25 30298.94 1.58 0 
miR-215-3p 71 4.24 1.08E-10 
miR-375 5822.53 3.29 8.78E-09 
miR-143 3606.59 2.85 6.71E-07 
miR-1249 60.83 2.53 1.30E-06 
miR-223 964.39 2.59 2.62E-06 
miR-197 682.82 2.39 7.49E-06 
miR-200a 104.62 2.96 7.49E-06 
miR-1306 138.77 1.87 1.34E-05 
miR-191-3p 180.47 2.37 1.79E-05 
miR-22-3p 8606.73 2.6 2.06E-05 
miR-141 110.19 2.64 5.21E-05 
miR-1343-3p 156.62 1.98 1.09E-04 
miR-125a 372.51 2.34 1.20E-04 
miR-1388-3p 324.67 2.53 1.28E-04 
miR-29a 580.34 2.39 1.36E-04 
miR-3600 28033.79 1.8 2.79E-04 
miR-140 579.98 2.02 4.13E-04 
miR-574-3p 897.9 1.66 2.44E-03 
miR-140-3p 2437.84 1.96 2.91E-03 
miR-1307-3p 310.47 1.39 3.48E-03 
miR-3431-3p 96.44 1.9 4.72E-03 
miR-425-5p 1754.73 1.59 5.82E-03 
miR-92b 7069.65 1 6.43E-03 
miR-221 2341.35 1.82 1.04E-02 
miR-125b-3p 66.36 1.87 1.20E-02 
miR-191 35549.07 1.37 1.28E-02 
miR-222-3p 1106.94 1.32 1.37E-02 
miR-16b-5p 574.09 1.17 2.17E-02 
miR-150 18775.4 1.14 2.87E-02 
miR-18a-3p 252.86 1.25 3.08E-02 
miR-532 491.04 1.42 3.25E-02 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 4.9. Differentially upregulated miRNAs between adult sheep and lambs. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-16b 858.46 1.27 3.73E-02 
let-7d-3p 1836.91 1.24 3.90E-02 
 
Table 4.10. Differentially downregulated miRNAs between adult sheep and lambs. 
miRNA average counts1 log2(fold change)2 FDR3 
let-7f 21326.46 -2.86 0 
miR-107 26198.08 -2.59 0 
miR-1246 137.57 -2.67 1.37E-07 
miR-6119-5p 1499.8 -3.4 1.97E-07 
miR-374a-3p 51.39 -3.89 2.81E-07 
miR-323c 254.67 -3.08 1.96E-06 
miR-196b 53.11 -2.76 1.47E-05 
miR-494-3p 80.84 -2.6 2.01E-05 
miR-411a-5p 395.06 -2.65 6.36E-05 
miR-21-5p 2083.75 -2.79 7.50E-05 
miR-3958-3p 198.11 -2.62 1.80E-04 
miR-330-5p 106.16 -2.05 4.62E-04 
miR-144 417.17 -2.3 4.86E-04 
miR-101 1078.57 -2.02 5.55E-04 
miR-335 112.9 -1.98 5.85E-04 
miR-98 575.55 -2.18 6.89E-04 
miR-142-3p 156.79 -2.18 9.71E-04 
miR-181b 1565.57 -1.83 1.93E-03 
miR-21-3p 451.44 -1.79 2.20E-03 
let-7a 6936.09 -1.8 2.51E-03 
let-7d 1139.44 -1.72 3.48E-03 
miR-103 14259.73 -1.71 3.66E-03 
let-7e 99.64 -1.45 4.67E-03 
miR-2284ab 52.83 -1.52 6.24E-03 
miR-199b 116.08 -1.69 7.31E-03 
miR-152 249.52 -1.26 7.31E-03 
miR-4448 1271.28 -1.11 7.31E-03 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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miR-142-5p 2686.58 -1.64 8.70E-03 
miR-345-3p 337.57 -1.97 9.31E-03 
miR-194 65.24 -1.62 1.33E-02 
let-7e-5p 115.83 -1.5 1.43E-02 
miR-23a 3951.25 -1.13 1.64E-02 
miR-2478 103.08 -1.76 2.03E-02 
miR-151-5p 890.23 -1.1 2.32E-02 
miR-126-5p 3471.37 -1.11 2.69E-02 
miR-432 59.82 -1.5 3.34E-02 
miR-1307-5p 1183.6 -1.12 3.61E-02 
miR-126-3p 346.89 -1.12 3.79E-02 
miR-181a 26473.75 -1.25 3.90E-02 
miR-2284z 66.05 -1.11 4.03E-02 
miR-20a 123.39 -1.29 4.17E-02 
miR-4634 189.5 -1.19 4.39E-02 
miR-4532 418.02 -1.13 4.57E-02 
 
4.2.3.2 Comparison of miRNA expression in adult cases of OPA 
The adult sheep samples of study 2 were classified into control, mid-stage OPA 
and advanced OPA cases, as per Table 4.5, to examine miRNA expression 
changes at different disease stages. Once miRNAs of low abundance had been 
filtered (section 2.5.1), a total of 200 miRNAs were detected in adult sheep sera. 
Differences in expression of these 200 miRNAs were explored by means of a PCA 
plot (Fig. 4.10), in which an overlap of samples of all three groups can be seen in 
the middle region of the plot. By PC1, mid-stage OPA samples were separated 
from control and advanced samples, which clustered closely towards the right of 
the plot, this separation was unexpected as a gradient corresponding to disease 
stage had been predicted. In contrast, by PC2, a gradient of control, mid-stage 
OPA and advanced OPA samples was observed. This representation suggests 
that although the disease stage of some animals could potentially be distinguished 
based on their global miRNA expression, in as much as 50% of the analysed 
samples, global miRNA expression is not an accurate classifier. Remarkably, the 
samples in the overlapping region were not the samples that could have been 
classified in either the mid-stage OPA or advanced OPA groups (i.e., B14, A29 
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and JA794) (Table 2.3). In the advanced OPA group, the  distribution of samples 
in the PCA plot seemed to correlate with condition score, with lowest condition 
scores samples seen at the top of the plot (JA811, JA874, JA875) and higher 
condition scores (A50, G22, B14) seen towards the bottom of the distribution.  
In order to further explore differences in miRNA expression, pairwise comparisons 
were then performed to detect DE miRNAs between groups.  
 
Figure 4.10 PCA plot of miRNA expression levels of adult serum samples in study 2. 
Advanced OPA samples (n=6) are represented as red circles, Mid-stage OPA samples (n=6) 
as blue squares, and adult control samples (n=6) as green triangles. Greater distance between 
samples in the plot indicates greater expression differences between samples. Although a 
tendency to form separate clusters can be observed, samples from all three groups overlap in 
the middle region of the plot.  
  
Chapter 4: Cell-free miRNAs in OPA 232 
1.6.1.1.1 Comparison 1: miRNA expression in advanced OPA cases and 
controls 
Differential expression of miRNAs was assessed in advanced OPA cases and 
compared to adult controls. Three miRNAs were found to be differentially 
expressed between the two groups (FDR ≤ 0.05, log2(fold change) ≥ |1|) (Fig. 4.11 
and Table 4.11). However, in all three miRNAs, expression levels in a single 
sample were found to be substantially higher than in other samples within the 
same group. In addition, expression levels of these three miRNAs did not result in 
clustering of samples into two separate groups by disease stage. 
 
Figure 4.11. Heatmap of DE miRNAs (FDR ≤ 0.05, log2(fold change) ≥ |1|) between 
advanced OPA cases  and control adults of sequencing study 2. Dendogram showing 
correlation clustering of individuals in groups. Legend represents values of log2 fold change. 
 
Table 4.11. Differentially expressed miRNAs between advanced OPA cases and control 
adults. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-150 16900.70 -1.70 0 
miR-133a-3p 247.99 2.12 3.44E-02 
miR-24-3p 739.85 2.09 3.60E-02 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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1.6.1.1.2 Comparison 2: miRNA expression in mid-stage OPA cases and 
controls 
Differential miRNA expression was then investigated in cases of mid-stage OPA 
compared to controls. 46 miRNAs were found to be differentially expressed 
between these two groups. 25 miRNAs were found upregulated and 21 
downregulated in mid-stage cases compared to controls (Fig. 4.12, Table 4.12 
and Table 4.13). Although separation of samples in the two clusters observed in 
the heatmap did not entirely correspond to the two groups, a pattern of miRNA 
expression in mid-stage OPA compared to controls was present in most of the 
analysed samples (Fig. 4.12). Causes of the unexpected observed clustering 
were investigated and were not found to be related to time of sample collection, 
gender or animal origin, and therefore are likely due to inter-individual variation.  
Interestingly, these results indicate that there are more dysregulated miRNAs in 
mid-stage OPA than in advanced OPA when compared to controls. It had been 
predicted that advanced cases of OPA would present a more distinct miRNA 
signature when compared to controls, given that they presented overt signs of the 
disease and greater tumour burden which might be reflected in the circulation. 
However, the present findings appear to contradict that assumption, discussed 
further in section 4.3.  
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Figure 4.12.  Heatmap of DE miRNAs (FDR ≤ 0.05, log2(fold change) ≥ |1|) between mid-
stage OPA cases and control adults of sequencing study 2.  Dendrogram showing 
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Table 4.12. Differentially upregulated miRNAs between mid-stage OPA cases and 
control adults. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-423-5p 344864.7 1.04 0 
miR-107 26453.58 2.6 0 
miR-133a-3p 362.98 2.77 4.64E-10 
miR-133a 55.53 2.9 6.70E-09 
miR-133 462.55 2.58 2.69E-08 
miR-2284f 65.51 2.66 5.12E-07 
miR-371b-3p 197 3.75 1.04E-06 
miR-1246 157.62 2.9 1.77E-06 
miR-451-3p 119.69 1.98 1.19E-04 
miR-152 382.3 2.07 3.97E-04 
miR-21-3p 618.58 2.35 6.76E-04 
miR-4532 566.61 1.73 9.07E-04 
miR-27a 5148.23 1.92 2.37E-03 
miR-193b-5p 101.28 1.77 3.49E-03 
miR-142-5p 3346.18 2.04 7.26E-03 
miR-1307-5p 1521.57 1.63 9.36E-03 
miR-361 1176.62 1.66 1.05E-02 
miR-6529a 18378.31 1.18 1.88E-02 
miR-877 452.13 1.28 1.89E-02 
miR-378c 360.53 1.69 1.89E-02 
miR-103 15123.63 1.82 2.26E-02 
miR-23a 4435.29 1.37 2.87E-02 
miR-29c 140.62 1.75 2.98E-02 
miR-877-5p 643.28 1.1 3.15E-02 
miR-365-3p 127.44 1.42 3.45E-02 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 4.13 Differentially downregulated miRNAs between mid-stage OPA cases and 
control adults. 
miRNA average counts1 log2(fold change)2 FDR3 
miR-150 15476.01 -2.34 0 
miR-223 955.59 -2.69 9.24E-10 
miR-223-5p 54.41 -1.78 4.56E-05 
miR-204 65.53 -1.95 1.00E-04 
miR-106b-3p 871.39 -1.74 1.00E-04 
miR-3596 161.25 -1.71 1.35E-04 
miR-26b-3p 54.23 -1.88 2.60E-04 
miR-215-3p 82.5 -2.16 3.58E-03 
miR-143 4105.04 -1.76 8.43E-03 
let-7b 717.74 -1.27 9.09E-03 
miR-197 852.69 -1.04 9.80E-03 
miR-30b-5p 452.84 -1.12 9.82E-03 
miR-222-3p 1094.35 -1.38 1.27E-02 
miR-16b-5p 549.89 -1.38 1.55E-02 
miR-1249 70.51 -1.47 1.89E-02 
miR-769 783.65 -1.22 1.89E-02 
miR-1307-3p 302.01 -1.54 2.62E-02 
miR-18a-3p 247.63 -1.36 2.93E-02 
miR-151-3p 1581.25 -1.18 3.53E-02 
miR-4448 564.14 -1.3 3.89E-02 
miR-148a-5p 115.04 -1.11 4.10E-02 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
                                            
 
1.6.1.1.3 Comparison 3: miRNA expression in advanced OPA cases and mid-
stage OPA cases 
Differences in miRNA expression were also compared between advanced OPA 
cases and mid-stage cases. 19 miRNAs were found to be DE between groups, of 
those, ten were upregulated and nine downregulated in advanced cases 
compared to mid-stage ones (Fig. 4.13, Table 4.14 and Table 4.15). Surprisingly, 
two separate clusters corresponding to the disease stages were seen, although 
no separate clustering had been observed in advanced OPA cases and controls. 
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Nevertheless, high variability in miRNA expression levels was observed within 
groups (Fig. 4.13).  
 
Figure 4.13. Heatmap of DE miRNAs (FDR ≤ 0.05, log2(fold change) ≥ |1|) between 
advanced OPA cases and mid-stage OPA cases of sequencing study 2.  The dendogram 
shows correlation clustering of individuals in groups. Legend represents values of log2 fold 
change. 
 
Table 4.14. Differentially upregulated miRNAs between advanced OPA cases and mid-
stage OPA cases.  
miRNA average counts1 log2(fold change)2 FDR3 
miR-451 51056.13 1.27 0 
miR-223 752.53 2.28 3.33E-04 
miR-223-5p 76.07 2.38 6.25E-04 
miR-3596 172.92 1.84 2.88E-03 
miR-425-3p 107.08 1.56 1.18E-02 
let-7g 1764.66 1.62 1.19E-02 
miR-204 51.52 1.49 1.64E-02 
miR-106b-3p 861.84 1.72 1.64E-02 
miR-222-3p 1326.34 1.75 2.14E-02 
miR-18a-3p 363.26 2.08 2.17E-02 
                                            
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
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Table 4.15. Differentially downregulated miRNAs between advanced OPA cases and 
mid-stage OPA cases.  
miRNA average counts1 log2(fold change)2 FDR3 
miR-2904 2132.94 -3.99 0 
miR-215 15159.64 -1.17 0 
miR-6529a 16000.8 -1.97 0 
miR-10b 27396.94 -1.25 0 
miR-107 28481.7 -1.98 0 
miR-423-5p 323008.2 -1.35 0 
miR-133 581.84 -1.1 4.42E-03 
miR-4532 454.47 -4.54 1.96E-02 
miR-203b-5p 62.99 -2.45 3.76E-02 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3 FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
                                            
 
4.2.3.3 miRNA expression in lambs with experimentally-induced OPA 
A total of 198 miRNAs were detected in the serum of lambs, once low abundance 
miRNAs had been removed. As before, PCA was performed and plotted to identify 
differences between groups (Fig. 4.14). Greater within-group variation than 
between-group variation was observed. However, a trend towards separate 
clusters could be observed in the PCA plot with overlapping between groups 
caused by the miRNA expression pattern of one individual of each group: SPF15 
and SPF22. This apparent overlapping did not appear to be directly related to the 
number of viral counts, library size or pathological findings (Table 2.2).  
Differential expression analysis was then performed and revealed four miRNAs 
DE between Early OPA samples and controls (Fig. 4.15 and Table 4.16). 
Clustering of samples did not identify two separate groups corresponding to OPA 
affected lambs and controls.  
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Figure 4.14.  PCA plot of miRNA expression levels of early OPA and controls samples 
from sequencing study 2.  Early OPA samples (n=6) are represented as red circles and 
control lambs (n=6) as turquoise triangles. Greater distance between samples in the plot 
indicates more expression differences between samples. Early OPA samples are seen 
clustering towards the right of the plot, whereas controls can be seen towards the left of the 
plot. The PCA plot presents a slight overlapping between the two groups tested.  
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Figure 4.15. Heatmap of DE miRNAs (FDR ≤ 0.05, log2(fold change) ≥ |1|) between 
advanced OPA cases and mid-stage OPA cases of sequencing study 2.  Dendogram 
showing correlation clustering of individuals in groups. Legend represents values of log2 fold.  
 
Table 4.16 Differentially expressed miRNAs between early OPA cases and control 
lambs.  
miRNA average counts1 log2(fold change)2 FDR3 
miR-486 4272554.10 1.54 0 
miR-2889 1318.38 3.38 2.85E-03 
miR-1224 53.67 2.61 2.74E-02 
miR-486-3p 555.46 2.51 3.66E-02 
1 Average normalised counts across all samples 
2 Threshold established at log2(fold change) ≥ |1| 
3  FDR corrected by Benjamini-Hochberg, threshold FDR ≤ 0.05 
                                            
 
4.2.3.4 Comparison of differentially expressed miRNAs between 
disease stages in serum 
Having analysed changes in miRNA expression at each disease stage compared 
to control samples, common DE miRNAs in all disease stages were investigated 
by contrasting the results of the three comparisons. No miRNAs were found to be 
differentially expressed in all disease stages. Nevertheless, both advanced and 
mid-stage cases of OPA showed significantly increased levels of miR-133a-3p 
and reduced levels of miR-150 when compared to controls, although this was not 
reflected in all samples. 
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Interestingly, 20 miRNAs were found to be dysregulated both in mid-stage OPA 
cases compared to adult controls, and in adult controls compared to lambs. Of 
those, 19 miRNAs (miR-223, miR-150, miR-215-3p, miR-143, miR-197, miR-
1307-3p, miR-1249, miR-16b-5p, miR-222-3p, miR-18a-3p, miR-1307-5p, miR-
4532, miR-103, miR-107, miR-1246, miR-142-5p, miR-152, miR-21-3p, miR-23a) 
had increased expression levels in mid-stage OPA and lambs compared to adult 
controls. miR-150 showed increased expression in advanced OPA cases, mid-
stage OPA cases and control lambs compared to adult sheep. These increased 
levels in lambs might contribute to the different pattern of miRNA dysregulation 
observed in Early OPA compared to other stages. Nevertheless, to investigate 
this effect further it would be necessary to source early cases of OPA in adult 
sheep, a challenging task due to the long asymptomatic period of OPA (section 
1.1.2). 
Comparison of DE miRNAs between the initial sequencing (study 1) and the 
present results (study 2) revealed common dysregulated miRNAs. Given that the 
three samples from sequencing study 1 belonged to 2 different OPA groups: mid-
stage OPA (B16 and G32) and advanced stage OPA (B14), the results were 
compared to both mid-stage cases of OPA and to advanced cases of OPA from 
study 2. Thirteen miRNAs were commonly dysregulated between mid-stage OPA 
cases and adult controls in both sequencing runs. Of those, six miRNAs were 
upregulated (miR-107, miR-103, miR-133a, miR-451-3p, miR-133, miR-133a-3p), 
four miRNAs were downregulated (miR-215-3p, miR-4448, miR-150, miR-1249), 
and three miRNAs presented opposed levels of expression (miR-4532, miR-1246, 
miR-18a-3p). miR-150 and miR-133a-3p were also dysregulated in advanced 
cases of OPA. miR-486 and miR-486-3p were found upregulated both in study 1 
and in early cases of OPA compared to lamb controls.  
Since only ten miRNAs were found dysregulated and following the same 
expression pattern between both sequencing runs, the biological relevance of the 
present results was questioned. Factors such as technical repeatability and the 
effect of sample size and, thus, increased biological variation were considered 
and further explored (4.2.4).  
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4.2.4 Comparison of results between two sequencing runs 
Considering that the six initial samples sequenced in study 1 were also included 
in study 2, the data statistics were compared for those six samples between both 
runs. The aim of the comparison was to investigate the effect of technical 
repeatability in the sequencing results.  
Samples S6230, S6318, S6354, B14, B16 and G32 from both runs were 
compared. Initially, library sizes and percentage of reads mapping to miRBase 
and other categories were compared between sequencing study 1 and study 2 
(Table 4.17 and Table 4.18). No statistically significant differences were found 
between the two runs in library size, selected length, percentage of reads mapped 
to miRBase or reads mapped to viral genome (t-student test p<0.05).  
Having found no significant differences in sequencing statistics between both 
runs, the normalised counts of the ten top differentially expressed miRNAs (five 
most upregulated and five most downregulated) between OPA cases and controls 
in study 1 were compared to their numbers in study 2 (Table 4.19). Generally, 
normalised counts were higher in sequencing study 1. No statistical differences 
were found in the normalised counts between sequencing runs in seven out of the 
ten miRNAs. However, three miRNAs (miR-146a, let-7e, and miR-455-5p) were 
found to have statistically different counts across samples between both 
sequencing runs. Interestingly, the average normalised counts of these miRNAs 
were the lowest of the selected miRNAs and in study 2 were filtered out due to 
low counts, suggesting that these DE signals could be an artefact of sequencing 
noise.  
Considering the miRNA fold changes between groups in the two sequencing runs, 
it could be seen that only seven miRNAs followed the same trend, and of those 
four showed differences in fold change levels of greater than 50% in value. These 
findings imply that in addition to the increased biological variation introduced with 
having more samples in sequencing study 2, technical sequencing repeatability 
also contributed to the results observed. Nevertheless, six of the top ten 
dysregulated miRNAs were found to DE in mid-stage cases of OPA of study 2, 
and two in advanced cases, indicating that focusing on miRNAs with the highest 
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fold changes and higher numbers of counts might permit biologically relevant 
signals to be discriminated from background noise. The biological roles of these 
miRNAs will be further discussed in section 4.3.  
Table 4.17. Comparison of read categories between sequencing study 1 and study 2. 
Average of six samples.  
 average (study 1) average (study 2) 












(17-28nt) 37.68 42.81 
Too short 26.73 22.46 

























miRBase 62.76 64.18 
cDNA 3.54 2.92 
snRNA 0.07 0.04 
Mt_rRNA 0.01 0.00 
snoRNA 0.19 0.06 
Mt_tRNA 0.01 0.01 
rRNA 0.13 0.06 
misc_RNA 1.97 3.60 
miRNA 1.24 1.21 
lincRNA 2.13 1.12 
JSRV genome 0.00 0.00 
DNA 19.40 15.73 
Unmapped 8.55 11.07 
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Table 4.18. Comparison of read categories between samples of both sequencing runs. 
 
Sheep ID 62301 62302 63181 63182 63541 63542 B141 B142 B161 B162 G321 G322 





l (17-28nt) 23.94 38.96 27.30 49.13 23.81 21.20 47.67 45.51 52.08 55.32 51.28 46.72 
Too short 20.64 26.18 33.27 14.75 26.87 27.39 29.44 12.11 30.89 24.46 19.29 29.86 















miRBase 47.32 59.01 56.88 72.86 39.48 28.43 81.44 73.15 76.45 77.23 75.00 74.42 
cDNA 4.11 3.20 4.76 2.32 6.85 4.88 2.05 1.32 2.06 2.56 1.41 3.25 
snRNA 0.13 0.05 0.07 0.03 0.10 0.08 0.03 0.02 0.03 0.02 0.03 0.04 
Mt_rRNA 0.01 0.00 0.01 0.00 0.02 0.00 0.02 0.01 0.01 0.01 0.01 0.01 
snoRNA 0.47 0.10 0.14 0.05 0.28 0.12 0.12 0.04 0.04 0.03 0.07 0.04 
Mt_tRNA 0.02 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.02 
rRNA 0.23 0.08 0.09 0.03 0.15 0.13 0.21 0.04 0.04 0.03 0.03 0.06 
misc_RNA 2.78 7.57 2.73 3.16 3.39 7.47 1.29 0.75 0.83 1.01 0.82 1.62 
miRNA 1.08 1.35 1.04 1.34 0.99 0.75 1.22 1.47 1.34 1.10 1.75 1.22 
lincRNA 3.72 1.23 3.60 1.68 2.46 1.71 0.85 0.26 1.14 0.68 0.99 1.14 
JSRV 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
DNA 27.92 16.02 20.45 11.72 32.41 35.68 6.81 7.23 13.88 11.21 14.94 12.53 
Unmapped 12.19 11.37 10.21 6.81 13.85 20.74 5.95 15.72 4.19 6.12 4.93 5.66 
1 Samples of sequencing study 1  
2 Samples of sequencing study 2 
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Table 4.19. Normalised counts of the top ten DE miRNAs in sequencing study 1 and comparison to study 2. 
 
 
Study 1 Study 2 
Log2 
(FC) 
S6230 S6318 S6354 B14 B16 G32 
Log2 
(FC)1 
S6230 S6318 S6354 B14 B16 G32 
miR-150 -2.58 64503.74 19284.44 60351.36 9250.64 9193.28 5594 -1.99 26541.11 19393.08 72187.65 18578.93 6657.51 4420.67 
miR-4532 -2.45 128.96 36.53 114.79 48.66 0.00 2.55 1.32 28.68 163.08 98.31 11.88 183.89 530.75 
miR-146a -2.38 280.69 87.04 261.71 57.00 19.46 44.22 0.92 4.41 9.09 0.00 2.64 9.61 13.35 
let-7e -2.30 251.43 417.99 318.34 57.00 64.57 79.09 -0.43 33.83 34.43 74.98 59.42 26.99 19.59 
miR-455-
5p 
-1.95 102.95 36.53 102.54 6.95 31.84 23.81 -2.04 22.06 6.22 11.66 0.00 6.86 2.84 
miR-425-
3p 
2.16 13.00 29.01 13.77 62.56 112.33 74.84 -0.52 51.48 36.82 41.66 5.28 46.66 38.62 
miR-133a 2.63 69.36 23.64 62.75 11.82 85.79 864.02 4.10 8.83 7.65 0.00 3.96 14.18 263.81 
miR-451-
3p 
3.10 69.36 70.92 32.14 215.49 347.60 912.49 5.02 19.86 20.56 0.00 378.97 397.51 531.61 
miR-133 3.16 286.11 250.36 146.93 221.05 472.31 5423.92 2.99 108.11 102.34 128.30 73.95 150.04 2464.64 
miR-
133a-3p 
4.76 167.98 214.90 16.84 106.35 421.90 10303.57 1.41 48.54 57.87 19.99 104.32 119.39 3116.08 
1 Log2 (fold change) calculated considering the six samples listed in the table. 
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4.2.5 Differentially expressed miRNAs in serum and lung 
tissue 
Expression of miRNAs found to be DE in more than one of the serum datasets 
was compared to DE miRNAs in the tissue datasets discussed in Chapter 3. 
These miRNAs were: miR-107, miR-103, miR-133a, miR-451-3p, miR-133, miR-
133a-3p, (upregulated in mid-stage or advanced OPA); miR-215-3p, miR-4448, 
miR-150, miR-1249 (downregulated in mid-stage or advanced OPA); miR-486 and 
miR-486-3p (upregulated in early OPA). 
None of the aforementioned miRNAs were found to be DE in lung tissue of OPA-
affected animals compared to controls nor in LCM tissue. However, miR-150 was 
found to be downregulated in BALF CD14+ macrophages of OPA-affected sheep 
compared to controls. These results suggest that miRNA expression detected in 
the serum of OPA-affected sheep is not directly related to tumoural miRNAs. 
Indeed, having found miR-150 in common suggests that some of the DE miRNAs 
in serum might be related to other changes occurring in OPA affected sheep, such 
as immune responses. The roles of miR-150 are reviewed in section 4.3. Taking 
into consideration that miR-150 was also found upregulated in lamb’s serum 
compared to adult’s serum, the fact that no miRNAs are found DE both in serum 
and tissue could be, in part, related to age differences. On the other hand, given 
the number of comparisons performed in this study and the great number of 
miRNAs analysed, some miRNAs could be expected to appear DE in multiple 
datasets by chance.  
Of the nine miRNAs further studied in tissue none were found DE in serum. miR-
182, miR-205 and miR-21 were detected in serum sequencing data; miR-31, miR-
183, miR-503 and miR-200b were detected but below the established threshold 
of abundance for DE analysis; miR-96 and miR-135b were not detected. 
4.2.6 Sequencing reads in sheep serum mapping to the JSRV 
genome 
Sequencing reads of length between 17-28 nt mapping to the genome of JSRV 
(AF105220.1) were analysed. In study 1, no differences were observed between 
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samples of the control and OPA groups. All reads from both groups mapped to 
the viral genome first 1000 nt, specifically between 128-178 nt and 620-645 nt, 
corresponding to the end of the LTR region and beginning of the gag gene. 
Nevertheless, these reads could have originated from enJSRV copies in the 
sheep genome. Indeed, the 128-178 nt region of JSRV is almost identical, with 
only one mismatch, to the 446-496 nt region of enJSRV (EF680301.1). The 620-
645 nt region was not found to be identical to this enJSRV provirus. However, the 
fact that both infected and uninfected sheep had reads in this region suggests that 
the presence of those reads is not JSRV related; the origin of those reads might 
be other enJSRV copies in the sheep genome.  
Similarly, in sequencing study 2, reads were found that map to the same regions 
of the JSRV genome mentioned above. A slight increase in reads mapping areas 
of the JSRV genome between 2000-7000 nt was observed in OPA-affected 
animals. However, differences are not likely to be meaningful due to the low 
number of reads, which in all cases did not add to 10 reads. JA874 showed an 
increase in reads mapping to the JSRV genome compared to other samples of 
the OPA-affected group. Nevertheless, the reads were scattered across the viral 
genome, and the number of reads in each region was lower than 5. Interestingly, 
JA874 did not show differences in number or percentage of RNA mapped to the 
viral genome compare to the other samples. This finding might be an indication of 
the sample being more degraded.  
No reads in the 6400 nt region, investigated as a candidate miRNA in Chapter 3, 
were found in any of the samples. As expected, fewer reads were found to map 
to the JSRV genome compared to tissue samples discussed in Chapter 3. 
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4.3 Discussion 
Previous studies in mice, humans and other species have investigated the 
potential exploitation of circulating miRNAs as diagnostic markers for disease 
(section 1.5.12). In this chapter, experiments were performed to profile circulating 
miRNAs in sheep and to identify miRNA species associated with OPA. 
Two sequencing studies were performed. In the first, performed with two groups 
of three sheep, miRNAs were identified in sheep sera, and differences in 
expression detected between OPA-affected and control sheep.  This provided the 
basis for a larger analysis performed by sequencing small RNA from the sera of 
30 sheep, including animals of differing OPA disease states and from adults and 
lambs. Analysis of the data found interesting trends relating to the pattern of 
miRNA expression in the different groups, but did not identify miRNAs that are DE 
in all stages of OPA. 
In order to assess miRNA expression changes at different stages of OPA, pairwise 
comparisons were performed. Initially, DE miRNAs were found between lambs 
and adult sheep, indicating that miRNA expression comparisons should be 
performed within age groups. Similarly to study 1, differentially expressed miRNAs 
were found between OPA and control cases, but no miRNA was found to be 
dysregulated at all stages of the disease. Similarities in DE miRNAs were found 
in advanced and mid-stage cases of OPA, relative to adult controls. Nevertheless, 
care should be taken when analysing the data due to relative low counts of some 
miRNAs, which might render their detection more influenced by background noise, 
and due to high within-group variability. Ten miRNAs were found differentially 
expressed in both study 1 and study 2.  
At the outset of the present study, it was anticipated that advanced OPA cases 
would have more DE miRNAs than mid-stage disease, relative to controls. Indeed, 
this prediction was based on published studies that found that miRNA 
dysregulation varies depending on disease stage, for instance miR-21 has been 
found to be downregulated at initial stages and upregulated in more advanced 
cases of lung cancer (reviewed by Zheng et al (2018)), and expression of certain 
miRNAs has been used as prognostic marker. Nevertheless, the fact that no 
miRNAs were found to be consistently DE in all disease stages, and that only ten 
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miRNAs were DE in both study 1 and study 2, suggested that either biological 
variation and small sample size, or technical factors were contributing to the 
inconsistencies observed. The small sample size of the study might have reduced 
the power to detect DE miRNAs in samples with background noise and high 
biological variation.  
Technical repeatability was assessed by comparing six samples sequenced in 
both studies, and given the variation observed in the top 10 DE miRNAs, found to 
influence the results. Indeed, several reports have argued that besides small 
sample size, technical factors contribute to the inconsistencies and variation 
observed in miRNA literature (sections 1.5.11 and 1.5.12). In addition, 
differentially expressed miRNAs with low fold changes between groups might be 
more difficult to validate and influenced by background noise to a greater degree, 
particularly in samples with low RNA concentration such as serum. In a study, six 
serum miRNAs with low fold change and p-adjusted value close to threshold failed 
to validate in the same samples using qPCR (Fernandez-Costa et al, 2016).  
Indeed, low RNA concentration and background noise might have also influenced 
the read mapping to different small RNA categories, which was highly variable 
between samples.  
To extend this study, and overcome some of the aforementioned limitations, it 
would be necessary to include a large number of animals per group. In many 
human studies around 100 samples have been used to identify miRNA signatures. 
Performing such a study in sheep would be expensive, but the cost could possibly 
be reduced by pooling samples for library preps. The pooling approach would 
involve losing some resolution of individual animals, but would allow obtaining 
higher RNA concentrations. In addition, if promising OPA-associated miRNAs had 
been identified, further validation could be performed by assaying expression of 
those miRNAs by RT-qPCR in archived serum samples. Shaughnessy et al. have 
previously reported stability of miRNA in frozen samples (Shaughnessy et al, 
2015).  
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4.3.1 Comparison to human serum lung cancer studies 
Data obtained in this chapter was compared to studies in human lung cancer to 
draw similarities between the two diseases. Taking into consideration the high 
variability observed in the results of this chapter, only miRNAs with the highest 
fold change values between OPA-affected and control sheep, DE in more than 
one of the analysed datasets, are reviewed here: upregulated miRNAs (miR-107, 
miR-103, miR-133a, miR-451, miR-133, miR-486) and downregulated miRNAs 
(miR-215, miR-4448, miR-150, miR-1249).  
miRNAs miR-103 and miR-107 are paralogous members of the miR-15 family, 
which includes miR-503. A limited number of studies has investigated 
dysregulation of these miRNAs. In lung cancer, they have been reported to act as 
tumour suppressors (Takahashi et al, 2009). A report found that miR-107 was 
upregulated in plasma of NSCLC patients with EGFR mutations (Qu et al, 2017), 
whereas miR-103 was upregulated in serum of early stage adenocarcinoma 
patients (Lv et al, 2017). 
miR-133 is considered a tumour suppressor in lung cancer, which targets include 
IGF-1R, TGFBR1, EGFFR (Wang et al, 2014a). A study reported that miR-133 
was downregulated in serum and tumour tissue of NSCLC (Petriella et al, 2016). 
miR-133 was found to be the most common upregulated miRNA in airway 
epithelial cells (Chen et al, 2018).  
miR-451 is highly expressed in erythrocytes and involved in erythrocyte 
differentiation and formation of epithelial cell basolateral polarity (Wang et al, 
2011) (Pan et al, 2013). miR-451 is considered a tumour suppressor in lung 
cancer, and targets RAB14, member of the Ras family (Wang et al, 2014b; Wang 
et al, 2011; Yin et al, 2015). It has been found downregulated in NSCLC tissue, 
but in a study authors saw no changes in plasma expression levels (Markou et al, 
2013). miR-451 targets c-myc and MIF which accelerates tumour growth by 
inducing MAPK, PI3K/Akt pathways (Goto et al, 2017).  
Downregulation of miR-486 was observed in lung tumour tissue of stage I 
adenocarcinoma patients (Yu et al, 2010a). A meta-analysis that reviewed 20 
studies on miRNA expression in serum of lung cancer patients found miR-486 
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downregulated as part of a 15-miRNA predictive signature (Vosa et al, 2013). This 
meta-analysis highlighted that studies performed in smaller number of patients 
tended to diverge more from the proposed signature (Vosa et al, 2013).  
No studies have investigated the expression of miR-215 in circulation of lung 
cancer patients and just a few have addressed its expression in lung cancer 
tissue. miR-215 was found downregulated in NSCLC lung cancer tissue (Cai et 
al, 2017b; Hou et al, 2015). A study related its downregulation with metastasis of 
NSCLC (Yao et al, 2018). miR-215 is considered a tumour suppressor, induced 
by p53 (Hou et al, 2015) and some of its validated targets are ZEB2, and MMP16 
(Burke et al, 2015; Yao et al, 2018). No studies have investigated miR-4448 
expression in serum or lung cancer. 
miR-150 is considered an immunomodulatory miRNA (Kroesen et al, 2015) and 
has been investigated in the context of both lung cancer and viral infections. Most 
studies of miR-150 expression in lung cancer have focused on tissue expression 
and found that is commonly upregulated in lung cancer tissue compared to normal 
tissue (Cao et al, 2014; Li et al, 2016; Wang et al, 2013; Zhang et al, 2013a). Only 
one study found miR-150 downregulated in NSCLC (Sun et al, 2013). miR-150 
targets the tumour suppressors TP53, FOXO4 and SRCIN1, and activates 
Src/Ras/ERK pathways (Cao et al, 2014; Li et al, 2016; Zhang et al, 2013a). In a 
study in serum of NSCLC patients, miR-150 was found to be predictive of relapse 
as part of a 5 miRNA signature (Zhang et al, 2018), and enriched in extracellular 
vesicles produced by four NSCLC cell lines (Lawson et al, 2017). In the context 
of viral infection, it was found to be downregulated in HIV-1 patients (Moghoofei 
et al, 2018) (Chiang et al, 2012) and was predictive of disease progression in 
plasma (Munshi et al, 2014). Downregulation of miR-150 was suggested to occur 
after CD4+ T cell activation and facilitate HIV-1 infection (Chiang et al, 2012; 
Munshi et al, 2014). In contrast, downregulation of miR-150 was linked to better 
protection levels against acute viral infection by Lymphocytic choriomeningitis 
virus (LCMV) (Chen et al, 2017). 
miR-1246 expression in lung cancer has been investigated in a limited number of 
studies. These studies found that miR-1246 is upregulated in NSCLC tissue and 
found that it was required for tumour initiation and metastasis (Kim et al, 2016; 
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Zhang et al, 2016). miR-1246 was also found upregulated in serum of stage I-III 
NSCLC compared to healthy controls (Zhang et al, 2016).  
Although most literature on the differentially expressed miRNAs in human lung 
cancer seems to describe findings opposed to the ones found in this chapter, it 
has to be considered that most studies in lung cancer have examined lung cancer 
tissue samples and not circulating miRNAs. Studies that have examined both 
tissue samples and plasma or serum have sometimes reported dysregulation in 
opposite directions (Markou et al, 2013). In addition, some studies considered in 
this discussion have shown how type of mutation, stage, prognosis and other 
factors can be predicted in circulating miRNA signatures, suggesting that they 
might influence the circulating miRNAs detected. Moreover, the infectious nature 
of OPA needs to be taken into account when comparing findings to human lung 
cancer. miR-150, for instance showed different dysregulation in lung cancer than 
viral infections, and JSRV and the host response might play an important role in 
the dysregulated miRNAs observed. In addition, human studies are usually 
performed in large cohorts of patients which are not always available in animal 
studies, limiting the power and reproducibility of the studies. 
4.3.2 Comparison with lung tissue results 
Of the miRNAs DE in serum datasets of either study 1 or study 2, none were found 
DE in lung tissue of OPA-affected animals. One miRNA, miR-150 was found to be 
differentially downregulated in both BALF CD14+ macrophages and natural cases 
of OPA. 
Although it was initially expected to observe more DE miRNAs in advanced OPA 
cases than mid-stage cases, as well as similarities in DE miRNAs between serum 
and lung tissue of OPA-affected sheep, a number of factors could be related to 
the observed result. Unlike tissue samples, serum composition might be 
influenced by several aspects of the individual, causing them to be more complex 
to analyse and differentiate background noise from signals that reflect tumour 
presence. Circulating miRNAs remain poorly understood and its origin remains 
largely unknown. A study on the levels of circulating miRNAs found that 66% of 
them reflected tissue levels of expression, whereas levels of other miRNAs were 
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enriched in circulation and other miRNAs were retained in cells and not released 
to the circulation (Pan et al, 2013). In addition, factors that have an impact in 
circulating miRNA levels are yet to be studied. Other authors have also reported 
that miRNAs dysregulated in tissue were not found in serum (Petriella et al, 2016).  
Enrichment of RNAs of 30-32 nt was observed in serum samples, which had not 
been observed in lung tissue sequencing, these could correspond to piwi-
interacting RNAs (piRNA). piRNAs are small non-coding RNAs that have also 
been investigated as cancer biomarkers (Cheng et al, 2011; Martinez et al, 2015; 
Umu et al, 2018), but although these were present in greater abundance in control 
samples from study 1, in study 2 no differences were observed between groups. 
These findings might indicate that the enrichment of a 30-32 nt RNA population 
might be an artefact from sequencing. Upon reviewing the mapping of reads of 
30-32 nt obtained from serum samples, only a small proportion of reads (0.08-
4.4%) mapped to piRNAs, while most corresponded to long non-coding RNA or 
tRNA fragments. The higher abundance of these fragments in serum samples 
compared to tissue samples might be due to a higher level of RNA degradation in 
serum samples.  These findings are in accordance with some reports, which have 
suggested that sequences of 30-32 nt have sometimes been wrongly catalogued 
as piRNAs and are likely to represent ubiquitous background from sequencing 
data (Genzor et al, 2019; Tosar et al, 2018). 
4.3.3 Sequencing reads mapping to the JSRV genome 
Sequencing reads that mapped to JSRV were low amongst all samples, and no 
differences were observed between OPA-affected sheep and controls. The 
enrichment of reads mapping to the 6400 nt region of the JSRV genome seen in 
lung tissue and CD14+ samples was not observed in the serum datasets. The 
reason for these findings might be the expected lower concentration of JSRV in 
serum compared to lung tissue.  
4.3.4 Cell-free miRNAs in lung fluid 
In a pilot study, examination of OPA-related miRNA signatures was performed in 
lung fluid, to investigate other potential sources of biomarker detection. miRNA 
expression was detected in lung fluid of seven natural OPA cases. However, 
  
Chapter 4: Cell-free miRNAs in OPA 254 
expression levels of the four tested miRNAs were low and they did not correlate 
with miRNA expression in matched lung tissues (data not shown).  
Other miRNAs could be tested to investigate significant correlations to lung tissue 
expression. Nevertheless, sheep that produce lung fluid are already presenting a 
pathognomonic sign of OPA thus, testing miRNA expression in lung fluid is not 
likely to render a biomarker with potential to be used as diagnostic. Nasal swabs 
could be investigated as minimally invasive tests for OPA biomarker miRNAs. In 
order to explore this possibility, miRNA patterns of expression and stability would 
first have to be investigated in nasal swabs from OPA-affected sheep and 
controls.  
4.3.5 Conclusions 
This first look at miRNA expression in OPA sheep sera has provided valuable 
information on the diversity of miRNA expression in sheep sera. Throughout this 
chapter, miRNA expression has been detected in serum of OPA affected and 
control sheep, and a trend towards group separation based on miRNA expression 
has been observed. However, extracting a miRNA signature related to OPA from 
the data presented here was challenging: DE miRNAs in OPA-affected sheep 
were identified but found to be inconsistent across datasets. In addition, they did 
not correlate with miRNA lung tissue expression. These findings are largely due 
to the nature of the sample analysed, in which low RNA concentration is liable to 
be affected by background signals. Background noise increases the challenge of 
differentiating biologically relevant signals from artefacts of the method.  
Some studies have examined miRNA signatures in the circulation of other 
ruminant species. Those studies, also had small sample sizes and reported within-
group variability in small-RNA composition (Farrell et al, 2015; Shaughnessy et al, 
2015; Zheng et al, 2014). 
Considering the large number of research studies examining miRNAs as 
circulating biomarkers, and their sometimes contradictive findings, it seems that 
the background noise and limitations of the present study are common. The great 
promise of miRNAs as biomarkers might need to be reassessed to be applied in 
clinical or field settings. A remarkable effort in understanding circulating miRNAs 
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as clinical markers has been performed in recent years by members of the 
Extracellular RNA Communication Consortium (ERCC). The ERCC was 
established to investigate extracellular vesicles and extracellular RNAs, and their 
potential role in intercellular communication and possible clinical applications (Das 
2019). One of the aims of the ERCC is to establish a catalogue of extracellular 
RNAs present in biofluids of healthy humans, which could be used as a reference 
in studies of clinical biomarkers (Das et al, 2019). The miRNA profiles from healthy 
sheep sequenced in this chapter could in the future serve a similar purpose and, 
help populate a database of circulating miRNA signatures in sheep. 
4.3.6 Further research 
Besides increasing the animal number in future studies of miRNA dysregulation 
in serum, an additional approach to obtain a cleaner miRNA dysregulation signal 
would be to concentrate and examine miRNA expression in serum exosomes. 
However, the value of this approach, as discussed in section 1.5.7, is 
controversial.  
In addition, another step towards understanding miRNA dysregulation in OPA 
would be to study the role of differentially expressed miRNAs in tissue and in vitro 
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Chapter 5 miRNA dysregulation in in vitro 
and ex vivo OPA models 
5.1 Introduction 
The finding of a set of miRNAs consistently upregulated in OPA lung tissue 
motivated the study of their role and importance in the oncogenic process.  JSRV 
env is the active oncogene of JSRV and is sufficient to cause transformation of 
cells in vitro and drive tumour formation in in vivo models. Due to the lack of a 
permissive cell line for JSRV, studies of JSRV transformation have been 
classically performed in cell lines transfected with JSRV Env-encoding plasmids. 
These studies have contributed valuable information on the signalling pathways 
activated by JSRV Env and, comparison with findings in sheep lung has revealed 
that activation of the MAPK and Akt signalling pathways is associated with JSRV-
driven transformation.  
Although activation of several protein kinases and signalling pathways is known 
to occur in OPA lung tissue, the mechanism by which JSRV Env initiates the 
signalling cascade that leads to cell transformation remains unknown. In addition, 
the importance and sequential activation of signalling pathways in OPA is not 
entirely understood. miRNAs are known to promote oncogenesis in several 
malignancies, reviewed in section 1.5.10, and have been reported to target 
members of signalling pathways important for transformation (section 1.5.10). 
Therefore, it is possible that miRNAs might play a role in JSRV Env-driven 
transformation and may help unveil the missing pieces of information. 
The set of miRNAs upregulated in OPA lung tissue (miR-135b, miR-182, miR-183, 
miR-200b, miR-205, miR-21, miR-31, miR-503 and miR-96) has been related to 
human forms of lung cancer. Moreover, targets of these miRNAs in humans 
include members of the Akt and MAPK pathways. For instance, miR-21 targets 
PTEN in the MAPK pathway, and miR-31 targets RASA1 (Edmonds et al, 2016; 
Zhang et al, 2010b). Nevertheless, targets of these miRNAs might be different in 
sheep lung.  
Several in vitro systems were selected and evaluated to study the role of miRNAs 
in JSRV Env transformation. In vitro systems permit the use of knock-down and 
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overexpression experiments to alter the expression of the miRNA of interest, 
whereas techniques such as reporter assays can help identify targets of the 
miRNAs. Differences in JSRV Env activation of signalling pathways have been 
noted depending on species (sections 1.2.6 and 1.3.3), suggesting that some in 
vitro findings might not translate to events occurring in sheep lung tissue. In order 
to identify the role of miRNAs in JSRV Env driven transformation in the sheep 
lung, an in vitro model that would closely resemble miRNA expression changes in 
the OPA sheep lung was sought. It could be anticipated that a model that mimics 
miRNA expression levels of the OPA sheep lung would be more likely to mimic 
the role of miRNA in transformation in vivo.  
With that aim in mind, in this chapter, miRNA expression was investigated in 
transfected cell lines, in sheep-derived primary cells and in an ex vivo culture of 
sheep tissue. 
5.1.1 Hypothesis and aims 
Following the findings from Chapter 3 that suggested that some miRNAs 
upregulated in OPA lung tissue are related to JSRV Env driven transformation, in 
this chapter, the hypothesis that these miRNAs are also upregulated in vitro, in 
models of JSRV transformation was explored. If found to be true, this would 
provide a tractable in vitro system for studying the role of these miRNAs and their 
function in transformation. To examine the working hypothesis, several in 
vitro experimental systems were studied, including cell lines and lung slice 
models. 
In order to test these hypotheses, the following aims were established for the 
present chapter: 
 Induce JSRV Env driven transformation in cell lines 
 Examine miRNA expression in JSRV Env transformed cell lines 
 Develop an in vitro model derived from sheep type II pneumocytes that 
resembles JSRV Env transformation in sheep lung 
 Detect miRNA expression after JSRV infection in ovine lung slices 
 Compare miRNA expression results of in vitro models to miRNA 
expression in OPA in vivo 
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5.2 Results 
5.2.1 Transfection of cell lines with JSRV Env-encoding 
plasmids 
In order to study miRNA expression in in vitro models of OPA, the initial approach 
taken was to induce JSRV Env driven transformation in cell lines. miRNA 
expression in transformed cells could then be compared to miRNA expression in 
non-transformed control cells. Cell lines previously used to study the molecular 
mechanisms of JSRV transformation, as described in section 1.3.2, were used, 
including a rat fibroblast line, 208F (Hofacre & Fan, 2004; Hull & Fan, 2006), a 
mouse fibroblast line, NIH 3T3 (Maeda et al, 2001), and a dog epithelial line, 
MDCK (Liu & Miller, 2005).   
Nevertheless, transfection of these cell lines with JSRV Env-encoding plasmids, 
and culture of the transfected cells for three weeks, did not result in morphological 
changes or an increased growth rate, which would have been suggestive of 
transformation, in any of the experiments performed. Immunocytochemical 
analysis for detection of JSRV Env in transfected cell lines, and comparison to 
primary cultured OPA tumour cells JA548 (Fig. 5.1), revealed that JSRV Env 
expression was low. As previous studies in our laboratory had demonstrated that 
plasmids pCAG-JSenv and pCMV3JS-ΔGPP are able to drive expression of JSRV 
Env in 208F cells (D. Griffiths, personal communication), this suggested that low 
transfection efficiency was the cause of the poor expression in this experiment.   
In an effort to establish a stably transformed cell line that could be compared to 
the parent cells, plasmid linearization and antibiotic selection were used. Plasmid 
pCAG-JSenv encodes a Geneticin resistance gene, Geneticin was added to 
select transfected cells and indirectly encourage permanent expression of JSRV 
Env. Nevertheless, neither of these approaches resulted in an improved 
transfection efficiency nor did they enhance the level of JSRV Env expression, 
and no transformation was observed.  
The transfection efficiency of three different methods was then tested 48 h post-
transfection by flow cytometry (2.16) to determine the optimal method (Table 5.1). 
Nucleofection (section 2.8.2) of MDCK and NIH 3T3 cells with the pmaxGFP 
plasmid showed high transfection efficiency. However, when nucleofection was 
  
Chapter 5: microRNA dysregulation in in vitro and ex vivo OPA models 260 
performed with the plasmid pCMV2JSRV-GFP2A-Env, encoding EGFP and JSRV 
Env, the transfection efficiency was again markedly reduced. The reason for this 
is unclear although might potentially be due to differences in the plasmid 
transfected, including size and preparation, which can affect transfection 
efficiency. Nonetheless, these results indicated that a more efficient means to 
deliver JSRV env into cell lines were needed to achieve JSRV Env driven 
transformation and explore miRNA expression in vitro.  
 
Figure 5.1.  Immunocytochemical detection of JSRV SU protein in cultured cells. A. 208F 
cells transfected with the JSRV Env-expressing pCAG-JSenv. B. JA548 cells. A and B were 
stained with an antibody to JSRV SU. C and D. Isotype control (IgG) stained 208F cells and 
JA548 cells respectively. Brown staining indicates positive staining of JSRV Env.  JA548 cells 
are a mixed primary culture of cells obtained from bronchioloalveolar lavage of an OPA-
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Table 5.1. Summary of efficiency and viability obtained by each transfection method in 
MDCK and NIH 3T3 cells. 
MDCK transfection 
Method Fugene HD Lipofectamine 3000 Nucleofection 
Cell count 1.18 × 106 cells/ml 1 × 106  cells/ml 2.31 × 106  cells/ml 
Viability 84.31% 80.06% 79.39% 
GFP expression 0.22% 2.05% 85.27% 
NIH 3T3 transfection 
Method Fugene HD Lipofectamine 3000 Nucleofection 
Cell count 1.18 × 105  cells/ml 1.64 × 105 cells/ml 2.02 × 105 cells/ml 
Viability 71.62% 78.76% 87.93% 
GFP expression 6.88% 6.04% 61.07% 
 
5.2.2 Transduction of cell lines with JSRV-env encoding 
lentiviral vectors 
The experiments described in 5.2.1 indicated that JSRV Env expression in 
transfected MDCK and NIH3T3 cells was low, seemingly due to the method used 
to deliver the transgene into cell lines. To achieve better delivery of JSRV Env into 
cell lines and efficient expression of the transgene, a transduction strategy using 
HIV-based lentiviral vectors was devised. In addition, this method would integrate 
the transgene into the genome, allowing for longer-lasting expression of JSRV 
Env. 
5.2.2.1 Construction of a lentiviral vector for JSRV Env expression 
The lentiviral vector system chosen to deliver JSRV Env was a third generation 
self-inactivating HIV system. This system consists of four plasmids that contain all 
the elements needed to create a lentiviral vector that is replication deficient and 
able to transduce cells at high efficiency. In this study, vectors were used that 
encode GFP (Miyoshi et al, 1998), JSRV Env (D. Griffiths unpublished) and a 
GFP-2A-Env fusion protein (D. Griffiths, unpublished) (see section 2.13 for 
details).  
5.2.2.2 Assessment of transfer plasmids 
As a first step to determine if the transfer plasmids created were able to drive 
expression of JSRV Env or GFP2AEnv in cell lines, these plasmids were 
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transfected into the easily transfected cell line 293T (section 2.8.1). In addition, 
other JSRV env or gfp encoding plasmids were transfected into cells to be used 
as positive controls (Table 5.2).  
Forty-eight hours after transfection, cells were harvested to perform cytospins 
(section 2.10.4) and protein extracts (section 2.19.1) to assess expression of 
JSRV Env and GFP by immunostaining and immunoblotting techniques (sections 
2.10 and 2.19).  
Table 5.2. Summary of plasmids transfected into 293T cells. 






pCMV2JS21 No No Yes Yes 
pCMV3-JSGPP No No Yes Yes 
pCMV2JSRV-GFP2A-
Env 
Yes Yes Yes Yes 
pCSC-GFP2AEnv Yes Yes Yes Yes 
pCSC-JSenv No No Yes No 
pEGFP-Flag Yes Yes No No 
pCSC-G Yes Yes No No 
Non- transfected No No No No 
 
Anti-JSRV SU immunostained 293T cells exhibited brown staining, indicative of 
JSRV Env expression, when transfected with plasmids pCMV2JS21 (not shown), 
pCMV3-JSGPP, pCMV2JSRV-GFP2A-Env and pCSC-JSenv (Fig. 5.2), albeit 
different levels of expression were observed, being the lowest in pCSC-JSenv 
transfected cells.  
When immunostained with anti-GFP antibody, 293T cells transfected with 2JSRV-
GFP2A-Env, pCSC-GFP2AEnv, pCSC-JSenv and pCSC-G (not shown) 
presented brown staining indicative of GFP expression (Fig. 5.2). These results 
were interpreted as specific because staining was not observed when cells 
transfected with any of the plasmids were incubated with an isotype control for 
anti-JSRV SU (mouse IgG) or anti-GFP (rabbit IgG).  
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JSRV Env and GFP expression in 293T cells was further analysed by western 
blotting (Fig. 5.3). Western blot for JSRV SU expression detected a band 
consistent with the expected size for JSRV SU (~ 49 kDa) in 293T cells transfected 
with JSRV env encoding plasmids: pCMV2JS21, pCMV3-JSdGPP, pCMV2JSRV-
GFP2A-Env, but not in pCSC-JSenv transfected 293T cells. These findings were 
consistent with the results of immunocytochemistry, which showed lower Env 
expression levels in pCSC-JSenv transfected 293T cells. A band of similar, but 
slightly smaller, size was detected in all samples, including the non-transfected 
negative control. A number of other bands were also detected in all samples 
analysed, indicating a high background staining level that is likely due to antibody 
cross-reactivity, further discussed in 5.3.  
Western blotting for detection of GFP expression in transfected 293T cells, 
revealed a band in protein extracts from 293T cells transfected with pCMV2JSRV-
GFP2A-Env, pCSC-GFP2AEnv, pEGFP-Flag and pCSC-G. The slightly different 
band sizes between samples are likely due to the form of GFP encoded by each 
of the plasmids: pCMV2JSRV-GFP2A-Env and pCSC-GFP2AEnv have an 
expected molecular GFP weight of ~35kDa, pEGFP-Flag of ~33kDa, and pCSC-
G of ~ 27kDa. Additional bands of lower molecular weight were detected in some 
samples. As these were only present in lanes containing samples expected to 
have GFP, they are likely to be cleavage products or truncated forms of GFP. 
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Figure 5.2. Immunostaining of transfected 293T cells with antibodies to GFP and JSRV 
SU. Top labels indicate the protein detected, labels to the left of the plot indicate the plasmid 
transfected into the cells. The presence of brown pigment indicates positive staining. 
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Figure 5.3. Western blot of extracts from 293T cells transfected with the indicated 
plasmids. A. Analysis of SU protein expression in transfected 293T cells. B. Analysis of GFP 
protein expression in transfected 293T cells. The red asterisks indicate the bands 
corresponding to the expected size of SU in panel A, and GFP in panel B.  
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Overall, these findings revealed that pCSC-GFP2AEnv was able to successfully 
drive expression of GFP and JSRV Env in 293T cells. On the other hand, pCSC-
JSenv was, unexpectedly, only able to drive low levels of JSRV Env expression 
in 293T cells. 
In order to investigate if the inability of pCSC-JSenv to drive efficient expression 
of JSRV Env was due to sequence mutations or errors introduced during the 
cloning process, DNA sequencing of pCSC-G, pCSC-JSenv and pCSC-
GFP2AEnv was performed (section 2.12.6). A mutation that disrupted a BglII 
restriction site in the backbone of the plasmid was found, indicating that the 
sequence for pCSC-G cited in the Addgene website contains inaccuracies; 
however, no mutations that could affect env transgene expression were detected.  
During the cloning process, other pCSC-JSenv plasmid preparations had been 
isolated from transformed E. coli clones (section 2.12), these were tested to 
investigate if any could drive JSRV Env expression in 293T cells more efficiently. 
The results of immunocytochemistry (Fig. 5.4) revealed similar and low JSRV Env 
expression efficiencies in all six plasmid preparations when transfected into 293T 
cells, confirming the results of (Fig. 5.2 and Fig. 5.3). Possible causes of inefficient 
JSRV Env expression from pCSC-JSenv are further discussed in 5.3.  
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Figure 5.4. Anti JSRV-SU staining of 293T cells transfected with six different plasmid 
preparations of pCSC-JSenv. A. p2953. B. p2954. C. p2955. D. p2956. E. p2957. F. 
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5.2.2.3 Transduction of cell lines with lentiviral vectors encoding JSRV 
Env 
Having confirmed that the transfer plasmid pCSC-GFP2AEnv was able to 
efficiently drive JSRV Env expression, and that pCSC-JSenv was also able to 
drive JSRV Env expression, albeit at low levels, production of lentiviral vectors 
was started. Lentiviral vectors were prepared using the four plasmid, 3rd 
generation system (section 2.13.2). The vectors produced encoded GFP, 
GFP2AEnv, or Env alone. 
Lentiviral vectors CSC-G, CSC-JSenv and CSC-GFP2AEnv, named after the 
transfer plasmid used for production, were used to transduce 208F cells and 
MDCK cells in culture (section 2.15). Using fluorescent microscopy, GFP 
fluorescence was observed in both cell lines transduced with CSC-G and CSC-
GFP2AEnv, as expected, suggesting that cells had been successfully transduced. 
Immunocytochemistry was performed to evaluate JSRV Env expression in 
transduced cell lines (Fig. 5.5) five days after transduction. 208F and MDCK cells 
transduced with GFP2AEnv expressed JSRV Env, as indicated by the presence 
of brown staining. CSC-G transduced cells did not express JSRV Env, as 
expected.  However, Env staining was also absent in cells transduced with CSC-
JSEnv. The reason for this is unclear but is consistent with the results of pCSC-
JSenv transfection in 293T cells (section 5.2.1). As CSC-JSenv did not drive 
expression of JSRV Env efficiently, it was excluded from further experiments.  
Importantly, CSC-GFP2AEnv was shown to transduce and drive efficient 
expression of GFP and JSRV Env in 208F and MDCK cells. GFP could, therefore, 
be used as transduction marker for this lentiviral vector. In addition, the present 
results suggested that the lentiviral vector system created was efficient at 
delivering and driving JSRV Env expression. 
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Figure 5.5. Immunostaining of transduced cell lines with an antibody anti-JSRV SU. The 
top labels indicate the cell line transduced, labels to the left indicate the lentiviral vector used 
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Titration of lentiviral vectors  
Titration of lentiviral vectors was performed by transducing 208F and MDCK cells 
and measuring GFP fluorescence by flow cytometry (section 2.16.1). Vector titre 
was greater for CSC-G than CSC-GFP2AEnv, and in 208F cells than MDCK cells 
(Table 5.4). These results reflect differences in lentiviral vector concentration as 
well as differences in susceptibility of each cell line to transduction.  
Table 5.3. Titre of lentiviral vectors in 208F cells and MDCK cells measured by flow 
cytometry.  
 Lentiviral vector 
Cell line CSC-G CSC-GFP2AEnv 
208F 2.32 × 106  TU/ml 1.58 × 106  TU/ml 
MDCK 1.22 × 106  TU/ml 4.98 × 105  TU/ml 
 
5.2.3 Transformation of transduced cell lines 
Having found an efficient system to drive JSRV Env expression in cell lines, I 
sought to investigate the transformation process. In order to investigate if 
transduction of 208F and MDCK cells with lentiviral vectors encoding JSRV Env 
was able to stimulate cellular transformation, 208F and MDCK cells were 
transduced with CSC-GFP and CSC-GFP2AEnv as above (5.2.2) at an MOI ~0.3, 
in 208F cells, and ~0.5 in MDCK cells, and maintained in culture with reduced 
serum media. The MOIs selected were the highest that could be used without 
inducing significant cytotoxicity. Cell morphology and GFP fluorescence were 
evaluated every three days by microscopy and any changes noted. GFP 
fluorescence observed in 208F (not shown) and MDCK cells transduced with 
CSC-G and CSC-GFP2AEnv, indicated cells had been successfully transduced 
(Fig. 5.6). 
In 208F cells, which were more sensitive to high MOIs, more dead cells were 
observed and fewer green cells. The percentage of cells expressing GFP was 
assessed by flow cytometry 3 days post-transduction and found to be ~ 40% in 
MDCK cells and ~25% in 208F cells transduced with CSC-G. When transduced 
with CSC-GFP2AEnv GFP-positive cells represented a ~35% in MDCK cells and 
~16% in 208F cells.  
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Figure 5.6. EGFP expression in transduced MDCKs 48 h after transduction. The labels 
above the panels indicate the lentiviral vector used for transduction. Differences in morphology 
can be observed: CSC-GFP2AEnv transduced MDCK cells appear more rounded than CSC-
G transduced cells. Images captured at 40x magnification.  
Seventeen days after transduction, morphological changes were observed in 
208F cells. The morphological changes observed consisted of focus formation, 
i.e., areas of increased cell density that protruded above the cell monolayer. 
Notably, these foci also exhibited GFP fluorescence. The changes observed were 
suggestive of transformation driven by JSRV Env, given that they were observed 
in CSC-GFP2AEnv transduced cells. A maximum of 5 foci per well, of a 24-well 
plate, were observed in CSC-GFP2AEnv transduced cells. No foci formation was 
observed in non-transduced cells or cells transduced with CSC-G.  
In order to isolate 208F transformed cells and create a pure culture of transformed 
208F cells, in which miRNA expression could be compared to non-transformed 
cells, individual foci were isolated and cultured with added conditioned media 
(section 2.15.1). Fluorescence and growth rate were monitored by microscopy. 
Three 208F foci were isolated and expanded in culture but new cells radiating 
from the original foci did not exhibit GFP fluorescence. In addition, immunostaining 
of the foci and cells growing from them (Fig. 5.7) revealed that these apparently 
transformed 208F foci did not express JSRV Env. Four weeks after transduction, 
foci detached from the culture plate and GFP fluorescence became fainter, foci 
did not keep on dividing. The three 208F isolated foci failed to keep dividing in 
culture and did not establish a pure culture of transformed 208F cells. Culture 
conditions might have had an effect on 208F foci growth, foci were small when 
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isolated and the medium used might have not fulfilled their growth requirements. 
In addition, it is possible that the isolated foci were a mix of transduced and non-
transduced cells, and non-transduced cells might have outgrown transduced cells. 
However, lack or loss of JSRV Env expression, the oncogene that supports 
increased growth, might also be the cause of their inability to keep expanding. 
These points will be further discussed in 5.3.  
 
Figure 5.7. Staining of transduced 208F cells with an anti-JSRV SU antibody. A. 208F 
focus isolated from culture and grow in a chamber slide, 16 days after isolation. B. 208F cells 
non-transduced. No brown pigment, indicative of positive staining was observed.   
Morphological changes were observed in MDCK cells 23 days after transduction 
with CSC-GFP2AEnv. In contrast, no morphological changes were observed in 
non-transduced MDCK cells. MDCK cells presented more subtle morphological 
changes, protuberant cells were observed as strings of cells across the culture 
plate, not organised in foci. These protuberant cells were invariably positive for 
GFP fluorescence, confirming they had been transduced by CSC-GFP2AEnv and 
suggesting they had also been transformed by JSRV Env. Immunostaining was 
performed in transformed cells and revealed the presence of JSRV Env.  
5.2.3.1 Cell sorting of transformed MDCK cells 
Transformed MDCK cells could not be easily isolated because they did not grow 
as discrete foci as did 208F cells. Therefore, cell sorting was performed in order 
to isolate transformed MDCK cells from the mixed population in culture. As 
transformed MDCK cells expressed GFP, this attribute was used to differentiate 
transformed cells from non-transformed cells by fluorescence activated cell 
sorting (FACS). 
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MDCK cells transduced with CSC-GFP2AEnv were maintained in culture with 
reduced serum media (section 2.15.1) until day 52 post-transduction. The cells 
were then harvested and prepared for FACS (section 2.17).  FACS was performed 
by Graeme Robertson and Robert Fleming (Roslin Institute). Non-transduced 
MDCK cells were used to determine gating parameters and a threshold to 
distinguish GFP-positive cells from GFP-negative cells was established (Fig. 5.8).  
Single GFP-positive cells were sorted directly into wells of four 96-well plates, with 
a single cell per well. GFP positive cells were also collected as a bulk population 
of sorted cells. The purpose of single cell isolation was to obtain clones with JSRV 
Env integrated in the same genetic location and therefore with less variability in 
expression.  
Single GFP-positive cells were expanded in culture (section 2.18) and their growth 
monitored by microscopy. The remaining bulk population of GFP-positive cells 
was seeded in two T-75 flasks. 
The bulk population of GFP-positive cells was assessed for JSRV Env expression 
by immunocytochemistry and western blotting (Fig. 5.9 and Fig. 5.10). 
Immunocytochemistry identified a small number of positively-staining cells, 
indicative of JSRV presence, close to the edge of the slide (Fig. 5.9) but not in 
cells observed in other areas of the slide. 
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Figure 5.8. Fluorescence activated cell sorting of MDCK cells. A. Gating of control MDCK cells. Cells were selected based on expected size (SSC 
vs. FSC) and fluorescence signal emitted detected in (SSC vs. FITC). Background MDCK fluorescence was established as threshold. B.  Sorting of CSC-
GFP2AEnv transduced MDCK cells. Cells were selected based on expected size. From the selected population two subpopulations can be seen, coloured 
in red and green, these cell populations differed in GFP expression levels, acquired as FITC-A.  The two populations can also be seen in the lower panel 
as two peaks corresponding to two levels of fluorescent signal acquired as FITC-A. 
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Western blot analysis indicated that 293T cells transfected with plasmids encoding 
JSRV Env yielded a band corresponding to the expected size of SU (~49 kDa). 
However, the intensity of the band was faint in some of the samples, indicating 
poor expression in those samples. A band representing Env was not detected in 
either MDCK parental cells or the bulk population of cells, consistent with the low 
expression identified by immunocytochemistry. Interestingly, at the time JSRV 
Env expression tests were performed, the cells continued to express GFP, 
although GFP expression was lost weeks later. These results are further 
discussed in 5.3.  
 
Figure 5.9. Staining of MDCK cells with anti-JSRV SU antibody. A and B. Bulk population 
of GFP-positive cells sorted by FACS. C. Non-transduced MDCK cells used as negative 
control. D. 293T cells transfected with pCSC-GFP2AEnv used as positive control. Brown 





Chapter 5: microRNA dysregulation in in vitro and ex vivo OPA models 276 
 
Figure 5.10. Western blot of JSRV Env expression in transformed sorted GFP-positive 
MDCK cells and controls, using anti-JSRV SU antibody. Top labels indicate the plasmids 
used for 293T transfection or MDCK sample phenotype. The asterisk marks the region were 
a band corresponding to JSRV SU is expected to be detected. The two panels correspond to 
the same western blot, lanes not-relevant for this study were removed.  
In the four 96-well plates seeded with GFP-positive single cells, clones started 
expanding at different rates. Ten days after FACS, 12 wells had successfully 
expanded from single cells, and 28 days after FACS, a total of 72 clones had 
expanded from single cells. All these clones presented GFP fluorescence and 
were sequentially transferred to 12-well plates, 6-well plates, T-25 flasks and T-
75 flasks to keep on expanding their population. In order to assess JSRV Env 
expression in these clones, cells were harvested and seeded in chamber slides 
(section 2.10.5) and immunocytochemistry was performed one month after 
sorting.  
Of the 72 screened clones, nine stained positively for JSRV Env by 
immunocytochemistry (Fig. 5.11). The nine Env positive clones were kept in 
  
Chapter 5: microRNA dysregulation in in vitro and ex vivo OPA models 277 
culture and tested again for JSRV Env expression one week and two weeks later, 
in order to examine the stability of JSRV Env expression. Clones 1E5, 2E3 and 
3C9 were found to exhibit high levels of JSRV Env expression at all tested time 
points, whereas JSRV Env expression in the remaining six clones, including 1C9, 
was markedly reduced over this time period (Fig. 5.12).  
Interestingly, and contrary to what was expected, two of the clones with a high 
level of JSRV Env expression by immunocytochemistry: 2E3 and 3C9, exhibited 
a slower growth rate than other transformed clones and untransformed MDCK 
cells. The reason for this is unclear as all clones were grown under the same 
conditions, and other clones expressing JSRV Env seemed to grow at faster rates.  
In addition, the fact that some of the clones expressing GFP fluorescence did not 
express JSRV Env was intriguing. These findings are further discussed in 5.3. 
JSRV Env expression in clone 1E5 was reduced after 31 days in culture and being 
frozen and thawed once. JSRV Env expression in clones 2E3 and 3C9 was 
reduced after 51 days in culture and being frozen and thawed once. These 
findings indicated that JSRV Env expression could be observed in some MDCK 
clones over a month after cell-sorting, and almost 3 months after transduction, 
leaving an ample time window to perform in vitro experiments.  
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Figure 5.11. Staining of GFP-positive clones with anti-JSRV SU antibody. A to I. Nine 
clones found to express JSRV-Env. J. Control MDCK cells. Brown pigment indicates positive 
staining. 
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Figure 5.12. Staining of GFP-positive clones with anti JSRV-SU antibody after two 
weeks. A. Clone 1C9. B. Clone 1E5. C. Clone 2E3. D. Clone 3C9. E. Control non-transduced 
MDCK cells. Brown pigment indicates positive staining. Note that IC9 had no detectable JSRV 





Chapter 5: microRNA dysregulation in in vitro and ex vivo OPA models 280 
5.2.3.2 Characterisation of transformed MDCK clones 
Morphological changes were the first suggestion of transformation observed in 
MDCK cells in culture. The morphology of isolated clones was assessed and 
compared to non-transduced MDCK cells that had been grown in culture for the 
same length of time.  
Differences in shape and growth were observed when clones expressing JSRV-
Env were compared to MDCK cells. Regarding shape, cells appeared more 
irregular in shape compared to control cells, their growth was accelerated in some 
cases, and growing patterns became more irregular and protruding from the 
culture surface, illustrated in Fig. 5.13. In contrast, clone 1C9, which was found 
not to express JSRV Env, had a morphology closer to that of control MDCK cells 
but still retained some features in common to transformed clones. Clones 1E5, 
2E3 and 3C9, which did express Env, became more loosely attached to the 
surface of culture flasks. For example, during passaging the incubation time 
required for their detachment was ~10 minutes, whereas control MDCK cells and 
clones that did not express JSRV Env, such as 1C9, required ~20 minutes of 
incubation to be successfully detached. Moreover, transformed clones did not 
form a confluent monolayer but instead started overgrowing, indicating loss of 
contact-inhibition, another hallmark of transformation.  
 
Figure 5.13. Microscopy images of MDCK cells in culture. A. JSRV-Env expressing clone 
1E5, cell morphology appears more irregular and protruding areas are observed. B. Control 




Chapter 5: microRNA dysregulation in in vitro and ex vivo OPA models 281 
Transformation markers 
Morphological changes observed in clones were indicative of transformation. But, 
in order to investigate this further, markers associated with JSRV Env 
transformation were analysed in the clones.   
Phosphorylation of Akt and ERK1/2 proteins are known markers of JSRV Env 
transformation that have been detected in several JSRV Env transformed cell 
lines, including MDCK cells (sections 1.2.6 and 1.3.2). The presence of 
phosphorylated Akt and ERK1/2 in JSRV-Env expressing clones (1E5, 2E3 and 
3C9), a non-JSRV-Env expressing clone 1C9, and untransformed MDCKs was 
examined by immunocytochemistry. As the presence of FBS in culture medium is 
known to activate these transformation markers and potentially interfere with 
results, the clones and parent cells were FBS starved for 24 h before 
immunocytochemistry. Cells growing in the presence of FBS were used as 
positive controls for detection of phosphorylated Akt and ERK1/2 expression.  
Clones 1E5, 2E3 and 3C9 were found to stain positively for Akt-P and ERK1/2-P 
(Fig. 5.14) although the expression levels of these two markers were consistently 
different in all three clones. While expression of ERK1/2-P was detected in all 
cells, Akt-P expression seemed limited to a subpopulation of cells. 
Control MDCK cells and clone 1C9 did not exhibit activated forms of Akt, but low 
levels of phosphorylated ERK1/2 were observed, indicating background levels of 
this protein are present in these cells, further discussed in 5.3. These results 
indicated differences in transformation marker expression between JSRV-Env 
expressing clones and control cells, suggesting that JSRV Env expression had 
driven transformation of these cells and confirming their transformed state.  
Interestingly, the transformation markers were detected in cells even when JSRV 
Env expression was later markedly reduced.  Suggesting that although Env may 
have initiated transformation in these clones, it is not required to maintain the 
transformed phenotype. Nevertheless, it is possible that expression of the 
transformation markers might be reduced and, eventually lost, at later time points, 
similarly to the observations of clone 1C9.  
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Figure 5.14. Immunocytochemical analysis of Akt-P and ERK1/2-P expression in MDCK 
clones. Top labels indicate the protein detected, labels to the left indicate clone names. Brown 
pigment indicates positive staining.  
  
Chapter 5: microRNA dysregulation in in vitro and ex vivo OPA models 283 
5.2.3.3 miRNA expression in transformed clones 
The analysis of transduced MDCK cell clones suggested that come of them had 
retained Env expression and exhibited features expected of transformed cells (i.e., 
morphological changes and phosphorylation of Akt and ERK1/2). Next, 
expression of miRNAs in these clones was studied. To investigate if expression 
levels of miR-135b, miR-182, miR-183, miR-200b, miR-205, miR-21, miR-31, 
miR-503 and miR-96 were upregulated in JSRV Env transformed cells, RT-qPCR 
was performed on RNA from the high expressing JSRV Env clones (1E5, 2E3, 
3C9) to compare miRNA expression levels of these clones to control non-
transformed MDCK cells (section 2.6) (Fig. 5.15).   
The results of RT-qPCR indicated that transformed MDCK clones expressing 
JSRV Env presented a different pattern of miRNA expression compared to control 
MDCKs. Expression levels of miR-135b, miR-205, miR-21 and miR-31 were found 
to be increased in JSRV Env expressing clones, following the pattern observed in 
OPA lung tissue. However, miRNAs miR-182, miR-183, miR-200b and miR-503 
showed differential expression in the opposite direction to that observed in OPA 
lung tissue. No differential expression was detected for miR-96. These results 
suggest that expression of the tested miRNAs is altered in JSRV Env induced 
transformed MDCK cells. However, expression of some of the miRNAs does not 
follow the trend observed in lung tissue. These results may be related to multiple 
factors, and, in particular, the changes observed in tissue might reflect the 
complexity of the tissue made up from several different types of cells as opposed 
to the clonal epithelial cell lines used here. In addition, they may reflect species-
specific differences between the canine cell line and the ovine lung tumour.  
Differing results from in vitro and in vivo studies have been reported in the 
literature (discussed further in section 5.3).  
The experiments described above showed that although cell lines can be used to 
study Env transformation and miRNA expression, this approach is complicated by 
poor transfection efficiency and the instability of transformed clones. Potential 
reasons for this are discussed in section 5.3.  However, as the aim of this study is 
to identify an in vitro system that closely models the role of miRNAs in JSRV Env-
induced transformation, it is required to find an in vitro model that can reflect as 
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closely as possible in vivo early events of transformation. However, alternative 
approaches to establish an in vitro model for transformation were explored, 
including primary AT2 culture (5.2.4) and ovine lung slice culture (5.2.5). 
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Figure 5.15. miRNA expression in JSRV Env transformed clones (n=3) compared to 
control MDCK cells (n=1) measured by RT-qPCR.  A. Relative miRNA expression (-dCt= -
Ct miR+Ct miR-191) of each individual sample. Boxes show standard deviations of the mean, 
represented with a horizontal line.  B. log2(fold change) expression between transformed 
clones and control MDCKs calculated (section 2.6.2). Error bars indicate standard deviation 
within groups. 
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5.2.4 Isolation of type II pneumocytes 
As a second approach to develop an in vitro model that would resemble in vivo 
miRNA expression in the sheep lung, the culture of cells derived from sheep was 
explored.  
However, there are few established sheep cell lines currently available and those 
there are represent tissues other than the lung. Therefore, it was decided to 
attempt to establish primary sheep cell cultures from isolated type II pneumocytes 
(AT2), the target of JSRV in the sheep lung. If successful, such cultures would 
conceivably result in an in vitro model close to the in vivo situation. In addition, it 
could potentially allow for culture and replication of JSRV, a break-through that 
would facilitate further studies of infection and transformation not only using JSRV 
Env, but the whole virus. This would allow more detailed study of virus:host cell 
interactions during JSRV infection.  
Isolation and culture of AT2 cells is notoriously challenging due to their sensitivity 
to the isolation procedures and due to their propensity to lose differentiation state 
(Witherden & Tetley, 2001). In addition, protocols that have been successfully 
developed in one species may not transfer successfully to other species (Lee et 
al, 2018). In the present study, isolation of AT2 cells was performed from lambs 
with no known lung pathologies. From each lamb three lung tissue pieces of ~12 
cm3 were collected, submerged in ice-cold HBSS and transferred to the lab. In the 
lab, tissue pieces were cut into ~5 cm3 pieces. Isolation and culture of AT2 cells 
was performed a total of four times with cells from six animals, following an 
isolation protocol previously used for human lung AT2 cells (Witherden & Tetley, 
2001) (section 2.11).  
In the first isolation trial, cells from two lambs were used. At day 5, patches of cells 
of epithelial morphology became apparent in some wells (Fig. 5.16) suggesting 
that cells had been successfully isolated. Nevertheless, bacterial contamination 
was present in most wells, Gentamicin was added to the cultures (section 2.11) in 
an effort to stop bacterial growth. In successive isolations gentamicin was added 
to culture medium and solutions at all steps of the isolation and culture process. 
Another variation between AT2 isolation attempts were the selective attachment 
incubations, which varied between 40 minutes and 1:30 hours. Nevertheless, no 
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significant differences in cell yield were observed by increasing the incubation 
time.  
 
Figure 5.16. Microscopy images of cells isolated following an AT2 protocol at day 5. A 
and B cells isolated and seeded at high and low density respectively.  
5.2.4.1 Characterisation of isolated cells 
In order to investigate if the isolated cells were AT2 cells, they were tested for the 
presence of SP-C, a specific marker present only in AT2 cells. Cells were 
harvested 6 days post-isolation and cytospin preparations performed for 
immunocytochemistry (sections 2.10.4 and 2.10.6). 
The presence of brown staining indicated that a high proportion of the isolated 
cells presented SP-C (Fig. 5.17), suggesting that they were AT2 cells. The isotype 
control presented no brown staining, indicating that staining was specific. 
Variability in size and morphology could be observed in SP-C positive cells.  
The presence of SP-C in purified AT2 cell preparations indicated that the isolation 
and culture procedure had been successful. Cells obtained following the isolation 
procedure were counted before seeding and ranged between 4 × 107 – 1 × 108 
cells/ lamb. However, an issue encountered in all isolations performed occurred 
during the initial steps performed to wash off monocytes, erythrocytes and alveolar 
macrophages of sheep tissue. Installation of saline as described in the protocol 
did not render a pale section of tissue, and the erythrocyte count remained high. 
High erythrocyte concentration was observed throughout the isolation process 
and this interfered with the cell counts performed to determine the AT2 cells 
seeding concentration. These erythrocytes remained in culture until day four post-
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isolation, when a PBS wash was performed in the cell culture plates and most 
were washed off.  
In addition, the presence of erythrocytes interfered with results of immunostaining 
(Fig. 5.18). Brown staining indicating the presence of SP-C was observed in two 
different cell types: AT2 cells and anucleated cells of smaller size. In the isotype 
control, brown staining was observed only in the anucleated cells. Presence of 
these smaller cells is consistent with observations of erythrocytes in culture, and 
the brown staining observed is not specific, but a false positive result produced by 
the presence of endogenous peroxidases in erythrocytes.  
 
Figure 5.17. Immunostaining for AT2 cell markers in purified cells from sheep lung at 
day 6 post-isolation. A. anti-SP-C staining of purified cells.  B. Isotype control. Brown pigment 
indicates positive staining.  
In order to mitigate the effect of erythrocytes in the isolation, a method to 
selectively lyse them was tested (section 2.11) after removal of macrophages by 
incubating cells without FBS. Although erythrocyte lysis was successful and fewer 
numbers were observed in culture, the population of AT2 cells also appeared 
reduced, and many cells appeared dead. These findings might indicate that the 
lysis solution had a detrimental effect on the isolation process by also affecting 
AT2 cells. Nevertheless, as this process was only tested in one occasion, other 
factors such as the tissue status could have caused the low number of cells 
observed.  
To further confirm that the isolated cells were AT2 cells other markers could be 
used. For example, AT2 cells also produce alkaline phosphatase which can be 
tested in vitro, but expression is lost when they start differentiating.  
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Interestingly, although AT2 isolation was attempted with lung tissue from 6 lambs, 
cells were obtained from only four lambs in all the isolation attempts performed. 
Given that the same isolation protocol had been performed in all cases, these 
differences might be an indication of biological variability in AT2 cell numbers or 
their accessibility in the tissue. In addition, as may be seen comparing Fig. 5.17 
and Fig. 5.18, variability in SP-C staining of AT2 cells was observed. Cells from 
Fig. 5.17 appeared to present higher expression of SP-C even though they were 
tested at a later time point.  
 
Figure 5.18. Staining of sheep lung cells at four different points during type AT2 cell 
isolation with an antibody anti-SP-C. A. anti-SP-C staining of the cell suspension after 
filtration (40 µm) and centrifugation. B. anti-SP-C staining of the cell suspension after selective 
removal of macrophages. C. anti-SP-C staining of the cell suspension after selective removal 
of fibroblasts. D. anti-SP-C staining of isolated cells 4 days after isolation. 
5.2.4.2 Infection of type II pneumocytes with JSRV 
In general, a low number of cells were present in the initial days after isolation but 
the cell population increased over time in culture, reaching 80% confluency by day 
6. However, by day 7 morphological changes were evident: cell morphology 
became less regular, some cells became flattened and enlarged. Morphological 
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changes became more obvious in successive days and were suggestive of AT2 
cell dedifferentiation. In addition, immunocytochemical analysis revealed that by 
day 8 SP-C expression could not be detected in cells (Fig. 5.19). The time window 
in which the cell population had increased sufficiently but no dedifferentiation 
changes were observed was, therefore only 2 to 3 days. These circumstances 
made it difficult to perform infections in cells to determine if JSRV was able to 
infect and replicate, and if JSRV Env induced transformation could be achieved.  
 
Figure 5.19. Immunostaining for AT2 cell markers in purified cells from sheep lung at 
day 8 post-isolation. A. anti-SP-C staining of purified cells.  B. Isotype control. Brown 
pigment indicates positive staining. 
Nevertheless, JSRV infection of AT2 cells was attempted on two occasions. 
Infections were performed on day 6 with JSRV21 (i.e., replication-competent virus) 
and a replication-deficient JSRV reporter virus  (JSRV-GFP) (Szafran, 2014). This 
vector encodes EGFP under the control of a HCMV promoter and allows an 
assessment of the ability of JSRV to complete early steps in JSRV replication by 
quantifying GFP-positive cells. Three days post infection, fluorescence was 
detected in cells in all infected wells and controls, for both JSRV21 and JSRV-GFP, 
indicating that the signal was due to autofluorescence in the AT2 cells. The 
fluorescent signal appeared greater in some cells in wells infected with JSRV-GFP 
but the limited number of cells available precluded the possibility of quantifying 
this by flow cytometry. Further analysis of JSRV21-infected cells was also not 
performed due to the limited number of cells.  Autofluorescence increased over 
subsequent days and cells died in all wells at day 10, indicating that the 
autofluorescence observed might have been a marker of cytotoxicity.   
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Although the infection experiments did not provide useful data, this work did 
demonstrate that the AT2 sheep cell isolation can be performed successfully 
following a protocol used for human lung, and this is a valuable starting point for 
future studies. Nevertheless, the low cell yields obtained complicated the JSRV 
studies. In order to improve the yield of viable cells, further optimisation and 
adaptation of the protocol to the ovine lung would be needed, discussed in section 
5.3. Although this system has potential to be an ideal in vitro model of JSRV 
infection, technical limitations and limited time to complete this project led to a 
decision to explore other systems in which miRNA expression could be studied. 
For this reason, further experiments were performed using ovine lung slices.  
 
5.2.5 Lung slices as OPA model 
As a further approach to develop a model that could recapitulate changes in 
miRNA expression in OPA-affected lung tissue, the use of ex vivo cultured lung 
slices was explored. Precision cut lung slices are an ex-vivo model of sheep lung 
that has the advantages of incorporating signals not only from infected AT2 cells 
but also surrounding cells. In addition, the system had already been successfully 
established in our laboratory and JSRV had been shown to be able to replicate in 
this system (Cousens et al, 2015) (section 1.3.3).  
Lung tissue was obtained from lambs and lung slices prepared and grown in 
culture (section 2.20). The condition of the lung slices was assessed under the 
microscope and cilia movement in airways considered a sign of cell viability. Lung 
slices in culture were either transduced with lentiviral vectors or infected with 
JSRV.  
5.2.5.1 Transduction of lung slices with lentiviral vectors 
Lentiviral vectors were produced, concentrated and titrated in MDCK cells by flow 
cytometry (section 2.16.1). The titre of CSC-G was 1.6 × 105 TU/ml and for 4.5 × 
104 TU/ml for CSC-GFP2AEnv. Nevertheless, due to time constraints the titration 
of vectors was performed after the transductions had been performed.  
Because the titres of the lentiviral vectors were initially unknown, lung slices were 
transduced with equal volumes of CSC-G, CSC-GFP2AEnv or mock-transduced 
with concentrated supernatant of 293T cells (2.20.3). Lung slices transduced with 
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CSC-G were transduced at two different concentrations: either 4.8 × 103 CSC-G 
TU or 9.6 × 103 CSC-G per lung slice. Lung slices transduced with CSC-
GFP2AENV were transduced with either 1.35 × 103 CSC-GFP2AEnv TU or 2.7 × 
103 CSC-GFP2AEnv TU per lung slice. These two concentrations were used to 
assess whether JSRV Env expression in lung slices was correlated with vector 
concentration. CSC-G vectors and 293T supernatants were used as negative 
controls to differentiate miRNA expression changes induced by time in culture or 
response to the lentiviral vector, to those changes due to JSRV Env expression.  
Lung slices exposed to either CSC-G or CSC-GFP2AEnv had foci of green 
fluorescent cells when observed under the microscope, suggesting that transgene 
expression and transduction had occurred successfully. The size of some green 
foci increased with time in culture indicating that the cells were dividing.  
Lung slices were harvested at day 0, before transduction, and at day 8 and day 
18 after transduction (section 2.20.5). Four lung slices were harvested and pooled 
together as samples for immunohistochemistry (section 2.10). The process was 
repeated to obtain four lung slices as samples for western blot (section 2.19), and 
four lung slices for RNA extraction (section 2.4.5).  
Green foci were counted 12 days after transduction (Table 5.4) and the number 
of green foci counted used to assess differences in transduction between the two 
concentrations used. Lung slices that had been exposed to either CSC-G or CSC-
JSenv had a greater number of green foci when transduced with a higher 
concentration of vector. In both cases, doubling the lentiviral vector input resulted 
in a 33% increase in the number of transduced foci. These differences suggested 
that the number of transduced cells could be increased further by increasing the 
amount of lentiviral vector particles used. However, the lowest concentrations of 
both vectors appeared to have the most favourable yield of transduced foci, as 
measured by the number of foci per TU. This unexpected result might be due to 
saturation of accessible and susceptible cells, or due to cytotoxicity of the vector 
at higher concentrations.  
The difference in total number of foci between CSC-G and CSC-GFP2AEnv 
transduced lung slices was found to be statistically significant (T-test p< 0.05). 
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However, this may also be due to the different concentration of lentiviral vectors 
used. 
Table 5.4. Number of green foci in  lung slices 12 days after transduction.  
 
CSC-G 
(4.8 × 103 TU) 
CSC-G 
(9.6 × 103 TU) 
CSC-GFP2AEnv 
(1.35 × 103 TU) 
CSC-GFP2AEnv 

























6 12 5 5 
5 13 3 6 
5 11 5 4 
10 8 4 5 
16 9 3 3 
9 7 1 4 
12 8 3 3 
5 19 2 5 
4 15 5 3 
8 7 4 6 
7 8 3 6 
10 13 5 8 
 
Average number of foci 
8.1 10.8 3.6 4.8 
Total number of foci 
97 130 43 58 
Number of foci per 103 TU of vector 
20.21 13.54 31.85 21.48 
 
JSRV Env expression in transduced lung slices 
In order to assess JSRV Env expression in transduced lung slices, 
immunohistochemistry was performed with samples harvested at day 8 and day 
18 (section 2.10). JSRV Env expression was not detected in any CSC-GFP2AEnv 
transduced slice at day 8, while at day 18, JSRV Env was detected in one of the 
transduced four lung slices (Fig. 5.20). As expected, JSRV Env was not detected 
in any CSC-G or mock-transduced lung slice. Isotype controls showed no brown 
pigment, indicating specificity of brown staining for JSRV Env presence.  
Because the lentiviral vectors used are able to drive JSRV Env expression in 
several cell types efficiently, a higher percentage of JSRV Env expressing cells 
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was expected than was observed. The results presented here might be due to the 
low concentration of the lentiviral vectors used. As seen in the number of green 
foci detected, increasing the vector concentration results in an increase of 
transduced foci. Nevertheless, the present system is at best semi-quantitative, so 
the effects of lentiviral concentration on JSRV Env expression should be further 
investigated.
 
Figure 5.20. Staining of transduced lung slices at day 18 with anti-JSRV SU antibody. 
Top labels indicate the vectors used for transduction, labels on the left indicate the 
magnification used. Brown pigment indicates positive staining. Arrows indicate foci with 
positive staining.  
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miRNA expression in transduced lung slices 
Despite the low number of positively transduced foci per slice, miRNA expression 
was evaluated from samples at day 8 and day 18 post-transduction to compare 
between CSC-C, CSC-GFP2AEnv and mock-transduced lung slices. This 
comparison aimed to identify miRNA expression changes due to JSRV Env 
expression.  
Expression levels of miR-135b, miR-182, miR-183, miR-200b, miR-205, miR-21, 
miR-31, miR-503 and miR-96 were assessed by RT-qPCR. Levels of miRNA 
expression of CSC-G transduced lung slices and CSC-GFP2AEnv transduced 
lung slices were compared to miRNA expression in mock-transduced lung slices.  
At day 8, differences in miRNA expression were observed between lung slices 
transduced at high and low concentrations of CSC-G and CSC-GFP2AEnv (Fig. 
5.21). However, expression levels of all the miRNAs tested, with the exception of 
miR-135b, were similar between CSC-G and CSC-GFP2AEnv transduced lung 
slices. miR-135b appeared downregulated in CSC-GFP2AENV transduced lung 
slices in comparison to mock-transduced (not represented) and CSC-G 
transduced lung slices at high concentration.  
At day 18, similar miRNA expression patterns were observed in lung slices 
transduced with low and high concentration of the vectors, but fold change 
differences were higher in lung slices exposed to the higher concentration (Fig. 
5.22). No differences in miRNA expression were observed between CSC-G and 
CSC-GFP2AEnv transduced lung slices, with the exception of miR-135b and miR-
200b. Comparing findings at day 8 and day 18, most miRNAs followed the same 
expression trend, with the exception of miR-135b.  
These findings indicated that there were differences in miRNA expression levels 
in lentiviral vector transduced lung slices compared to mock-transduced lung 
slices. However, in most cases, no differences in expression were observed 
between those transduced with CSC-G and CSC-GFP2AEnv, suggesting that the 
observed miRNA expression changes is caused by the lentiviral transduction and 
not by JSRV Env expression. Notably, the miRNA expression pattern in 
transduced lung slices did not mirror than of infected lung tissue. This difference 
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in miRNA expression between transduced lung slices and lung tissue could be 
due to a number of factors: miRNAs might become upregulated later on the 
transformation process or other proteins of JSRV might also play a role in their 
upregulation. In addition, these results seemed to indicate that expression of miR-
135b was the most variable under the present transduction and culture conditions. 
In order to further investigate if the changes in miR-135b observed were related 
to JSRV Env expression, and to address the role of other JSRV proteins in miRNA 
expression changes, further experiments were performed with JSRV21.  
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Figure 5.21. miRNA expression at day 8 in transduced lung slices with CSC-GFP2AEnv 
and CSC-G.  The figure shows miRNA expression relative to mock-transduced lung slices (not 
represented) measured by RT-qPCR.  A and B. log2(fold change) expression of transduced 
lung slices with low (A) and high (B) concentrations of lentiviral vectors. 
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Figure 5.22. miRNA expression at day 18 in transduced lung slices with CSC-GFP2AEnv 
and CSC-G. The figure shows miRNA expression relative to mock-transduced lung slices (not 
represented) measured by RT-qPCR.  A and B. log2(fold change) expression of transduced 
lung slices with low (A) and high (B) concentrations of lentiviral vectors. 
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5.2.5.2 Infection of lung slices with JSRV21 
In order to address the possibility that miRNA changes had not been observed 
due to other JSRV proteins playing a role in upregulation of the tested miRNAs, 
infections with JSRV were performed. In addition, lung slices from two lambs were 
used to assess the effect of biological variation and perform statistical tests.   
JSRV21 was produced in vitro by transient transfection of 293T cells, and 
concentrated by ultracentrifugation. As there is no permissive cell line for JSRV 
replication, it is not possible to determine the infectious titre. Therefore, the virus 
was quantified by assaying for reverse transcriptase activity (section 2.20.5). As 
a negative control, lung slices were mock-infected with concentrated 293T 
supernatant, the cells used to produce the virus.  
JSRV (10.5 ng RT/slice) was used to infect lung slices in culture (section 2.20.4). 
The viability of lung slices post-infection was assessed by microscopy: cilia 
mobility was considered a sign of good viability, whereas detachment of cells from 
the lung slices and media acidification were considered signs of a poor lung slice 
status. Infected and mock-infected lung slices presented good viability.  
Lung slices were harvested at day 0, before infection and day 10 after infection 
(section 2.20.5). At each time point, four lung slices were collected for 
immunohistochemistry, and four lung slices collected for RNA extraction. 
Supernatant from lung slices was also collected to measure JSRV presence by 
RT-qPCR (section 2.20.5.1).  
JSRV Env expression in infected lung slices 
To assess JSRV Env expression in infected lung slices, immunohistochemistry 
was performed (section 2.10) with samples harvested at day 10 after infection.  
In lung slices infected with JSRV a small number of foci of cells expressing JSRV 
Env was found (Fig. 5.23). The brown staining observed was only observed on 
cells on the periphery of the slices and not on cells in the interior of the slice. No 
brown staining indicative of JSRV Env expression was detected in mock-infected 
lung slices or in cells treated with the isotype control antibody.  
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Similar to lentiviral vector transduced lung slices, the number of foci staining 
positive for JSRV Env represented a low percentage of the tissue. Lentiviral 
vectors are able to infect and potentially drive protein expression in several cell 
types of the lung slices due to JSRV env expression being driven by a CMV 
promoter, which was expected to result in a higher number of cells expressing 
JSRV Env. In contrast, JSRV can only efficiently express its proteins in AT2 cells 
but is able to replicate, meaning that re-infection is possible.  
In order to investigate if JSRV expression could be detected in lung slices and if 
replication had occurred, RT-qPCR was performed to detect JSRV expression 
(section 2.20.5.1) in the supernatants of lung slices and controls.  
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Figure 5.23. Staining of lung slices at day 10 post-infection with anti-JSRV SU antibody. 
Top labels indicate the lamb from which lung slices were derived, labels on the left indicate 
the virus used for infection. Arrows identify areas in which brown pigment was observed. 
Brown pigment indicates positive staining.  
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The results of RT-qPCR (Table. 5.5) indicated that JSRV was present in the 
supernatant of lung slices of both lambs at day 10. Compared to the positive 
controls used, higher Ct values were obtained, indicating a lower concentration of 
JSRV. Nevertheless, when comparing these results, it needs to be considered 
that the input virus is a concentrated stock produced from 293T cells, where more 
than 50% of the cells in culture are producing virus. In lung slices, only a small 
number of cells produce virus. JSRV was not observed in the supernatant of lung 
slices before infection or in mock-infected lung slices. These results suggested 
that JSRV had successfully replicated in the lung slices and had been released to 
the medium. It could be argued that presence of JSRV in supernatants might be 
residual from the initial inoculate. However, supernatants had been collected 10 
days after infections and medium changes performed every day since infection, 
making the JSRV expression observed unlikely to originate from the inoculate. In 
addition, previous work (Cousens et al, 2015) suggested that all input virus was 
undetectable at day 4 post-infection.  




JSRV21 virus preparation 14.01 
Lung fluid 16.38 






 Supernatant before infection 40 
Supernatant day 10- JSRV21 infected 23.85 






 Supernatant before infection 40 
Supernatant day 10- JSRV21 infected 22.87 
Supernatant day 10- Mock infected 40 
 
miRNA expression in transduced lung slices 
Having successfully detected the presence and replication of JSRV in lung slices, 
albeit with only a small number of positive foci, RT-qPCR was performed to study 
miRNA expression. In order to compare miRNA expression in infected lung slices, 
RNA was prepared and expression levels assessed by RT-qPCR (method). 
miRNA expression in lung slices infected with JSRV or mock-infected were 
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compared to miRNA expression in lung slices before infection.  The use of mock-
infected lung slices controlled for miRNA changes occurring due to lung slices 
aging in culture.  
Levels of miRNA expression in lung slices of Lamb 1 and Lamb 2 (Fig. 5.24) 
presented in some cases differences, most notable in expression levels of miR-
135 and miR-503. Levels of all tested miRNAs changed compared to miRNA 
levels before infection (Fig. 5.24). However, levels of miRNA expression were 
similar in mock-infected and JSRV-infected lung slices. These findings indicated 
that miRNA expression changed with time in culture, maybe due to lung slices 
aging.  
In addition, the results indicated that the infection conditions used did not alter 
miRNA expression by day 10. Lack of miRNA expression changes in infected lung 
slices might be due to several factors: because few cells were seen to express 
JSRV Env it could be that miRNA expression changes due to aging in culture 
might have masked miRNA expression changes due to JSRV infection. It might 
also indicate that miRNA changes do not occur shortly after infection but later on, 
after other molecular events.  
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Figure 5.24. miRNA expression in lung slices at day 10 post-infection, compared to 
miRNA expression at day 0 (not represented) measured by RT-qPCR.  A. Relative miRNA 
expression (-dCt= -Ct miR+Ct miR-191) of lung slices infected with JSRV (n=2) and mock-
infected (n=2). Boxes show standard deviations of the mean, represented with a horizontal 
line. B. log2(fold change) expression between JSRV and mock-infected lung slices at day 10 
compared to day 0, calculated as explained in section 2.6.2. 
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5.2.5.3 Infection of lung slices with JSRV21- study 2 
In order to investigate if the lack of miRNA changes in JSRV infection were due 
to the low number of JSRV Env expressing cells or due to the time window 
selected to analyse miRNA expression, another experiment was performed.  
To address whether low levels of infection were responsible for the results 
obtained, JSRV concentration in lung slices was increased, expecting it would 
have an effect in the number of infected cells. To address whether 10 days were 
insufficient to observe miRNA expression changes in JSRV infection, sample 
points were increased. 
Lung slices from three lambs were used and infected with 143.52 ngRT, 13.7-fold 
more JSRV than used in the previous study, as measured by RT-assay (section 
2.20.5.2). In addition, the initial infection time was increased from 24 h to 48 h and 
medium changes were performed every two days instead of every day to increase 
chances of re-infection. As before, a parallel series of lung slices was treated with 
293T supernatant to provide a mock-infected control. Samples for 
immunohistochemistry, RNA extraction and western blotting were collected before 
infection and at day 7, day 14 and day 28 post-infection.  
Lung slices were observed under the microscope every day to assess their 
viability. From day 10 after infection, the viability appeared to decrease both in 
JSRV infected and mock-infected lung slices, cells detached from the tissue slice 
at an increased rate and the culture medium became a yellowish colour, indicating 
acidification. These changes had not been observed in published studies until day 
21 in culture (Cousens et al, 2015) (section 1.3.3), suggesting that the culture 
conditions had accelerated aging and degradation of the lung slices. Because the 
main change performed was the frequency of medium changes, exhaustion and 
acidification of the culture medium might have been responsible for the 
degradation observed. From day 14 after infection, the culture medium volume 
was doubled to avoid exhaustion. However, progressive degradation was 
observed and the experiment was ended at day 28, but no immunocytochemistry 
samples could be collected at this point due to extensive degradation.  
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JSRV Env expression in infected lung slices 
In order to determine if increasing JSRV concentration in infection had caused an 
increase in cells expressing JSRV Env, immunocytochemistry was performed with 
samples taken before infection, and at day 7 and day 14 after infection.   
The results of immunohistochemistry revealed that brown staining indicative of 
JSRV Env was present at day 7 and day 14 after JSRV infection of lung slices 
from lambs 3, 4 and 5. In contrast JSRV Env was detected in lung slices from 
lambs 2 and 3 infected with JSRV only at day 7 after infection. Therefore, the 
increase in virus inoculum did not result in the expected increase in JSRV-positive 
cells compared to the previous experiment. In fact, in lambs 2 and 3, infection was 
lower than in previous studies. Fig. 5.25 is a sample of the immunohistochemistry 
results obtained, and shows the foci with the greatest positive staining at each 
time point. Mock-infected lung slices of all lambs were negative for JSRV Env 
presence as expected, as were isotype controls, indicating specificity. Positive 
controls of JSRV Env presence (Fig. 5.25) presented brown staining as expected.  
These findings indicated that increasing JSRV concentration during infection did 
not result in an increased number of cells expressing JSRV Env. These results 
added to differences in cells expressing JSRV Env between lambs, suggested 
that the frequency of JSRV Env expressing cells was not directly correlated to 
JSRV concentration, but could be related to biological variability in susceptible 
cells. This and alternatives to increase JSRV Env expression will be further 
discussed in 5.3.  
miRNA expression in these samples was not measured due to the low number of 
cells expressing JSRV Env and the lung slice degradation observed, which could 
have masked changes in miRNA expression by the low number of JSRV Env 
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Figure 5.25. Staining of lung slices and controls with anti-JSRV SU antibody. Top labels 
indicate the virus used to infect lung slices, the labels to the left indicate sampling time points 
post-infection. G. lung tissue from a natural OPA case. H. Lung slice from a previous infection. 
Arrows indicate areas with brown pigment. Brown pigment indicates positive staining.  
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5.3 Discussion 
The ultimate aim of this chapter was to explore the role of miRNAs that are 
upregulated in OPA lung tissue, in JSRV Env mediated transformation. 
Nevertheless, to achieve this, an in vitro model that would allow the study of 
miRNAs had to be established. Initially, previously established JSRV Env 
transformation models were explored. However, cell lines were not efficiently 
transfected, which ruled out analysis of miRNA changes mediated by JSRV Env. 
The use of lentiviral vectors proved to be an efficient delivery system of JSRV Env, 
but transformed cells were unstable and did not reflect miRNA expression 
changes observed in lung tissue. To obtain an in vitro model that would more 
closely reflect changes in the OPA lung, sheep AT2 cells were isolated from sheep 
lung and cultured. The isolation process was successful, but due to low yield and 
cell dedifferentiation the system could not be used to study JSRV infection. Ovine 
lung slices were then explored as an ex vivo model of JSRV infection. Infection of 
lung slices was successful but, it appears that due to the small number of foci 
expressing JSRV Env, miRNA changes due to JSRV Env expression were not 
observed. Increasing JSRV concentration did not result in an increase in JSRV 
Env expression, indicating that availability and susceptibility of AT2 cells might be 
the limiting factor. Overall, this chapter has applied new and established 
approaches to study JSRV Env transformation to the study of miRNA expression. 
However, further work is required to establish a model in which miRNA changes 
associated to JSRV can be studied.  
5.3.1 JSRV Env transformation of cell lines 
Transformation of in vitro cultured cell lines with oncogene-carrying retrovirus is a 
long-standing technique used in the study of these virus. In the JSRV field, this 
approach has been used to establish the role of Env and determine some 
activated pathways. However, when transfection was used to deliver plasmids 
encoding JSRV Env into cell lines no transfection was achieved. Cell lines 
transfected with JSRV env encoding plasmids expressed JSRV Env in only a low 
percentage of cells, suggesting the transfection efficiency was suboptimal. The 
efficiency of three transfection methods was assessed in MDCK and NIH 3T3 
cells, and nucleofection was found to be the method with the highest efficiency. 
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Nevertheless, transfection efficiency was markedly reduced when plasmids 
encoding JSRV Env, rather than pGFPmax, were used to transfect cells. 
Subsequently, Induction of transformation by JSRV Env was successfully 
achieved using lentiviral vectors to deliver JSRV env into MDCK and 208F cells. 
Lentiviral vectors encoding gfp2Aenv or env were produced, and their ability to 
drive GFP and Env expression assessed in 293T cells by immunostaining and 
immunoblotting. Whereas immunostaining of JSRV Env with an anti-JSRV SU 
antibody appeared specific, the use of the same antibody to validate findings by 
western blot resulted in background unspecific staining of JSRV Env. Because in 
immunostaining the proteins are in their native state and in immunoblotting the 
proteins assessed are denatured proteins, these findings might indicate that the 
anti-JSRV SU antibody used recognises a specific protein conformation or part of 
a sequence that is close in space, but not in the primary protein sequence.  
Whereas pCSC-gfp2Aenv was found to efficiently express GFP and Env in 
transfected 293T cells, pCSC-JSenv only elicited expression of JSRV Env in a low 
proportion of cells in culture. Because transfections were performed 
simultaneously with pCSC-GFP2AEnv, which resulted in high expression of JSRV 
Env, the transfection process was not likely to be the cause of it. A possibility is 
that insertion of the env ORF into the CSC backbone allowed for unanticipated 
splicing that prevented expression of the full-length env transcript. This hypothesis 
could be tested by performing an RT-qPCR or northern blot and looking for 
expression of transcripts of different length. However, if that is the explanation it 
is unclear why it did not affect expression in GFP2AEnv.  
CSC-GFP2AEnv was used to transduce MDCK and 208F cells and morphological 
changes consistent with transformation events observed between 2-3 weeks after 
transduction. Transformed 208F cells presented foci formation and GFP 
expression, these foci were expanded in culture but cells growing from them were 
not GFP or JSRV Env positive, indicating that they had lost expression of the 
transgenes.  
Transformed MDCK cells were sorted based on their expression of GFP. Sorted 
clones were successfully expanded in culture from single cells expressing GFP, 
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and their JSRV Env expression assessed by immunocytochemistry. Nine clones 
were found to express both JSRV and GFP and of those, three expressed JSRV 
Env in most of the cells tested. Interestingly, two of the clones presented a slower 
growth rate than other clones or parental MDCKs. These findings could be due to 
differences in the site of insertion of the transgene, or due to heterogeneity of 
MDCK cells (Arthur, 2000). Interestingly, the loss of JSRV Env expression was 
also observed in some of the clones. Because the construct GFP2AEnv is under 
control of the same promoter (CMV) and expressed as a single mRNA, GFP 
expression was expected to be indicative of JSRV Env expression. It has been 
reported that use of the self-cleaving peptide P2A does not result in 100% efficient 
cleaving, which might result in protein forms that are not functional (Cai et al, 
2017b), and the first protein in the transcript being expressed more efficiently than 
the second one (Liu et al, 2017). These might explain differences in expression 
levels between GFP and JSRV Env. However, this would appear to be unlikely to 
explain the total lack of JSRV Env expression. Another possibility is that splicing 
variants might exist for the produced mRNA, resulting in functional and non-
functional versions of JSRV Env, and these splicing variants might be expressed 
in MDCK cells. Expression of JSRV Env might represent a burden to the cells and 
cells expressing it might have been negatively selected. The presence of splicing 
variants of the gfp2Aenv in transduced MDCK cells could be tested for by RT-
qPCR or northern blot.  
Another possibility is the accumulation of point mutations in the JSRV env gene 
inserted in MDCKs, which could result in a non-functional version of the protein 
while not affecting GFP expression. If JSRV Env is cytotoxic to MDCK cells these 
mutations could confer a selective advantage. This hypothesis could be tested by 
performing DNA extraction from the clones and performing a PCR to amplify the 
JSRV env gene, the amplified gene could then be sequenced and mutations 
identified. 
The three clones were assessed for presence of transformation markers and were 
found to present Akt-P and ERK1/2-P, markers of JSRV Env driven 
transformation. These results indicated that MDCK cells had successfully been 
transformed with JSRV Env. The expression pattern of ERK1/2-P and Akt-P was 
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found to be different in the transformed clones, since ERK1/2-P was expressed 
by all cells and Akt-P only by a subpopulation. These findings are in contrast with 
studies of transformation in JSRV-infected lung slices and OPA lung tissue, in 
which Akt-P is detected in more cells and more intensely than ERK1/2-P (Cousens 
et al, 2015). These differences might indicate that the importance of these 
signalling pathways in JSRV Env transformation is species dependent. Another 
explanation is that activation, transduction and transformation with JSRV Env 
might present signalling differences compared to infection and transformation with 
the whole JSRV virus; other viral proteins might play a role in signalling in sheep.  
5.3.2 miRNA expression in transformed MDCK clones 
Expression of upregulated miRNAs in OPA lung tissue was measured in 
transformed clones and compared to miRNA expression in parental MDCKs. 
Differences in expression were found between transformed clones and parental 
MDCKs, these differences are likely to reflect the effects of JSRV Env 
transformation in MDCKs. Nevertheless, expression of some tested miRNAs did 
not follow the same upregulation pattern observed in OPA lung tissue. Although 
further testing would be needed to achieve better representation of miRNA 
expression in MDCKs, there are several factors that could explain the difference 
in miRNA expression between transformed MDCKs and OPA lung tissue. MDCK 
cells are a cell line derived from dog cells, but sheep are the natural host of JSRV, 
so there might be species differences in miRNA response to JSRV Env 
expression. This explanation is consistent with the observation that JSRV Env 
activates different signalling pathways depending on cell type (Hofacre & Fan, 
2010; Liu & Miller, 2007). Another potential reason for differences in miRNA 
expression is that MDCK cells represent only one cell type, whereas lung tissue 
is a complex tissue made up from diverse cell types, which includes not only 
infected and transformed cells but also cells responding to transformation such as 
macrophages. Differences between miRNA expression in tissue and cell lines 
have been reported (Dambal et al, 2015; Patnaik et al, 2012). In addition, culture 
conditions have the potential to alter the expression levels of certain miRNAs, and 
a study found that the use of FBS could interfere with miRNA detection in 
extracellular vesicles (Ikari et al, 2015; Kuosmanen et al, 2017; Wei et al, 2016). 
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Expression of miR-200b was markedly different between transformed MDCK cells 
and OPA tissue. miR-200b is a miRNA involved in EMT. MDCK cells have been 
widely used to study EMT, and it has been shown that activation of the MAPK 
pathway in these cells causes autocrine production of TGF-β (Lehmann et al, 
2000). Synergistic action between TGF-β and ERK MAPK promotes phenotypic 
changes in the cell, from epithelial to mesenchymal (Nicolas et al, 2003). 
Therefore, it might be possible that miR-200b is different between transformed 
MDCK cells and OPA lung tissue due to differences in EMT activation. 
Transformed MDCK cells might be undergoing EMT, whereas OPA tumours in 
lung tissue are not usually highly invasive or undifferentiated, suggesting that they 
might not be undergoing EMT.  
In summary, MDCK cells did not replicate miRNA expression seen in sheep lung, 
but they may be a useful model for investigating miRNAs with similar expression 
levels to sheep lung. In that case, levels of specific miRNAs could be knockdown 
or overexpressed to study their effect in JSRV Env transformation. In addition, 
targets of specific miRNAs could be investigated by performing reporter assays or 
approaches such as CLASH-seq (section 1.5.3).  
5.3.3 Isolation and culture of AT2 cells 
An alternative approach to develop an in vitro system for studying miRNAs in Env-
mediated transformation, the isolation and culture of ovine AT2 cells was 
attempted. Such a system might resemble the events of natural infection more 
closely than MDCK and other cell lines, and help address the issue of species 
specificity. Isolation of AT2 cells is known to be challenging, and methods that 
work in one species such as mice, might not work in sheep. Here a method 
previously used for human lung was selected. Isolation of AT2 cells was 
successful as confirmed by the presence of SP-C in isolated cells. However, the 
number of cells obtained during the isolation process was low and this was an 
impediment to performing infections with JSRV in the short time window before 
dedifferentiation of the cells. One issue was the presence of erythrocytes that 
were not successfully removed from culture, which interfered with cell counts and 
identification. In addition, the low yield of AT2 cells might also be due to the 
isolation process performed. The protocol performed was optimised for the use of 
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human AT2 cells and there might be differences in tissue structure between sheep 
and human that make the protocol used not optimal for the release and isolation 
of sheep AT2 cells. Isolation of AT2 cells from normal and tumour tissue of sheep 
lung has been reported in a study (Archer et al, 2007). However, the study was 
centred on isolation of tumour AT2 cells and reported that AT2 cells from normal 
lung tissue could be maintained in culture for less than 10 days. In addition, SP-C 
expression was tested only 4-7 days after isolation. Review of the isolation 
protocol in that study revealed no selective adherence steps, which could result 
in isolation of other cell types. The study found that JSRV could be detected in 
AT2 tumour-derived cells in culture, but expression of JSRV was lost after ~5 
passages. The authors reported that JSRV expression in AT2 cells was extended 
when cells were cultured in 3-D, consistent with previous findings (Johnson & Fan, 
2011).  
A recently published study reported a protocol for the isolation of bovine AT2 cells 
(Lee & Chambers, 2019; Lee et al, 2018). This protocol for AT2 cell isolation might 
be better adapted for sheep than the human lung isolation protocol, due to 
expected similarities between lung tissue of ruminant species. The article also 
reported dedifferentiation of AT2 cells, but culture in matrigel resulted in formation 
of structures similar to alveoli.  
Future work would be important to compare the protocols of Lee et al (2018)with 
that used in the present study (Witherden & Tetley, 2001). In addition, isolation of 
AT2 cells could be optimised to improve cell yields and perform infections with 
JSRV. However, the effect that JSRV infection would have on these cells in in 
vitro culture remains unknown. Improved cell yields would also permit the use of 
3D culture systems in matrigel or prefabricated scaffolds (reviewed in Duval et al 
(2017)). 3D culture has been previously used to culture both cell lines and primary 
cells (Elia & Lippincott-Schwartz, 2009; Gkatzis et al, 2018; Johnson & Fan, 2011) 
and has been able to maintain cell polarity and adhesion for extended periods of 
time (Baker & Chen, 2012). Nevertheless, the culture of cells in 3-D remains low-
throughput and standardisation more troublesome (Duval et al, 2017). 
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5.3.4 miRNA expression in lung slices transduced with JSRV 
Env encoding vectors 
As previous work had confirmed that JSRV can infect and transform cells in lung 
slices, dysregulation of miRNAs in response to JSRV Env was investigated in lung 
slices in culture. Lentiviral vectors encoding gfp or gfp2Aenv were used to 
transduce lung slices in culture. Immunostaining revealed that the vector CSC-
GFP2AEnv was able to drive expression of JSRV Env, but only in a low number 
of cells within each lung slice. miRNA expression in CSC-GFP2AEnv transduced 
lung slices was compared to expression in control mock-transduced and CSC-G 
transduced, lung slices at two different time points. Differences in miRNA 
expression were found between mock-transduced and lentiviral vector transduced 
lung slices, indicating miRNA expression changed in response to lentiviral vectors. 
However, no significant differences in expression were found between the 
miRNAs assessed in the two groups at the two different time points. Low lentiviral 
vector titres and JSRV Env expression might be the reason why no changes were 
observed between them. Nevertheless, miRNA expression changes triggered by 
a lentiviral vector encoding JSRV Env might differ from those triggered by the 
whole length virus.  
5.3.5 miRNA expression in JSRV-infected lung slices 
In order to evaluate if infection of lung slices with JSRV induced the miRNA 
expression pattern observed in OPA lung tissue, infections with JSRV and 
JSRVGFP were performed. Immunostaining revealed that JSRV infection had 
been successful at driving JSRV Env expression in cells. However, as with 
lentiviral transduction, only a very small number of cells expressed JSRV Env. 
miRNA expression in infected and mock-infected lung slices at day 10 post-
infection was compared to miRNA expression before infection to identify changes. 
Expression levels of the tested miRNAs at day 10 were found to be altered in 
comparison to levels before infection. However, miRNA expression levels were 
not found to be different between JSRV infected and mock-infected lung slices, 
indicating that the changes were likely a result of lung slices aging in culture. 
These findings might suggest that the expression levels of the miRNAs tested 
does not change in early events of transformation in infected cells, miRNA 
expression changes in OPA lung tissue might occur later on in transformation or 
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might originate from other cells responding to infection and transformation. In 
addition, it could be that the miRNA signal of the low number of cells expressing 
JSRV Env is masked by the aging process taking place in all the lung slice. In 
order to investigate these hypotheses, another study of JSRV infection of lung 
slices was performed extending the sampling time and points, and increasing viral 
concentration.  
A 14-fold increase in JSRV concentration did not produce an increase in cells 
expressing JSRV Env within the lung slices. These findings suggest that infection 
of cells in lung slices might be more dependent on the availability of target cells 
than on the viral concentration used. JSRV, unlike lentiviral vectors, preferentially 
infects and replicates in actively dividing cells, and, in particular, AT2 cells. It is 
then anticipated that above a certain JSRV concentration threshold, the increase 
of viral particles would not result in more infected cells. Nevertheless, using tissue 
from younger lambs could potentially result in higher numbers of JSRV infected 
cells in lung slices, and help address if the lack of miRNA changes observed in 
this study is due to the miRNA expression being masked. Age effects in lung slices 
have been previously described (Cousens et al, 2015) and are consistent with 
observations of natural cases of OPA and experimental infections. Dividing AT2 
cells are found at higher frequency in early stages of development and, in lambs 
compared to adult sheep (Murgia et al, 2011). Murgia et al (2011) showed that 
lung damage in adult sheep promotes proliferation of AT2 cells and permits JSRV 
infection and tumourigenesis. This suggests that in natural disease, lung damage 
by infection might increase AT2 cell proliferation in a similar way and promote 
infection by JSRV (Murgia et al, 2011). 
It should be noted that the finding of low infection levels is consistent with previous 
work in our lab (Cousens et al, 2015). However, these results contrast with a study 
of JSRV infection in lung slices of 6-month old lambs, in which high levels of JSRV 
infection and Env expression were reported (Rosales Gerpe et al, 2018). 
Nevertheless, caution should be taken when interpreting the results of that study 
due to background staining observed in uninfected lung slices, and due to the 
detection of JSRV Env in cells other than AT2 cells, which are not expected in a 
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JSRV infection. It is likely that the immunostaining conditions used for JSRV Env 
detection made the technique not entirely specific.  
Reduced survival of lung slices in the last experiment performed is likely to be due 
to decrease in cell culture changes that resulted in media acidification damaging 
cells (Ian Freshney, 2005). In the future these could be easily resolved by 
changing media more frequently, increasing medium volume or adding a buffering 
reagent to prevent media acidification.  
5.3.6 Conclusions and future work 
Lack of an in vitro model of JSRV infection and transformation continues to hinder 
research into the molecular pathology and transformation events caused by the 
virus. Although models of JSRV transformation are available, these do not 
accurately reflect miRNA changes in OPA lung tissue. In order to study miRNA 
expression in JSRV Env transformation and the involvement of miRNAs in 
pathogenicity, development of a model that permits JSRV infection and replication 
is needed.  
Currently, the model more likely to resemble events in natural infection is the use 
of lung slices for JSRV infection. However, the use of lung slices has limitations 
on the length of study and the tests that can be performed to study miRNA 
involvement in JSRV infection and transformation. In addition, it is not a 
quantitative system.  
In summary, despite taking several approaches the work described in this chapter 
did not result in an in vitro model suitable for replicating miRNA expression in 
OPA. Nevertheless, the results of MDCK transformation and AT2 cell isolation 
provide important information for future studies in this area.  
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Chapter 6 Summary, conclusions and future 
work 
Ovine pulmonary adenocarcinoma is an important disease that causes significant 
economic losses for farmers. To date, no reliable early-stage diagnostic tests are 
available for OPA, making disease control problematic. Moreover, OPA is a 
valuable model for human lung adenocarcinoma and a fascinating disease in 
which to investigate the interplay of viral infection, oncogenesis, immunity and 
tolerance. Nevertheless, study of the molecular pathogenesis of OPA and Env-
driven transformation has been hindered due to the lack of a permissive cell line 
for JSRV replication. A better understanding of the disease is needed to stimulate 
the creation of new control strategies, and to increase our knowledge of the 
similarities and differences with human lung adenocarcinoma. miRNAs are 
regulators of gene expression, and study of their prevalence in OPA could 
advance the current knowledge on the molecular pathogenesis of OPA and 
improve disease control strategies. miRNAs are involved in many cell processes 
and are being extensively studied as biomarkers of several diseases, including 
cancer. In this thesis, miRNA expression in OPA was examined with two 
overarching aims: to study their role in the early oncogenic events in OPA and to 
explore their potential as disease biomarkers. 
In the first experimental chapter, global miRNA expression was studied in sheep 
lung and 40 miRNAs DE in OPA-affected sheep were identified. RT-qPCR 
confirmed DE of nine of these miRNAs in experimental cases and natural cases 
of the disease, representing early and advanced forms of the disease. However, 
due to the limited sensitivity of analysing whole specimens of lung tissue, miRNA 
expression was subsequently examined in samples enriched for specific cell 
types. Isolation of tumour cells by LCM was complex and technically challenging. 
Nevertheless, sequencing of enriched tumour samples largely confirmed the 
upregulation of the nine selected miRNAs, indicating that they might be associated 
with OPA tumours. Sequencing of CD14+ macrophages purified from sheep lung 
also revealed DE miRNAs in OPA-affected sheep. These results suggest that 
immune cells might change their phenotype as a response to the presence of 
JSRV in the lung.  
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In addition to studying host miRNA expression, the potential for JSRV to encode 
miRNAs was investigated. Small RNA sequencing revealed a region of the JSRV 
genome that was overrepresented in the sequencing data, and that was not 
present in uninfected samples. RNA folding indicated the presence of a stem-loop 
enclosing the area with high read abundance. However, the existence of this 
putative JSRV-encoded miRNA could not be confirmed experimentally. Although 
these results appear to indicate that it is unlikely that JSRV encodes miRNAs, it is 
difficult to completely rule this out due to the sensitivity of the method used.  
In the second experimental chapter, the presence of miRNAs in sheep serum was 
explored to investigate their potential as biomarkers. The nine miRNAs 
upregulated in lung tissue were found not to be DE in serum. Small RNA 
sequencing was then performed on ovine sera and successfully identified 74 DE 
miRNAs in the serum of OPA-affected sheep. However, additional sequencing of 
a larger number of samples revealed that no miRNAs were consistently DE at all 
stages of the disease. The disagreement between the two studies was discovered 
to be partly due to low repeatability between experiments. Lung fluid was then 
investigated as a source of miRNAs, but low miRNA expression levels were 
detected, and no correlation with tissue levels was found. The findings of the 
second experimental chapter suggested that it would be difficult to exploit 
circulating miRNAs as diagnostic markers for OPA in serum or lung fluid.  
In parallel with studying miRNA expression in vivo, in the third experimental 
chapter, I sought to establish a model in which the role of DE miRNAs could be 
studied. Such a model could help to elucidate the mechanism by which JSRV Env 
activates signalling pathways in the host cell, and support the association of the 
selected miRNAs with OPA. Initially, established cell lines were used, but low 
transfection efficiency and Env expression prevented the study of the 
transformation process. JSRV Env expression in cell lines was improved by using 
lentiviral vectors encoding GFP-2A-Env. MDCK and 208F cells were successfully 
transformed by JSRV Env. Three transformed MDCK clones were found to 
express JSRV Env and associated transformation markers P-Akt and P-ERK1/2 
for approximately three months after transduction. However, the differences found 
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in miRNA expression between transformed MDCK clones and non-transformed 
MDCK cells did not resemble the changes seen in OPA-affected lung tissue. 
Sheep-derived cells and tissue were then explored as model systems to study 
miRNA expression in OPA. Isolation and culture of AT2 cells was successful, as 
indicated by the presence of the AT2-specific marker SP-C. However, variability 
in cell yield and SP-C expression was observed between cells derived from 
different lambs. The low yield of AT2 cells retrieved per animal, together with their 
rapid dedifferentiation restricted the time window in which infections with JSRV 
could be performed. Overall, this experiment was a valuable first step towards 
developing a future in vitro system that could potentially support JSRV replication. 
However, further development of the current protocol is needed to maximise 
recovery of AT2 cells from sheep lung and to optimise conditions for their in vitro 
culture.  
miRNA expression was also investigated in ovine lung slices exposed to lentiviral 
vectors encoding GFP2AEnv or JSRV21. In both cases, immunohistochemistry 
revealed expression of JSRV Env in only a small proportion of cells and no miRNA 
changes that could be related to Env expression were detected. The proportion of 
infected cells was not increased by adding larger amounts of virus. This finding 
suggested that the availability of target cells rather than viral concentration might 
be the bottleneck to achieving high levels of JSRV Env expression. Overall, 
the results from experiments performed in cell lines and sheep cells emphasise 
the need for improved in vitro models of OPA, and in particular, systems that are 
more quantitative and not subject to the high degree of technical variability 
observed here.  
This is the first study to explore miRNA expression in OPA, and the first to identify 
the association of some miRNAs with OPA. The upregulation of miR-135b, miR-
182, miR-183, miR-200b, miR-205, miR-21, miR-31, miR-503 and miR-96 
observed in lung tissue of OPA-affected sheep, correlates with findings in human 
lung cancer studies. Nevertheless, in human lung cancer, some studies have 
reported contradictory findings, which might be related to the heterogeneous 
nature of the disease or to demographic differences in the groups studied. In OPA, 
a trend towards upregulation of the selected miRNAs was observed in all tissue 
  
Chapter 6: Summary, conclusions and future work 320 
samples analysed. However, the number of samples analysed here is limited 
compared to human lung cancer studies. Further investigation on miRNA 
expression in larger animal cohorts would be needed to ensure that the miRNA 
upregulation observed is a consistent feature of OPA-affected animals. On the 
other hand, inconsistent results in human lung cancer studies might also stem 
from classifying different forms of the disease, with different histopathology an 
oncogene activation, under the umbrella term of lung cancer. OPA might, thus, be 
expected to exhibit a more uniform miRNA expression pattern across samples 
due to the similarities in lesions and transformation markers observed across 
cases. 
Given the limitations of assessing gene expression in whole tissue samples or 
pooled cell populations, in the future, single-cell sequencing could be used to 
dissect specific patterns in miRNA expression and to correlate these patterns with 
specific cell types. This approach would facilitate the study of miRNA expression 
in specific cell types, for example normal and Env transformed AT2 cells. One of 
the most popular approaches for single-cell sequencing is to use droplet-based 
technologies for high-throughput sequencing (Zhang et al, 2019). Of the droplet-
based technologies, Chromium 10x is reported to be the most sensitive and to 
have lower levels of technical noise (Zhang et al, 2019). However, Chromium 10x 
offers shallow sequencing depth, which might not detect low abundance 
transcripts or miRNAs (Baran-Gale et al, 2018; Zhang et al, 2019). Approaches to 
obtain higher read-depth are also available; for example Smart-seq 2 (Baran-Gale 
et al, 2018). Nevertheless, this approach might, in the case of OPA, require some 
prior purification of AT2 cells or tumour cells to ensure a representative amount of 
the cells of interest are sequenced. Another current major obstacle is the absence 
of commercially available kits for small RNA single-cell sequencing. It is expected 
that such reagents will become available in the near future, and some protocols 
have recently been developed to allow single-cell sequencing of small RNAs 
(Faridani et al, 2016; Hagemann-Jensen et al, 2018). In addition, single-cell 
sequencing has been successfully applied to co-sequence mRNA and miRNA 
from single cells, allowing the study of the correlation between them (Wang et al, 
2019b; Xiao et al, 2018).  
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In this thesis, the serum analysis did not identify any miRNAs as potential 
diagnostic markers for OPA. This finding echoes the current status of miRNA 
biomarker development in human diseases. Although the number of miRNA 
studies continues to increase, reaching ~11000 studies in 2018  (Bonneau et al, 
2019), no FDA or EMA approved diagnostic tests are currently available 
(www.fda.gov, www.ema.europa.eu).  Nevertheless, diagnostic tests to classify 
cancers of unknown origin, and osteoporosis-linked risk of fractures are 
commercially available in the US (Heilmeier et al, 2016; Kocijan et al, 2016) 
(osteomiRTM, TAmiRNA GmbH, Austria). These tests use panels of more than ten 
miRNAs to increase sensitivity and specificity, and might be useful in conjunction 
with other diagnostic tests. In addition, another commercially available test seeks 
to improve the diagnostic accuracy for thyroid cancer by using a combination of a 
miRNA panel and an oncogene panel (Labourier et al, 2015) (ThyraMIR®, 
Interpace Diagnostics, LLC, NJ  USA). Overall, the work in this thesis, and review 
of the literature highlight the potential of miRNAs as biomarkers but, emphasise 
that further research and development is needed in order for them to be used in a 
clinical or field setting.  
Another approach towards increasing the sensitivity of miRNAs as diagnostic 
markers would be the use of new detection methods. For example, DestiNA 
Genomics, an Edinburgh based company, has developed a highly-sensitive 
detection system that does not require prior RNA extraction or PCR, with 
applications in field and clinical settings (Detassis et al, 2019; Marín-Romero et 
al, 2018; Rissin et al, 2017). Besides the use of miRNAs as biomarkers of OPA, 
other molecules could be considered as part of integrative approaches such as 
multi-omics (Hasin et al, 2017). However, although hugely informative, multi-
omics approaches remain time-consuming and expensive, requiring further 
development for their clinical application (Hasin et al, 2017).  
In case miRNA detection is not suitable for the diagnosis of OPA, other recently 
developed methods and approaches could be investigated for this purpose. 
Considering the viral origin of OPA, detection of the pathogen’s genome in sheep 
offers a route to early diagnosis and effective disease control. In the past, 
detection of JSRV in the blood using PCR has not proved to be a sensitive 
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approach due to the low number of viral copies present in circulation (Lewis et al, 
2011). Nevertheless, highly sensitive methods for pathogen detection continue to 
be developed, which could make sensitive JSRV detection in the blood a reality 
in the future. One example is SHERLOCK2, a method based on isothermal 
amplification and Cas13, able to detect viral RNA at low concentrations (2 
attomolar) (Gootenberg et al, 2018). In addition, to its sensitivity SHERLOCK2 
produces quantitative detection data, which could provide information on viral load 
and relation to pathological findings.  
At present, miRNAs might not offer diagnostic accuracy for OPA but, studying their 
role in OPA has the potential to reveal information on the early events of JSRV 
Env-mediated transformation. The studies performed in in vitro models in this 
thesis sought to explore the role of miRNAs in OPA. Nevertheless, problems with 
their agreement with the in vivo findings, and variability in primary cultures were 
encountered. These issues highlight that better models are needed to continue 
the study of JSRV infection and oncogenesis. In addition, better in vitro models of 
OPA would result in a reduced need for experimental animals, driving research in 
a more ethical and less costly direction.  
Ideally, a model of OPA would be able to support replication of JSRV. The problem 
in developing such model has been the challenge of maintaining AT2 cells in vitro. 
However, culture systems such as 3D systems allow for extended culture of AT2 
cells expressing their features (Nandkumar et al, 2015; Sucre et al, 2018), which 
could result in efficient replication of JSRV. New advances have also made 
possible the culture of lung organoids from stem-cells and their co-culture with 
endothelial or mesenchymal cells (Gkatzis et al, 2018). In addition, a revolutionary 
system: Lung-on-chip, based on the use of microfluidics, has made possible to 
reproduce interactions between cells and critical functions of the lung (Benam et 
al, 2016; Huh et al, 2010). A combination of organoids and the lung on-chip 
approach has also been suggested to overcome limitations of the methods 
(Takebe et al, 2017). Although these models would suppose an exciting new 
platform for studying lung diseases such as OPA, they are currently not 
quantitative.  
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In conclusion, this study has provided new knowledge on the expression of 
miRNAs in OPA and provides a foundation for future work examining the role of 
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Table 0.2. Summary of Ct values from the qPCR results reported in Chapter 5. 
miRNA Sample Ct value 
Fig. 5.15 
miR-135b 1E5 28.06 
miR-182 1E5 29.83 
miR-183 1E5 30.18 
miR-200b 1E5 40.00 
miR-205 1E5 32.78 
miR-21 1E5 20.20 
miR-31 1E5 26.96 
miR-503 1E5 33.99 
miR-96 1E5 28.97 
miR-191 1E5 27.50 
miR-135b 2E3 26.83 
miR-182 2E3 27.88 
miR-183 2E3 28.35 
miR-200b 2E3 40.00 
miR-205 2E3 32.46 
miR-21 2E3 18.79 
miR-31 2E3 25.09 
miR-503 2E3 31.32 
miR-96 2E3 27.54 
miR-191 2E3 25.96 
miR-135b 3C9 26.15 
miR-182 3C9 27.94 
miR-183 3C9 28.99 
miR-200b 3C9 40.00 
miR-205 3C9 33.32 
miR-21 3C9 17.97 
miR-31 3C9 24.55 
miR-503 3C9 31.13 
miR-96 3C9 26.88 
miR-191 3C9 25.53 
miR-135b Control MDCKs 26.96 
miR-182 Control MDCKs 26.98 
miR-183 Control MDCKs 27.84 
miR-200b Control MDCKs 33.01 
miR-205 Control MDCKs 33.99 
miR-21 Control MDCKs 19.16 
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Table 0.2. Summary of Ct values from the qPCR results reported in Chapter 5. 
miRNA Sample Ct value 
miR-31 Control MDCKs 25.48 
miR-503 Control MDCKs 29.62 
miR-96 Control MDCKs 26.83 
miR-191 Control MDCKs 25.73 
Fig. 5.21. A 
miR-135b Lung slices mock-infected- day 8 31.27 
miR-182 Lung slices mock-infected- day 8 29.32 
miR-183 Lung slices mock-infected- day 8 25.71 
miR-200b Lung slices mock-infected- day 8 30.49 
miR-205 Lung slices mock-infected- day 8 22.93 
miR-21 Lung slices mock-infected- day 8 18.73 
miR-31 Lung slices mock-infected- day 8 24.34 
miR-503 Lung slices mock-infected- day 8 31.51 
miR-96 Lung slices mock-infected- day 8 27.79 
miR-191 Lung slices mock-infected- day 8 24.48 
miR-135b Lung slices CSC-GFP- day 8 33.16 
miR-182 Lung slices CSC-GFP- day 8 29.59 
miR-183 Lung slices CSC-GFP- day 8 27.12 
miR-200b Lung slices CSC-GFP- day 8 31.72 
miR-205 Lung slices CSC-GFP- day 8 24.01 
miR-21 Lung slices CSC-GFP- day 8 18.79 
miR-31 Lung slices CSC-GFP- day 8 25.29 
miR-503 Lung slices CSC-GFP- day 8 31.76 
miR-96 Lung slices CSC-GFP- day 8 28.33 
miR-191 Lung slices CSC-GFP- day 8 24.48 
miR-135b Lung slices CSC-GFP2AEnv- day 8 34.20 
miR-182 Lung slices CSC-GFP2AEnv- day 8 30.88 
miR-183 Lung slices CSC-GFP2AEnv- day 8 27.98 
miR-200b Lung slices CSC-GFP2AEnv- day 8 31.83 
miR-205 Lung slices CSC-GFP2AEnv- day 8 24.39 
miR-21 Lung slices CSC-GFP2AEnv- day 8 20.58 
miR-31 Lung slices CSC-GFP2AEnv- day 8 25.66 
miR-503 Lung slices CSC-GFP2AEnv- day 8 32.95 
miR-96 Lung slices CSC-GFP2AEnv- day 8 29.92 
miR-191 Lung slices CSC-GFP2AEnv- day 8 25.21 
Fig. 5.21. B 
miR-135b Lung slices mock-infected- day 8 31.27 
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Table 0.2. Summary of Ct values from the qPCR results reported in Chapter 5. 
miRNA Sample Ct value 
miR-182 Lung slices mock-infected- day 8 29.32 
miR-183 Lung slices mock-infected- day 8 25.71 
miR-200b Lung slices mock-infected- day 8 30.49 
miR-205 Lung slices mock-infected- day 8 22.93 
miR-21 Lung slices mock-infected- day 8 18.73 
miR-31 Lung slices mock-infected- day 8 24.34 
miR-503 Lung slices mock-infected- day 8 31.51 
miR-96 Lung slices mock-infected- day 8 27.79 
miR-191 Lung slices mock-infected- day 8 24.48 
miR-135b Lung slices CSC-GFP- day 8 31.35 
miR-182 Lung slices CSC-GFP- day 8 28.87 
miR-183 Lung slices CSC-GFP- day 8 25.99 
miR-200b Lung slices CSC-GFP- day 8 31.44 
miR-205 Lung slices CSC-GFP- day 8 23.26 
miR-21 Lung slices CSC-GFP- day 8 18.59 
miR-31 Lung slices CSC-GFP- day 8 24.43 
miR-503 Lung slices CSC-GFP- day 8 33.01 
miR-96 Lung slices CSC-GFP- day 8 27.24 
miR-191 Lung slices CSC-GFP- day 8 24.61 
miR-135b Lung slices CSC-GFP2AEnv- day 8 33.62 
miR-182 Lung slices CSC-GFP2AEnv- day 8 28.13 
miR-183 Lung slices CSC-GFP2AEnv- day 8 25.50 
miR-200b Lung slices CSC-GFP2AEnv- day 8 30.65 
miR-205 Lung slices CSC-GFP2AEnv- day 8 22.56 
miR-21 Lung slices CSC-GFP2AEnv- day 8 17.98 
miR-31 Lung slices CSC-GFP2AEnv- day 8 23.94 
miR-503 Lung slices CSC-GFP2AEnv- day 8 32.87 
miR-96 Lung slices CSC-GFP2AEnv- day 8 26.75 
miR-191 Lung slices CSC-GFP2AEnv- day 8 24.08 
Fig. 5.22. A 
miR-135b Lung slices mock-infected- day 18 34.14 
miR-182 Lung slices mock-infected- day 18 27.39 
miR-183 Lung slices mock-infected- day 18 24.40 
miR-200b Lung slices mock-infected- day 18 30.80 
miR-205 Lung slices mock-infected- day 18 22.51 
miR-21 Lung slices mock-infected- day 18 17.92 
miR-31 Lung slices mock-infected- day 18 23.81 
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Table 0.2. Summary of Ct values from the qPCR results reported in Chapter 5. 
miRNA Sample Ct value 
miR-503 Lung slices mock-infected- day 18 32.27 
miR-96 Lung slices mock-infected- day 18 25.99 
miR-191 Lung slices mock-infected- day 18 24.49 
miR-135b Lung slices CSC-GFP- day 18 31.85 
miR-182 Lung slices CSC-GFP- day 18 26.88 
miR-183 Lung slices CSC-GFP- day 18 24.06 
miR-200b Lung slices CSC-GFP- day 18 30.94 
miR-205 Lung slices CSC-GFP- day 18 21.77 
miR-21 Lung slices CSC-GFP- day 18 17.41 
miR-31 Lung slices CSC-GFP- day 18 23.07 
miR-503 Lung slices CSC-GFP- day 18 33.74 
miR-96 Lung slices CSC-GFP- day 18 25.30 
miR-191 Lung slices CSC-GFP- day 18 23.94 
miR-135b Lung slices CSC-GFP2AEnv- day 18 32.51 
miR-182 Lung slices CSC-GFP2AEnv- day 18 27.48 
miR-183 Lung slices CSC-GFP2AEnv- day 18 24.47 
miR-200b Lung slices CSC-GFP2AEnv- day 18 29.95 
miR-205 Lung slices CSC-GFP2AEnv- day 18 21.46 
miR-21 Lung slices CSC-GFP2AEnv- day 18 18.72 
miR-31 Lung slices CSC-GFP2AEnv- day 18 23.31 
miR-503 Lung slices CSC-GFP2AEnv- day 18 33.38 
miR-96 Lung slices CSC-GFP2AEnv- day 18 26.33 
miR-191 Lung slices CSC-GFP2AEnv- day 18 23.96 
Fig. 5.22. B 
miR-135b Lung slices mock-infected- day 18 34.14 
miR-182 Lung slices mock-infected- day 18 27.39 
miR-183 Lung slices mock-infected- day 18 24.40 
miR-200b Lung slices mock-infected- day 18 30.80 
miR-205 Lung slices mock-infected- day 18 22.51 
miR-21 Lung slices mock-infected- day 18 17.92 
miR-31 Lung slices mock-infected- day 18 23.81 
miR-503 Lung slices mock-infected- day 18 32.27 
miR-96 Lung slices mock-infected- day 18 25.99 
miR-191 Lung slices mock-infected- day 18 24.49 
miR-135b Lung slices CSC-GFP- day 18 32.32 
miR-182 Lung slices CSC-GFP- day 18 27.07 
miR-183 Lung slices CSC-GFP- day 18 24.47 
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Table 0.2. Summary of Ct values from the qPCR results reported in Chapter 5. 
miRNA Sample Ct value 
miR-200b Lung slices CSC-GFP- day 18 30.27 
miR-205 Lung slices CSC-GFP- day 18 22.44 
miR-21 Lung slices CSC-GFP- day 18 17.68 
miR-31 Lung slices CSC-GFP- day 18 23.55 
miR-503 Lung slices CSC-GFP- day 18 32.05 
miR-96 Lung slices CSC-GFP- day 18 25.48 
miR-191 Lung slices CSC-GFP- day 18 24.24 
miR-135b Lung slices CSC-GFP2AEnv- day 18 35.22 
miR-182 Lung slices CSC-GFP2AEnv- day 18 27.63 
miR-183 Lung slices CSC-GFP2AEnv- day 18 24.80 
miR-200b Lung slices CSC-GFP2AEnv- day 18 31.77 
miR-205 Lung slices CSC-GFP2AEnv- day 18 22.80 
miR-21 Lung slices CSC-GFP2AEnv- day 18 18.42 
miR-31 Lung slices CSC-GFP2AEnv- day 18 23.99 
miR-503 Lung slices CSC-GFP2AEnv- day 18 32.46 
miR-96 Lung slices CSC-GFP2AEnv- day 18 25.96 
miR-191 Lung slices CSC-GFP2AEnv- day 18 24.69 
Fig. 5.24 
miR-135b lung slices not-infected 1- day 0 30.49 
miR-182 lung slices not-infected 1- day 0 29.86 
miR-183 lung slices not-infected 1- day 0 40.00 
miR-200b lung slices not-infected 1- day 0 34.18 
miR-205 lung slices not-infected 1- day 0 26.93 
miR-21 lung slices not-infected 1- day 0 21.61 
miR-31 lung slices not-infected 1- day 0 27.57 
miR-503 lung slices not-infected 1- day 0 37.09 
miR-96 lung slices not-infected 1- day 0 30.61 
miR-191 lung slices not-infected 1- day 0 24.26 
miR-135b lung slices not-infected 2- day 0 34.45 
miR-182 lung slices not-infected 2- day 0 31.06 
miR-183 lung slices not-infected 2- day 0 40.00 
miR-200b lung slices not-infected 2- day 0 34.83 
miR-205 lung slices not-infected 2- day 0 27.97 
miR-21 lung slices not-infected 2- day 0 21.42 
miR-31 lung slices not-infected 2- day 0 27.76 
miR-503 lung slices not-infected 2- day 0 40.00 
miR-96 lung slices not-infected 2- day 0 40.00 
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Table 0.2. Summary of Ct values from the qPCR results reported in Chapter 5. 
miRNA Sample Ct value 
miR-191 lung slices not-infected 2- day 0 23.80 
miR-135b lung slices JSRV-infected 1- day 10 32.24 
miR-182 lung slices JSRV-infected 1- day 10 23.44 
miR-183 lung slices JSRV-infected 1- day 10 27.61 
miR-200b lung slices JSRV-infected 1- day 10 29.50 
miR-205 lung slices JSRV-infected 1- day 10 23.06 
miR-21 lung slices JSRV-infected 1- day 10 19.35 
miR-31 lung slices JSRV-infected 1- day 10 24.42 
miR-503 lung slices JSRV-infected 1- day 10 29.55 
miR-96 lung slices JSRV-infected 1- day 10 24.74 
miR-191 lung slices JSRV-infected 1- day 10 24.53 
miR-135b lung slices JSRV-infected 2- day 10 40.00 
miR-182 lung slices JSRV-infected 2- day 10 22.44 
miR-183 lung slices JSRV-infected 2- day 10 26.53 
miR-200b lung slices JSRV-infected 2- day 10 28.93 
miR-205 lung slices JSRV-infected 2- day 10 21.98 
miR-21 lung slices JSRV-infected 2- day 10 18.96 
miR-31 lung slices JSRV-infected 2- day 10 23.84 
miR-503 lung slices JSRV-infected 2- day 10 30.83 
miR-96 lung slices JSRV-infected 2- day 10 23.55 
miR-191 lung slices JSRV-infected 2- day 10 24.00 
miR-135b lung slices Mock-infected 1- day 10 34.61 
miR-182 lung slices Mock-infected 1- day 10 23.81 
miR-183 lung slices Mock-infected 1- day 10 28.17 
miR-200b lung slices Mock-infected 1- day 10 29.47 
miR-205 lung slices Mock-infected 1- day 10 23.16 
miR-21 lung slices Mock-infected 1- day 10 19.81 
miR-31 lung slices Mock-infected 1- day 10 24.66 
miR-503 lung slices Mock-infected 1- day 10 29.97 
miR-96 lung slices Mock-infected 1- day 10 24.91 
miR-191 lung slices Mock-infected 1- day 10 25.00 
miR-135b lung slices Mock-infected 2- day 10 40.00 
miR-182 lung slices Mock-infected 2- day 10 23.33 
miR-183 lung slices Mock-infected 2- day 10 26.91 
miR-200b lung slices Mock-infected 2- day 10 29.54 
miR-205 lung slices Mock-infected 2- day 10 22.90 
miR-21 lung slices Mock-infected 2- day 10 19.84 
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Table 0.2. Summary of Ct values from the qPCR results reported in Chapter 5. 
miRNA Sample Ct value 
miR-31 lung slices Mock-infected 2- day 10 24.59 
miR-503 lung slices Mock-infected 2- day 10 31.01 
miR-96 lung slices Mock-infected 2- day 10 24.41 
miR-191 lung slices Mock-infected 2- day 10 24.83 
 
